RXFP1 AGONISTS

Abstract

The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

##STR00001##

Claims

1. A compound of Formula (I): ##STR00299## or a pharmaceutically acceptable salt thereof, wherein: L is O or NH; R.sup.1 is C.sub.1-3 alkyl substituted with 0-1 aryl or C.sub.3-6 cycloalkyl substituent; R.sup.2 is H; provided when R.sup.1 is C.sub.1-3 alkyl substituted with 0 aryl or C.sub.3-6 cycloalkyl, R.sup.9 is not absent; or R.sup.1 and R.sup.2 are combined to be CR.sup.6R.sup.7 or NOC.sub.1-4 alkyl wherein is a double bond; or R.sup.1 and R.sup.2 together with the carbon atom to which they are both attached form a dioxolanyl substituted with 0-1 aryl substituent; R.sup.3 is C.sub.1-8 alkyl substituted with 0-5 halo, CN, OH, or OC.sub.1-3 alkyl substituents, (CR.sup.dR.sup.d).sub.nC.sub.3-10-carbocyclyl substituted with 0-5 R.sup.4, or (CR.sup.dR.sup.d).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-5 R.sup.4; R.sup.4 is halo, CN, OH, SF.sub.5, S(O).sub.pR.sup.4, C.sub.1-4 alkyl substituted with 0-5 halo, OH, or OC.sub.1-4 alkyl substituents, OC.sub.1-4 alkyl substituted with 0-5 halo substituents, (CR.sup.dR.sup.d).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CR.sup.dR.sup.d).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-5 R.sup.e; R.sup.4c is H, C.sub.1-4 alkyl, or S(O).sub.2CF.sub.3; each R.sup.5 is H, halo, OH, C.sub.1-4 alkyl substituted with 0-5 halo substituents, or OC.sub.1-4 alkyl substituted with 0-5 halo substituents; R.sup.6 is H, halo, CN, C.sub.1-7 alkyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)NR.sup.6bR.sup.6b, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.14, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, or NR.sup.14a, and substituted with 0-5 R.sup.14; R.sup.6a is halo, OH, OC.sub.1-4 alkyl, C.sub.1-4 alkyl, aryl, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; R.sup.6b is H, C.sub.1-4 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; R.sup.7 is H or C.sub.1-4 alkyl; or R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indenyl; R.sup.8 is H, halo, CN, NR.sup.7R.sup.7, C.sub.1-4 alkyl substituted with 0-5 halo or OH substituents, or OC.sub.1-4 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, aryl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OC.sub.1-4 alkyl substituted with 0-1 OC.sub.1-3 alkyl substituents; R.sup.9 is aryl substituted with 0-3 R.sup.10 and 0-2 R.sup.11 or 3- to 12-membered heterocyclyl comprising 1-5 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-2 R.sup.11; R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-4 alkyl substituted with 0-4 R.sup.12 and 0-2 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.5, and substituted with 0-5 R.sup.e; R.sup.11a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, aryl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.5, and substituted with 0-5 R.sup.e; R.sup.11b is halo, OH, C(O)OH, C(O)OC.sub.1-4 alkyl, or aryl; R.sup.12 is halo, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents, or C.sub.3-6 cycloalkyl; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, S(O).sub.pR.sup.c, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.nNR.sup.aR.sup.a, (CH.sub.2).sub.n-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-4 alkyl, or C.sub.1-3 alkyl substituted with 0-3 Si(C.sub.1-3 alkyl).sub.3 or aryl substituted with 0-2 halo substituents; R.sup.15 is H, C.sub.1-4 alkyl, or aryl; R.sup.a is H, OC.sub.1-6 alkyl, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.c is C.sub.1-6 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.d is H, C.sub.1-4 alkyl, or C.sub.3-6 cycloalkyl; R.sup.e is halo, CN, NO.sub.2, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, S(O).sub.pNR.sup.fR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; R.sup.f is H, C.sub.1-6 alkyl substituted with 0-2 OH or OC.sub.1-4 alkyl substituents, C.sub.3-6 cycloalkyl, aryl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; R.sup.g is halo, CN, OH, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; n is zero, 1, 2, or 3; and p is zero, 1, or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is C.sub.1-6 alkyl substituted with 0-4 halo or OH substituents, (CHR.sup.d).sub.0-1C.sub.3-6 cycloalkyl substituted with 0-4 R.sup.4, C.sub.6-9 spirocycloalkyl substituted with 0-4 R.sup.4, C.sub.6-10 bicyclic carbocyclyl substituted with 0-4 R.sup.4, or 3 to 6-membered heterocyclyl comprising 1-2 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-4 R.sup.4; R.sup.4 is halo or C.sub.1-3 alkyl substituted with 0-4 halo substituents; R.sup.4c is H or C.sub.1-4 alkyl; and R.sup.d is C.sub.1-3 alkyl.

3. The compound of claim 1, having Formula (II): ##STR00300## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4 is halo, S(O).sub.pC.sub.1-4 alkyl substituted with 0-4 halo substituents, C.sub.1-4 alkyl substituted with 0-4 halo substituents, or OC.sub.1-4 alkyl substituted with 0-4 halo substituents; R.sup.5 is H or halo; R.sup.6 is halo, CN, C.sub.1-7 alkyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)NR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, aryl substituted with 0-3 R.sup.14, or 4- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a and substituted with 0-3 R.sup.14; R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or aryl; R.sup.6b is H, C.sub.1-4 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; R.sup.7 is H or C.sub.1-3 alkyl; R.sup.8 is halo, CN, N(C.sub.1-2 alkyl).sub.2, C.sub.1-4 alkyl substituted with 0-5 halo or OH substituents, or OC.sub.1-4 alkyl substituted with 0-4 halo, OH, aryl or OC.sub.1-4 alkyl substituents; R.sup.9 is aryl substituted with 0-3 R.sup.10 and 0-2 R.sup.11, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-1 R.sup.11; R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-4 alkyl substituted with 0-3 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; R.sup.11b is OH, C(O)OH, or aryl; R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-3NR.sup.aR.sup.a, (CH.sub.2).sub.0-3-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-4 alkyl, or C.sub.1-3 alkyl substituted with 0-3 aryl substituted with 0-2 halo substituents; R.sup.15 is H, C.sub.1-3 alkyl, or aryl; R.sup.a is H, C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.b is H, C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.c is C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.d is H or C.sub.1-4 alkyl; R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.9, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-aryl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.g, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; R.sup.f is H, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a 3- to 9-membered heterocyclyl; R.sup.g is halo, CN, OH, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; n is zero, 1, 2, or 3; and p is zero, 1, or 2.

4. The compound of claim 1, having Formula (III): ##STR00301## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; R.sup.5 is H or F; R.sup.6 is halo, C.sub.1-4 alkyl substituted with 0-3 R.sup.6a, C.sub.2-4 alkenyl substituted with 0-1 phenyl or OH substituent, C(O)OR.sup.6b, C(O)NHR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, naphthyl, or 5- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, N, and NR.sup.14a and substituted with 0-3 R.sup.14; R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or phenyl; R.sup.6b is H or C.sub.1-4 alkyl; R.sup.7 is H or C.sub.1-3 alkyl; or R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indenyl; R.sup.8 is N(C.sub.1-4 alkyl).sub.2 or OC.sub.1-4 alkyl substituted with 0-1 OC.sub.1-4 alkyl substituent; R.sup.8a is halo; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-3 aryl substituted with 0-2 halo substituents; R.sup.a is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.n-phenyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.0-1-phenyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.e is halo, CN, NO.sub.2, O, C.sub.1-6 alkyl, or C(O)OH; and n is zero, 1, 2, or 3.

5. The compound of claim 3, having Formula (IV): ##STR00302## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4 is halo, C.sub.1-4 alkyl substituted with 0-3 halo substituents, or OC.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.5 is H or F; R.sup.6 is halo, CN, C.sub.1-6 alkyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)NR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a, and substituted with 0-3 R.sup.14; R.sup.6a is halo, C.sub.3-6 cycloalkyl, or phenyl; R.sup.6b is H, C.sub.1-3 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; R.sup.7 is H or C.sub.1-2 alkyl; R.sup.8 is OC.sub.1-4 alkyl substituted with 0-4 halo, OH, aryl, or OC.sub.1-4 alkyl substituents; R.sup.10 is halo, CN, C.sub.1-3 alkyl, OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or CL-4 alkyl substituted with 0-3 halo or OH substituents; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-3alkyl, C.sub.1-3 alkyl substituted with 0-2 aryl substituted with 0-2 halo substituents; R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; R.sup.a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.b is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.c is C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; R.sup.e is halo, CN, NO.sub.2, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl, (CH.sub.2).sub.n-aryl, (CH.sub.2).sub.n4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, (CH.sub.2).sub.nOR.sup.f, S(O).sub.pR.sup.f, C(O)NR.sup.fR.sup.f, C(O)OR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pNR.sup.fR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; R.sup.g is halo, CN, OH, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; n is zero, 1, 2, or 3; and p is zero, 1, or 2.

6. The compound of claim 5, having Formula (V): ##STR00303## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo or C.sub.1-2 alkyl; R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; R.sup.5 is H or F; R.sup.6 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 R.sup.6a, C.sub.2-4 alkenyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)NR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a and substituted with 0-3 R.sup.14; R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or phenyl; R.sup.6b is H, C.sub.1-3 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl; R.sup.7 is H or C.sub.1-2 alkyl; R.sup.8 is OC.sub.1-4alkyl substituted with 0-4 halo, OH, OC.sub.1-4 alkyl, or aryl substituents; R.sup.10 is halo or C.sub.1-3 alkyl; R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-1 R.sup.13, OH, OC.sub.1-4 alkyl, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-3 R.sup.e; R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, or OC(O)NR.sup.aOR.sup.b; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-1-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-1-3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-3 alkyl, C.sub.1-3 alkyl substituted with 0-1 aryl substituted with 0-2 halo substituents; R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; R.sup.a is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; R.sup.c is C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl, (CH.sub.2).sub.n-aryl, (CH.sub.2).sub.n4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, (CH.sub.2).sub.nOR.sup.f, S(O).sub.pR.sup.f, C(O)NR.sup.fR.sup.f, C(O)OR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pNR.sup.fR.sup.f, NRS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; R.sup.g is halo CN, OH, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; n is zero, 1, 2, or 3; and p is zero, 1, or 2.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is CF.sub.3; R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 halo substituents or C.sub.3-6 cycloalkyl substituted with 0-3 halo substituents; R.sup.8 is OC.sub.1-4alkyl; R.sup.10 is F; R.sup.11 is OH, OC.sub.1-4 alkyl, NR.sup.aC(O)R.sup.b, NR.sup.aS(O).sub.pR.sup.c, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, or 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; R.sup.15 is H or C.sub.1-2 alkyl; R.sup.a is H or C.sub.1-4 alkyl substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together is ##STR00304## R.sup.b is H or C.sub.1-4 alkyl substituted with 0-5 R.sup.e; R.sup.c is C.sub.1-3 alkyl substituted with 0-5 R.sup.e or C.sub.3-6 carbocyclyl; R.sup.e is halo, O, C.sub.1-4 alkyl substituted with 0-5 R.sup.g, C(O)OH, OR.sup.f, or NR.sup.fR.sup.f; R.sup.f is H and C.sub.1-6 alkyl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; and R.sup.g is halo.

8. The compound of claim 6, having Formula (VI): ##STR00305## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is CF.sub.3; R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 halo substituents or C.sub.3-6 cycloalkyl substituted with 0-3 halo substituents; R.sup.7 is H; R.sup.8 is OC.sub.1-4alkyl substituted with 0-1 aryl substituent; R.sup.10 is halo; R.sup.12 is C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl, C(O)NHOC.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-3 halo substituents; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.b, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, or OC(O)NR.sup.aOR.sup.b; R.sup.a is H, C.sub.1-4 alkyl substituted with 0-5 halo substituents, phenyl substituted with 0-4 R.sup.e, C.sub.3-10 cycloalkyl substituted with 0-4 R.sup.e, spirocycloalkyl substituted with 0-4 R.sup.e, or 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from 0, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.n-phenyl substituted with 0-4 halo substituents, C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.c is C.sub.1-4 alkyl substituted with 0-4 R.sup.e; R.sup.e is halo, CN, O, C.sub.1-5 alkyl substituted with 0-5 R.sup.g, C.sub.3-6 cycloalkyl, aryl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OR.sup.f; R.sup.f is H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, or aryl; R.sup.g is halo; n is zero or 1; and p is zero, 1, or 2.

9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is F R.sup.4b is CF.sub.3; R.sup.6 is CF.sub.3 or C.sub.3-6 cycloalkyl; R.sup.8 is OCH.sub.3 or OCH.sub.2-phenyl; R.sup.10 is F; R.sup.12 is C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl, C(O)NHOC.sub.1-3 alkyl, CH.sub.3, CHF.sub.2, or CF.sub.3; R.sup.13 is OH, NR.sup.aR.sup.a, NHC(O)R.sup.b, NHS(O).sub.pC.sub.1-4 alkyl, OC(O)NR.sup.aR.sup.a, or OC(O)NHOC.sub.1-4 alkyl; R.sup.a is H, C.sub.1-4 alkyl substituted with 0-4 F substituents, ##STR00306## or R.sup.a and R.sup.a together is ##STR00307## R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, phenyl, or ##STR00308## and R.sup.e is halo, O, aryl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OR.sup.f; and R.sup.f is H, C.sub.1-3 alkyl, C.sub.3-6 cycloalkyl, or phenyl.

10. The compound of claim 3, having Formula (VII): ##STR00309## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents, or OC.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.5 is H or F; R.sup.6 is halo, CN, C.sub.1-6 alkyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkynyl substituted with 0-3 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a, and substituted with 0-3 R.sup.14; R.sup.6a is halo, C.sub.3-6 cycloalkyl, or phenyl; R.sup.7 is H or C.sub.1-2 alkyl; R.sup.8 is halo, CN, or OC.sub.1-4 alkyl substituted with 0-4 halo, OH, or OC.sub.1-4 alkyl substituents; R.sup.8a is halo or CN; R.sup.9 is a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from 0, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-1 R.sup.11; R.sup.10 is halo, CN, C.sub.1-3 alkyl, O, OH, or OC.sub.1-3 alkyl; R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; R.sup.11b is OH, C(O)OH, or aryl; R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; R.sup.14a is H, C(O)C.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-2 aryl substituted with 0-2 halo substituents; R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; R.sup.a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.b is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; R.sup.c is C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-4 R.sup.g, C.sub.2-6 alkenyl substituted with 0-4 R.sup.g, C.sub.2-6 alkynyl substituted with 0-4 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-aryl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; R.sup.g is halo, CN, OH, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, or phenyl; n is zero, 1, 2, or 3; and p is zero, 1, or 2.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.5 is H; R.sup.6 is C.sub.1-2 alkyl substituted with 0-2 F substituents or C.sub.3-6 cycloalkyl; R.sup.8 is OC.sub.1-3 alkyl; R.sup.8a is F or CN; R.sup.9 is ##STR00310## R.sup.10 is halo, CN, C.sub.1-2 alkyl, O, OH, or OC.sub.1-2 alkyl; R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e; R.sup.11a is H, C(O)R.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.1-4 alkyl substituted with 0-1R.sup.11b; R.sup.11b is OH or aryl; R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-2 halo or OH substituents; R.sup.13 is OH, OC.sub.1-4 alkyl substituted with 0-2 OH substituents, or S(O).sub.2C.sub.1-4alkyl; R.sup.a is H or C.sub.1-4 alkyl or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3 to 9-membered heterocyclyl substituted with 0-4 R.sup.e; R.sup.b is H, C.sub.1-4 alkyl substituted with 0-1 R.sup.e, or C.sub.3-6 cycloalkyl substituted with 0-1 R.sup.e; R.sup.e is OR.sup.f; and R.sup.f is H or C.sub.1-4 alkyl.

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is CF.sub.3; R.sup.5 is H; R.sup.6 is CF.sub.3 or C.sub.3-6 cyclopropyl; R.sup.8 is OC.sub.1-3 alkyl; R.sup.9 is ##STR00311## R.sup.10 is C.sub.1-2 alkyl, OH, or OC.sub.1-2 alkyl; R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, C(O)OR.sup.b, or C(O)NR.sup.aR.sup.a; R.sup.12 is C(O)OR.sup.b; R.sup.13 is OH; R.sup.a is H or C.sub.1-4 alkyl; and R.sup.b is H or C.sub.1-4 alkyl.

13. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.5 is H; R.sup.6 is C.sub.1-3 alkyl substituted with 0-3 F substituents or C.sub.3-6 cycloalkyl; R.sup.8 is OC.sub.1-3 alkyl; R.sup.9 is ##STR00312## ##STR00313## R.sup.10 is halo, C.sub.1-3 alkyl, OH, or OC.sub.1-3 alkyl; R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13; R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, or C(O)OC.sub.1-4 alkyl; R.sup.11b is OH, C(O)OH, or aryl; R.sup.12 is C(O)OR.sup.b or C.sub.1-3 alkyl substituted with 0-3 halo substituents; R.sup.13 is OH; and R.sup.b is H or C.sub.1-4 alkyl.

14. The compound of claim 3, having Formula (VIII): ##STR00314## or a pharmaceutically acceptable salt thereof, wherein: R.sup.4a is halo; R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; R.sup.6 is C.sub.1-2 alkyl substituted with 0-2 F substituents, C.sub.3-6 cycloalkyl, or aryl; R.sup.7 is H; R.sup.8 is OC.sub.1-3 alkyl; R.sup.9 is ##STR00315## R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-2 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, or C(O)OR.sup.b; R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; R.sup.13 is OH or NR.sup.aC(O)R.sup.b; R.sup.a is H or C.sub.1-4 alkyl; and R.sup.b is H, C.sub.1-4 alkyl, or 3 to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N.

15. The compound of claim 1, having Formula (IX): ##STR00316## or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is C.sub.1-5 alkyl, CF.sub.3, (CR.sup.dR.sup.d).sub.0-1C.sub.3-6 cycloalkyl substituted with 0-4 R.sup.4, or phenyl substituted with 0-4 R.sup.4; R.sup.4 is halo, CN, CH.sub.3, or CF.sub.3; R.sup.6 is C.sub.1-6 alkyl, CF.sub.3, or C.sub.3-6 cycloalkyl substituted with 0-2 F substituents; R.sup.7 is H; R.sup.8 is halo, N(C.sub.1-3 alkyl).sub.2, OC.sub.1-3 alkyl substituted with 0-1 OC.sub.1-4 alkyl substituent; R.sup.9 is ##STR00317## R.sup.10 is halo, C.sub.1-4 alkyl, OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-2 R.sup.13, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.e; R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, or C(O)OC.sub.1-4 alkyl; R.sup.11b is OH; R.sup.12 is C.sub.1-3 alkyl substituted with 0-3 halo substituents or C(O)OR.sup.b; R.sup.13 is OH; R.sup.a is H or C.sub.1-3 alkyl; R.sup.b is H or C.sub.1-4 alkyl substituted with 0-1 R.sup.e; R.sup.e is OR.sup.f; and R.sup.f is H or C.sub.1-6 alkyl.

16. The compound of claim 1, having Formula (X): ##STR00318## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is C.sub.1-2 alkyl substituted with C.sub.3-6 cycloalkyl substituent; R.sup.2 is H; or R.sup.1 and R.sup.2 are combined to be CR.sup.6R.sup.7; R.sup.3 is C.sub.1-6 alkyl substituted with 0-5 halo, CN, or OC.sub.1-3 alkyl substituents, (CHR.sup.d).sub.nC.sub.3-10-carbocyclyl substituted with 0-5 R.sup.4, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S, N, and substituted with 0-3 R.sup.4; R.sup.4 is halo, S(O).sub.2CF.sub.3, CN, or C.sub.1-4 alkyl substituted with 0-5 halo substituents; R.sup.6 is halo, C.sub.1-5 alkyl substituted with 0-3 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, or 5- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, and N, and substituted with 0-3 R.sup.14; R.sup.6a is halo, OH, or C.sub.3-6 cycloalkyl; R.sup.7 is H; R.sup.8 is H, halo, CN, C.sub.1-4 alkyl, or OC.sub.1-4 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, or OC.sub.1-4 alkyl substituents; R.sup.9 is ##STR00319## R.sup.10 is halo, CN, C.sub.1-4 alkyl, or OH; R.sup.11 is C.sub.1-3 alkyl substituted with 0-3 R.sup.12 and 0-1 R.sup.3, OR.sup.b, NHC(O)R.sup.b, or C(O)OR.sup.b; R.sup.12 is halo; R.sup.13 is OR.sup.b or C.sub.3-6 carbocyclyl; R.sup.14 is halo, CN, or C.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.b is H or C.sub.1-3 alkyl substituted with 0-5 R.sup.e; R.sup.d is H or C.sub.1-4 alkyl; R.sup.e is OH; and n is zero or 1.

17. The compound of claim 16, having formula (XI): ##STR00320## or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is C.sub.1-5 alkyl or ##STR00321## R.sup.4 is halo, CN, S(O).sub.2CF.sub.3, C.sub.1-4 alkyl substituted with 0-5 halo substituents; R.sup.6 is C.sub.1-5 alkyl substituted with 0-2 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.14, or 5- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, and N, and substituted with 0-2 R.sup.14; R.sup.6a is halo, OH, or C.sub.3-6 cycloalkyl; R.sup.7 is H; R.sup.8 is OC.sub.1-3 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, or OC.sub.1-3 alkyl substituents; R.sup.8a is H, halo, CN, or C.sub.1-3 alkyl; R.sup.9 is ##STR00322## R.sup.10 is halo, CN, C.sub.1-4 alkyl, or OH; R.sup.11 is C.sub.1-3 alkyl substituted with 0-3 R.sup.11 and 0-1 R.sup.13, OR.sup.b, NHC(O)R.sup.b, or C(O)OR.sup.b; R.sup.12 is halo; R.sup.13 is OR.sup.b or C.sub.3-6 carbocyclyl; R.sup.14 is halo or C.sub.1-4 alkyl substituted with 0-3 halo substituents; R.sup.b is H or C.sub.1-3 alkyl substituted with 0-5 R.sup.e; R.sup.d is H or C.sub.1-2 alkyl; and n is zero or 1.

18. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

19. A method for treating a relaxin-associated disease comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 18 to a patient in need thereof.

20. The method of claim 19 wherein the disease is selected from the group consisting of angina pectoris, unstable angina, myocardial infarction, heart failure, acute coronary disease, acute heart failure, chronic heart failure, and cardiac iatrogenic damage.

21. The method of claim 20 wherein the disease is heart failure.

22. The method of claim 19 wherein the disease is fibrosis.

Description

DESCRIPTION OF THE INVENTION

[0017] The invention encompasses compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them.

[0018] In a first aspect, the present invention provides, inter alia, compounds of Formula (I):

##STR00002##

or pharmaceutically acceptable salts thereof, wherein: [0019] L is O or NH; [0020] R.sup.1 is C.sub.1-3 alkyl substituted with 0-1 aryl or C.sub.3-6 cycloalkyl substituent; [0021] R.sup.2 is H; provided when R.sup.1 is C.sub.1-3 alkyl substituted with 0 aryl or C.sub.3-6 cycloalkyl substituents, R.sup.9 is not absent; [0022] or R.sup.1 and R.sup.2 are combined to be CR.sup.6R.sup.7 or NOC.sub.1-4 alkyl wherein is a double bond; or R.sup.1 and R.sup.2 together with the carbon atom to which they are both attached form a dioxolanyl substituted with 0-1 aryl substituent; [0023] R.sup.3 is C.sub.1-8 alkyl substituted with 0-5 halo, CN, OH, or OC.sub.1-3 alkyl substituents, (CR.sup.dR.sup.d).sub.nC.sub.3-10-carbocyclyl substituted with 0-5 R.sup.4, or (CR.sup.dR.sup.d).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-5 R.sup.4; [0024] R.sup.4 is halo, CN, OH, SF.sub.5, S(O).sub.pR.sup.c, C.sub.1-4 alkyl substituted with 0-5 halo, OH, or OC.sub.1-4 alkyl substituents, OC.sub.1-4 alkyl substituted with 0-5 halo substituents, (CR.sup.dR.sup.d).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CR.sup.dR.sup.d).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-5 R.sup.e; [0025] R.sup.4c is H, C.sub.1-4 alkyl, or S(O).sub.2CF.sub.3; [0026] each R.sup.5 is H, halo, OH, C.sub.1-4 alkyl substituted with 0-5 halo substituents, or OC.sub.1-4 alkyl substituted with 0-5 halo substituents; [0027] R.sup.6 is H, halo, CN, C.sub.1-7 alkyl substituted with 0-3 R.sup.6a C.sub.2-7 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, CONR.sup.6bR.sup.6b, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.14, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, or NR.sup.14a, and substituted with 0-5 R.sup.14; [0028] R.sup.6a is halo, OH, OC.sub.1-4 alkyl, C.sub.1-4 alkyl, aryl, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; [0029] R.sup.6b is H, C.sub.1-4 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; [0030] R.sup.7 is H or C.sub.1-4 alkyl; [0031] or R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indenyl; [0032] R.sup.8 is H, halo, CN, NR.sup.7R.sup.7, C.sub.1-4 alkyl substituted with 0-5 halo or OH substituents, or OC.sub.1-4 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, aryl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OC.sub.1-3 alkyl substituted with 0-1 OC.sub.1-3 alkyl substituents; [0033] R.sup.9 is aryl substituted with 0-3 R.sup.10 and 0-2 R.sup.11 or 3- to 12-membered heterocyclyl comprising 1-5 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-2 R.sup.11; [0034] R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; [0035] R.sup.11 is C.sub.1-5 alkyl substituted with 0-4 R.sup.12 and 0-2 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-9 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; [0036] R.sup.11a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, aryl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e. [0037] R.sup.11b is halo, OH, C(O)OH, C(O)OC.sub.1-4 alkyl, or aryl; [0038] R.sup.12 is halo, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aOR.sup.b, C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents, or C.sub.3-6 cycloalkyl; [0039] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, S(O).sub.pR.sup.c, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0040] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.nNR.sup.aR.sup.a, (CH.sub.2).sub.n-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0041] R.sup.14a is H, C(O)C.sub.1-4 alkyl, or C.sub.1-3 alkyl substituted with 0-3 Si(C.sub.1-3 alkyl).sub.3 or aryl substituted with 0-2 halo substituents; [0042] R.sup.15 is H, C.sub.1-4 alkyl, or aryl; [0043] R.sup.a is H, OC.sub.1-6 alkyl, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0044] R.sup.b is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0045] R.sup.c is C.sub.16 alkyl substituted with 0-5 R.sup.e, C.sub.2-6 alkenyl substituted with 0-5 R.sup.e, C.sub.2-6 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0046] R.sup.d is H, C.sub.1-4 alkyl, or C.sub.3-6 cycloalkyl; [0047] R.sup.e is halo, CN, NO.sub.2, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, S(O).sub.pNR.sup.fR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; [0048] R.sup.f is H, C.sub.1-6 alkyl substituted with 0-2 OH or OC.sub.1-4 alkyl substituents, C.sub.3-6 cycloalkyl, aryl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N and; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; [0049] R.sup.g is halo, CN, OH, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0050] n is zero, 1, 2, or 3; and [0051] p is zero, 1, or 2.

[0052] In a second aspect within the scope of the first aspect, the present invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein: [0053] R.sup.3 is C.sub.1-6 alkyl substituted with 0-4 halo or OH substituents, (CHR.sup.d).sub.0-1C.sub.3-6 cycloalkyl substituted with 0-4 R.sup.4, C.sub.6-9 spirocycloalkyl substituted with 0-4 R.sup.4, C.sub.6-10 bicyclic carbocyclyl substituted with 0-4 R.sup.4, or 3 to 6-membered heterocyclyl comprising 1-2 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.4c, and substituted with 0-4 R.sup.4; [0054] R.sup.4 is halo or C.sub.1-3 alkyl substituted with 0-4 halo substituents; [0055] R.sup.4c is H or C.sub.1-4 alkyl; [0056] R.sup.d is C.sub.1-3 alkyl.

[0057] In a third aspect within the scope of the first aspect, the present invention provides compounds of Formula (II):

##STR00003##

or pharmaceutically acceptable salts thereof, wherein: [0058] R.sup.4 is halo, S(O).sub.pC.sub.1-4 alkyl substituted with 0-4 halo substituents, C.sub.1-4 alkyl substituted with 0-4 halo substituents, OC.sub.1-4 alkyl substituted with 0-4 halo substituents; [0059] R.sup.5 is H or halo; [0060] R.sup.6 is halo, CN, C.sub.1-7 alkyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-7 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, CONR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, aryl substituted with 0-3 R.sup.14, or 4- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a and substituted with 0-3 R.sup.14; [0061] R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or aryl; [0062] R.sup.6b is H, C.sub.1-4 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; [0063] R.sup.7 is H or C.sub.1-3 alkyl; [0064] R.sup.8 is halo, CN, N(C.sub.1-2 alkyl).sub.2, C.sub.1-4 alkyl substituted with 0-5 halo or OH substituents, or OC.sub.1-4 alkyl substituted with 0-4 halo, OH, aryl, or OC.sub.1-4 alkyl substituents; [0065] R.sup.9 is C.sub.6 aryl substituted with 0-3 R.sup.10 and 0-2 R.sup.11, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-1 R.sup.11; [0066] R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; [0067] R.sup.11 is C.sub.1-4 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; [0068] R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; [0069] R.sup.11b is OH, C(O)OH, or aryl; [0070] R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; [0071] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; [0072] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-3-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-3-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0073] R.sup.14a is H, C(O)C.sub.1-4 alkyl, or C.sub.1-3 alkyl substituted with 0-3 aryl substituted with 0-2 halo substituents; [0074] R.sup.15 is H, C.sub.1-3 alkyl, or aryl; [0075] R.sup.a is H, C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0076] R.sup.b is H, C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0077] R.sup.c is C.sub.1-5 alkyl substituted with 0-5 R.sup.e, C.sub.2-5 alkenyl substituted with 0-5 R.sup.e, C.sub.2-5 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl substituted with 0-5 R.sup.e, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0078] R.sup.d is H or C.sub.1-4 alkyl; [0079] R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.n-aryl substituted with 0 5 R.sup.g, (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; [0080] R.sup.f is H, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; [0081] R.sup.g is halo, CN, OH, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0082] n is zero, 1, 2, or 3; and [0083] p is zero, 1, or 2.

[0084] In a fourth aspect within the scope of the first aspect, the present invention provides compounds of Formula (III):

##STR00004##

or pharmaceutically acceptable salts thereof, wherein: [0085] R.sup.4a is halo; [0086] R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; [0087] R.sup.5 is H or F; [0088] R.sup.6 is halo, C.sub.1-4 alkyl substituted with 0-3 R.sup.6a, C.sub.2-4 alkenyl substituted with 0-1 phenyl or OH substituent, C(O)OR.sup.6b, C(O)NHR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, naphthyl substituted with 0-3 R.sup.14, or 5- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, N, and NR.sup.14a and substituted with 0-3 R.sup.14; [0089] R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or phenyl; [0090] R.sup.6b is H or C.sub.1-4 alkyl; [0091] R.sup.7 is H or C.sub.1-3 alkyl; [0092] or R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indenyl; [0093] R.sup.8 is N(C.sub.1-4 alkyl).sub.2 or OC.sub.1-4 alkyl substituted with 0-1 OC.sub.1-4 alkyl substituent; [0094] R.sup.8a is halo; [0095] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e. [0096] R.sup.14a is H, C(O)C.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-3 aryl substituted with 0-2 halo substituents; [0097] R.sup.a is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.n-phenyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0098] R.sup.b is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.0-1-phenyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0099] R.sup.e is halo, CN, O, C.sub.1-6 alkyl, or C(O)OH; and [0100] n is zero, 1, 2, or 3.

[0101] In a fifth aspect within the scope of the first to third aspects, the present invention provides compounds of Formula (IV):

##STR00005##

or pharmaceutically acceptable salts thereof, wherein: [0102] R.sup.4 is halo, C.sub.1-4 alkyl substituted with 0-3 halo substituents, or OC.sub.1-4 alkyl substituted with 0-3 halo substituents; [0103] R.sup.5 is H or F; [0104] R.sup.6 is halo, CN, C.sub.1-6 alkyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkynyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)NR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a, and substituted with 0-3 R.sup.14; [0105] R.sup.6a is halo, C.sub.3-6 cycloalkyl, or phenyl; [0106] R.sup.6b is H, C.sub.1-3 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents; [0107] R.sup.7 is H or C.sub.1-2 alkyl; [0108] R.sup.8 is OC.sub.1-4 alkyl substituted with 0-4 halo, OH, aryl or OC.sub.1-4 alkyl substituents; [0109] R.sup.10 is halo, CN, C.sub.1-3 alkyl, OH, or OC.sub.1-4 alkyl; [0110] R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; [0111] R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; [0112] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; [0113] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e. [0114] R.sup.14a is H, C(O)C.sub.1-3alkyl, C.sub.1-3 alkyl substituted with 0-2 aryl substituted with 0-2 halo substituents; [0115] R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; [0116] R.sup.a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0117] R.sup.b is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0118] R.sup.c is C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; [0119] R.sup.e is halo, CN, NO.sub.2, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl, (CH.sub.2).sub.n-aryl, (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, (CH.sub.2).sub.nOR.sup.f, S(O).sub.pR.sup.f, C(O)NR.sup.fR.sup.f, C(O)OR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pNR.sup.fR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; [0120] R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; [0121] R.sup.g is halo, CN, OH, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0122] n is zero, 1, 2, or 3; and [0123] p is zero, 1, or 2.

[0124] In a sixth aspect within the scope of the fifth aspect, the present invention provides compounds of Formula (V):

##STR00006##

or pharmaceutically acceptable salts thereof, wherein: [0125] R.sup.4a is halo or C.sub.1-2 alkyl; [0126] R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; [0127] R.sup.5 is H or F; [0128] R.sup.6 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 R.sup.6a, C.sub.2-4 alkenyl substituted with 0-3 R.sup.6a, C(O)OR.sup.6b, C(O)ONR.sup.6bR.sup.6b, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a and substituted with 0-3 R.sup.14; [0129] R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or phenyl; [0130] R.sup.6b is H, C.sub.1-3 alkyl substituted with 0-1 aryl substituent, or C.sub.3-6 cycloalkyl; [0131] R.sup.7 is H or C.sub.1-2 alkyl; [0132] R.sup.8 is OC.sub.1-4 alkyl substituted with 0-4 halo, OH, OC.sub.1-4 alkyl, or aryl substituents; [0133] R.sup.10 is halo or C.sub.1-3 alkyl; [0134] R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-1 R.sup.13, OH, OC.sub.1-4 alkyl, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-3 R.sup.e; [0135] R.sup.12 is halo, C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; [0136] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, or OC(O)NR.sup.aOR.sup.b; [0137] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-1-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-1-3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0138] R.sup.14a is H, C(O)C.sub.1-3 alkyl, C.sub.1-3 alkyl substituted with 0-1 aryl substituted with 0-2 halo substituents; [0139] R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; [0140] R.sup.a is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0141] R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-5 R.sup.e, or (CH.sub.2).sub.n-3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-5 R.sup.e; [0142] R.sup.c is C.sub.1-4 alkyl substituted with 0-5 R.sup.e, C.sub.2-4 alkenyl substituted with 0-5 R.sup.e, C.sub.2-4 alkynyl substituted with 0-5 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; [0143] R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-5 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl, (CH.sub.2).sub.n-aryl, (CH.sub.2).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, (CH.sub.2).sub.nOR.sup.f, S(O).sub.pR.sup.f, C(O)NR.sup.fR.sup.f, C(O)OR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pNR.sup.fR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; [0144] R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; [0145] R.sup.g is, halo CN, OH, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0146] n is zero, 1, 2, or 3; and [0147] p is zero, 1, or 2.

[0148] In one embodiment of Formula (V), R.sup.4a is F or CH.sub.3; R.sup.4b is CF.sub.3; R.sup.6 is phenyl or 5-membered heteroaryl comprising 1-2 heteroatoms selected from 0 and N; R.sup.7 is H; R.sup.8 is OC.sub.1-2alkyl; R.sup.10 is halo; R.sup.11 is CH.sub.3, CH.sub.2CH.sub.3, CF.sub.3 OCF.sub.3, NHS(O).sub.2C.sub.1-2 alkyl, C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl substituted with 0-1 R.sup.e, or a 5-membered heterocyclyl comprising 1-4 heteroatoms selected from O, N, and NR.sup.15 and substituted with 0-3 R.sup.e; R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; and R.sup.e is O or C(O)OH.

[0149] In a seventh aspect within the scope of the sixth aspect, the present invention provides compounds of Formula (V) or pharmaceutically acceptable salts thereof, wherein: [0150] R.sup.4a is halo; [0151] R.sup.4b is CF.sub.3; [0152] R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 halo substituents or C.sub.3-6 cycloalkyl substituted with 0-3 halo substituents; [0153] R.sup.8 is OC.sub.1-4alkyl; [0154] R.sup.10 is F; [0155] R.sup.11 is OH, OC.sub.1-4 alkyl, NR.sup.aC(O)R.sup.b, NR.sup.aS(O).sub.pR.sup.c, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, 4 to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-5 R.sup.e; [0156] R.sup.15 is H or C.sub.1-2 alkyl; [0157] R.sup.a is H or C.sub.1-4 alkyl substituted with 0-5 R.sup.e; [0158] or R.sup.a and R.sup.a together is

##STR00007## [0159] R.sup.b is H or C.sub.1-4 alkyl substituted with 0-5 R.sup.e; [0160] R.sup.c is C.sub.1-3 alkyl substituted with 0-5 R.sup.e or C.sub.3-6 carbocyclyl; [0161] R.sup.e is halo, O, C.sub.1-4 alkyl substituted with 0-5 R.sup.g, C(O)OH, OR.sup.f, or NR.sup.fR.sup.f; and [0162] R.sup.f is H and C.sub.1-6 alkyl; or R.sup.f and R.sup.f together with the nitrogen atom to which they are both attached form a heterocyclyl; and [0163] R.sup.g is halo.

[0164] In an eighth aspect within the scope of the six aspect, the present invention provides compounds of Formula (VI):

##STR00008##

or pharmaceutically acceptable salts thereof, wherein: [0165] R.sup.4a is halo; [0166] R.sup.4b is CF.sub.3; [0167] R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 halo substituents or C.sub.3-6 cycloalkyl substituted with 0-3 halo substituents; [0168] R.sup.7 is H; [0169] R.sup.8 is-OC.sub.1-4alkyl substituted with 0-1 aryl substituent; [0170] R.sup.10 is halo; [0171] R.sup.12 is C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl, C(O)NHOC.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-3 halo substituents; [0172] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, or OC(O)NR.sup.aOR.sup.b; [0173] R.sup.a is H, C.sub.1-4 alkyl substituted with 0-5 halo substituents, phenyl substituted with 0-4 R.sup.e, C.sub.3-10 cycloalkyl substituted with 0-4 R.sup.e, spirocycloalkyl substituted with 0-4 R.sup.e, or 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from 0, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0174] R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.n-phenyl substituted with 0-4 R.sup.e, C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0175] R.sup.c is C.sub.1-4 alkyl substituted with 0-4 R.sup.e, [0176] R.sup.e is halo, CN, O, C.sub.1-5 alkyl substituted with 0-5 R.sup.g, C.sub.3-6 cycloalkyl, aryl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OR.sup.f; [0177] R.sup.f is H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl or aryl; [0178] R.sup.g is halo; [0179] n is zero or 1; and [0180] p is zero, 1, or 2.

[0181] In a ninth aspect within the scope of the eighth aspect, the present invention provides compounds of Formula (VI) or pharmaceutically acceptable salts thereof, wherein: [0182] R.sup.4a is F [0183] R.sup.4b is CF.sub.3; [0184] R.sup.6 is CF.sub.3 or C.sub.3-6 cycloalkyl; [0185] R.sup.8 is OCH.sub.3 or OCH.sub.2-phenyl; [0186] R.sup.10 is F; [0187] R.sup.12 is C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl, C(O)NHOC.sub.1-4 alkyl, CH.sub.3, CHF.sub.2, or CF.sub.3; [0188] R.sup.13 is OH, NR.sup.aR.sup.a, NHC(O)R.sup.b, NHS(O).sub.pC.sub.1-4 alkyl, OC(O)NR.sup.aR.sup.a, or OC(O)NHOC.sub.1-4 alkyl; [0189] R.sup.a is H, C.sub.1-4 alkyl substituted with 0-4 F substituents,

##STR00009## [0190] or R.sup.a and R.sup.a together is

##STR00010## [0191] R.sup.b is H, C.sub.1-4 alkyl substituted with 0-5 R.sup.e, phenyl, or

##STR00011## and [0192] R.sup.e is halo, O, aryl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, or OR.sup.f; and [0193] R.sup.f is H, C.sub.1-3 alkyl, C.sub.3-6 cycloalkyl, or phenyl.

[0194] In a tenth aspect within the scope of the third aspect, the present invention provides compounds of Formula (VII):

##STR00012##

or pharmaceutically acceptable salts thereof, wherein: [0195] R.sup.4a is halo; [0196] R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents, or OC.sub.1-4 alkyl substituted with 0-3 halo substituents; [0197] R.sup.5 is H or F; [0198] R.sup.6 is halo, CN, C.sub.1-6 alkyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkenyl substituted with 0-3 R.sup.6a, C.sub.2-6 alkynyl substituted with 0-3 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, or 5- to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.14a, and substituted with 0-3 R.sup.14; [0199] R.sup.6a is halo, C.sub.3-6 cycloalkyl, or phenyl; [0200] R.sup.7 is H or C.sub.1-2 alkyl; [0201] R.sup.8 is halo, CN, or OC.sub.1-4 alkyl substituted with 0-4 halo, OH, or OC.sub.1-4 alkyl substituents; [0202] R.sup.8a is halo or CN; [0203] R.sup.9 is a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-1 R.sup.11; [0204] R.sup.10 is halo, CN, C.sub.1-3 alkyl, O, OH, or OC.sub.1-3 alkyl; [0205] R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aC(O)NR.sup.aR.sup.a, NR.sup.aS(O).sub.pR.sup.c, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C(O)NR.sup.aS(O).sub.pR.sup.c, OC(O)R.sup.b, S(O).sub.pR.sup.c, S(O).sub.pNR.sup.aR.sup.a, C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; [0206] R.sup.11aa is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, C.sub.3-6 cycloalkyl, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-4 R.sup.e; [0207] R.sup.11b is OH, C(O)OH, or aryl; [0208] R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; [0209] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; [0210] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo, OC.sub.1-4 alkyl substituted with 0-3 halo, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0211] R.sup.14a is H, C(O)C.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-2 aryl substituted with 0-2 halo substituents; [0212] R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; [0213] R.sup.a is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0214] R.sup.b is H, C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, (CH.sub.2).sub.nC.sub.3-10 carbocyclyl substituted with 0-4 R.sup.e, or (CH.sub.2).sub.n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0215] R.sup.c is C.sub.1-5 alkyl substituted with 0-4 R.sup.e, C.sub.2-5 alkenyl substituted with 0-4 R.sup.e, C.sub.2-5 alkynyl substituted with 0-4 R.sup.e, C.sub.3-6 carbocyclyl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N; [0216] R.sup.e is halo, CN, O, C.sub.1-6 alkyl substituted with 0-4 R.sup.g, C.sub.2-6 alkenyl substituted with 0-5 R.sup.g, C.sub.2-6 alkynyl substituted with 0-5 R.sup.g, (CH.sub.2).sub.nC.sub.3-6 cycloalkyl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-aryl substituted with 0-4 R.sup.g, (CH.sub.2).sub.n-4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.g, (CH.sub.2).sub.nOR.sup.f, C(O)OR.sup.f, C(O)NR.sup.fR.sup.f, NR.sup.fC(O)R.sup.f, S(O).sub.pR.sup.f, NR.sup.fS(O).sub.pR.sup.f, NR.sup.fC(O)OR.sup.f, OC(O)NR.sup.fR.sup.f, or (CH.sub.2).sub.nNR.sup.fR.sup.f; [0217] R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0218] R.sup.g is halo, CN, OH, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, or aryl; [0219] n is zero, 1, 2, or 3; and [0220] p is zero, 1, or 2.

[0221] In an eleventh aspect within the scope of the tenth aspect, the present invention provides compounds of Formula (VII) or pharmaceutically acceptable salts, thereof, wherein: [0222] R.sup.4a is halo; [0223] R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents; [0224] R.sup.5 is H; [0225] R.sup.6 is C.sub.1-2 alkyl substituted with 0-2 F substituents or C.sub.3-6 cycloalkyl; [0226] R.sup.8 is OC.sub.1-3 alkyl; [0227] R.sup.8a is F or CN; [0228] R.sup.9 is

##STR00013## [0229] R.sup.10 is halo, CN, C.sub.1-2 alkyl, O, OH, or OC.sub.1-2 alkyl; [0230] R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, C(O)R.sup.b, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.3-6 cycloalkyl substituted with 0-5 R.sup.e; [0231] R.sup.11a is H, C(O)R.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.1-4 alkyl substituted with 0-1 R.sup.11b; [0232] R.sup.11b is OH or aryl; [0233] R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-2 halo or OH substituents; [0234] R.sup.13 is OH, OC.sub.1-4 alkyl substituted with 0-2 OH substituents, or S(O).sub.2C.sub.1-4alkyl; [0235] R.sup.a is H or C.sub.1-6 alkyl or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a 3 to 9-membered heterocyclyl substituted with 0-4 R.sup.e; [0236] R.sup.b is H, C.sub.1-4 alkyl substituted with 0-1 R.sup.e, or C.sub.3-6 cycloalkyl substituted with 0-1 R.sup.e; [0237] R.sup.e is OR.sup.f; and [0238] R.sup.f is H or C.sub.1-4 alkyl.

[0239] In a twelfth aspect within the scope of the eleventh aspect, the present invention provides compounds of Formula (VII) or pharmaceutically acceptable salts thereof, wherein: [0240] R.sup.4a is halo; [0241] R.sup.4b is CF.sub.3; [0242] R.sup.5 is H; [0243] R.sup.6 is CF.sub.3 or C.sub.3-6 cyclopropyl; [0244] R.sup.8 is OC.sub.1-3 alkyl; [0245] R.sup.9 is

##STR00014## [0246] R.sup.10 is C.sub.1-2 alkyl, OH, or OC.sub.1-4 alkyl; [0247] R.sup.11 is C.sub.1-2 alkyl substituted with 0-1 R.sup.1 and 0-1 R.sup.13, C(O)OR.sup.b, or C(O)NR.sup.a; [0248] R.sup.12 is C(O)OR.sup.b; [0249] R.sup.13 is OH; [0250] R.sup.a is H or C.sub.1-4 alkyl; and [0251] R.sup.b is H or C.sub.1-4 alkyl.

[0252] In a thirteenth aspect within the scope of the tenth aspect, the present invention provides compounds of Formula (VI) or pharmaceutically acceptable salts thereof, wherein: [0253] R.sup.4a is halo; [0254] R.sup.4b is C.sub.1-4 alkyl substituted with 0-3 halo substituents; [0255] R.sup.5 is H; [0256] R.sup.6 is C.sub.1-3 alkyl substituted with 0-3 F substituents or C.sub.3-6 cycloalkyl; [0257] R.sup.8 is OC.sub.1-3 alkyl; [0258] R.sup.9 is

##STR00015## ##STR00016## [0259] R.sup.10 is halo, C.sub.1-3 alkyl, OH, or OC.sub.1-3 alkyl; [0260] R.sup.11 is C.sub.1-3 alkyl substituted with 0-1 R.sup.11 and 0-1 R.sup.13 or C(O)NH.sub.2; [0261] R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, or C(O)OC.sub.1-4 alkyl; [0262] R.sup.11b is OH, C(O)OH, or aryl; [0263] R.sup.12 is C(O)OR.sup.b or C.sub.1-3 alkyl substituted with 0-3 halo substituents; [0264] R.sup.13 is OH; and [0265] R.sup.b is H or C.sub.1-4 alkyl.

[0266] In one embodiment of Formula (VII), R.sup.4a is F; R.sup.4b is CF.sub.3; R.sup.5 is H; R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 F substituents or C.sub.3-6 cycloalkyl; R.sup.8 is OCH.sub.3 or OCH.sub.3(CH.sub.2).sub.2OCH.sub.3; R.sup.9 is

##STR00017## [0267] R.sup.11 is C.sub.1-2 alkyl substituted with 0-1 R.sup.13; [0268] R.sup.11a is H, C.sub.1-3 alkyl substituted with 0-2 R.sup.11b, C(O)C.sub.1-4 alkyl substituted with 0-1 R.sup.11b, or C(O)OC.sub.1-4 alkyl; and R.sup.11b is OH, C(O)OH, or aryl; and [0269] R.sup.13 is OH.

[0270] In one embodiment of Formula (VII), R.sup.4a is F; R.sup.4b is CF.sub.3; R.sup.5 is H; R.sup.6 is C.sub.1-3 alkyl substituted with 0-3 F substituents or C.sub.3-6 cycloalkyl; R.sup.8 is OCH.sub.3; R.sup.9 is

##STR00018## [0271] R.sup.11a is H or C.sub.1-2 alkyl substituted with 0-1 R.sup.11b; and R.sup.11b is C(O)OH.

[0272] In a fourteenth aspect within the scope of the third aspect, the present invention provides compounds of Formula (VIII):

##STR00019##

or pharmaceutically acceptable salts thereof, wherein: [0273] R.sup.4a is halo; [0274] R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; [0275] R.sup.6 is C.sub.1-2 alkyl substituted with 0-2 F substituents, C.sub.3-6 cycloalkyl, or aryl; [0276] R.sup.7 is H; [0277] R.sup.8 is OC.sub.1-3 alkyl; [0278] R.sup.9 is

##STR00020## [0279] R.sup.10 is halo, CN, C.sub.1-4 alkyl, O, OH, or OC.sub.1-4 alkyl; [0280] R.sup.11 is C.sub.1-2 alkyl substituted with 0-1 R.sup.12 and 0-1 R.sup.13, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, or C(O)OR.sup.b; [0281] R.sup.12 is C(O)OR.sup.b, C(O)NHR.sup.a, C(O)NHOR.sup.b, or C.sub.1-4 alkyl substituted with 0-3 halo or OH substituents; [0282] R.sup.13 is OH or NR.sup.aC(O)R.sup.b; [0283] R.sup.a is H or C.sub.1-4 alkyl; and [0284] R.sup.b is H, C.sub.1-4 alkyl, or 3 to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N.

[0285] In one embodiment of Formula (VIII), R.sup.4a is F; R.sup.4b is CF.sub.3; R.sup.5 is H; R.sup.6 is CF.sub.3 or cyclopropyl; R.sup.8 is OCH.sub.3; R.sup.9 is

##STR00021##

[0286] In a fifteenth aspect within the scope of the first aspect, the present invention provides compounds of Formula (IX):

##STR00022##

or a pharmaceutically acceptable salt thereof, wherein: [0287] R.sup.3 is C.sub.1-6 alkyl, CF.sub.3, (CR.sub.dR.sub.d).sub.0-1C.sub.3-6 cycloalkyl substituted with 0-4 R.sup.4, or phenyl substituted with 0-4 R.sup.4; [0288] R.sup.4 is halo, CN, CH.sub.3, or CF.sub.3; [0289] R.sup.5 is H; [0290] R.sup.6 is C.sub.1-5 alkyl, CF.sub.3, or C.sub.3-6 cycloalkyl substituted with 0-2 F substituents; [0291] R.sup.7 is H; [0292] R.sup.8 is halo, N(C.sub.1-3 alkyl).sub.2, OC.sub.1-3 alkyl substituted with 0-1 OC.sub.1-4 alkyl substituent; [0293] R.sup.9 is

##STR00023## [0294] R.sup.10 is halo, C.sub.1-4 alkyl, OH, or OC.sub.1-4 alkyl; [0295] R.sup.11 is C.sub.1-4 alkyl substituted with 0-2 R.sup.12 and 0-2 R.sup.13, C(O)OR.sup.b, C(O)NR.sup.aR.sup.a, or C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.e. [0296] R.sup.11a is H, C.sub.1-4 alkyl substituted with 0-2 R.sup.11b, C(O)R.sup.b, or C(O)OC.sub.1-4 alkyl; [0297] R.sup.11b is OH; [0298] R.sup.12 is C.sub.1-3 alkyl substituted with 0-3 halo substituents or C(O)OR.sup.b; [0299] R.sup.13 is OH; [0300] R.sup.a is H or C.sub.1-3 alkyl; [0301] R.sup.b is H or C.sub.1-4 alkyl substituted with 0-1 R.sup.e; [0302] R.sup.e is OR.sup.f; and [0303] R.sup.f is H or C.sub.1-6 alkyl.

[0304] In a sixteenth aspect within the scope of the first aspect, the present invention provides compounds of Formula (X):

##STR00024##

or a pharmaceutically acceptable salt thereof, wherein: [0305] R.sup.1 is C.sub.1-2 alkyl substituted with C.sub.3-6 cycloalkyl; [0306] R.sup.2 is H; [0307] or R.sup.1 and R.sup.2 are combined to be CR.sup.6R.sup.7; [0308] R.sup.3 is C.sub.1-6 alkyl substituted with 0-5 halo, CN, or OC.sub.1-3 alkyl substituents, (CHR.sup.d).sub.nC.sub.3-10carbocyclyl substituted with 0-5 R.sup.4, or 5 to 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, S(O).sub.p, N, and substituted with 0-3 R.sup.4; [0309] R.sup.4 is halo, CN, S(O).sub.2CF.sub.3, or C.sub.1-4 alkyl substituted with 0-5 halo substituents; [0310] R.sup.6 is halo, C.sub.1-5 alkyl substituted with 0-3 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, or 5 to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, and N, and substituted with 0-3 R.sup.14; [0311] R.sup.6a is halo, OH, or C.sub.3-6 cycloalkyl; [0312] R.sup.7 is H; [0313] R.sup.8 is H, halo, CN, C.sub.1-4 alkyl, or OC.sub.1-4 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, or OC.sub.1-4 alkyl substituents; [0314] R.sup.9 is

##STR00025## [0315] R.sup.10 is halo, CN, C.sub.1-4 alkyl, or OH; [0316] R.sup.11 is C.sub.1-3 alkyl substituted with 0-3 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NHC(O)R.sup.b, or C(O)OR.sup.b; [0317] R.sup.12 is halo; [0318] R.sup.13 is OR.sup.b or C.sub.3-6 carbocyclyl; [0319] R.sup.14 is halo, CN, or C.sub.1-4 alkyl substituted with 0-3 halo substituents; [0320] R.sup.b is H or C.sub.1-3 alkyl substituted with 0-5 R.sup.e; [0321] R.sup.d is H or C.sub.1-4 alkyl; [0322] R.sup.e is OH; and [0323] n is zero or 1.

[0324] In a seventeenth aspect within the scope of the first aspect, the present invention provides compounds of Formula (XI):

##STR00026##

or a pharmaceutically acceptable salt thereof, wherein: [0325] R.sup.3 is C.sub.1-5 alkyl or

##STR00027## [0326] R.sup.4 is halo, CN, S(O).sub.2CF.sub.3, or C.sub.1-4 alkyl substituted with 0-5 halo substituents; [0327] R.sup.6 is C.sub.1-5 alkyl substituted with 0-4 R.sup.6a, C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.14, or 5 to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, and N, and substituted with 0-2 R.sup.14; [0328] R.sup.6a is halo, OH, or C.sub.3-6 cycloalkyl; [0329] R.sup.7 is H; [0330] R.sup.8 is OC.sub.1-3 alkyl substituted with 0-5 halo, OH, C.sub.3-6 cycloalkyl, or OC.sub.1-3 alkyl substituents; [0331] R.sup.8a is H, halo, CN, or C.sub.1-3 alkyl; [0332] R.sup.9 is

##STR00028## [0333] R.sup.10 is halo, CN, C.sub.1-4 alkyl, or OH; [0334] R.sup.11 is C.sub.1-3 alkyl substituted with 0-3 R.sup.12 and 0-1 R.sup.13, OR.sup.b, NHC(O)R.sup.b, or C(O)OR.sup.b; [0335] R.sup.12 is halo; [0336] R.sup.13 is OR.sup.b or C.sub.3-6 carbocyclyl; [0337] R.sup.14 is halo or C.sub.1-4 alkyl substituted with 0-3 halo substituents; [0338] R.sup.b is H or C.sub.1-3 alkyl substituted with 0-5 R.sup.e; [0339] R.sup.d is H or C.sub.1-2 alkyl; and [0340] n is zero or 1.

[0341] For a compound of Formula (I), the scope of any instance of a variable substituent, including R.sup.1, R.sup.2, R.sup.3, R.sup.4 (R.sup.4a, R.sup.4b), R.sup.4c, R.sup.5, R.sup.6, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8 (R.sup.8a), R.sup.9, R.sup.10, R.sup.11, R.sup.11a, R.sup.11b, R.sup.12, R.sup.13, R.sup.14, R.sup.14a, R.sup.15, R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f, and R.sup.g can be used independently with the scope ofany other instance of a variable substituent. As such, the invention includes combinations of the different aspects. In particular, R.sup.4a and R.sup.4b are a subset of variable R.sup.4 and R.sup.8a subset of variable R.sup.8.

[0342] In one embodiment of Formula (XI), R.sup.3 is

##STR00029##

R.sup.4 is halo, CF.sub.3, or OCF.sub.3; R.sup.6 is C.sub.3-6 cycloalkyl or C.sub.1-3 alkyl substituted with 0-3 R.sup.6a; R.sup.6a is halo; R.sup.7 is H; R.sup.8 is OC.sub.1-3 alkyl substituted with 0-1 CF.sub.3 or OCH.sub.3 substituent; R.sup.9 is

##STR00030##

R.sup.10 is C.sub.1-4 alkyl or OH; R.sup.11 is C.sub.1-3 alkyl substituted with with 0-3 R.sup.12 and 0-1 R.sup.13; R.sup.12 is halo; and R.sup.13 is OH.

[0343] In another embodiment of Formula (XI), R.sup.3 is

##STR00031##

R.sup.4 is halo or C.sub.1-2 alkyl substituted with 0-3 halo substituents; R.sup.d is C.sub.1-2 alkyl; R.sup.6 is

##STR00032##

C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.6a, or C.sub.1-3 alkyl substituted with 0-3 R.sup.6a; R.sup.6a is halo or OH; R.sup.14 is C.sub.1-2 alkyl substituted with 0-3 halo substituents; R.sup.7 is H; R.sup.8 is OC.sub.1-2 alkyl substituted with 0-1 C.sub.3-6 cycloalkyl substituents; R.sup.8a is H or halo; R.sup.9 is

##STR00033##

R.sup.10 is C.sub.1-4 alkyl or OH; R.sup.11 is C.sub.1-3 alkyl substituted with with 0-3 R.sup.12 and 0-1 R.sup.13; R.sup.12 is halo; and R.sup.13 is OH.

[0344] In one embodiment of Formula (IX), R.sup.3 is C.sub.1-4 alkyl; R.sup.6 is CF.sub.3 or cyclopropyl; R.sup.7 is H; R.sup.8 is OC.sub.1-2 alkyl; R.sup.9 is

##STR00034##

R.sup.10 is OH, or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-2 alkyl substituted with 0-2 R.sup.12 and 0-2 R.sup.13; R.sup.12 is C.sub.1-3 alkyl substituted with 0-3 halo or C(O)OR.sup.b; and R.sup.13 is OH.

[0345] In another embodiment of Formula (IX), R.sup.3 is cyclopentyl substituted with 0-1 R.sup.4, R.sup.4 is CN or C.sub.1-2 alkyl; R.sup.6 is CF.sub.3 or cyclopropyl; R.sup.7 is H; R.sup.8 is OC.sub.1-2 alkyl; R.sup.9 is

##STR00035##

R.sup.10 is OH or OC.sub.1-4 alkyl; R.sup.11 is C.sub.1-2 alkyl substituted with 0-2 R.sup.12 and 0-2 R.sup.13; R.sup.12 is C.sub.1-3 alkyl substituted with 0-3 halo substituents or C(O)OR.sup.b; and R.sup.13 is OH.

[0346] In another embodiment of Formula (IX), R.sup.3 is phenyl substituted with 0-2 R.sup.4, R.sup.4 is halo or CF.sub.3; R.sup.6 is CF.sub.3 or cyclopropyl; R.sup.7 is H; R.sup.8 is OC.sub.1-2 alkyl; R.sup.9 is

##STR00036##

R.sup.11a is H, C.sub.1-2 alkyl substituted with 0-2 R.sup.11b; R.sup.11b is OH.

[0347] In another embodiment of Formula (I), R.sup.1 and R.sup.2 together with the carbon atom to which they are both attached form a dioxolanyl.

[0348] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are NOC.sub.1-4 alkyl wherein is a double bond.

[0349] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7 wherein is a double bond.

[0350] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 and R.sup.7 are both methyl.

[0351] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is methyl ethyl, propyl, or butyl, each optionally substituted with OH or halo; R.sup.7 is H.

[0352] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is CF.sub.3; R.sup.7 is H.

[0353] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is halo; R.sup.7 is H.

[0354] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is phenyl substituted with 0-1 R.sup.14; R.sup.7 is H; R.sup.14 is halo, OC.sub.1-4 alkyl, or phenyl.

[0355] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is 5-membered heterocyclyl comprising 1-3 heteroatoms selected from 0 and N; R.sup.7 is H.

[0356] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is C(O)NH-phenyl; R.sup.7 is H.

[0357] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is C(O)OC.sub.1-4 alkyl; R.sup.7 is H.

[0358] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is C(O)N(Me).sub.2; R.sup.7 is H.

[0359] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is C.sub.3-6 cycloalkyl; R.sup.7 is H.

[0360] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is CH.sub.2C.sub.3-6 cycloalkyl substituted with halo; R.sup.7 is H.

[0361] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 is cyclopropyl; R.sup.7 is H.

[0362] In another embodiment of Formula (I), R.sup.1 and R.sup.2 combined are CR.sup.6R.sup.7; R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indeny.

[0363] In one embodiment of Formula (I), R.sup.3 is C.sub.1-6 alkyl substituted with 0-2 R.sup.4.

[0364] In another embodiment of Formula (I), R.sup.3 is methyl, ethyl, propyl, or butyl, or pentyl.

[0365] In another embodiment of Formula (I), R.sup.3 is

##STR00037##

[0366] In another embodiment of Formula (I), R.sup.3 is C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.4.

[0367] In another embodiment of Formula (I), R.sup.3 is C.sub.3-6 cycloalkenyl substituted with 0-2 R.sup.4. In another embodiment of Formula (I), R.sup.3 is

##STR00038##

[0368] In another embodiment of Formula (I), R.sup.3 is

##STR00039##

[0369] In another embodiment of Formula (I), R.sup.3 is

##STR00040##

[0370] In another embodiment of Formula (I), R.sup.3 is (CR.sup.dR.sup.d).sub.1-2-phenyl substituted with 0-2 R.sup.4; R.sup.4 is halo, CF.sub.3 or OCF.sub.3; R.sup.d is H or methyl.

[0371] In another embodiment of Formula (I), R.sup.3 is (CHR.sup.d)C.sub.3-6 cycloalkyl substituted with 0-2 R.sup.4; R.sup.4 is halo or C.sub.1-2 alkyl; R.sup.d is H or C.sub.1-2 alkyl.

[0372] In another embodiment of Formula (I), R.sup.3 is

##STR00041##

R.sup.4 is halo or C.sub.1-3 alkyl.

[0373] In another embodiment of Formula (I), R.sup.3 is

##STR00042##

R.sup.4 is C.sub.1-2 alkyl.

[0374] In another embodiment of Formula (I), R.sup.3 is

##STR00043##

R.sup.4 is halo or CN.

[0375] In another embodiment of Formula (I), R.sup.3 is (CR.sup.dR.sup.d).sub.1-2-5-membered heterocyclyl comprising 1-2 heteroatoms selected from 0 and N; R.sup.d is H or methyl.

[0376] In another embodiment of Formula (I), R.sup.4 is halo, CN, C.sub.1-2 alkyl substituted with 0-3 halo.

[0377] In another embodiment of Formula (I), R.sup.3 is cyclopropyl, cyclobutyl, cyclopentyl substituted with 0-1 R.sup.4, or cyclohexyl; R.sup.4 is CN or C.sub.1-2 alkyl.

[0378] In one embodiment of Formula (I), R.sup.5 is H, halo, or OH.

[0379] In another embodiment of Formula (I), R.sup.5 is H or OH.

[0380] In one embodiment of Formula (I), R.sup.6 is C.sub.1-4 alkyl substituted with 0-3 R.sup.6a or C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14, or 5 to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, N, and NR.sup.14a and substituted with 0-3 R.sup.14; R.sup.6a is halo, OH, or C.sub.3-6 cycloalkyl substituted with 0-3 halo substituents; R.sup.14 is halo or C.sub.1-3 alkyl substituted with 0-3 halo substituents.

[0381] In another embodiment of Formula (I), R.sup.6 is C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.14; R.sup.14 is halo substituents.

[0382] In another embodiment of Formula (I), R.sup.6 is isopropyl.

[0383] In one embodiment of Formula (I), R.sup.7 is H or C.sub.1-2 alkyl.

[0384] In one embodiment of Formula (I), there are two R.sup.8 variables. One of R.sup.8 is OC.sub.1-3 alkyl. The other R.sup.8, sometimes referenced as R.sup.8a, is halo or CN.

[0385] In one embodiment of Formula (I), R.sup.9 is phenyl substituted with 0-3 R.sup.10 and 0-2 R.sup.11.

[0386] In another embodiment of Formula (I), R.sup.9 is phenyl substituted with 0-3 R.sup.10 and 0-2 R.sup.11; R.sup.10 is halo; R.sup.11 is C.sub.1-5 alkyl substituted with 0-4 R.sup.12 and 0-2 R.sup.13; R.sup.12 is halo or C(O)OH; R.sup.13 is OC(O)NHR.sup.a; R.sup.a is C.sub.1-4 alkyl, C.sub.3-6 alkyl, or phenyl.

[0387] In another embodiment of Formula (I), R.sup.9 is phenyl substituted with 0-3 R.sup.10 and 0-2 R.sup.11; R.sup.10 is halo; R.sup.11 is C.sub.1-5 alkyl substituted with 0-4 R.sup.12 and 0-2 R.sup.13; R.sup.12 is halo or C(O)OH; R.sup.13 is NHC(O)R.sup.b; R.sup.b is 3- to 6 membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, and N.

[0388] In another embodiment of Formula (I), R.sup.9 is phenyl substituted with 0-1 R.sup.10 and 0-1 R.sup.11; R.sup.10 is halo; R.sup.11 is 4- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.15, and substituted with 0-3 R.sup.e; R.sup.e is COOH or C.sub.1-3 alkyl substituted with 0-5 R.sup.g; R.sup.g is OH.

[0389] In one embodiment of Formula (I), R.sup.9 is 3- to 12-membered heterocyclyl comprising 1-5 heteroatoms selected from O, S(O).sub.p, N, and NR.sup.11a, and substituted with 0-3 R.sup.10 and 0-2 R.sup.11.

[0390] In another embodiment of Formula (I), R.sup.9 is

##STR00044##

R.sup.10 is C.sub.1-2 alkyl; R.sup.11 is C.sub.1-3 alkyl substituted with OH substituent, R.sup.11a is C(O)C.sub.1-4 alkyl substituted with 0-1 R.sup.11b; R.sup.11b is OH.

[0391] In another aspect, the present invention provides compounds of Formula (IIIa):

##STR00045##

or pharmaceutically acceptable salts thereof, wherein: [0392] R.sup.4a is halo; [0393] R.sup.4b is C.sub.1-4 alkyl substituted with 0-4 halo substituents; [0394] R.sup.6 is halo, C.sub.1-4 alkyl substituted with 0-3 R.sup.6a, C.sub.2-4 alkenyl substituted with 0-1 phenyl or OH, C(O)OR.sup.b, C(O)NHR.sup.a, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkenyl substituted with 0-3 R.sup.14, phenyl substituted with 0-3 R.sup.14, naphthyl, or 5 to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S, N, and NR.sup.14a and substituted with 0-3 R.sup.14; [0395] R.sup.6a is halo, OH, C.sub.3-6 cycloalkyl, or phenyl; [0396] R.sup.7 is H; [0397] or R.sup.6 and R.sup.7 together with the carbon atom to which they are both attached form a cyclopentadienyl, an indanyl, or an indenyl; [0398] R.sup.14 is halo, CN, C.sub.1-4 alkyl substituted with 0-3 halo substituents, OC.sub.1-4 alkyl substituted with 0-3 halo substituents, (CH.sub.2).sub.0-2NR.sup.aR.sup.a, (CH.sub.2).sub.0-2-aryl substituted with 0-3 R.sup.e, O-aryl substituted with 0-3 R.sup.e, or (CH.sub.2).sub.0-2-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-3 R.sup.e; [0399] R.sup.14a is H or C.sub.1-3 alkyl; [0400] R.sup.a is H or C.sub.1-3 alkyl; [0401] R.sup.b is H or C.sub.1-3 alkyl; and [0402] p is zero or 2.

[0403] In one embodiment of Formula (V), R.sup.4a is F or CH.sub.3; R.sup.4b is CF.sub.3; R.sup.6 is phenyl or 5-membered heteroaryl comprising 1-2 heteroatoms selected from 0 and N; R.sup.7 is H; R.sup.8 is OC.sub.1-2alkyl; R.sup.10 is halo; R.sup.11 is NHS(O).sub.2C.sub.1-2 alkyl, C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl substituted with 0-1 R.sup.e, or a 5-membered heterocyclyl comprising 1-4 heteroatoms selected from O, N, and NR.sup.15 and substituted with 0-3 R.sup.e; R.sup.15 is H, C.sub.1-2 alkyl, or phenyl; and R.sup.e is O or C(O)OH.

[0404] In another aspect, the present invention provides compounds of Formula (VIb):

##STR00046##

or pharmaceutically acceptable salts thereof, wherein: [0405] R.sup.4a is halo; [0406] R.sup.4b is CF.sub.3; [0407] R.sup.8 is-OC.sub.1-4alkyl; [0408] R.sup.10 is halo; [0409] R.sup.12 is C(O)OH, C(O)OC.sub.1-4 alkyl, C(O)NHC.sub.1-4 alkyl, C(O)NHOC.sub.1-3 alkyl, or C.sub.1-3 alkyl substituted with 0-3 halo; [0410] R.sup.13 is OR.sup.b, NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.b, NR.sup.aC(O)OR.sup.b, NR.sup.aS(O).sub.pR.sup.c, NR.sup.aS(O).sub.pNR.sup.aR.sup.a, OC(O)NR.sup.aR.sup.a, OC(O)NR.sup.aOR.sup.b, S(O).sub.pNR.sup.aR.sup.a, or S(O).sub.pR.sup.c; [0411] R.sup.a is H, C.sub.1-6 alkyl substituted with 0-5 halo substituents, phenyl, C.sub.3-6 cycloalkyl substituted with 0-4 R.sup.e, spirocycloalkyl, or heterocyclyl substituted with 0-4 R.sup.e; or R.sup.a and R.sup.a together with the nitrogen atom to which they are both attached form a heterocyclyl substituted with 0-4 R.sup.e; [0412] R.sup.b is H, C.sub.1-6 alkyl substituted with 0-5 R.sup.e, (CH.sub.2).sub.n-phenyl, C.sub.3-6 cycloalkyl substituted with 0-4 halo substituents, or 3- to 9-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(O).sub.p, and N, and substituted with 0-4 R.sup.e; [0413] R.sup.c is C.sub.1-6 alkyl substituted with 0-4 R.sup.e, [0414] R.sup.e is halo, CN, O, C.sub.1-5 alkyl substituted with 0-5 R.sup.9, C.sub.3-6 cycloalkyl, aryl, 4- to 6-membered heterocyclyl, or OR.sup.f; [0415] R.sup.f is H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or aryl; [0416] R.sup.g is halo; [0417] n is zero or 1; and [0418] p is zero, 1, or 2.

[0419] In another aspect, the present invention provides compounds of Formula (VII), or pharmaceutically acceptable salts thereof, wherein: [0420] R.sup.4a is F; [0421] R.sup.4b is CF.sub.3; [0422] R.sup.5 is H; [0423] R.sup.6 is C.sub.1-3 alkyl substituted with 0-3 F substituents or C.sub.3-6 cycloalkyl; [0424] R.sup.8 is OCH.sub.3; [0425] R.sup.9 is

##STR00047## [0426] R.sup.11a is H, C.sub.1-3 alkyl substituted with 0-2 R.sup.11b, C(O)C.sub.1-4 alkyl substituted with 0-1 R.sup.11b, or C(O)OC.sub.1-4 alkyl; and [0427] R.sup.11b is OH, C(O)OH, or aryl.

[0428] Unless specified otherwise, these terms have the following meanings.

[0429] Halo includes fluoro, chloro, bromo, and iodo.

[0430] Alkyl or alkylene is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, C.sub.1 to C.sub.10 alkyl or C.sub.1-10 alkyl (or alkylene), is intended to include C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.7, C.sub.8, C.sub.9, and C.sub.10 alkyl groups. Additionally, for example, C.sub.1 to C.sub.6 alkyl or C.sub.1-C.sub.6 alkyl denotes alkyl having 1 to 6 carbon atoms. Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group. Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl). When C.sub.0 alkyl or C.sub.0 alkylene is used, it is intended to denote a direct bond. Alkyl also includes deuteroalkyl such as CD.sub.3.

[0431] Alkenyl or alkenylene is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three, carbon-carbon double bonds that may occur in any stable point along the chain. For example, C.sub.2 to C.sub.6 alkenyl or C.sub.2-6 alkenyl (or alkenylene), is intended to include C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkenyl groups; such as ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0432] Alkynyl or alkynylene is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three, carbon-carbon triple bonds that may occur in any stable point along the chain. For example, C.sub.2 to C.sub.6 alkynyl or C.sub.2-6 alkynyl (or alkynylene), is intended to include C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0433] Carbocycle, carbocyclyl, or carbocyclic residue is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic hydrocarbon ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocyclyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As shown above, bridged rings are also included in the definition of carbocyclyl (e.g., [2.2.2]bicyclooctane). A bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. When the term carbocyclyl is used, it is intended to include aryl, cycloalkyl, spirocycloalkyl, cycloalkenyl. Preferred carbocyclyls, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and indanyl.

[0434] Cycloalkyl is intended to mean cyclized alkyl groups, including mono-, bi- or multicyclic ring systems. C.sub.3 to C.sub.7 cycloalkyl or C.sub.3-7 cycloalkyl is intended to include C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7 cycloalkyl groups. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Non-limiting examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl and adamantyl.

[0435] Cycloalkenyl is intended to mean cyclized alkenyl groups, including mono- or multi-cyclic ring systems that contain one or more double bonds in at least one ring; although, if there is more than one, the double bonds cannot form a fully delocalized pi-electron system throughout all the rings (otherwise the group would be aryl, as defined herein). C.sub.3 to C.sub.7 cycloalkenyl or C.sub.3-7 cycloalkenyl is intended to include C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7 cycloalkenyl groups.

[0436] Spirocycloalkyl is intended to mean hydrocarbon bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane.

[0437] Bicyclic carbocyclyl or bicyclic carbocyclic group is intended to mean a stable 9- or 10-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is saturated, partially unsaturated, or unsaturated. The bicyclic carbocyclic group may be attached to its pendant group at any carbon atom which results in a stable structure. The bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable. Examples of a bicyclic carbocyclic group are, but not limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

[0438] Aryl groups refer to monocyclic or polycyclic aromatic hydrocarbons, including, for example, phenyl, naphthyl, and phenanthranyl. Aryl moieties are well known and described, for example, in Lewis, R. J., ed., Hawley's Condensed Chemical Dictionary, 13th Edition, John Wiley & Sons, Inc., New York (1997).

[0439] Benzyl is intended to mean a methyl group on which one of the hydrogen atoms is replaced by a phenyl group, wherein said phenyl group may optionally be substituted with 1 to 5 groups, preferably 1 to 3 groups.

[0440] Heterocycle, heterocyclyl or heterocyclic ring is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated, or fully unsaturated, and that contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any polycyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and S(O).sub.p, wherein p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocyclyl may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocyclyl is not more than 1. Bridged rings are also included in the definition of heterocyclyl. When the term heterocyclyl is used, it is intended to include heteroaryl.

[0441] Examples of heterocyclyls include, but are not limited to, acridinyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl, oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocyclyls.

[0442] Bicyclic heterocyclyl bicyclic heterocyclyl or bicyclic heterocyclic group is intended to mean a stable 9- or 10-membered heterocyclic ring system which contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring. The second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocyclyl, a 6-membered heterocyclyl or a carbocyclyl (provided the first ring is not benzo when the second ring is a carbocyclyl).

[0443] The bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocyclyl is not more than 1.

[0444] Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1H-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 1,2,3,4-tetrahydroquinoxalinyl, and 1,2,3,4-tetrahydroquinazolinyl.

[0445] Heteroaryl is intended to mean stable monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl, and benzodioxane. Heteroaryl groups are substituted or unsubstituted. The nitrogen atom is substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and S(O).sub.p, wherein p is 0, 1 or 2).

[0446] As referred to herein, the term substituted means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound. When a substituent is keto (i.e., O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. When a ring system (e.g., carbocyclic or heterocyclic) is said to be substituted with a carbonyl group or a double bond, it is intended that the carbonyl group or double bond be part (i.e., within) of the ring. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., CC, CN, or NN).

[0447] In cases wherein there are nitrogen atoms (e.g., amines) on compounds of the present invention, these may be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and/or hydrogen peroxides) to afford other compounds of this invention. Thus, shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N.fwdarw.O) derivative.

[0448] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R groups, then said group may optionally be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0449] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom in which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0450] The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

[0451] Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates thereof where such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the invention. Enantiomers and diastereomers are examples of stereoisomers. The term enantiomer refers to one of a pair of molecular species that are mirror images of each other and are not superimposable. The term diastereomer refers to stereoisomers that are not mirror images. The term racemate or racemic mixture refers to a composition composed of equimolar quantities of two enantiomeric species, wherein the composition is devoid of optical activity.

[0452] The invention includes all tautomeric forms of the compounds, atropisomers and rotational isomers.

[0453] The term counterion is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

[0454] All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention.

[0455] The symbols R and S represent the configuration of substituents around a chiral carbon atom(s). The isomeric descriptors R and S are used as described herein for indicating atom configuration(s) relative to a core molecule and are intended to be used as defined in the literature (IUPAC Recommendations 1996, Pure and Applied Chemistry, 68:2193-2222 (1996)).

[0456] The term chiral refers to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. The term homochiral refers to a state of enantiomeric purity. The term optical activity refers to the degree to which a homochiral molecule or nonracemic mixture of chiral molecules rotates a plane of polarized light.

[0457] The invention is intended to include all isotopes of atoms occurring in the compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include .sup.13C and .sup.14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

Biological Methods

[0458] RXFP1 Cyclic Adenosine Monophosphate (cAMP) Assays. Human embryonic kidney cells 293 (HEK293) cells and HEK293 cells stably expressing human RXFP1, were cultured in MEM medium supplemented with 10% qualified FBS, and 300 g/ml hygromycin (Life Technologies). Cells were dissociated and suspended in assay buffer. The assay buffer was HBSS buffer (with calcium and magnesium) containing 20 mM HEPES, 0.05% BSA, and 0.5 mM IBMX. Cells (3000 cells per well, except 1500 cell per well for HEK293 cells stably expressing human RXFP1) were added to 384-well Proxiplates (Perkin-Elmer). Cells were immediately treated with test compounds in DMSO (2% final) at final concentrations in the range of 0.010 nM to 50 M. Cells were incubated for 30 min at room temperature. The level of intracellular cAMP was determined using the HTRF HiRange cAMP assay reagent kit (Cisbio) according to manufacturer's instructions. Solutions of cryptate conjugated anti-cAMP and d2 fluorophore-labelled cAMP were made in a supplied lysis buffer separately. Upon completion of the reaction, the cells were lysed with equal volume of the d2-cAMP solution and anti-cAMP solution. After a 1 h room temperature incubation, time-resolved fluorescence intensity was measured using the Envision (Perkin-Elmer) at 400 nm excitation and dual emission at 590 nm and 665 nm. A calibration curve was constructed with an external cAMP standard at concentrations ranging from 2.7 M to 0.1 pM by plotting the fluorescent intensity ratio from 665 nm emission to the intensity from the 590 nm emission against cAMP concentrations. The potency and activity of a compound to inhibit cAMP production was then determined by fitting to a 4-parametric logistic equation from a plot of cAMP level versus compound concentrations.

[0459] The examples disclosed below were tested in the human RXFP1 (hRXFP1) HEK293 cAMP assay described above and found to have agonist activity. Table 1 lists EC.sub.50 values in the hRXFP1 HEK293 cAMP assay measured for the examples.

TABLE-US-00001 TABLE 1 cAMP hRXFP1 HEK293 Assay EC.sub.50 (nM) Ex. No. EC.sub.50 5 2,200 6 140 7 270 8 110 9 310 10 1,100 11 230 12 410 13 1,100 14 220 15 110 16 770 17 120 18 630 19 720 20 940 21 55 22 700 23 1,400 24 94 25 200 26 77 27 380 28 400 29 110 30 55 33 310 34 4,600 35 30 36 19 37 15 38 360 39 88 40 20 41 27 42 130 43 70 44 26 45 59 46 120 47 47 48 220 49 200 50 150 51 790 52 3,000 53 240 54 160 55 230 56 270 57 550 58 1,100 59 890 60 920 61 570 62 710 63 510 64 520 65 2,000 66 1,700 67 1,700 68 3,200 69 3,700 70 2,900 71 350 72 250 73 2,400 74 3,800 75 2,600 76 400 77 330 78 1,900 79 11 80 11 81 39 82 41 83 66 84 110 85 130 86 150 87 160 88 190 89 330 90 330 91 360 92 380 93 390 94 400 95 420 96 460 97 490 98 510 99 540 100 560 101 580 102 590 103 910 104 1,600 105 1,200 106 2,700 107 180 108 330 109 390 110 800 111 860 113 1,800 114 1,100 115 1,100 119 3,900 120 7 121 16 122 13 123 210 124 210 125 240 126 23 127 49 128 55 129 60 130 440 131 130 132 220 133 1,700 134 1,400 135 370 136 270 137 480 138 370 139 550 140 700 141 720 142 2,900 143 2,800 144 2,100 145 1,300 146 2,200 147 1,800 148 910 149 4,500 150 190 151 240 152 8 153 140 154 33 155 87 156 11 157 610 158 100 159 21 160 26 161 110 162 40 163 13 164 14 165 40 166 11 167 16 168 11 169 44 170 59 171 5 172 5 173 7 174 8 175 17 176 57 177 5 178 11 179 5 180 5 181 6 182 5 183 5 184 11 185 15 186 25 187 19 188 20 189 10 190 74 191 42 192 135 193 300 194 5 195 29 196 45 197 51 198 76 199 128 200 37 201 76 202 180 203 322 204 3,200 205 1 206 1 207 1 208 1 209 1 210 1 211 1 212 1 213 2 214 2 215 2 216 2 217 2 218 2 219 3 220 8 221 26 222 1 223 2 224 2 225 3 226 3 227 3 228 3 229 7 230 1 231 1 232 1 233 2 234 1 235 1 236 3 237 2 238 1 239 1 240 1 241 3 242 3 243 4 244 7 245 3 246 9 247 73 248 4 249 5 250 12 251 36 252 11 253 17 254 71 255 3 256 14 257 16 258 283 259 815 260 2,972 261 1,883 262 139 263 294 264 3,183 265 5 266 3,947 267 505 268 15 269 370 270 25 271 664 272 3,826 274 16 275 25 276 72 277 12 278 32 279 15 280 12 281 15 282 25 283 69 284 109 285 7 286 5 287 7 288 127 289 548 290 20 291 506 292 1,858 293 32 294 47 295 53 296 205 297 73 298 70 299 227 300 575 301 850 302 889 303 1,697 304 1,713 305 1,384 306 540 307 958 308 2,391 309 4,380 310 162 311 38 312 9 313 90 314 5 315 60 316 81 317 31 318 11 319 13 320 1,949 321 91 322 1,088 323 854 324 2,244 325 4,835 326 2,270 327 2,039 328 673 329 4,810 330 369 331 601 331 534 333 1,362 334 1,371 335 3,561 336 1,933 337 2,075 338 750 339 67 340 62 341 1,175 342 390 343 707 344 757 345 1,405 346 169 347 62 348 1,307 349 2,792 350 2,521 351 2,871 352 64 353 11 354 11 355 3 356 5 357 211 358 18 359 2 360 1,944 361 747 362 807 363 254 364 2,231 365 234 366 1,663 367 267 368 639 369 65 370 788 371 338 372 12 373 9 374 59 375 213 376 662 377 1,042 378 16 379 26 380 23 381 20 382 118 383 127 384 123 385 8 386 71 387 11 388 152 389 54 390 37 391 49 392 50 393 73 394 49 395 104 396 320 397 912 398 37 399 42 400 31 401 786 402 70 403 1,394 404 45 406 48 407 21 408 3 409 9 410 168 411 435 412 85 413 39 414 364 415 1,200 416 1 417 172 418 170 419 17 420 1 421 831 422 55 423 28 424 11 425 19 426 45 427 54 428 6 429 2 430 194 431 250 432 2 433 2 434 24 435 49 436 4 437 31 438 24 439 30 440 25 441 360 442 25 443 5 444 410 445 0.5 446 0.6 447 0.8 448 1.2 449 1.6 450 1.6 452 1.8 453 1.9 454 1.9 455 2 457 2.1 458 2.2 459 2.5 460 2.5 461 2.6 462 3 463 3.1 464 3.2 465 3.5 466 3.9 467 4 469 4.3 471 4.5 472 4.7 473 4.9 474 5 475 5.6 476 6.1 477 6.4 478 6.5 480 6.7 481 6.7 482 6.8 483 7.3 484 7.4 485 7.8 486 7.8 488 8.2 489 8.5 491 8.7 493 9.5 494 10.4 495 10.5 496 10.5 497 10.6 499 11 500 11 501 11.6 502 11.9 504 12.1 505 12.1 506 12.7 507 12.9 508 13 509 15.2 510 15.2 511 15.3 512 15.7 513 16.5 514 17.2 515 17.2 516 17.6 517 18 518 18.4 520 19.3 521 19.5 522 21.1 523 21.3 524 21.9 526 22.4 527 22.4 528 22.4 530 22.7 531 22.7 532 22.9 533 23.4 534 23.9 535 24 536 24.7 537 26 538 26.3 539 29.3 540 29.4 541 30 543 30.5 545 31.5 546 32.1 548 32.6 549 33 550 34.9 551 36.6 552 36.7 553 37.4 554 37.6 555 41.4 556 41.7 558 44.3 559 44.9 560 45.3 564 47.3 565 50.7 566 56.3 567 58.1 568 59.4 570 62.7 571 65.3 572 66.4 573 67.4 574 67.8 575 68.8 576 69.2 577 70.7 578 70.8 579 71.6 580 72.8 582 74.9 583 74.9 584 77.3 585 78.3 586 79.1 587 80.8 588 82 589 83.5 590 86.1 591 86.6 592 87.1 593 89.8 594 91.4 595 92.7 596 101.9 597 101.9 598 102 599 104.2 600 106.3 601 108 602 110 603 111.7 605 118.3 606 120.7 607 128.4 609 130.4 610 132.2 611 132.7 612 133.7 613 137.1 614 138.3 615 139.2 616 141.4 617 153 618 154.7 619 156.4 620 163 621 163.9 622 167.7 623 168.7 624 168.7 626 171.3 627 175.6 628 177 629 179.5 630 185.1 631 185.3 632 190.1 633 190.4 634 190.7 635 191 636 195.8 637 206.1 638 207.2 639 212.2 640 213.7 641 216.6 642 219 644 238.4 645 239.1 646 240.4 647 241.4 648 241.9 649 250.4 650 261.6 651 269.4 652 277.9 653 285.3 654 299.5 655 303.2 656 311.4 657 312 658 314.1 659 347.3 660 349.9 661 359.1 662 359.9 664 367.2 665 372.6 666 373.2 667 384.1 669 416.4 670 447.6 671 450.8 672 454.9 673 476.6 674 481 675 485.2 676 485.8 677 500.5 678 507.4 679 562.7 680 581.6 681 605.7 682 612.2 683 626.1 684 642.1 685 644.8 686 653.2 687 658 688 675 689 683.6 690 711.6 691 734.7 692 789 693 791.4 694 796.3 695 836.1 696 965.8 697 972 698 1,007 699 1,026 700 1,046 701 1,086 702 1,150 703 1,194 704 1,298 705 1,302 706 1,305 707 1,333 708 1,357 710 1,470 711 1,561 712 1,599 713 1,673 714 1,745 715 1,960 716 1,982 717 2,319 718 2,347 719 2,491 720 3,139 721 3,907 722 4,181 723 4,984 724 4,995 725 360 726 417 727 381 728 41 729 82 730 263 731 10 732 99 733 6.3 734 23 735 1.3 736 2.4 737 3.2 738 3.3 739 3.4 740 3.4 741 1.7 742 4.7 743 5 744 2.5 745 1.2 748 3.3 749 3.3 750 3.5 751 2.2 752 2.5 753 3.3 754 3.6 755 5 756 0.4 757 0.9 758 0.9 759 1 760 1.2 761 1.9 762 2 763 2.1 764 2.3 765 2.5 766 2.7 767 3 768 3 769 3.3 770 3.6 771 3.8 772 3.8 773 3.9 774 4.1 775 4.4 776 5 777 13.9 778 1.1 779 1.6 780 1.8 781 2.7 782 3.2 783 3.4 784 3.4 785 4 786 4 787 4.2 788 4.3 789 4.4 790 4.9 791 0.8 792 1.4 793 2.2 794 3.2 795 3.5 796 3.7 797 4.1 798 4.7 799 4.7 800 1 801 2 802 3 803 3.5 804 4 805 4.1 806 4.9 807 2.1 808 4.2 809 4.6 810 4.7 811 0.6 812 0.8 813 1 814 1.2 815 1.5 816 1.6 817 1.9 818 2.2 819 2.3 820 2.4 821 2.5 822 2.5 823 2.6 824 2.9 825 2.9 826 3 827 3.1 828 3.3 829 3.4 830 3.4 831 3.5 832 3.6 833 3.7 834 3.8 835 3.9 836 4.1 837 4.3 838 4.4 839 4.4 840 4.5 841 4.7 842 4.9 843 0.9 844 1.2 845 1.3 846 1.8 847 2.5 848 2.5 849 2.7 850 2.7 851 2.8 852 3.1 853 3.6 854 3.9 855 4.5 856 4.7 857 5 858 1.3 859 1.8 862 3.4 864 3.8 866 4.8 867 3.7 868 3.8 869 1.4 870 2.2 871 4.8 872 8 873 3.3 875 1.8 876 0.9 878 5.1 879 0.9 880 1.6 881 3.1 883 2.5 884 1 886 2.7 887 5.5 888 2.7 889 8.5 890 2.4 891 3.7 892 9.9 893 2.2 894 1.3 895 0.2 896 8.2 897 1 898 3.9 899 3 901 4.5 902 8.7 905 7 906 6.8 907 0.1 908 3.5 909 4 910 3.4 911 7.6 913 9 914 7.8 915 4 916 3.6 917 1.3 918 5.5 919 3.6 920 2.4 921 8.2 922 2.2 923 4.7 924 5.7 925 5.2 926 2.8 927 0.4 928 1.4 929 1.6 930 1.1 931 2.5 932 3.9 933 0.9 934 1.4 935 2.5 936 1.4 937 5.8 938 1.7 939 0.6 940 4.1 941 1.2 942 1.3 943 1.7 944 1.9 945 5.4 946 0.9 947 8.6 948 8.6 949 3.6 950 4.9 951 1 952 1.5 953 7 954 5.3 955 0.1 956 6.1 957 5.3 958 0.9 959 6.1 960 0.4 961 1 962 3.1 963 2.9 964 6.2 965 4.8 966 6.9 967 2.1 969 3.6 970 2 971 2.8 972 1.9 973 5.8 974 4.5 975 1,000 976 710

Pharmaceutical Compositions and Methods of Use

[0460] The compounds of Formula (I) are RXFP1 receptor agonists and may find use in the treatment of medical indications such as heart failure (e.g., heart failure with reduced ejection fraction (HFREF) or heart failure with preserved ejection fraction. (HFPEF)), fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis or pulmonary hypertension), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension). The compounds of Formula (I) can also be used to treat disorders that are a result of or a cause of arterial stiffness, reduced arterial elasticity, reduced arterial compliance and distensibility including hypertension, kidney disease, peripheral arterial disease, carotid and cerebrovascular disease (i.e stroke and dementia), diabetes, microvascular disease resulting in end organ damage, coronary artery disease, and heart failure. The compounds described herein may also be used in the treatment of pre-eclampsia.

[0461] Another aspect of the invention is a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

[0462] Another aspect of the invention is a pharmaceutical composition comprising a compound of Formula (I) for the treatment of a relaxin-associated disorder and a pharmaceutically acceptable carrier.

[0463] Another aspect of the invention is a method of treating a disease associated with relaxin comprising administering an effective amount of a compound of Formula (I).

[0464] Another aspect of the invention is a method of treating a cardiovascular disease comprising administering an effective amount of a compound of Formula (I) to a patient in need thereof.

[0465] Another aspect of the invention is a method of treating heart failure comprising administering an effective amount of a compound of Formula (I) to a patient in need thereof.

[0466] Another aspect of the invention is a method of treating fibrosis comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0467] Another aspect of the invention is a method of treating a disease associated with fibrosis comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0468] Another aspect of the invention is a method of treating idiopathic pulmonary fibrosis comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0469] Another aspect of the invention is a method of treating a kidney disease (e.g., chronic kidney disease), comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0470] Another aspect of the invention is a method of treating or preventing kidney failure, comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0471] Another aspect of the invention is a method of improving, stabilizing or restoring renal function in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of Formula (I) to the patient.

[0472] Another aspect of the invention is a method of treating idiopathic pulmonary fibrosis comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0473] Another aspect of the invention is a method of treating a kidney disease (e.g., chronic kidney disease), comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0474] Another aspect of the invention is a method of treating a hepatic disease comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0475] Another aspect of the invention is a method of treating non-alcoholic steatohepatitis and portal hypertension comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need thereof.

[0476] Another aspect of the invention is use of a compound of Formula (I) for prophylaxis and/or treatment of a relaxin-associated disorder.

[0477] Another aspect of the invention is a compound of Formula (I) for use in the prophylaxis and/or treatment of a relaxin-associated disorder.

[0478] Unless otherwise specified, the following terms have the stated meanings.

[0479] The term patient or subject refers to any human or non-human organism that could potentially benefit from treatment with a RXFP1 agonist as understood by practioners in this field. Exemplary subjects include human beings of any age with risk factors for cardiovascular disease. Common risk factors include, but are not limited to, age, sex, weight, family history, sleep apnea, alcohol or tobacco use, physical inactivity arrhythmia or signs of insulin resistance such as acanthosis nigricans, hypertension, dyslipidemia, or polycystic ovary syndrome (PCOS).

[0480] Treating or treatment cover the treatment of a disease-state as understood by practitioners in this field and include the following: (a) inhibiting the disease-state, i.e., arresting it development; (b) relieving the disease-state, i.e., causing regression of the disease state; and/or (c) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it.

[0481] Preventing or prevention cover the preventive treatment (i.e., prophylaxis and/or risk reduction) of a subclinical disease-state aimed at reducing the probability of the occurrence of a clinical disease-state as understood by practitioners in this field. Patients are selected for preventative therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population. Prophylaxis therapies can be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as treatment in a subject that has not yet presented with a clinical disease state, whereas secondary prevention is defined as preventing a second occurrence of the same or similar clinical disease state. Risk reduction or reducing risk covers therapies that lower the incidence of development of a clinical disease state. As such, primary and secondary prevention therapies are examples of risk reduction.

[0482] Therapeutically effective amount is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination with other agents to treat disorders as understood by practitioners in this field. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the preventive or therapeutic effect, whether administered in combination, serially, or simultaneously.

[0483] Disorders of the cardiovascular system or cardiovascular disorders include for example the following disorders: hypertension (high blood pressure), peripheral and cardiac vascular disorders, coronary heart disease, stable and unstable angina pectoris, heart attack, myocardial insufficiency, abnormal heart rhythms (or arrhythmias), persistent ischemic dysfunction (hibernating myocardium), temporary postischemic dysfunction (stunned myocardium), heart failure, disturbances of peripheral blood flow, acute coronary syndrome, heart failure, heart muscle disease (cardiomyopathy), myocardial infarction and vascular disease (blood vessel disease).

[0484] Heart failure includes both acute and chronic manifestations of heart failure, as well as more specific or related types of disease, such as advanced heart failure, post-acute heart failure, cardio-renal syndrome, heart failure with impaired kidney function, chronic heart failure, chronic heart failure with mid-range ejection fraction (HFmEF), compensated heart failure, decompensated heart failure, right heart failure, left heart failure, global failure, ischemic cardiomyopathy, dilated cardiomyopathy, heart failure associated with congenital heart defects, heart valve defects, heart failure associated with heart valve defects, mitral stenosis, mitral insufficiency, aortic stenosis, aortic insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary stenosis, pulmonary valve insufficiency, heart failure associated with combined heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, heart failure associated with cardiac storage disorders, diastolic heart failure, systolic heart failure, acute phases of worsening heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure with reduced ejection fraction (HFrEF), chronic heart failure with preserved ejection fraction (HFpEF), post myocardial remodeling, angina, hypertension, pulmonary hypertension and pulmonary artery hypertension.

[0485] Fibrotic disorders encompasses diseases and disorders characterized by fibrosis, including among others the following diseases and disorders: hepatic fibrosis, cirrhosis of the liver, NASH, pulmonary fibrosis or lung fibrosis, cardiac fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

[0486] Relaxin-associated disorders include but are not limited to disorders of the cardiovascular system and fibrotic disorders.

[0487] The compounds of this invention can be administered by any suitable means, for example, orally, such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups, and emulsions; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

[0488] Pharmaceutical composition means a composition comprising a compound of the invention in combination with at least one additional pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals, including, i.e., adjuvant, excipient or vehicle, such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, anti-bacterial agents, anti-fungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.

[0489] Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Allen, L. V., Jr. et al., Remington: The Science and Practice of Pharmacy (2 Volumes), 22nd Edition, Pharmaceutical Press (2012).

[0490] The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.

[0491] By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.01 to about 5000 mg per day, preferably between about 0.1 to about 1000 mg per day, and most preferably between about 0.1 to about 250 mg per day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

[0492] The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, e.g., oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practices.

[0493] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 2000 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.1-95% by weight based on the total weight of the composition. A typical capsule for oral administration contains at least one of the compounds of the present invention (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule. A typical injectable preparation is produced by aseptically placing at least one of the compounds of the present invention (250 mg) into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

[0494] The compounds may be employed in combination with other suitable therapeutic agents useful in the treatment of diseases or disorders including: anti-atherosclerotic agents, anti-dyslipidemic agents, anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-thrombotic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, agents for treating heart failure, agents for treating peripheral arterial disease, agents for treating malignant tumors, and anti-inflammatory agents.

[0495] The additional therapeutic agents may include ACE inhibitors, -blockers, diuretics, mineralocorticoid receptor antagonists, ryanodine receptor modulators, SERCA2a activators, renin inhibitors, calcium channel blockers, adenosine A1 receptor agonists, partial adenosine A1 receptor, dopamine -hydroxylase inhibitors, angiotensin II receptor antagonists, angiotensin II receptor antagonists with biased agonism for select cell signaling pathways, combinations of angiotensin II receptor antagonists and neprilysin enzyme inhibitors, neprilysin enzyme inhibitors, soluble guanylate cyclase activators, myosin ATPase activators, rho-kinase 1 inhibitors, rho-kinase 2 inhibitors, apelin receptor agonists, nitroxyl donating compounds, calcium-dependent kinase II inhibitors, antifibrotic agents, galectin-3 inhibitors, vasopressin receptor antagonists, RXFP1 receptor modulators, natriuretic peptide receptor agonists, transient receptor potential vanilloid-4 channel blockers, anti-arrhythmic agents, I.sub.f funny current channel blockers, nitrates, digitalis compounds, inotropic agents and -receptor agonists, cell membrane resealing agents for example Poloxamer 188, anti-hyperlipidemic agents, plasma HDL-raising agents, anti-hypercholesterolemic agents, cholesterol biosynthesis inhibitors (such as HMG CoA reductase inhibitors), LXR agonist, FXR agonist, probucol, raloxifene, nicotinic acid, niacinamide, cholesterol absorption inhibitors, bile acid sequestrants, anion exchange resins, quaternary amines, cholestyramine, colestipol, low density lipoprotein receptor inducers, clofibrate, fenofibrate, bezafibrate, ciprofibrate, gemfibrizol, vitamin B6, vitamin B12, anti-oxidant vitamins, anti-diabetes agents, platelet aggregation inhibitors, fibrinogen receptor antagonists, aspirin and fibric acid derivatives, PCSK9 inhibitors, aspirin, and P2Y12 Inhibitors such as Clopidogrel.

[0496] The additional therapeutic agents may also include nintedanib, Pirfenidone, LPA1 antagonists, LPA1 receptor antagonists, GLP1 analogs, tralokinumab (IL-13, AstraZeneca), vismodegib (hedgehog antagonist, Roche), PRM-151 (pentraxin-2, TGF beta-1, Promedior), SAR-156597 (bispecific Mab IL-4&IL-13, Sanofi), simtuzumab ((anti-lysyl oxidase-like 2 (anti-LOXL2) antibody, Gilead), CKD-942, PTL-202 (PDE inh./pentoxifylline/NAC oral control. release, Pacific Ther.), omipalisib (oral PI3K/mTOR inhibitor, GSK), IW-001 (oral sol. bovine type V collagen mod., ImmuneWorks), STX-100 (integrin alpha V/beta-6 ant, Stromedix/Biogen), Actimmune (IFN gamma), PC-SOD (midismase; inhaled, LTT Bio-Pharma/CKD Pharm), lebrikizumab (anti-IL-13 SC humanized mAb, Roche), AQX-1125 (SHIP1 activator, Aquinox), CC-539 (JNK inhibitor, Celgene), FG-3019 (FibroGen), SAR-100842 (Sanofi), and obeticholic acid (OCA or INT-747, Intercept).

[0497] The above other therapeutic agents, when employed in combination with the compounds of the present invention may be used, for example, in those amounts indicated in the Physicians' Desk Reference, as in the patents set out above, or as otherwise determined by practitioners in the art.

[0498] Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of the present invention and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material that affects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

[0499] The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the RXFP1. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving RXFP1 activity. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving RXFP1.

[0500] The present invention also encompasses an article of manufacture. As used herein, article of manufacture is intended to include, but not be limited to, kits and packages. The article of manufacture of the present invention, comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition, comprises a first therapeutic agent, comprising a compound of the present invention or a pharmaceutically acceptable salt form thereof; and, (c) a package insert stating that the pharmaceutical composition can be used for the treatment of dyslipidemias and the sequelae thereof. In another embodiment, the package insert states that the pharmaceutical composition can be used in combination (as defined previously) with a second therapeutic agent for the treatment of dyslipidemias and the sequelae thereof. The article of manufacture can further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container. Located within the first and second containers means that the respective container holds the item within its boundaries.

[0501] The first container is a receptacle used to hold a pharmaceutical composition. This container can be for manufacturing, storing, shipping, and/or individual/bulk selling. First container is intended to cover a bottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.

[0502] The second container is one used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), pouches, and sacks. The package insert can be physically attached to the outside of the first container via tape, glue, staple, or another method of attachment, or it can rest inside the second container without any physical means of attachment to the first container. Alternatively, the package insert is located on the outside of the second container. When located on the outside of the second container, it is preferable that the package insert is physically attached via tape, glue, staple, or another method of attachment. Alternatively, it can be adjacent to or touching the outside of the second container without being physically attached.

[0503] The package insert is a label, tag, marker, etc. that recites information relating to the pharmaceutical composition located within the first container. The information recited will usually be determined by the regulatory agency governing the area in which the article of manufacture is to be sold (e.g., the United States Food and Drug Administration). Preferably, the package insert specifically recites the indications for which the pharmaceutical composition has been approved. The package insert may be made of any material on which a person can read information contained therein or thereon. Preferably, the package insert is a printable material (e.g., paper, plastic, cardboard, foil, adhesive-backed paper or plastic, etc.) on which the desired information has been formed (e.g., printed or applied).

Chemical Methods

[0504] The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. The structure numbering and variable numbering shown in the synthetic schemes are distinct from, and should not be confused with, the structure or variable numbering in the claims or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention.

[0505] The disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.

[0506] It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene, T. W. et al., Protecting Groups in Organic Synthesis, 4th Edition, Wiley (2007)).

[0507] Abbreviations are defined as follows: 1 for once, 2 for twice, 3 for thrice, C. for degrees Celsius, aq for aqueous, eq or equiv. for equivalent or equivalents, g for gram or grams, mg for milligram or milligrams, L for liter or liters, mL for milliliter or milliliters, L for microliter or microliters, N for normal, M for molar, nM for nanomolar, pM for picomolar, mol for mole or moles, mmol for millimole or millimoles, min for minute or minutes, h for hour or hours, rt for room temperature, RT for retention time, atm for atmosphere, psi for pounds per square inch, conc. for concentrate, aq for aqueous, sat. for saturated, MW for molecular weight, MS or Mass Spec for mass spectrometry, ESI for electrospray ionization mass spectroscopy, LC-MS for liquid chromatography mass spectrometry, HPLC for high pressure liquid chromatography, RP HPLC for reverse phase HPLC, NMR for nuclear magnetic resonance spectroscopy, SFC for super critical fluid chromatography, .sup.1H for proton, for delta, s for singlet, d for doublet, t for triplet, q for quartet, m for multiplet, br for broad, Hz for hertz, MHz for megahertz, and , , R, S, E, and Z are stereochemical designations familiar to one skilled in the art. [0508] AcCl acetyl chloride [0509] AcOH acetic acid [0510] AIBN Azobisisobutyronitrile [0511] BHFFT bis(tetramethylene)fluoroformadmidinium hexafluorophosphate [0512] Boc tert-butyloxycarbonyl [0513] BuLi butyl lithium [0514] DAST Diethylaminosulfur trifluoroide [0515] DCE Dichloroethane [0516] DCM Dichloromethane [0517] DIEA diispropyl ethylamine [0518] DMAP 4-dimethylamino pyridine [0519] DMF Dimethylformamide [0520] DPPA Diphenyl phosphorylazide [0521] Et.sub.2O diethyl ether [0522] EtOAc Ethylacetate [0523] EtOH Ethanol [0524] HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) [0525] HMPA hexamethylphosphoramide [0526] IPA isopropanol [0527] i-Pr Isopropyl [0528] KHMDS potassium bis(trimethylsilyl)amide [0529] LDA lithium diisopropyl amide [0530] MeCN Acetonitrile [0531] MeOH Methanol [0532] Me Methyl [0533] NBS N-bromosuccinimide [0534] Pd/C palladium on carbon [0535] pTsOH p-toluenesulfonic acid [0536] PyBroP Bromotripyrrolidinophosphonium hexafluorophosphate [0537] T3P 2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide [0538] TBAF tetra-n-butyl ammonium fluoride [0539] t-Bu tert-butyl [0540] Teoc 2-(trimethylsilyl)ethyl carboxylate [0541] TFA trifluoro acetic acid [0542] TFAA trifluoro acetic anhydride [0543] THF Tetrahydrofuran [0544] TsOH Tolulenesulfonic acid [0545] XPhos-Pd-G2 2nd generation XPhos precatalyst CAS no. 1310584-14-5

[0546] The following methods were used in the exemplified examples, except where noted otherwise. Purification of intermediates and final products was carried out via either normal or reverse phase chromatography. Normal phase chromatography was carried out using prepacked SiO.sub.2 cartridges eluting with either gradients of hexanes and ethyl acetate or DCM and MeOH unless otherwise indicated. Reverse phase preparative HPLC was carried out using C18 columns with UV 220 nm or prep LCMS detection eluting with gradients of Solvent A (90% water, 10% MeOH, 0.1% TFA) and Solvent B (10% water, 90% MeOH, 0.1% TFA) or with gradients of Solvent A (95% water, 5% ACN, 0.1% TFA) and Solvent B (5% water, 95% ACN, 0.1% TFA) or with gradients of Solvent A (95% water, 2% ACN, 0.1% HCOOH) and Solvent B (98% ACN, 2% water, 0.1% HCOOH) or with gradients of Solvent A (95% water, 5% ACN, 10 mM NH.sub.4OAc) and Solvent B (98% ACN, 2% water, 10 mM NH.sub.4OAc) or with gradients of Solvent A (98% water, 2% ACN, 0.1% NH.sub.4OH) and Solvent B (98% ACN, 2% water, 0.1% NH.sub.4OH).

LC/MS methods employed in characterization of examples are listed below.

Method A:

[0547] Instrument: Waters Acquity coupled with a Waters MICROMASS ZQ Mass Spectrometer [0548] Linear gradient of 2 to 98% B over 1 min, with 0.5 min hold time at 98% B [0549] UV visualization at 220 nm [0550] Column: Waters BEH C18, 2.150 mm [0551] Flow rate: 0.8 mL/min (Method A) [0552] Mobile Phase A: 0.05% TFA, 100% water [0553] Mobile Phase B: 0.05% TFA, 100% acetonitrile

Method B:

[0554] Instrument: Shimadzu Prominence HPLC coupled with a Shimadzu LCMS-2020 Mass Spectrometer [0555] Linear gradient of 0 to 100% B over 3 min, with 0.75 min hold time at 100% B [0556] UV visualization at 220 nm [0557] Column: Waters Xbridge C18, 2.150 mm, 1.7 um particles [0558] Flow rate: 1 mL/min [0559] Mobile Phase A: 10 mM ammonium acetate, 95:5 water:acetonitrile [0560] Mobile Phase B: 10 mM ammonium acetate, 5:95 water:acetonitrile

Method C:

[0561] Instrument: Shimadzu Prominence HPLC coupled with a Shimadzu LCMS-2020 Mass Spectrometer [0562] Linear gradient of 0 to 100% B over 3 min, with 0.75 min hold time at 100% B [0563] UV visualization at 220 nm [0564] Column: Waters Xbridge C18, 2.150 mm, 1.7 um particles [0565] Flow rate: 1 mL/min [0566] Mobile Phase A: 0.1% TFA, 95:5 water:acetonitrile [0567] Mobile Phase B: 0.1% TFA, 5:95 water:acetonitrile

Method D:

[0568] Instrument: Waters Acquity coupled with a Waters MICROMASS ZQ Mass Spectrometer [0569] Linear gradient of 10% B to 98% B over 1 min, with 0.5 min hold time at 98% B [0570] UV visualization at 220 nm [0571] Column: Waters Acquity GEN C18, 2.150 mm, 1.7 um particles [0572] Flow rate: 1 mL/min [0573] Mobile Phase A: 0.05% TFA, 100% water [0574] Mobile Phase B: 0.05% TFA, 100% acetonitrile

Method E:

[0575] Instrument: Shimadzu Prominence HPLC coupled with a Shimadzu LCMS-2020 Mass Spectrometer [0576] Linear gradient of 0 to 100% B over 1 min, with 0.5 min hold time at 100% B [0577] UV visualization at 220 nm [0578] Column: Waters Acquity BEH C18, 2.150 mm, 1.7 um particles [0579] Flow rate: 1 mL/min [0580] Mobile Phase A: 10 mM ammonium acetate, 95:5 water:acetonitrile [0581] Mobile Phase B: 10 mM ammonium acetate, 5:95 water:acetonitrile
NMR Employed in Characterization of Examples. .sup.1H NMR spectra were obtained with Bruker or JEOL Fourier transform spectrometers operating at frequencies as follows: .sup.1H NMR: 400 MHz (Bruker or JEOL) or 500 MHz (Bruker or JEOL). Spectra data are reported in the format: chemical shift (multiplicity, coupling constants, number of hydrogens). Chemical shifts are specified in ppm downfield of a tetramethylsilane internal standard ( units, tetramethylsilane=0 ppm) and/or referenced to solvent peaks, which in .sup.1H NMR spectra appear at 2.51 ppm for DMSO-d.sub.6, 3.30 ppm for CD.sub.3OD, 1.94 ppm for CD.sub.3CN, and 7.24 ppm for CDCl.sub.3.

[0582] Scheme I describes how norbornyl examples may be prepared starting from norbornyl intermediates I-1, which are either commercially available (R.sup.1=R.sup.2=H) or prepared as described in subsequent Schemes. Starting from protected amino esters such as I-1, the olefin may be reduced under hydrogenation conditions (e.g., Pd/C, H.sub.2). The resulting Boc-protected amine I-2 may then be deprotected using TFA, followed by subsequent acylation with a benzoic acid employing a variety of amide bond forming conditions (e.g., HATU or BOPCl, with DIEA) to furnish I-3. Ester I-3 could then be converted directly to examples of the general structure I by treatment with an appropriate amine and AlMe.sub.3. Alternatively, the sequence of amide bond forming reactions may be reversed starting with saponification of I-2 followed by treatment with T3P and an appropriate amine to produce I-4. Deprotection and acylation according to the previously described conditions would then also yield Examples of the general structure I. In addition, the initial hydrogenation step may be delayed until any point in the sequence without altering the outcome of the steps described in Scheme 1.

##STR00048##

Scheme II shows one method for the production of norbornyl analogs with substitution at the C7 position starting from II-1. Treatment of II-1 with malic anhydride furnished II-2, which was selectively hydrogenated and solvolyzed to produce II-3. Curtius reaction of II-3 with DPPA in the presence of trimethylsilanol led to the formation of II-4. Deprotection of the Teoc group under standard conditions led to the formation of amine II-5 which could be elaborated to Examples of the general structure II directly. Alternatively, structure II could be treated with ozone to furnish ketone II-6, which could in turn be functionalized via a variety of standard transformations including but not limited to organometallic addition (e.g., RLi, RMgBr), Wittig or Homer-Wadsworth Emmons (HWE) olefination, or acetal formation. These products could serve as Examples of the general structure I or II themselves, or alternatively could serve as intermediates for further elaboration. In addition, the ozonolysis step could be conducted earlier in the synthetic sequence for strategic reasons without altering the outcome of the synthetic steps outline in Scheme II.

##STR00049##

##STR00050## ##STR00051##

[0583] Scheme III shows how the norbornyl cores may be fluorinated. Staring with II-4, the material was deprotonated with LDA and fluorinated with N-fluoro-bisbenezenesulfonimide, then subsequently elaborated to Examples of the general structure III according to the path outlined in Scheme I. Alternatively, III-1 could be treated with ozone similarly to as in Scheme II to furnish III-2. Intermediate III-2 could then be treated with Wittig or HWE conditions and processed as in Scheme II to furnish Examples of the general structure III).

##STR00052##

[0584] Scheme IV demonstrates the preparation of a variety of diverse C-7 methylidene substituted norbornyl cores from a common intermediate bromide. II-4 was converted to IV-1 through standard Teoc-deprotection, TFA acylation procedure. Ester IV-1 was converted to amide IV-2 according to the AlMe3 procedure outlined in Scheme I and IV-2 was ozonolyzed to ketone IV-3 as in Scheme II. Wittig methylination furnished olefin IV-4, which was treated with bromine and KHMDS to furnish IV-5 and IV-6 as a mixture of isomers that was separated by silica gel chromatography. Isomer IV-6 was then subjected to chiral SFC purification to produce a single enanatiomer of IV, which was then deprotected to IV-7. Amine IV-7 could then be acylated according to the methods outlined in Scheme 1 to yield IV-8. Vinyl bromides may also be further functionalized (e.g., Suzuki, Negishi and Semmelhack reaction conditions, among others) which led to diverse Examples of the general structure IV or corresponding intermediates which could then be elaborated further. Alternatively, the vinyl bromide functionalization steps could be performed on the IV-6, and the resulting material processed similarly to Examples of the general structure IV.

##STR00053## ##STR00054##

[0585] Scheme V demonstrates a method for the introduction of diverse amides on highly elaborated norbornyl carboxylates. An intermediate V-1, prepared according to the methods described in Schemes I-IV, could be treated with pivaloyl chloride, DMAP, and DIEA to furnish V-2. The resulting imide could be displaced directly with an amine in the presence of AlMe.sub.3 to furnish Examples of the general structure II. Alternatively, V-2 could be hydrolyzed through the use of hydroxide (e.g., LiOH, NaOH, etc.) to furnish V-3, which could functionalized further according the methods outlined in Scheme I to furnish Examples of the general structure II.

##STR00055##

[0586] Scheme VI describes the synthesis of bicyclic benzoates (Ar1=ArAr, where Ar=substituted phenyl, heteroaryl, or heterocyclic olefin) for use in Schemes I-IV. Aryl bromides VI-1 (where R can be H, Me, Bn, tBu among others) were treated with aryl, heteroaryl, and heterocyclic vinyl boronic acids (or esters) VI-2, a palladium catalyst (e.g., Pd(PPh.sub.3).sub.4, PdCl.sub.2(dppf), etc.), an appropriate base (e.g., Na.sub.2CO.sub.3, K.sub.3PO.sub.4, etc.) under Suzuki reaction conditions to furnish bicycle VI-3. Alternatively the coupling partners could be reversed, employing aryl boronic acid VI-4 and halide VI-5 under similar conditions to likewise yield VI-3. Where VI-3, RH, the benzoate could be cleaved employing saponification (e.g., LiOH, water for R=Me), acidic (e.g., TFA/DCM for R=tBu), or hydrogenolytic conditions (e.g., Pd/C, H.sub.2 for R=Bn) to furnish VI-6. Benzoic acid VI-6 could then be coupled to the norbornyl cores as is outlined in Schemes I-IV to furnish Examples of the general structures I or II or intermediates that could be further elaborated to Examples.

##STR00056##

[0587] Scheme VII, outlines a synthesis of N-linked nitrogen-heterocycle bicyclic benzoates from benzoate intermediates VI-1 or VI-4. Treatment of VI-1 with amine VII-1 under either Hartwig-Buchwald reaction (e.g., Pd(OAc).sub.2, BINAP, Cs.sub.2CO.sub.3 among others) or Ullman reaction (e.g., CuI, proline, Cs.sub.2CO.sub.3 among others) conditions to furnish bicycle VII-2. Alternatively, VII-2 could be prepared from VI-4 according to Chan-Evans-Lam conditions (e.g., Cu(OAc).sub.2, TEA, O.sub.2 among others). Intermediates VII-2 could then be further functionalized in a similar manner to VI-3 in Scheme VI via ester cleavage where required and further manipulation according to Schemes I-IV either directly to Examples of the general structures I or II or to intermediates that could be further elaborated to Examples.

##STR00057##

[0588] Scheme VIII illustrates a general route to mandelic acid-based biaryl analogs. Commercially available VIII-1 was converted to the t-butyl ester VIII-2, then brominated to furnish VIII-3. Displacement of the bromide with acetic acid furnished intermediate VIII-4, which was then subjected to a Suzuki reaction as was described in Scheme VI to furnish VIII-5 (acetate cleavage was concomitant with biaryl formation). The resulting acid was directly coupled to a norbornyl amine intermediate VIII-6 as was described in Scheme I to furnish VIII-7. The t-butyl ester VIII-7 could then be cleaved (TFA/DCM) to furnish Examples of the general structure VIIIa. Alternatively, the hydroxyl group in VIII-7 could be elaborated with either the appropriate isocyanate or a two-step carbamate forming protocol (e.g., nitrophenyl chloroformate, TEA, followed by an amine) to furnish VIII-8, which could then be cleaved (TFA/DCM) to furnish Examples of the general structure VIIIb.

##STR00058## ##STR00059##

Scheme IX shows a modification to the steps in Scheme VIII that allow for the preparation of phenylglycine-based biaryl analogs. Intermediate VIII-3 was treated with ammonia, followed by acylation to furnish intermediate IX-1, which was elaborated according to the methods outlined in Scheme VIII to furnish Examples of the general structure IX.

##STR00060##

[0589] Scheme X describes a method whereby analogs with diverse aliphatic C-7 substituents could be prepared from Intermediate X-1, itself prepared according to the route outlined in Scheme VIII. Treatment of intermediate X-1 with alkyl bromides under the conditions outlined in MacMillan et. al. (J. Am. Chem. Soc. 2016, 138, 8084-8087) followed by subsequent deprotection of the tBu ester led to Examples of the general structure X.

##STR00061##

[0590] Scheme XI demonstrated a route to the preparation of analogs with diverse aliphatic aryl-substituents (R) which can be prepared from Example 292. Treatment of Example 292 with alkyl bromides under the conditions outlined in MacMillan et. al. (J. Am. Chem. Soc. 2016, 138, 8084-8087) provided analogs of the general structure XI.

##STR00062##

Scheme XII describes a route for the production of substituted isoxazoline analogs. Treatment of XII-1 with NaOCl, followed by a substituted olefin with subsequent saponification of the ester provided intermediates XII-2. These intermediates were coupled with norbornyl amines according to the methods outlined in Scheme 1 to furnish Examples of the general structure XII.

##STR00063##

[0591] Scheme XIII describes a route for generation of analogs with diverse aryl substituents (Ar). Boronic acid VI-4 was treated with pinacol, followed by amide coupling with a norbornyl amide (prepared according to the Schemes above) to furnish XIII-1. Treatment of XIII-1 with aryl halides under standard anhydrous Suzuki conditions led to the formation of analogs XIII.

##STR00064##

EXAMPLES

Example 5

##STR00065## ##STR00066##

[0592] Intermediate II-2: At 0 C., into the reaction vessel was added Et.sub.2O (100 mL), 5-(propan-2-ylidene)cyclopenta-1,3-diene (II-1, 10 g, 94 mmol), and furan-2,5-dione (10 g, 102 mmol). The reaction mixture was stirred at 0 C. for 18 h, concentrated under reduced pressure and purified via silica gel chromatography to provide II-2 (3.74 g, 18.3 mmol, 19.0% yield). Intermediate II-2 is a known compound; please see: PCT Int. Appl., 2011163502, 29 Dec. 2011.

[0593] Intermediate II-3: Into the reaction vessel was added II-2 (2.74 g, 13.4 mmol), EtOAc (100 mL), pyridine (0.540 mL, 6.71 mmol), and Pd/C (70 mg, 0.070 mmol). The reaction mixture was stirred at 23 C. under 1 atm H.sub.2 (H.sub.2 balloon) for 60 min filtered through Celite, and concentrated under reduced pressure. The resulting intermediate was dissolved in methanol (50 mL) and heated at 50 C. for 12 h. Concentration of the reaction mixture under reduced pressure (azeotrope with toluene 315 mL) produced II-3 (3.21 g, 13.5 mmol, 100% yield) that was used without further purification.

[0594] Intermediate II-4: Into the reaction vessel was added II-3 (3.2 g, 13 mmol), Et.sub.3N (3.38 mL, 24.3 mmol), toluene (75 mL), and diphenylphosphoryl azide (4.35 mL, 20.2 mmol). The reaction mixture was stirred at 23 C. for 1 h. The reaction mixture was subsequently heated at 85 C. for 30 min and 2-(trimethylsilyl)ethanol (4.83 mL, 33.7 mmol) was added. After stirring at 85 C. for 66 h, the reaction mixture was allowed to cool to 23 C. and purified via silica gel chromatography to provide racemic II-4 (3.71 g, 10.5 mmol, 78.0% yield) LC-MS RT=1.25 min; (M+H)=354.1. Method A. Racemic II-4 was separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Thar 350 SFC; Column: Whelko-RR, 550 cm, 10 micron; Mobile phase: 13% IPA/87% CO.sub.2; Flow conditions: 300 mL/min, 100 Bar, 35 C.; Detector wavelength: 220 nm; Injections details: 4 injections of 3.5 mL of 59 g/490 mL MeOH:DCM (4:1) 120 mg/mL in IPA. Analytical chromatographic conditions: Instrument: Thar analytical SFC; Column: Whelko-RR (0.4625 cm, 5 micron; Mobile phase: 5% IPA/95% CO.sub.2; Flow conditions: 3 mL/min, 140 Bar, 40 C.; Detector wavelength: 200-400 nm UV. Peak 1, RT=3.496 min, >99% ee; Peak 2, RT=4.417 min, >99% ee. Intermediate II-4 product Peak #1 was collected and carried forward to produce chiral 5-5.

[0595] Intermediate 5-5: Into the reaction vessel was added chiral II-4 (3.71 g, 10.5 mmol), THF (80 mL), and TBAF (31.5 mL, 31.5 mmol). The reaction mixture was stirred at 23 C. for 12 h, diluted with EtOAc (15 mL), and the organic portion washed with sat. NaHCO.sub.3 (15 mL). The organic phase was collected, dried over Na.sub.2SO.sub.4, concentrated under reduced pressure and dissolved in DCM (50 mL). After cooling to 0 C., DIEA (5.50 mL, 31.5 mmol), and 4,5-difluoro-2-methoxybenzoyl chloride (2.4 g, 12 mmol) were added. The reaction mixture was stirred at 0 C. for 1 h, then allowed to warm to 23 C., concentrated under reduced pressure, and the residue purified via silica gel chromatography to produce 5-5 (2.9 g, 7.7 mmol, 74% yield). LC-MS RT=1.13 min; (M+H)=380.1. Method A.

[0596] Example 56: Into the reaction vessel was added 4-fluoro-3-(trifluoromethyl)aniline (4.87 g, 27.2 mmol), toluene (40 mL) and trimethylaluminum (13.59 mL, 27.20 mmol). After stirring at 23 C. for 30 min, 5-6 (2.95 g, 7.76 mmol) in toluene (80 mL) was added. The reaction mixture was stirred at 65 C. for 30 min. After allowing to cool to 23 C., the reaction mixture was diluted with EtOAc (50 mL) and washed with an aqueous solution sat. with Rochelle salt. The organic layer was dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure and purified via silica gel chromatography to Example 56 (3.23 g, 6.14 mmol, 79.0% yield). LCMS RT=1.23 min; (M+H)=527.1; Method A.

[0597] Intermediate 5-6: Into the reaction vessel was added Example 56 (110 mg, 0.210 mmol) and EtOAc (5 mL). The reaction mixture was cooled to 78 C. and O.sub.3 was bubbled through the solution for 10 min, (until blue color appeared). After bubbling N.sub.2 to remove excess 03, dimethyl disulfide (0.370 mL, 4.18 mmol) was subsequently added and the reaction mixture was allowed to warm to 23 C. and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to produce a residue, 5-6 (100 mg, 0.20 mmol, 96% yield) that was used without further purification. LC-MS RT=1.08 min; (M+H)=501.1; Method A.

[0598] Procedure for example 5: Into the reaction vessel was added diethyl benzylphosphonate (0.290 mL, 1.40 mmol), THF (10 mL). The mixture was cooled to 78 C. and KHMDS (1.4 mL, 1.4 mmol) was added. This mixture was stirred at 78 C. for 15 min and 5-6 was added at 78 C. After stirring at 78 C. for 10 min, the mixture was allowed to warm to 23 C., stirred at 23 C. for 1 h, quenched with sat. NaHCO.sub.3 and extracted with EtOAc. The organic phase was collected, dried over Na.sub.2SO.sub.4, filtered, concentrated, and purified via silica gel chromatography to produce the E-isomer example 5 (59 mg, 0.10 mmol, 51% yield) and the Z-isomer example 6 (34 mg, 0.060 mmol, 29% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 9.53 (d, J=7.7 Hz, 1H), 8.03 (dd, J=11.2, 9.5 Hz, 1H), 7.93 (dd, J=6.1, 2.5 Hz, 1H), 7.83 (s, 1H), 7.55-7.47 (m, 1H), 7.37-7.21 (m, 5H), 7.10 (t, J=9.4 Hz, 1H), 6.78 (dd, J=11.6, 6.1 Hz, 1H), 6.31 (s, 1H), 4.83-4.72 (m, 1H), 4.00 (s, 3H), 3.46-3.39 (m, 1H), 3.12 (dd, J=10.7, 4.1 Hz, 1H), 2.89 (t, J=4.0 Hz, 1H), 2.31-2.20 (m, 1H), 1.94-1.84 (m, 1H), 1.79-1.65 (m, 2H). LC-MS RT: 1.25 min; MS (ESI) m/z=575.2 (M+H)+; Method A.

Example 6

##STR00067##

[0599] Procedure for example 6: Example 6 was prepared as a byproduct of example 5. .sup.1H NMR (400 MHz, CDCl.sub.3) 9.51 (d, J=7.7 Hz, 1H), 8.03 (dd, J=11.4, 9.5 Hz, 1H), 7.94 (dd, J=6.2, 2.6 Hz, 1H), 7.72 (s, 1H), 7.53 (dt, J=8.5, 3.7 Hz, 1H), 7.37-7.30 (m, 4H), 7.25-7.19 (m, 1H), 7.12 (t, J=9.4 Hz, 1H), 6.78 (dd, J=11.7, 6.2 Hz, 1H), 6.33 (s, 1H), 4.83 (ddd, J=10.9, 7.6, 3.9 Hz, 1H), 3.99 (s, 3H), 3.49 (br. s., 1H), 3.16 (dd, J=10.8, 3.7 Hz, 1H), 2.87 (br. s., 1H), 2.22 (t, J=8.8 Hz, 1H), 1.91 (t, J=8.7 Hz, 1H), 1.69 (d, J=6.4 Hz, 2H). LC-MS RT: 1.25 min; MS (ESI) m/z=575.2 (M+H)+; Method A.

Example 11

##STR00068##

[0600] Procedure for example 11: Example 11 was prepared from 5-6, employing bromo(bromomethyl)triphenylphosphorane, according to the method described for example 5. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.31 (d, J=8.0 Hz, 1H), 8.01 (dd, J=11.3, 9.4 Hz, 1H), 7.94-7.86 (m, 2H), 7.51 (dt, J=8.7, 3.6 Hz, 1H), 7.10 (t, J=9.4 Hz, 1H), 6.78 (dd, J=11.6, 6.1 Hz, 1H), 5.98 (s, 1H), 4.87-4.76 (m, 1H), 3.97 (s, 3H), 3.28 (t, J=3.7 Hz, 1H), 3.16-3.09 (m, 1H), 2.93 (t, J=3.7 Hz, 1H), 2.35-2.25 (m, 1H), 1.91-1.82 (m, 1H), 1.75-1.63 (m, 2H). LC-MS RT: 1.22 min; MS (ESI) m/z=578.9 (M+H)+; Method A.

Example 12

##STR00069##

[0601] Procedure for example 12: Into the reaction vessel example 11 (10 mg, 0.020 mmol) was added followed by furan-3-ylboronic acid (9.7 mg, 0.090 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (4.2 mg, 5.2 mol), (THF 2 mL), and Na.sub.2CO.sub.3 (0.5 mL, 1.00 mmol). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 60 C. for 2 h. After the reaction mixture was allowed to cool to 23 C., the reaction mixture was concentrated and the residue was purified via preparative RP-HPLC to produce example 12 (7.7 mg, 0.010 mmol, 77% yield), .sup.1H NMR (500 MHz, CDCl.sub.3) 9.54 (d, J=7.4 Hz, 1H), 8.03 (dd, J=11.3, 9.4 Hz, 1H), 7.94 (dd, J=6.3, 2.8 Hz, 1H), 7.69 (s, 1H), 7.53 (dt, J=8.9, 3.4 Hz, 1H), 7.44 (d, J=0.8 Hz, 1H), 7.39 (t, J=1.7 Hz, 1H), 7.12 (t, J=9.4 Hz, 1H), 6.79 (dd, J=11.6, 6.3 Hz, 1H), 6.54 (d, J=1.1 Hz, 1H), 6.08 (s, 1H), 4.82-4.73 (m, 1H), 4.00 (s, 3H), 3.37 (t, J=3.6 Hz, 1H), 3.12 (dd, J=10.7, 3.9 Hz, 1H), 2.84 (t, J=3.3 Hz, 1H), 2.20-2.14 (m, 1H), 1.90 (t, J=8.5 Hz, 1H), 1.69-1.65 (m, 2H). LC-MS RT: 1.22 min; MS (ESI) m/z=565.0 (M+H)+; Method C.

Example 13

##STR00070##

[0602] Procedure for example 13: Example 13 was prepared from 5-6 (5.0 mg, 8.7 mol), employing [1,1-biphenyl]-4-ylboronic acid, according to the method described for example 12. In the case of the formation of example 13, the cross-coupled product was not obtained, but the dehalogenated byproduct was observed and isolated (2.3 mg, 4.6 gmol, 53%). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.44 (d, J=6.6 Hz, 1H), 8.05 (dd, J=11.3, 9.5 Hz, 1H), 7.99-7.93 (m, 1H), 7.76 (bs, 1H), 7.58-7.50 (m, 1H), 7.13 (t, J=9.3 Hz, 1H), 6.80 (dd, J=11.6, 6.1 Hz, 1H), 4.86 (s, 1H), 4.85 (s, 1H), 4.79-4.73 (m, 1H), 3.11 (dd, J=10.8, 4.0 Hz, 1H), 2.83 (br. s., 1H), 2.79 (br. s., 1H), 2.24-2.15 (m, 1H), 1.88-1.80 (m, 1H), 1.69-1.63 (m, 2H). LC-MS RT: 1.17 min; MS (ESI) m/z=499.1 (M+H)+; Method C.

Example 33

##STR00071##

[0603] Procedure for example 33: Into the reaction vessel was added 1H-indene (34.8 mg, 0.300 mmol) and THF (2 mL). The reaction mixture was cooled to 78 C. and nBuLi (0.19 mL, 0.30 mmol) was added. After stirring at 78 C. for 10 min and at 23 C. for 10 min, the reaction mixture was again cooled to 78 C. and 5-6 (15 mg, 0.030 mmol) was added. The reaction mixture was allowed to warm to 23 C., stirred for 15 min, and quenched by the addition of sat. NaHCO.sub.3 and extracted with EtOAc. The organic phase was dried over Na.sub.2SO.sub.4, filtered, concentrated, and dissolved in Et.sub.2O (2 mL). After the addition of Burgess reagent (14.3 mg, 0.0600 mmol) (1 equiv. was added and then added another 1 equiv. after 3 h), the reaction mixture was stirred at 45 C. for 12 h. The resulting solution was concentrated, and purified via silica gel chromatography to produce the E-isomeric product (3.4 mg, 5.6 mol, 19% yield) and Z-isomer example 33 (4.6 mg, 7.5 mol, 25% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.63 (d, J=7.7 Hz, 1H), 8.07 (dd, J=11.3, 9.4 Hz, 1H), 8.00 (dd, J=6.2, 2.6 Hz, 1H), 7.87 (d, J=7.4 Hz, 1H), 7.80 (s, 1H), 7.57 (dt, J=8.7, 3.5 Hz, 1H), 7.37 (d, J=7.4 Hz, 1H), 7.32-7.26 (m, 1H), 7.25-7.21 (m, 1H), 7.17 (t, J=9.4 Hz, 1H), 6.90 (d, J=5.5 Hz, 1H), 6.83 (dd, J=11.6, 6.1 Hz, 1H), 6.67 (d, J=5.5 Hz, 1H), 4.94-4.86 (m, 1H), 4.04 (s, 3H), 3.98 (t, J=4.0 Hz, 1H), 3.43 (t, J=3.9 Hz, 1H), 3.19 (dd, J=10.9, 4.0 Hz, 1H), 2.40-2.33 (m, 1H), 2.14-2.07 (m, 1H), 1.84-1.70 (m, 2H). LC-MS RT: 1.27 min; MS (ESI) m/z=599.1 (M+H)+; Method A.

Example 34

##STR00072## ##STR00073##

[0604] Intermediate 34-1: Intermediate 34-1 was prepared from 5-6 and tert-butyl 2-(diethoxyphosphoryl)acetate in the same manner as the general Wittig reaction in Example 5. LC-MS RT=1.25 min; (M+H)=599.1; Method A. Intermediate 34-2: Into the reaction vessel was added 34-1 (50 mg, 0.080 mmol), DCM (2 mL), and TFA (0.200 mL, 2.59 mmol). After stirring at 23 C. for 12 h, concentration of the reaction contents, under reduced pressure, provided 34-2 (46 mg, 0.080 mmol, 98% yield), that was used without further purification. LC-MS RT=1.08 min, (M+H)=543.1; Method A.

[0605] Procedure for example 34: Into the reaction vessel was added 34-2 (5 mg, 9 gmol), MeCN (1 mL), DIEA (5 l, 0.03 mmol), and HATU (7 mg, 0.02 mmol). The reaction mixture was stirred at 23 C. for 3 h, the solution concentrated under reduced pressure, and the residue was purified via preparative HPLC to produce example 34 (3.8 mg, 6.8 mol, 74% yield). LC-MS RT: 1.18 min; MS (ESI) m/z=618.1 (M+H)+; Method B.

Example 51

##STR00074## ##STR00075##

[0606] Intermediate III-1: Into the reaction vessel was added II-4 (100 mg, 0.28 mmol) and THF (5 mL). After cooling to 78 C., LDA (prepared from BuLi (0.53 mL, 0.85 mmol) and diisopropylamine (0.12 mL, 0.85 mmol) at 0 C.) was added and the reaction mixture was stirred at 78 C. for 15 min. Subsequently, N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (223 mg, 0.710 mmol) was added at 78 C. After stirring at 78 C. for 1 h, the reaction mixture was quenched by the addition of sat. NaHCO.sub.3 and the aqueous portion extracted with EtOAc. The combined organic portion was dried over Na.sub.2SO.sub.4, concentrated under reduced pressure, and purified via silica gel chromatography to produce III-1 (59.5 mg, 0.160 mmol, 57.0% yield) (1st peak) along with the trans-isomer (17.5 mg, 0.0500 mmol, 17.0% yield) (2nd peak). LC-MS RT=1.21 min, (M+H)=372.1; Method A.

[0607] Intermediate 51-2: Into the reaction vessel was added III-1 (20 mg, 0.050 mmol), THF (1 mL), and TBAF (0.270 mL, 0.270 mmol). The reaction mixture was stirred at 23 C. for 3 h, diluted with EtOAc, and the organic portion washed with sat. NaHCO.sub.3. The organic phase was collected, dried over Na.sub.2SO.sub.4, concentrated under reduced pressure and redissolved in DCM (1 mL). DIEA (0.02 mL, 0.11 mmol) and 4,5-difluoro-2-methoxybenzoyl chloride (16.7 mg, 0.0800 mmol) were subsequently added. After stirring at 23 C. for 1 h, the reaction mixture was concentrated under reduced pressure and purified via silica gel chromatography to produce 51-2 (7.2 mg, 0.020 mmol, 34% yield). LC-MS RT=1.11 min, (M+H)=398.1; Method A.

[0608] Intermediate 51-3: Into the reaction vessel was added 51-2 (7.5 mg, 0.020 mmol), THF (1 mL), water (0.5 mL), and lithium hydroxide monohydrate (4.0 mg, 0.090 mmol). The reaction mixture was stirred at 23 C. for 1 h, diluted with EtOAc (10 mL), and the organic portion washed with 10 mL sat. NH.sub.4Cl containing 0.1 mmol HCl. The organic phase was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to provide 51-3 (7.5 mg, 0.020 mmol, 100% yield) that was used without further purification. LC-MS RT=0.98 min, (M+H)=384.1; Method A.

[0609] Procedure for example 51: Into the reaction vessel was added 51-3 (7.0 mg, 0.020 mmol), 4-fluoro-3-(trifluoromethyl)aniline (6.5 mg, 0.040 mmol), MeCN (1 mL), DIEA (6 l, 0.04 mmol), and HATU (14 mg, 0.040 mmol). The reaction mixture was stirred at 50 C. for 1 h, allowed to cool to 23 C., concentrated under reduced pressure, and purified via silica gel chromatography to produce example 51 (4.7 mg, 8.3 mol, 45% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.21 (d, J=8.3 Hz, 1H), 8.33 (d, J=8.8 Hz, 1), 8.09 (dd, J=6.2, 2.6 Hz, 1H), 8.02 (dd, J=11.3, 9.4 Hz, 1H), 7.54 (dt, J=8.8, 3.4 Hz, 1H), 7.18 (t, J=9.2 Hz, 1H), 6.78 (dd, J=11.7, 6.2 Hz, 1H), 4.70-4.54 (m, 1H), 3.13 (t, J=3.9 Hz, 1H), 2.98 (dd, J=9.4, 3.9 Hz, 1H), 2.07-2.00 (m, 1H), 1.79 (s, 3H), 1.74 (s, 3H), 1.57-1.43 (m, 3H). LC-MS RT: 1.23 min; MS (ESI) m/z=545.1 (M+H)+; Method A.

Example 52

##STR00076## ##STR00077##

[0610] Intermediate III-2: Into the reaction vessel was added III-1 (50 mg, 0.14 mmol) and EtOAc (3 mL). The reaction mixture was cooled to 78 C. and 03 was bubbled through the solution for 10 min. Dimethyl disulfide (0.24 mL, 2.7 mmol) was subsequently added and the reaction mixture was allowed to warm to 23 C. and stirred for 12 h. After concentration under reduced pressure, the residue was dissolved in EtOAc and filtered through silica gel. Concentration of the filtrate under reduced pressure gave III-2 (50.5 mg, 0.15) mmol, 100% yield) that was used without further purification. LCMS RT=1.24 min, (M+H)=346.0; Method A.

[0611] Intermediate 52-2: Into the reaction vessel was added diethyl benzylphosphonate (0.14 mL, 0.65 mmol), THF (5 mL). The reaction mixture was cooled to 78 C. and KHMDS (0.65 mL, 0.65 mmol) was added. This mixture was stirred at 78 C. for 20 min and III-2 (45 mg, 0.13 mmol) was added at 78 C. After stirring at 78 C. for 5 min and at 23 C. for 1 h, the reaction mixture was quenched by the addition of sat. NaHCO.sub.3 and the aqueous portion extracted with EtOAc. The organic portions were combined, dried over Na.sub.2SO.sub.4, concentrated under reduced pressure, and purified via silica gel chromatography to give 52-2 (17.4 mg, 0.0400 mmol, 31.0% yield, 1.45:1 mixture of olefin isomers). LC-MS RT=1.27 min, (M+H-Et)=406.0; Method A.

[0612] Intermediate 52-3: Intermediate 52-3 was prepared utilizing the procedure described for the synthesis of intermediate 51-2.

[0613] Intermediate 52-4: Intermediate 52-4 was prepared utilizing the procedure described for the synthesis of intermediate 51-3.

##STR00078##

[0614] Procedure for example 52: Example 52 was prepared from 52-4, according to the method described for example 51. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.25 (d, J=8.0 Hz, 1H), 8.33 (d, J=8.5 Hz, 1H), 8.10 (dd, J=6.2, 2.6 Hz, 1H), 8.04 (dd, J=11.1, 9.5 Hz, 1H), 7.58-7.50 (m, 1H), 7.39-7.31 (m, 4H), 7.18 (t, J=9.4 Hz, 1H), 6.79 (dd, J=11.6, 6.1 Hz, 1H), 6.56 (s, 1H), 4.92-4.73 (m, 1H), 4.00 (s, 3H), 3.41 (dd, J=8.7, 3.4 Hz, 1H), 3.06 (t, J=3.9 Hz, 1H), 2.24-2.13 (m, 1H), 1.79-1.72 (m, 1H), 1.71-1.57 (m, 3H). LC-MS RT: 1.27 min; MS (ESI) m/z=593.0 (M+H)+; Method A.

Example 53

##STR00079##

[0615] Procedure for example 53: Example 53 was prepared from 52-4, according to the method described for example 51. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.28 (d, J=7.4 Hz, 1H), 8.33 (d, J=8.3 Hz, 1H), 8.11 (d, J=4.1 Hz, 1H), 8.02 (t, J=10.3 Hz, 1H), 7.55 (d, J=7.7 Hz, 1H), 7.40-7.31 (m, 4H), 7.19 (t, J=9.2 Hz, 1H), 6.79 (dd, J=11.6, 6.1 Hz, 1H), 6.45 (s, 1H), 4.89-4.72 (m, 1H), 4.01 (s, 3H), 3.61 (br. s., 1H), 2.85 (d, J=6.1 Hz, 1H), 2.25-2.13 (m, 1H), 1.85-1.76 (m, 1H), 1.75-1.58 (m, 3H). LC-MS RT: 1.27 min; MS (ESI) m/z=593.0 (M+H)+; Method A.

Example 65

##STR00080##

[0616] Intermediate 65-1: Intermediate 65-1 was prepared from 5-6 and methyl 2-(dimethoxyphosphoryl)acetate in a similar manner to the Wittig reaction described in Example 5.

[0617] Procedure for example 65: Into the reaction vessel was added 65-1 (5.0 mg, 9.0 mol) and THF (1 mL). After the reaction mixture was cooled to 78 C., methylmagnesium chloride (0.06 mL, 0.2 mmol) was added. The reaction mixture was allowed to warm to 23 C., stirred at 23 C. for 2 h. The reaction was quenched by the addition of sat. NaHCO.sub.3 and the solution extracted with EtOAc. The organic layer was dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via preparative RP-HPLC purification to produce example 65 (3.2 mg, 5.3 mol, 59% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.46 (d, J=7.7 Hz, 1H), 8.03-7.91 (m, 3H), 7.53 (dt, J=8.6, 3.5 Hz, 1H), 7.10 (t, J=9.4 Hz, 1H), 6.78 (dd, J=11.6, 6.3 Hz, 1H), 5.49 (s, 1H), 4.77-4.67 (m, 1H), 3.98 (s, 3H), 3.49 (t, J=4.0 Hz, 1H), 3.07 (dd, J=11.0, 4.1 Hz, 1H), 2.69 (t, J=3.9 Hz, 1H), 2.17-2.09 (m, 1H), 1.89-1.81 (m, 1H), 1.68-1.55 (m, 2H), 1.42 (s, 6H). LC-MS RT: 1.14 min; MS (ESI) m/z=557.0 (M+H)+; Method C.

Example 76

##STR00081##

[0618] Intermediate 76-1: To a 20 mL vial containing 11-4 (1.77 g, 5.00 mmol) was added DCM (20 mL). TFA (2.02 mL, 26.3 mmol) was then added and the reaction mixture was stirred at 23 C. for 48 h. The resulting solution was concentrated under reduced pressure and dried under high vacuum for 5 hours. The residue was carried forward to the acylation step without further purification. 5-bromo-2-methoxybenzoyl chloride was prepared in the following manner: To a 100 mL flask charged with 5-bromo-2-methoxybenzoic acid (1.39 g, 6.00 mmol) was added DCM (30 mL) followed by oxalyl chloride (0.6 mL, 7 mmol) and DMF (0.05, mL 0.6 mmol). The solution was stirred for 18 h at 23 C. and was converted to the amide in the same manner described for intermediate 5-5 to produce 76-1 (878 mg, 2.10 mmol, 56.0% yield). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.49 (d, J=7.0 Hz, 1H), 8.04-7.87 (m, 1H), 7.74-7.59 (m, 1H), 7.17 (d, J=8.8 Hz, 1H), 4.26 (br. s., 1H), 3.98 (s, 3H), 3.63 (s, 1H), 3.51 (br. s., 1H), 3.42 (d, J=18.1 Hz, 3H), 3.13-3.01 (m, 1H), 2.92 (d, J=13.5 Hz, 2H), 1.67 (s, 511), 1.64-1.47 (m, 3H), 1.36 (br. s., 2H).

[0619] Procedure for example 76: Example 76 was prepared from 76-1, employing 4-fluoro-3-(trifluoromethyl)aniline, according to the method described for example 56, 1H NMR (500 MHz, DMSO-d6) 10.52 (s, 1H), 9.88 (d, J=7.0 Hz, 1H), 8.19 (d, J=4.3 Hz, 1H), 7.97 (d, J=2.7 Hz, 1H), 7.78 (d, J=8.5 Hz, 1H), 7.65 (dd, J=8.7, 2.6 Hz, 1H), 7.47 (t, J=9.8 Hz, 1H), 7.16 (d, J=8.9 Hz, 1H), 4.31 (br. s., 1H), 3.98 (s, 3H), 3.55-3.40 (m, 3H), 3.09 (dd, J=10.7, 4.0 Hz, 1H), 3.02 (br. s., 1H), 2.91 (br. s., 1H), 1.80 (t, J=8.9 Hz, 1H), 1.75-1.62 (m, 7H), 1.33 (d, J=6.1 Hz, 2H).

[0620] LC-MS RT: 2.69 min; MS (ESI) m/z=569.1 (MH)+; Method B.

Example 77

##STR00082##

[0621] Intermediate 77-1: Intermediate 77-1 was prepared from example 76 in the same general manner described for intermediate 5-6. LC-MS RT=1.0 min; (M+H)=544.0; Method A.

[0622] Procedure for example 77: Example 77 was prepared from 77-1, employing diethyl benzylphosphonate, according to the general method described for example 5. .sup.1H NMR (500 MHz, DMSO-d6) 10.66-10.50 (m, 1H), 10.06-9.88 (m, 1H), 8.27-8.13 (m, 1H), 8.06-7.94 (m, 1H), 7.86-7.73 (m, 1H), 7.71-7.59 (m, 1H), 7.53-7.43 (m, 1H), 7.43-7.31 (m, 4H), 7.31-7.21 (m, 1H), 7.21-7.09 (m, 1H), 6.47-6.22 (m, 1H), 4.55-4.37 (m, 1H), 4.09-3.95 (m, 3H), 3.33-3.19 (m, 1H), 2.90-2.76 (m, 1H), 2.02-1.88 (m, 1H), 1.87-1.71 (m, 1H), 1.64-1.42 (m, 2H), 1.06-0.91 (m, 1H). LC-MS RT: 2.83 min; MS (ESI) m/z=617.20 (MH)+; Method B.

Example 78

##STR00083##

[0623] Procedure for example 78: Example 78 was prepared as a byproduct in the production of Example 77. .sup.1H NMR (500 MHz, DMSO-d6) 10.66-10.50 (m, 1H), 10.06-9.88 (m, 1H), 8.27-8.13 (m, 1H), 8.06-7.94 (m, 1H), 7.86-7.73 (m, 1H), 7.71-7.59 (m, 1H), 7.53-7.43 (m, 1H), 7.43-7.31 (m, 4H), 7.31-7.21 (m, 1H), 7.21-7.09 (m, 1H), 6.47-6.22 (m, 1H), 4.55-4.37 (m, 1H), 4.09-3.95 (m, 3H), 3.33-3.19 (m, 1H), 2.90-2.76 (m, 1H), 2.02-1.88 (m, 1H), 1.87-1.71 (m, 1H), 1.64-1.42 (m, 2H), 1.06-0.91 (m, 1H). LC-MS RT: 2.82 min; MS (ESI) m/z=617.35 (MH)+; Method B.

Example 79

##STR00084##

[0624] Procedure for example 79: To a 0.5 to 2.0 mL microwave reaction via charged with example 77 (15 mg, 0.024 mmol) was added 4-boronobenzoic acid (6 mg, 0.04 mmol) followed by THF (490 l) and a solution of K.sub.3PO.sub.4 (97 l, 0.049 mmol) in water. Finally, XPhos-Pd-G2 (CAS 1310584-14-5) (2 mg, 0.002 mmol, small spatula tip) was added. The vial was capped and heated in the microwave to 100 C. for 30 min. The reaction was diluted with DMF to a total volume of 2 mL, filtered, and purified by preparative RP-HPLC to give example 79 (5.2 mg, 0.01 mmol, 33% yield). .sup.1H NMR (500 MHz, DMSO-d6) 9.95 (d, J=7.0 Hz, 1H), 8.26 (d, J=4.3 Hz, 1H), 7.94 (d, J=6.7 Hz, 1H), 7.81 (br. s., 1H), 7.50 (t, J=8.2 Hz, 3H), 7.44-7.32 (m, 6H), 7.25 (br. s., 2H), 7.18 (d, J=8.2 Hz, 1H), 7.04 (t, J=7.5 Hz, 1l), 6.39 (s, 1H), 4.52 (br. s., 1H), 3.28 (br. s., 1H), 2.93 (br. s., 1H), 2.02-1.79 (m, 3H), 1.53 (br. s., 3H). LC-MS RT: 2.2 min; MS (ESI) m/z=659.4 (MH)+; Method B.

Example 107

##STR00085## ##STR00086##

[0625] Intermediate IV-1: Deprotection of II-4 to intermediate IV-1 utilized the same conditions described in 76-1. Installation of the trifluoroacetyl protecting group was conducted as follows: II-4 was deprotected to the corresponding amine intermediate and the amine (1.7 g, 8.1 mmol) was added DCM (41 mL) and the flask was cooled to 0 C. via an ice bath. TFAA (1.26 mL, 8.90 mmol) and DIEA (5.7 mL, 33 mmol) were added. The reaction flask was removed from the ice bath after 5 min, and was stirred at 23 C. for 30 min. The reaction mixture was quenched with sat. NaHCO.sub.3 (50 mL) and extracted with EtOAc (350 mL). The combined organic portions were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford IV-1 (2.48 g, 8.12 mmol, 100% yield) that was used without further purification. LC-MS RT=1.11 min; MS (ESI) m/z=306.1 (M+H).sup.+; Method A.

[0626] Intermediate IV-2: Intermediate IV-2 was prepared from IV-1 in the same manner as described for 5-6. (2.5 g, 5.5 mmol, 63% yield); LC-MS RT=1.20 min; MS (ESI) m/z=453.0 (M+H).sup.+; Method A.

[0627] Intermediate 107-3: Intermediate IV-2 (133 mg, 0.290 mmol) was dissolved in water (2.9 mL) and MeOH (2.9 mL). K.sub.2CO.sub.3 (2.03 g, 1.47 mmol) was added and the reaction mixture was stirred at 40 C. for 4 h. The reaction mixture was allowed to cool to room temperature then water (5 mL) was added. The resulting solution was extracted with EtOAc (310 mL). The combined organic extracts were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 107-3 (105 mg, 0.290 mmol, 100% yield) that was used without further purification. LC-MS RT=0.82 min; MS (ESI) m/z=357.1 (M+H).sup.+; Method A.

[0628] Intermediate 107-4 was prepared from 107-3 using the sample procedure employed for 76-1.

[0629] Procedure for example 107: Example 107 was prepared from 107-4, employing 3-borono-4-fluorobenzoic acid, according to the method described for example 79. .sup.1H NMR (500 MHz, DMSO-d6) 10.64 (s, 1H), 10.34 (br d, J=7.3 Hz, 1H), 8.23 (dd, J=6.1, 1.8 Hz, 1H), 7.99 (br d, J=7.6 Hz, 1H), 7.93 (s, 1H), 7.91-7.86 (m, 1H), 7.80 (br d, J=8.2 Hz, 1H), 7.61 (br d, J=8.2 Hz, 1H), 7.44 (br t, J=9.8 Hz, 1H), 7.33 (d, J=8.5 Hz, 1H), 7.24 (br t, J=9.6 Hz, 1H), 4.46-4.38 (m, 1H), 3.13 (br dd, J=10.4, 4.0 Hz, 1H), 3.03 (br s, 1H), 2.93 (br s, 1H), 2.71 (s, 6H), 1.94-1.87 (m, 2H), 1.84-1.75 (m, 1H), 1.71 (s, 6H), 1.45-1.30 (m, 2H). LC-MS RT: 2.2 min; MS (ESI) m/z=642.2 (M+H)+; Method B.

Example 108

##STR00087##

[0630] Intermediate 108-1: To a vial was added 5-(3-bromo-4-fluorophenyl)-1H-tetrazole (50 mg, 0.21 mmol), 5-borono-2-methoxybenzoic acid (60.5 mg, 0.309 mmol), XPhos-Pd-G2 catalyst (32 mg, 0.042 mmol) and K.sub.3PO.sub.4 (131 mg, 0.617 mmol) followed by THF (1.8 mL) and water (257 l). The reaction mixture was degassed with nitrogen for 2 min, then sealed and heated at 150 C. for 2.5 h with microwave irradiation. The reaction mixture was partitioned between 1 N HCl (5 mL) and extracted with EtOAc (35 mL). The combined organic portions were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure. The resulting residue was purified by preparative RP-HPLC to give 108-1 (13 mg, 0.041 mmol, 20% yield). LC-MS RT=0.77 min; MS (ESI) m/z=315.1 (M+H).sup.+; Method A.

[0631] Procedure for example 108: Into the reaction vessel was added 107-3 (10 mg, 0.03 mmol), 108-1 (13.2 mg, 0.0400 mmol), MeCN (1 mL), DIEA (0.02 mL, 0.1 mmol), and HATU (16 mg, 0.040 mmol). The reaction mixture was stirred at 23 C. for 3 h, concentrated under reduced pressure, and subjected to preparative RP-HPLC purification to afford example 108 (12.3 mg, 0.0200 mmol, 65.0% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.93 (d, J=7.0 Hz, 1H), 8.26-8.19 (m, 2H), 8.17 (br d, J=6.4 Hz, 1H), 8.09-8.02 (m, 1H), 7.83-7.75 (m, 2H), 7.54 (dd, J=10.2, 9.0 Hz, 1H), 7.47 (t, J=9.8 Hz, 1H), 7.34 (d, J=8.5 Hz, 1H), 4.41-4.34 (m, 1H), 4.05 (s, 3H), 3.11 (dd, J=10.8, 4.1 Hz, 1H), 3.05-3.02 (m, 1H), 2.99-2.92 (m, 1H), 1.86-1.80 (m, 1H), 1.77-1.69 (m, 7H), 1.41-1.31 (m, 2H). LC-MS RT: 2.17 min; MS (ESI) m/z=653.6 (M+H)+; Method B.

Example 110

##STR00088##

[0632] Intermediate 110-1: To a vial was added 5-borono-2-methoxybenzoic acid (100 mg, 0.51 mmol), ethyl 2-bromooxazole-4-carboxylate (75 mg, 0.34 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (28 mg, 0.030 mmol), K.sub.2CO.sub.3 (470 mg, 3.40 mmol), toluene (1.7 mL), and ethanol (1.7 mL). The reaction mixture was heated at 120 C. for 3 h after which it became a gel. The reaction mixture was diluted with DMF, filtered, and purified by preparative RP-HPLC to afford 110-1 (24 mg, 0.080 mmol, 24% yield). RT=0.73 min; MS (ESI) m/z=292.1 (M+H).sup.+; Method A.

[0633] Procedure for example 110: Example 110 was prepared from 107-3, employing 110-1, according to the method described for example 108. .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.93 (d, J=7.0 Hz, 1H), 8.88 (s, 1H), 8.58 (d, J=2.4 Hz, 1H), 8.20 (dd, J=6.4, 2.1 Hz, 1H), 8.12 (dd, J=8.7, 2.3 Hz, 1H), 7.81 (br dd, J=8.4, 4.1 Hz, 1H), 7.48 (t, J=9.8 Hz, 1H), 7.37 (d, J=8.9 Hz, 1H), 4.41-4.35 (m, 1H), 4.31 (q, J=7.0 Hz, 2H), 4.08 (s, 3H), 3.12 (br dd, J=10.7, 4.0 Hz, 1H), 3.07-3.02 (m, 1H), 2.98-2.93 (m, 1H), 1.86-1.79 (m, 1H), 1.78-1.69 (m, 7H), 1.38-1.33 (m, 2H), 1.31 (t, J=7.0 Hz, 3H). LC-MS RT: 2.61 min; MS (ESI) m/z=630.5 (M+H)+; Method B.

Example 113

##STR00089##

[0634] Procedure for example 113: To a vial containing example 110 (11.5 mg, 0.02 mmol) in THF (180 l)/water (90 l)/MeOH (90 l) was added a 1.5 M solution of lithium hydroxide (61 l, 0.09 mmol), and the reaction was stirred at 23 C. for 5 min. The reaction mixture was quenched by the addition of TN HCl (1 mL) and extracted with EtOAc (35 mL). The combined organics were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure. The resulting crude product was purified via preparative RP-HPLC to afford example 113 (6.3 mg, 0.01 mmol, 56% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.57 (s, 1H), 9.93 (d, J=7.3 Hz, 1H), 8.57 (s, 1H), 8.54 (d, J=2.1 Hz, 1H), 8.18 (dd, J=6.1, 2.1 Hz, 1H), 8.10 (dd, J=8.7, 2.3 Hz, 1H), 7.79 (dd, J=8.1, 3.8 Hz, 1H), 7.46 (t, J=9.8 Hz, 1H), 7.35 (d, J=8.9 Hz, 1H), 4.41-4.30 (m, 1H), 4.06 (s, 3H), 3.10 (dd, J=10.7, 4.0 Hz, 1H), 3.05-2.99 (m, 1H), 2.98-2.91 (m, 1H), 1.81 (t, J=8.7 Hz, 1H), 1.76-1.65 (m, 7H), 1.41-1.28 (m, 2H). LC-MS RT: 1.92 min; MS (ESI) m/z=601.9 (M+H)+; Method B.

[0635] Procedure for example 114: Example 114 was prepared from 14-3, employing 5-cyano-2-fluorobenzoic acid, according to the method described for example 108. .sup.1H NMR. LC-MS RT: 2.53 min; MS (ESI) m/z=504.1 (M+H)+; Method C.

Example 120

##STR00090## ##STR00091##

[0636] Intermediate IV-3: Intermediate IV-3 was prepared from IV-2 in the same manner as 5-6. (101 mg, 0.240 mmol, 97.0% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.61 (br d, J=6.3 Hz, 1H), 7.76 (dd, J=5.9, 2.6 Hz, 1H), 7.71 (dt, J=8.9, 3.4 Hz, 1H), 7.66 (s, 1H), 7.23 (t. J=9.4 Hz, 1H), 4.70 (dt, J=10.3, 5.3 Hz, 1H), 3.33 (dd, J=10.5, 4.4 Hz, 1H), 2.54 (t, J=4.3 Hz, 1H), 2.42 (t, J=4.1 Hz, 1H), 2.20-2.10 (m, 1H), 2.06-1.99 (m, 1H), 1.96-1.81 (m, 2H).

[0637] Intermediate IV-4: Into the reaction vessel was added bromo(methyl)triphenylphosphorane (419 mg, 1.17 mmol) (fine powder by grinding the commercial material) and THF (7 mL). The reaction mixture was cooled to 78 C. and KHMDS (1.2 mL, 1.17 mmol) was added. This reaction mixture was stirred vigorously at 78 C. for 30 min and IV-3 (100 mg, 0.240 mmol) was added at 78 C. After stirring at 78 C. for a further 10 min, the reaction mixture was allowed to warm to 23 C. and stirred for 1.5 h. The reaction mixture was cooled to 40 C. and quenched by the addition of sat. NaHCO.sub.3. The solution was extracted with EtOAc. The organic phase was dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to produce IV-4 (71 mg, 0.17 mmol, 71% yield). LCMS RT=1.16 min; (M+H)=425.0; Method A.

[0638] Intermediates IV-5 and IV-6: Into the reaction vessel was added IV-4 (71 mg, 0.17 mmol), DCM (3 mL), and Br.sub.2 (0.03 mL, 0.6 mmol). The reaction mixture was stirred at 23 C. for 20 min and concentrated under reduced pressure with sat. Na.sub.2S.sub.2O.sub.3 trap to quench excess Br.sub.2. The resulting dibromide was dissolved in THF (3 mL). After cooling the flask to 78 C., KHMDS (1.0 mL, 1.0 mmol) was added. The reaction mixture was kept at 78 C. for 12 h and 40 C. for 2 h, then quenched by the addition of sat. NaHCO.sub.3 at 40 C. The resulting solution was extracted with EtOAc. The organic phase was collected, dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to produce IV-6 (27 mg, 0.050 mmol, 32% yield) (Z-isomer, peak2. LCMS RT=1.19 min; (M+H)=504.9; Method A. and the corresponding E-isomer IV-5 (28 mg, 0.060 mmol, 33% yield) (peak 1). IV-6 was produced as a racemate as outlined above and separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Thar 350 SFC; Column: Chiralcel OD-H, 550 cm, 5 micron; Mobile phase: 20% MeOH/80% CO.sub.2; Flow conditions: 340 mL/min, 100 Bar, 35 C.; Detector wavelength: 220 nm; Injections details: 3.75 mL of 30 mg/mL in MeOH. Peak 1, RT=7.81 min, >99% ee; Peak 2, RT=10.97 min, >99% ee. Intermediate IV-6 product peak #1 (1.9 grams) was collected and carried forward to produce chiral IV-7.

[0639] Intermediate IV-7: Into the reaction was added MeOH (3 mL) and AcCl (0.3 mL, 4.2 mmol). After stirring for 5 min, chiral IV-6 (1.sup.st eluting peak from chiral SFC, 75 mg, 0.15 mmol) was added and the reaction mixture was stirred at 40 C. for 48 h. The resulting solution was concentrated under reduced pressure to generate IV-7 (67 mg, 0.16 mmol, 100%) that was used without further purification. LC-MS RT=0.78 min; (M+H)=408.9; Method A.

##STR00092##

[0640] Intermediate 120-6: To a vial was added 5-borono-2-methoxybenzoic acid (500 mg, 2.55 mmol), tert-butyl 3-bromo-4-fluorobenzoate (842 mg, 3.06 mmol), tert-butyl 3-bromo-4-fluorobenzoate (842 mg, 3.06 mmol), K.sub.2CO.sub.3 (1.76 g, 12.8 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (313 mg, 0.380 mmol), and THF (22.3 mL). The reaction mixture was degassed for 2 min with nitrogen, then heated at 80 C. for 18 h. After cooling to room temperature, the reaction mixture was diluted with 1N HCl (25 mL) and the solution extracted with EtOAc (325 mL). The combined organic portions were dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and the resulting residue was dissolved in DMF and purified by preparative RP-HPLC to afford 120-6 (586 mg, 1.69 mmol, 66.0% yield). LC-MS RT=1.02 min; (M+H)=347.1; Method A.

[0641] The Suzuki reaction may be performed with alternative aryl halides with the remainder of the steps conducted similarly to generate biaryl analogs.

[0642] Intermediate 120-7: In the reaction vessel was added IV-7 (7 mg, 0.02 mmol) and 120-6 (6.6 mg, 0.020 mmol), MeCN (1 mL), DIEA (9.64 uL, 0.0600 mmol) and HATU (12.0 mg, 0.0300 mmol). The reaction mixture was stirred at 23 C. for 3 h, concentrated under reduced pressure and purified via silica gel chromatography to produce 120-7 (10 mg, 0.014 mmol, 86% yield). LC-MS RT=1.33 min; (M+H)=735.2; Method A.

[0643] Intermediate 120-8: Intermediate 120-8 was prepared from 120-7 in the same manner as intermediate 34-2 (5 mg, 0.07 mmol, 100% yield). LC-MS RT=1.15 min; (M+H)=679.08; Method A.

[0644] Procedure for example 120: Into the reaction vessel containing 120-8 (10 mg, 0.01 mmol) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (13.3 mg, 0.07 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (3 mg, 0.004 mmol, small spatula tip), and Na.sub.2CO.sub.3 (0.5 mL, 1.0 mmol). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 60 C. for 2 h. After allowing to cool to 23 C., the reaction mixture was concentrated under reduced pressure and purified via preparative RP-HPLC to produce the intermediate tert-butyl ester. Treatment of the ester with 10:1 DCM/TFA followed by purification by reverse phase HPLC produced example 120 (7.0 mg, 0.01 mmol, 72% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 10.03 (br d, J=6.3 Hz, 1H), 8.50 (br s, 1H), 8.43 (br s, 1H), 8.31 (br s, 1H), 8.21 (br d, J=5.2 Hz, 1H), 8.10-7.91 (m, 3H), 7.73 (br d, J=8.3 Hz, 1H), 7.53 (br d, J=3.9 Hz, 1H), 7.27-7.19 (m, 1H), 7.19-7.08 (m, 2H), 6.06 (s, 1H), 4.86 (br s, 1H), 4.11 (br s, 3H), 3.31 (br s, 1H), 3.22 (br d, J=7.2 Hz, 1H), 2.93 (br s, 1H), 2.37-2.25 (m, 1H), 2.03 (br d, J=11.8 Hz, 1H), 1.75-1.65 (m, 2H). LC-MS RT: 1.14 min; MS (ESI) m/z=668.3 (M+H)+; Method A.

Example 121

##STR00093##

[0645] Procedure for example 121: Into the reaction vessel was added example 87 (3 mg, 4.77 mol), ethanesulfonamide (1.6 mg, 0.01 mmol), MeCN (1 mL), DIEA (3 l, 0.017 mmol), and BOPCl (4 mg, 0.01 mmol). The reaction was stirred at 40 C. for 12 h, concentrated under reduced pressure, and purified via preparative RP-HPLC to produce only the primary amide by-product 121 (3.0 mg, 0.0040 mmol, 93% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.65 (br d, J=8.0 Hz, 1H), 8.41 (d, J=2.2 Hz, 1H), 7.96 (dd, J=7.2, 2.2 Hz, 2H), 7.90-7.83 (m, 2H), 7.73 (dt, J=8.5, 2.2 Hz, 1H), 7.56 (dt, J=8.7, 3.5 Hz, 1H), 7.25 (dd, J=9.9, 8.8 Hz, 1H), 7.16-7.06 (m, 2H), 6.69-6.68 (m, 1H), 4.72 (br t, J=11.0 Hz, 1H), 4.08 (s, 3H), 3.06 (br d, J=8.8 Hz, 3H), 2.21-2.14 (m, 1H), 1.84 (br t, J=8.7 Hz, 1H), 1.76 (s, 3H), 1.75 (s, 3H), 1.64-1.54 (m, 2H). LC-MS RT: 1.26 min; MS (ESI) m/z=628.3 (M+H)+; Method A.

##STR00094##

Example 125

[0646] Intermediate 125-1: Intermediate 125-1 was prepared from IV-3 in the same manner as example 5 and purified via silica gel chromatography (49 mg, 0.10 mmol, 30% yield). RT=1.23 min; MS (ESI) m/z=501.1 (M+H).sup.+; Method A.

[0647] Intermediate 125-2: Intermediate 125-2 was prepared from 125-1 in the same manner as intermediate IV-7 (73 mg, 0.18 mmol, 96% yield). RT=0.87 min; MS (ESI) m/z=405.1 (M+H).sup.+; Method A.

##STR00095##

[0648] Intermediate 125-3: Into the reaction vessel was added methyl piperazine-1-carboxylate (103 mg, 0.710 mmol), DCE (1 mL), MeCN (1 mL), copper (II) acetate (130 mg, 0.71 mmol), (4-methoxy-3-(methoxycarbonyl)phenyl)boronic acid (50 mg, 0.24 mmol), and 4 molecular sieves (300 mg). The reaction mixture was stirred at 23 C. for 12 h (open to air), filtered, concentrated under reduced pressure, and purified via preparative RP-HPLC to produce 125-3 (37 mg, 0.12 mmol, 50% yield). LC-MS RT=0.72 min; MS (ESI) m/z=309.1 (M+H).sup.+; Method A.

[0649] Intermediate 125-4: Into the reaction vessel was added 125-3 (37 mg, 0.12 mmol), THF (1 mL), water (0.5 mL), and lithium hydroxide monohydrate (34.4 mg, 0.820 mmol). The reaction mixture was stirred at 23 C. for 2.5 h, diluted with EtOAc (10 mL), and washed with 10 mL sat. NH.sub.4Cl containing 0.82 mmol HCl. The organic phased was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide 125-4 (35.3 mg, 0.120 mmol, 100% yield) that was used without further purification. LC-MS RT=0.62 min; MS (ESI) m/z=295.0 (M+H).sup.+; Method A.

[0650] Procedure for example 125: Example 125 was prepared from 125-2, employing 125-4, according to the method described for example 108. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.63 (br d, J=7.7 Hz, 1H), 7.96-7.84 (m, 3H), 7.59 (dt, J=8.8, 3.4 Hz, 1), 7.33 (d, J=4.1 Hz, 4H), 7.29 (dd, J=8.9, 3.2 Hz, 1H), 7.25-7.20 (m, 1H), 7.10 (t, J=9.4 Hz, 1H), 6.95 (d, J=9.1 Hz, 1H), 6.33 (s, 1H), 4.89-4.80 (m, 1H), 3.99 (s, 3H), 3.75 (s, 3H), 3.74-3.69 (m, 4H), 3.49 (t. J=3.3 Hz, 1H), 3.23-3.14 (m, 5H), 2.89 (m, 1H), 2.27-2.19 (m, 1H), 1.97-1.87 (m, 1H), 1.75-1.66 (m, 2H). LC-MS RT: 1.16 min; MS (ESI) m/z=681.3 (M+H)+; Method A.

Example 126

##STR00096##

[0651] Intermediate 126-1: Into the reaction vessel containing IV-6 (125 mg, 0.25 mmol) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (125 mg, 0.610 mmol) PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (50.7 mg, 0.0620 mmol), and Na.sub.2CO.sub.3 (1.5 mL, 3.0 mmol). The reaction mixture was degassed by bubbling nitrogen for 3 min, sealed, and stirred at 60 C. for 2 h. After allowing to cool to 23 C., the reaction mixture was extracted with EtOAc, the combined organic portions dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to produce 126-1 (101 mg, 0.210 mmol, 83.0% yield). LC-MS RT=1.07 min; MS (ESI) m/z=492.1 (M+H).sup.+; Method A.

[0652] Intermediate 126-2: Intermediate 126-2 was prepared from 126-1 in the same manner as intermediate IV-7 (67 mg, 0.16 mmol, 100% yield), RT=0.76 min; MS (ESI) m/z=396.0 (M+H).sup.+; Method A.

##STR00097##

[0653] Intermediate 126-3: Into the reaction vessel was added methanesulfonamide (521 mg, 5.48 mmol), 3-bromo-4-fluorobenzoic acid (400 mg, 1.83 mmol), MeCN (3.7 mL), DIEA (1.1 mL, 6.40 mmol), and HATU (833 mg, 2.19 mmol). The reaction mixture was stirred at 40 C. for 12 h, allowed to cool, concentrated under reduced pressure, and subjected to preparative RP-HPLC purification to produce 126-3 (450 mg, 1.52 mmol, 83% yield). LC-MS RT=0.76 min; (M+H)=297.7; Method A

[0654] Intermediate 126-4: Into the reaction vessel containing 126-3 (200 mg, 0.68 mmol) was added 5-borono-2-methoxybenzoic acid (199 mg, 1.01 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (83 mg, 0.10 mmol), THF (6.7 mL) and 1 M Na.sub.2CO.sub.3 (4.0 mL, 4.1 mmol). The reaction mixture was degassed by bubbling nitrogen for 10 min, sealed, and stirred at 70 C. for 2 h. After allowing to cool to 23 C., the reaction mixture was concentrated under reduced pressure and purified by preparative RP-HPLC to afford 126-4 (158 mg, 0.430 mmol, 64.0% yield). LC-MS RT=0.70 min; MS (ESI) m/z=368.1 (M+H)+; Method A.

[0655] Procedure for example 126: Example 126 was prepared from 126-2, employing 126-4, according to the method described for example 108. .sup.1H NMR (500 MHz, CDCl.sub.3) 10.32 (br s, 1H), 9.86 (br d, J=7.7 Hz, 1H), 8.41 (s, 1H), 8.34 (s, 1H), 8.25 (d, J=1.7 Hz, 1H), 8.10 (br s, 1H), 8.04 (dd, J=6.1, 2.5 Hz, 1H), 7.98 (dd, J=7.3, 2.1 Hz, 1H), 7.89 (ddd, J=8.5, 4.5, 2.2 Hz, 1H), 7.68 (br d, J=8.8 Hz, 1H), 7.58 (dt, J=8.6, 3.5 Hz, 1H), 7.19-7.06 (m, 3H), 5.95 (s, 1H), 4.72-4.63 (m, 1H), 4.08 (s, 3H), 3.45 (s, 3H), 3.25-3.20 (m, 1H), 3.15 (dd, J=10.7, 4.1 Hz, 1H), 2.89-2.84 (m, 1H), 2.28-2.23 (m, 1H), 2.01-1.96 (m, 1H), 1.71-1.62 (m, 2H). LC-MS RT: 1.09 min; MS (ESI) m/z=745.2 (M+H)+; Method A.

Example 127

##STR00098##

[0656] Intermediate 127-1: Into the reaction vessel was added example 6 (10 mg, 0.017 mmol), DCM (1 mL), DIEA (0.015 mL, 0.087 mmol), and DMAP (1.06 mg, 8.70 mol). After stirring at 23 C. for 12 h, the residue was purified via silica gel chromatography to produce 127-1 (10.5 mg, 0.0160 mmol, 92.0% yield). LC-MS RT=1.31 min; MS (ESI) m/z=659.3 (M+H).sup.+; Method A.

[0657] Procedure for example 127: Into the reaction vessel was added 3-((trifluoromethyl)sulfonyl)aniline (24 mg, 0.11 mmol), toluene (0.5 mL) and trimethylaluminum (0.05 mL, 0.11 mmol). After stirring at 23 C. for 15 min, intermediate 127-1 (5 mg, 7.6 mol) in toluene (0.5 mL) was added. The reaction was stirred at 23 C. for 1 h, quenched with sat. Rochelle salt and extracted with EtOAc. The organic phase was dried over Na.sub.2SO.sub.4, concentrated, and purified via preparative RP-HPLC to produce example 127 (3.6 mg, 5.80 mol, 76% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.56 (br d, J=7.7 Hz, 1H), 8.56-8.47 (m, 1H), 8.06-7.98 (m, 2H), 7.78-7.71 (m, 2H), 7.58 (t, J=8.0 Hz, 1H), 7.37-7.30 (m, 4H), 7.25-7.21 (m, 1H), 6.79 (dd, J=11.7, 6.2 Hz, 1H), 6.33 (s, 1H), 4.88-4.81 (m, 1H), 4.03 (s, 3H), 3.52-3.47 (m, 1H), 3.20 (dd, J=10.7, 3.9 Hz, 1H), 2.91-2.87 (m, 1H), 2.26-2.18 (m, 1H), 1.95-1.88 (m, 1H), 1.74-1.70 (m, 2H). LC-MS RT: 1.25 min; MS (ESI) m/z=621.2 (M+H)+; Method A.

Example 130

##STR00099##

[0658] Intermediate 130-1: Intermediate 130-1 was prepared from example 87 in the same manner as described for 77-1 (19 mg, 0.030 mmol, 100% yield). LC-MS RT=1.06 min; MS (ESI) m/z=603.1 (M+H).sup.+; Method A.

[0659] Procedure for example 130: Into the reaction vessel containing 130-1 (17 mg, 0.03 mmol) was added DCE (1.5 mL), DIEA (0.09 mL, 0.51 mmol), and O-ethylhydroxylamine, HCl (41.3 mg, 0.42 mmol). The mixture was stirred 40 C. at 23 C. for 24 h, concentrated under reduced pressure, and subjected to preparative RP-HPLC purification to give example 130 as a mixture of Z/E isomers (15 mg, 0.023 mmol, 82% yield). LC-MS RT: 1.13 min; MS (ESI) m/z=464.2 (M+H)+; Method A.

Example 134

##STR00100##

[0660] Procedure for example 134: Into the reaction vessel was added example 140 (6 mg, 10 mol), DCM (1 mL), DIEA (6 l, 0.03 mmol), and methyl chloroformate (2 l, 0.02 mmol). After stirring at 23 C. for 30 min, the reaction mixture was concentrated under reduced pressure and purified via preparative RP-HPLC to produce example 134 (3.5 mg, 5.4 mol, 51% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.42-9.17 (m, 1H), 8.25-8.02 (m, 2H), 7.87 (dd, J=6.1, 2.4 Hz, 1H), 7.62-7.53 (m, 1H), 7.43 (br s, 1H), 7.07 (t, J=9.5 Hz, 1H), 6.92 (br d, J=8.6 Hz, 1H), 6.17 (br s, 1H), 4.78-4.66 (m, 1H), 4.38-4.23 (m, 2H), 3.98 (s, 3H), 3.75 (s, 3H), 3.66-3.52 (m, 2H), 3.08-2.97 (m, 3H), 2.37-2.26 (m, 2H), 2.23-2.11 (m, 1H), 1.83-1.75 (m, 1H), 1.74-1.72 (m, 3H), 1.72 (s, 3H), 1.62-1.53 (m, 2H). LC-MS RT: 1.25 min; MS (ESI) m/z=630.3 (M+H)+; Method B.

Example 136

##STR00101##

[0661] Intermediate 136-1: Into the reaction vessel was added methyl 5-bromo-2-methoxybenzoate (33.1 mg, 0.135 mmol), tert-butyl piperidine-3-carboxylate (25 mg, 0.14 mmol), toluene (1 mL), tert-butyl piperidine-3-carboxylate (25 mg, 0.14 mmol), BINAP (10.5 mg, 0.0200 mmol) and Pd.sub.2(dba).sub.3 (6 mg, 0.01 mmol). The reaction mixture was degassed with nitrogen for 3 min and was stirred at 100 C. for 12 h, allowed to cool to 23 C., diluted with EtOAc, and the solution washed with sat. NaHCO.sub.3 (210 mL). The organic layer was dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via preparative RP-HPLC to produce 136-1 (39 mg, 0.084 mmol, 62% yield). LC-MS RT=0.82 min; MS (ESI) m/z=350.1 (M+H).sup.+; Method A.

[0662] Intermediate 136-2: Into the reaction vessel was added 136-1 (26 mg, 0.060 mmol), THF (1 mL), water (0.5 mL), and lithium hydroxide monohydrate (19.1 mg, 0.460 mmol). The reaction mixture was stirred at 23 C. for 3 h, diluted with EtOAc (10 mL), and washed with 10 mL sat. NH.sub.4Cl containing 0.5 mmol HCl. The organic phase was dried over Na.sub.2SO.sub.4 filtered and concentrated under reduced pressure to provide 136-2 (19 mg, 0.060 mmol, 100% yield) which was used without further purification. LC-MS RT=0.74 min; MS (ESI) m/z=336.1 (M+H).sup.+; Method A.

[0663] Procedure for example 136: Example 136 was prepared from 125-2, employing racemic 136-2, according to the method described for example 108. A subsequent removal of the tert-butyl ester was accomplished as in the procedure to prepare example 120. Example 136 (Peak 1) was separated from its diastereomer (Peak 2), example 138, via SFC chromatography. Peak 1, RT=8.80 min, >99.5% ee; Peak 2, RT=9.97 min, >99.5% ee.

[0664] Preparative Chromatographic Conditions: Instrument: Berger MG II; Column: Chiralpak IA, 30250 mm, 5 micron; Mobile Phase: 25% EtOH/75% CO.sub.2; Flow Conditions: 70 mL/min, 150 Bar, 40 C.; Detector Wavelength: 220 nm; Injection Details: 0.5 mL of 3 mg/mL in ACN. Analytical Chromatographic Conditions: Instrument: Berger Analytical SFC; Column: Chiralpak IA, 4.6250 mm, 5 micron; Mobile Phase: 25% EtOH/75% CO.sub.2; Flow Conditions: 2.0 mL/min, 150 Bar, 40 C.; Detector Wavelength: 220 nm; Injection Details: 10 L of concentrated sample in EtOH. LC-MS RT: 1.07 min; MS (ESI) m/z=666.3 (M+H)+; Method A.

Example 140

##STR00102## ##STR00103##

[0665] Intermediate 140-1: Into the reaction vessel containing methyl 5-bromo-2-methoxybenzoate (47.6 mg, 0.190 mmol) was added tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (50 mg, 0.16 mmol) PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (19.8 mg, 0.0240 mmol), and Na.sub.2CO.sub.3 (1 mL, 2 mmol). The reaction mixture was degassed by bubbling nitrogen for 3 min. sealed, and stirred at 65 C. for 2 h. After allowing to cool to 23 C., the reaction mixture was extracted with EtOAc. The organic phase was dried over Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to produce 140-1 (57.4 mg, 0.17 mmol, 100% yield). LC-MS RT=1.04 min; MS (ESI) m/z=348.0 (M+H).sup.+; Method A.

[0666] Intermediate 140-2: Into the reaction vessel was added 140-1 (28 mg, 0.081 mmol), THF (1 mL), water (0.5 mL), and lithium hydroxide monohydrate (16.9 mg, 0.400 mmol). The reaction mixture was stirred at 23 C. for 1 h, diluted with EtOAc (10 mL), and the resulting solution washed with 10 mL sat. NH.sub.4Cl containing 0.5 mmol HCl. The organic phase was dried over Na.sub.2SO.sub.4 filtered and concentrated under reduced pressure to provide 140-2 (25 mg, 0.080 mmol, 93% yield) that was used without further purification.

[0667] Intermediate 140-3: Intermediate 140-3 was prepared from 140-2 and 107-3 using the general amide coupling procedure employed in Example 108 (67 mg, 0.16 mmol, 100% yield). RT=1.32 min; MS (ESI) m/z=672.3 (M+H).sup.+; Method A.

[0668] Procedure for example 140: Into the reaction vessel was added 140-3 (11.4 mg, 0.02 mmol), DCM (1 mL), and TFA (0.1 mL, 1.30 mmol). After stirring at 23 C. for 3 h, concentration of the reaction contents under reduction pressure provided example 140 (3.7 mg, 5.13 mol, 30% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.29 (br d, J=7.9 Hz, 1H), 8.59 (br s, 1H), 8.08 (d, J=2.3 Hz, 1H), 7.94 (br d, J=4.5 Hz, 1H), 7.67-7.57 (m, 1H), 7.18 (br d, J=8.3 Hz, 1H), 7.06 (t, J=9.4 Hz, 1H), 6.82 (d, J=8.6 Hz, 1H), 6.16 (br s, 1H), 4.75-4.60 (m, 1H), 3.97 (s, 3H), 3.79-3.59 (m, 2H), 3.20-3.12 (m, 1H), 3.11-3.05 (m, 2H), 3.04-3.00 (m, 1H), 2.98-2.95 (m, 1H), 2.46-2.34 (m, 2H), 2.22 (br t, J=8.7 Hz, 1H), 1.77 (br t, J=8.7 Hz, 1H), 1.72 (s, 3H), 1.71 (s, 3H), 1.60-1.53 (m, 2H). LC-MS RT: 0.98 min; MS (ESI) m/z=572.4 (M+H)+; Method B.

Example 144

##STR00104##

[0669] Procedure for example 144: Into the reaction vessel was added example 114 (3.4 mg, 6.6 gmol), sodium azide (12.9 mg, 0.198 mmol), ammonium chloride (10.6 mg, 0.198 mmol), and DMF. The reaction mixture was stirred at 105 C. for 4 h, allowed to cool to 23 C., diluted with MeOH, filtered, and purified via preparative RP-HPLC to produce example 144 (2.3 mg, 4.0 mol, 60% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 10.01 (d, J=9.4 Hz, 1H), 9.30 (d, J=2.5 Hz, 1H), 8.51 (dd, J=8.8, 2.5 Hz, 1H), 8.44 (s, 1H), 8.11 (dd, J=6.3, 2.8 Hz, 1H), 7.41 (dt, J=8.7, 3.3 Hz, 1H), 7.25-7.22 (m, 1H), 7.08-6.99 (m, 1H), 4.96 (td, J=9.8, 4.3 Hz, 1H), 4.21 (s, 3H), 3.31 (dd, J=10.7, 3.9 Hz, 1H), 3.04 (t, J=3.7 Hz, 1H), 2.88 (t, J=4.0 Hz, 1H), 2.51-2.44 (m, 1H), 1.87-1.80 (m, 2H), 1.67 (s, 3H), 1.60-1.50 (m, 2H), 1.48 (s, 3H). LC-MS RT: 1.11 min; MS (ESI) m/z=559.1 (M+H)+; Method A.

Example 145

##STR00105##

[0670] Procedure for example 145: Example 145 was prepared from 5-6, employing 2-methyloxazole: Into the reaction vessel was added 2-methyloxazole (24.9 mg, 0.300 mmol) and THF (1 mL). After the reaction mixture was cooled to 78 C. KHMDS (0.30 mL, 0.30 mmol) was added. The mixture was stirred at 78 C. for 10 min and additional 2-methyloxazole (24.9 mg, 0.300 mmol) was added. The mixture was allowed to warm to 23 C., stirred at 23 C. for 3 h, and quenched by the addition of sat. Na.sub.2CO.sub.3. The organic phase was dried over Na.sub.2SO.sub.4, filtered, concentrated, and purified via silica gel chromatography to produce the intermediate alcohol (17 mg, 0.029 mmol, 97% yield). The intermediate alcohol was dehydrated according to the method described for example 33. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.53 (br d, J=7.4 Hz, 1H), 8.06-7.99 (m, 2H), 7.97 (dd, J=6.2, 2.6 Hz, 1H), 7.63 (s, 1H), 7.53 (dt, J=8.9, 3.4 Hz, 1H), 7.18-7.09 (m, 2H), 6.80 (dd, J=11.6, 6.1 Hz, 1H), 6.28 (s, 1H), 4.88-4.80 (m, 1H), 4.00 (s, 3H), 3.93 (t, J=4.0 Hz, 1H), 3.19 (dd, J=10.9, 3.7 Hz, 1H), 2.99-2.92 (m, 1H), 2.35-2.27 (m, 1H), 2.02-1.94 (m, 1H), 1.78-1.71 (m, 2H). LC-MS RT: 1.17 min; MS (ESI) m/z=566.0 (M+H)+; Method A.

Example 147

##STR00106##

[0671] Procedure for example 147: Into the reaction vessel was added 5-6 (10 mg, 0.020 benzene (1 mL) ethane-1,2-diol (24.81 mg, 0.4000 mmol), MgSO.sub.4 (200 mg, 1.66 mmol), and pTsOH monohydrate (3.8 mg, 0.020 mmol). After stirring at 50 C. for 12 h, the reaction mixture was filtered, concentrated under reduced pressure, and purified via preparative RP-HPLC to produce example 147 (2.1 mg, 3.8 mol, 19% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.35 (br d, J=7.8 Hz, 1H), 8.04 (dd, J=11.4, 9.4 Hz, 1H), 7.93 (dd, J=6.3, 2.6 Hz, 1H), 7.77 (s, 1H), 7.52 (dt, J=8.7, 3.6 Hz, 1H), 7.12 (t, J=9.4 Hz, 1H), 6.79 (dd, J=11.6, 6.1 Hz, 1H), 5.05-4.97 (m, 1H), 4.08-4.01 (m, 4H), 3.99 (s, 3H), 3.49-3.41 (m, 1H), 2.23 (t, J=4.0 Hz, 1H), 2.20-2.11 (m, 2H), 1.93-1.81 (m, 2H), 1.75-1.67 (m, 1H). LC-MS RT: 1.14 min; MS (ESI) m/z=545.1 (M+H)+; Method C.

Example 150

##STR00107##

[0672] Procedure for example 150: Into the reaction vessel was added example 87 (5 mg, 8 mol), benzenesulfonamide (3.8 mg, 0.020 mmol), MeCN (1 mL), DIEA (5 l, 0.03 mmol), and BOPCl (6.0 mg, 0.024 mmol). The reaction mixture was stirred at 40 C. for 12 h, concentrated under reduced pressure, and purified via preparative RP-HPLC to produce example 150 (2.2 mg, 2.7 mol, 34% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.65 (br d, J=8.0 Hz, 1H), 8.41 (d, J=2.2 Hz, 1H), 7.96 (dd, J=7.2, 2.2 Hz, 2H), 7.90-7.84 (m, 2H), 7.73 (dt, J=8.5, 2.2 Hz, 1H), 7.56 (dt, J=8.7, 3.5 Hz, 1H), 7.25 (dd, J=9.9, 8.8 Hz, 1H), 7.16-7.03 (m, 2H), 4.75-4.68 (m, 1H), 4.08 (s, 3H), 3.06 (br d, J=8.8 Hz, 3H), 2.21-2.14 (m, 1H), 1.87-1.81 (m, 1H), 1.76 (s, 3H), 1.75 (s, 3H), 1.63-1.56 (m, 2H). LC-MS RT: 1.4 min; MS (ESI) m/z=768.2 (M+H)+; Method C.

Example 166

##STR00108##

[0673] Intermediate 166-1: Intermediate 166-1 was prepared from IV-6 in the same manner as intermediate 126-1 (5.1 mg, 0.010 mmol, 23% yield). RT=1.21 min; MS (ESI) m/z=465.1 (M+H).sup.+; Method A.

[0674] Intermediate 166-2: Intermediate 166-2 was prepared from 166-1 in the same manner as intermediate IV-7 (4.0 mg, 0.010 mmol, 100% yield). RT=0.84 min; MS (ESI) m/z=369.1 (M+H).sup.+; Method A.

##STR00109##

[0675] Intermediate 166-3: Intermediate 166-3 was prepared from 3-bromo-4-fluoro-N-methylbenzamide and 5-borono-2-methoxybenzoic acid in the same manner as intermediate 140-1 (28 mg, 0.080 mmol, 41% yield). LC-MS RT=0.99 min; MS (ESI) m/z=304.9 (M+H).sup.+; Method A.

[0676] Procedure for example 166: Example 166 was prepared from 166-2, employing 166-3, according to the method described for example 108. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.73 (br d, J=7.7 Hz, 1H), 8.39 (d, J=1.9 Hz, 1H), 7.97 (dd, J=6.2, 2.3 Hz, 1H), 7.90 (s, 1H), 7.85 (dd, J=7.4, 2.2 Hz, 1H), 7.81 (ddd, J=8.5, 4.7, 2.2 Hz, 1H), 7.72 (dt, J=8.8, 2.2 Hz, 1H), 7.56 (dt, J=8.7, 3.4 Hz, 1H), 7.24-7.19 (m, 1H), 7.15-7.10 (m, 1H), 7.08 (d, J=8.8 Hz, 1H), 6.47 (br s, 1H), 4.85-4.76 (m, 1H), 4.66 (d, J=9.6 Hz, 1H), 4.09 (s, 3H), 3.22 (t, J=3.7 Hz, 1H), 3.10 (dd, J=10.7, 3.3 Hz, 1H), 3.05 (d, J=4.7 Hz, 3H), 2.77-2.67 (m, 1H), 2.19-2.12 (m, 1H), 1.94-1.86 (m, 1H), 1.71-1.61 (m, 2H), 1.53-1.46 (m, 1H), 0.81-0.71 (m, 2H), 0.41-0.30 (m, 2H). LC-MS RT: 1.18 min; MS (ESI) m/z=654.2 (M+H)+; Method A.

Example 168

##STR00110##

[0677] Procedure for example 168: Example 168 was prepared from 166-2, employing 120-6, according to the method described for example 108. Cleavage of the tert-butyl ester was accomplished in DCM (1 mL) and stirring with ZnBr.sub.2 (20 equiv.) at 23 C. for 12 h. After quenching the reaction by the addition of HCl (1.0 M) and extracting the resulting solution with ethyl acetate, the organic phase was dried over Na.sub.2SO.sub.4 filtered, concentrated under reduced pressure and the residue purified via preparative RP-HPLC to produce example 168. Analytical data for example 168: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.42 (br d, J=7.7 Hz, 1H), 8.43 (br s, 1H), 8.30-8.21 (m, 1H), 8.12-8.02 (m, 1H), 7.96 (br s, 2H), 7.71 (dt, J=8.7, 2.0 Hz, 1H), 7.54-7.47 (m, 1H), 7.26-7.21 (m, 1H), 7.13-7.06 (m, 2H), 4.95-4.85 (m, 1H), 4.66 (d, J=9.6 Hz, 1H), 4.07 (s, 3H), 3.27-3.19 (m, 1H), 3.14 (br dd, J=10.9, 3.2 Hz, 1H), 2.75 (t, J=3.9 Hz, 1H), 2.32-2.23 (m, 1H), 1.94-1.87 (m, 1H), 1.74-1.63 (m, 2H), 1.54-1.48 (m, 1H), 0.76 (m, 2H), 0.36 (m, 2H). LC-MS RT: 1.19 min; MS (ESI) m/z=641.1 (M+H)+; Method A.

Example 170

##STR00111##

[0678] Intermediate 170-1: To a 20 mL vial charged with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (volume ?, 0.15 mmol) in anhydrous DMF (0.5 mL) was added dropwise via syringe to a suspension of IV-6 and CuI (mass?, 0.07 mmol) in anhydrous DMF (1 mL) and HMPA (0.5 mL) at 75 C. under a nitrogen atmosphere for 30 min. The resulting mixture was stirred at the same temperature for 12 h. The reaction mixture was allowed to cool and filtered via an HPLC filter and purified by RP-HPLC to produce 170-1 (24 mg, 81% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.38 (br d, J=6.1 Hz, 1H), 7.77-7.69 (m, 2H), 7.46 (s, 1H), 7.24 (t, J=9.1 Hz, 1H), 5.62 (q, J=7.2 Hz, 1H), 4.50 (dt, J=10.5, 5.3 Hz, 1H), 3.50-3.42 (m, 1H), 3.13-3.04 (m, 1H), 2.89 (t, J=4.0 Hz, 1H), 2.02-1.90 (m, 2H), 1.76-1.60 (m, 2H).

[0679] Intermediate 170-2: Intermediate 170-2 was prepared from 170-1. MeOH (1.5 mL) and acetyl chloride (2.1 mmol) were charged into a 2 dram vial and stirred at 23 C. for 5 min. 170-1 was added to the reaction vial and the contents heated to 40 C. for 24 h. The reaction mixture was concentration with a stream of nitrogen gave 170-2 as the HCl salt which was used without further purification. LC-MS RT=0.75 min; MS (ESI) m/z=397.1 (M+H).sup.+; Method A.

[0680] Procedure for example 170: Example 170 was prepared from 170-2, employing 120-6, according to the method described example 120. Analytical data for example 170: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.28 (br d, J=6.6 Hz, 1H), 8.41 (br s, 1H), 8.37 (br s, 1H), 8.27 (br d, J=6.1 Hz, 1H), 8.08 (br s, 1H), 7.92 (br s, 1H), 7.80-7.70 (m, 1H), 7.47 (dt, J=8.6, 3.7 Hz, 1H), 7.27-7.20 (m, 1H), 7.13-7.02 (m, 2H), 5.60 (q, J=7.3 Hz, 1H), 5.05-4.92 (m, 1H), 4.06 (s, 3H), 3.42 (br s, 1H), 3.25 (br dd, J=10.6, 3.4 Hz, 1H), 2.95 (t, J=4.0 Hz, 1H), 2.61-2.50 (m, 1H), 2.05-1.97 (m, 1H), 1.82-1.72 (m, 2H). LC-MS RT: 1.15 min; MS (ESI) m/z=669.2 (M+H)+; Method A.

Example 171

##STR00112##

[0681] Procedure for example 171: Example 171 was prepared from example 186. To a 1 dram vial charged with example 186 (0.008 mmol), DCM (0.3 mL), and MeOH (0.1 mL) was added TMS-diazomethane (0.5 M in DCM, 0.34 mL, 0.17 mmol, 20 equiv.), and the reaction mixture stirred at 23 C. for 1 h. The reaction mixture was concentrated under reduced pressure and purified via silica gel normal phase chromatography to give 6.1 mg of example 171. Analytical data for example 171: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.45 (br d, J=8.0 Hz, 1H), 8.38-8.35 (m, 1H), 8.00-7.92 (m, 2H), 7.64 (dt, J=8.7, 2.0 Hz, 1H), 7.54 (dt, J=8.7, 3.5 Hz, 1H), 7.43 (dd, J=7.3, 2.3 Hz, 1H), 7.32 (ddd, J=8.4, 4.5, 2.5 Hz, 1H), 7.17-7.03 (m, 3H), 6.59 (br d, J=6.9 Hz, 1H), 5.61 (d, J=6.9 Hz, 1H), 4.89-4.81 (m, 1H), 4.65 (d, J=9.6 Hz, 1H), 4.06 (s, 3H), 3.77 (s, 3H), 3.21 (t, J=4.1 Hz, 1H), 3.15-3.08 (m, 1H), 2.73 (t, J=4.0 Hz, 1H), 2.24-2.16 (m, 1H), 2.08 (s, 3H), 1.95-1.86 (m, 1H), 1.72-1.63 (m, 2H), 1.54-1.45 (m, 1H), 0.79-0.72 (m, 2H), 0.39-0.32 (m, 2H). LC-MS RT: 1.15 min; MS (ESI) m/z=726.3 (M+H)+; Method A.

Example 172

##STR00113##

[0682] Procedure for example 172: Example 172 was prepared from example 171. To ice bath cooled 1 dram vial charged with example 171 (0.009 mmol) and THF (0.5 mL) was added LiBH.sub.4 (0.027, 3.0 equiv.). The reaction mixture was stirred at 0 C. for 5 min and then allowed to warm to 23 C. and stirred for an additional 30 min. The reaction mixture was diluted with ethyl acetate (10 mL). The solution was washed with saturated aqueous ammonium chloride (20 mL). The aqueous phase was extracted with EtOAc, the combined organic portions dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure and the residue purified via preparative RP-HPLC to give example 172. Analytical data for example 172: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.54 (d, J=8.0 Hz, 1H), 8.29 (d, J=1.7 Hz, 1H), 8.21 (s, 1H), 7.96 (dd, J=6.1, 2.5 Hz, 1H), 7.57-7.47 (m, 2H), 7.32-7.29 (m, 1H), 7.23 (ddd, J=8.3, 4.6, 2.5 Hz, 1H), 7.12-7.00 (m, 3H), 6.45 (br d, J=6.9 Hz, 1H), 5.10-5.03 (m, 1H), 4.85-4.76 (m, 1H), 4.62 (d, J=9.4 Hz, 1H), 4.08 (s, 3H), 3.93-3.86 (m, 2H), 3.18 (t, J=4.1 Hz, 1H), 3.13-3.06 (m, 1H), 2.71 (t, J=4.0 Hz, 1H), 2.26-2.18 (m, 1H), 2.08 (s, 3H), 1.95-1.87 (m, 1H), 1.70-1.62 (m, 2H), 1.51-1.43 (m, 1H), 0.77-0.72 (m, 2H), 0.37-0.30 (m, 2H). LC-MS RT: 1.08 min; MS (ESI) m/z=698.4 (M+H)+; Method A.

Example 177

##STR00114## ##STR00115##

[0683] Intermediate VIII-2: Intermediate VIII-2 was prepared employing known conditions for analogous substrates (Ludwig, J.; Lehr, M. Syn. Comm. 2004, 34, 3691-3695), except the reaction temperature was maintained at 80 C. for 12 h. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.49 (dd, J=6.6, 2.2 Hz, 1H), 7.20 (ddd, J=8.3, 4.6, 2.2 Hz, 1H), 7.13-7.03 (m, 1H), 3.49 (s, 2H), 1.46 (s, 9H).

[0684] Intermediate VIII-3: To a 20 mL reaction vial charged with intermediate VIII-2 (266 mg, 0.920 mmol) was added NBS (196 mg, 1.10 mmol), carbon tetrachloride (10 mL), and AIBN (15 mg, 0.090 mmol). The solution was stirred at 77 C., for 3 h. The solution was concentrated under reduced pressure and purified by normal phase silica gel chromatography to give intermediate VIII-3 (308 mg, 0.840 mmol, 91.0% yield).

[0685] Intermediate VIII-4: To a 2 dram vial charged with intermediate VIII-3 was added ethyl acetate (2 mL), triethyl amine (0.27 mL, 2.0 mmol), and acetic acid (0.1 mL, 2 mmol). The reaction mixture was stirred at 80 C. for 12 h. The reaction mixture was concentrated under reduced pressure and purified by normal phase silica gel chromatography to give intermediate VIII-4. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.70 (dd, J=6.6, 2.2 Hz, 1H), 7.41 (ddd, J=8.4, 4.7, 2.1 Hz, 1H), 7.15 (t, J=8.4 Hz, 1H), 5.77 (s, 1H), 2.22 (s, 3H), 1.43 (s, 9H).

[0686] Intermediate VIII-5: Intermediate VIII-5 was prepared from intermediate VIII-4, employing 5-borono-2-methoxybenzoic acid as the same conditions that were used for intermediate 140-1. Half of the material was isolated as the O-acetate (85 mg, 0.60 mmol, 34%); .sup.1H NMR (500 MHz, CDCl.sub.3) 8.43-8.36 (m, 1H), 7.81 (dt, J=8.7, 2.0 Hz, 1H), 7.56 (dd, J=7.3, 2.3 Hz, 1H), 7.45 (ddd, J=8.5, 4.6, 2.3 Hz, 1H), 7.23-7.16 (m, 2H), 5.84 (s, 1H), 4.17 (s, 3H), 2.23 (s, 3H), 1.45 (s, 9H) while the other half was isolated as the free alcohol (70 mg, 0.19 mmol, 31%); .sup.1H NMR (500 MHz, CDCl.sub.3) 8.40 (d, J=2.2 Hz, 1H), 7.82 (dt, J=8.6, 2.2 Hz, 1H), 7.54 (dd, J=7.4, 2.5 Hz, 1H), 7.41 (ddd, J=8.4, 4.8, 2.2 Hz, 1H), 7.19-7.14 (m, 2H), 5.09 (s, 1H), 4.16 (s, 3H), 1.47 (s, 9H). Racemic VIII-5 was separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Berger MG II; Column: Chiralpak ID, 21250 mm, 5 micron; Mobile phase: 25% IPA/75% CO.sub.2; Flow conditions; 45 mL/min, 120 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 8 injections of 0.36 mL of 20 mg/mL in IPA. Analytical chromatographic conditions: Instrument: Waters UPC2 analytical SFC; Column: Chiralpak ID 4.6100 mm, 3 micron; Mobile phase: 25% IPA/75% CO.sub.2; Flow conditions: 2 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm. Peak 1, RT=3.89 min, >99.5% ee; Peak 2, RT=5.44 min, >99.5% ee. Intermediate VIII-5 product Peak #2 was collected and carried forward to produce chiral intermediate 177-5.

[0687] Intermediate 177-5: Intermediate 177-5 was prepared from VIII-5 peak 2, according to the method described for example 108. Intermediate 177-5 (14.2 mg, 0.0200 mmol, 79.0% yield). LC-MS RT=1.22 min; MS (ESI) m/z=727.1 (M+H).sup.+; Method A.

[0688] Intermediate 177-6: To a 1 dram vial charged with 177-5 was added DCM (1 mL) and phenyl isocyanate (82 mg, 0.69 mmol). The solution stirred for 4 days at 23 C., concentrated under reduced pressure and purified by RP-HPLC to give intermediate 177-6 (6.2 mg, 0.0070 mmol, 53% yield).

[0689] Procedure for example 177: Example 177 was prepared from 177-6 by employing the tert-butyl ester cleavage method described for example 168. Analytical data for example 177: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.74 (br d, J=8.0 Hz, 1H), 8.22 (d, J=2.2 Hz, 1H), 8.06-7.97 (m, 2H), 7.73 (br s, 1H), 7.65 (td, J=8.7, 2.1 Hz, 2H), 7.46 (dt, J=8.8, 3.4 Hz, 1H), 7.41-7.33 (m, 3H), 7.24 (t, J=7.8 Hz, 2H), 7.09-6.98 (m, 4H), 6.15 (s, 1H), 4.84-4.74 (m, 1H), 4.59 (d, J=9.6 Hz, 1H), 4.04 (s, 3H), 3.16 (t, J=4.0 Hz, 1H), 3.09 (br dd, J=10.6, 3.7 Hz, 1H), 2.67 (br t, J=3.7 Hz, 1H), 2.21-2.14 (m, 1H), 1.91-1.82 (m, 1H), 1.68-1.52 (m, 2H), 1.51-1.41 (m, 1H), 0.79-0.69 (m, 2H), 0.36-0.29 (m, 2H). LC-MS RT: 1.26 min; MS (ESI) m/z=790.4 (M+H)+; Method A.

Example 178

##STR00116##

[0690] Procedure for example 178: Example 178 was prepared from 34-1. To a 2 dram vial charged with 34-1, DCM (1.5 mL), and DIEA (0.12 mL, 0.70 mmol, 30 equiv.) was added acetyl chloride (0.03, 0.5 mmol, 20 equiv.) and stirred 1 h at 23 C. The reaction was quenched by the addition of MeOH (1 mL) and the tert-butyl ester was removed according to the method described for example 168. Analytical data for example 178: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.82 (d, J=8.3 Hz, 1H), 8.45 (s, 1H), 8.36 (s, 1H), 8.29 (s, 1H), 8.26 (d, J=2.5 Hz, 1H), 8.00 (dd, J=6.3, 2.5 Hz, 1H), 7.70 (dt, J=8.5, 2.2 Hz, 1H), 7.62 (dd, J=7.4, 2.2 Hz, 1H), 7.46 (ddd, J=8.5, 4.3, 2.6 Hz, 2H), 7.14 (dd, J=10.0, 8.7 Hz, 1H), 7.08-7.00 (m, 2H), 5.98 (s, 1H), 5.98 (s, 1H), 4.88-4.79 (m, 1H), 4.06 (s, 3H), 3.25-3.19 (m, 2H), 2.91-2.86 (m, 1H), 2.40-2.33 (m, 1H), 2.19 (s, 3H), 2.00-1.93 (m, 1H), 1.72-1.60 (m, 2H) LC-MS RT: 1.11 mi; MS (ESI) m/z=740.1 (M+H)+; Method A.

Example 179

##STR00117##

[0691] Intermediate 179-1: To a 20 mL vial charged with 177-5 was added DCM (4 mL), 4-nitrophenyl carbonochloridate (volume or mass, 0.43 mmol) and DMAP (mass, 0.04 mmol). The reaction solution was stirred for at 23 C. for 12 h. Methylamine (0.85 mmol) was added and the reaction solution stirred for an additional 1 h. The reaction solution was concentrated under reduced pressure and purified by RP-HPLC to give intermediate 179-1 (65 mg, 0.083 mmol, 97%). LC-MS RT=1.24 min; MS (ESI) m/z=784.4 (M+H).sup.+; Method A.

[0692] Procedure for example 179: Example 179 was prepared from 179-1 according to the method described for the tert-butyl ester cleavage as in example 168. Analytical data for example 179: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.70 (br d, J=8.0 Hz, 1H), 8.28 (d, J=1.9 Hz, 1H), 8.19 (s, 1H), 8.01 (dd, J=6.2, 2.6 Hz, 1H), 7.68 (dt, J=8.6, 2.2 Hz, 1H), 7.60 (br d, J=5.5 Hz, 1H), 7.52-7.45 (m, 1H), 7.45-7.37 (m, 1H), 7.15-7.00 (m, 3H), 6.05 (s, 1H), 5.38-5.28 (m, 1H), 4.82-4.75 (m, 1H), 4.60 (d, J=9.4 Hz, 1H), 4.07 (s, 3H), 3.16 (t, J=4.1 Hz, 1H), 3.10 (dd, J=10.5, 3.3 Hz, 1H), 2.85 (br d, J=3.3 Hz, 3H), 2.71-2.67 (m, 1H), 2.25-2.20 (m, 1H), 1.92-1.86 (m, 1H), 1.68-1.53 (m, 2H), 1.49-1.42 (m, 1H), 0.78-0.69 (m, 2H), 0.36-0.30 (m, 2H). LC-MS RT: 1.13 min; MS (ESI) m/z=728.3 (M+H)+; Method A.

Example 182

##STR00118## ##STR00119##

[0693] Intermediate 182-1: To a 1 dram vial charged with intermediate VIII-3 was added ammonia (0.5 mL, 4 mmol, 7 M in MeOH). The solution was stirred at 23 C. for 12 h. The solution was concentrated under reduced pressure and the residue, was treated with acetic anhydride (7.2 L, 0.076 mmol) in DCM (1 mL) and stirred at 23 C. for 1 h. The resulting residue was purified by normal phase silica gel chromatography to give intermediate 182-1 (26 mg, 0.074 mmol, 97% yield). LC-MS RT=0.92 min; MS (ESI) m/z=346.1 (M+H).sup.+; Method A.

[0694] Intermediate 182-2: Intermediate 182-2 was prepared employing similar conditions described for intermediate 140-1, except at a temperature of 65 C. for 18 h. .sup.1H NMR (500 MHz, CDCl3) 8.37 (d, J=1.9 Hz, 1H), 7.81 (dt, J=8.5, 2.1 Hz, 1H), 7.45 (dd, J=7.3, 2.3 Hz, 1H), 7.35 (ddd, J=8.5, 4.6, 2.3 Hz, 1H), 7.21-7.13 (m, 2H), 6.74 (br d, J=6.9 Hz, 1H), 5.51 (d, J=6.9 Hz, 1H), 4.17 (s, 3H), 2.12 (s, 3H), 1.45 (s, 9H). Racemic 182-2 was separated into it's enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Berger MG II; Column: Chiralpak ID, 21250 mm, 5 micron; Mobile phase: 20% IPA/80% CO.sub.2; Flow conditions; 45 mL/min, 120 Bar, 40 C.; Detector wavelength: 215 nm; Injection details: 3 injections of 15 mg/mL in MeOH. Analytical chromatographic conditions: Instrument: Aurora Infinity analytical SFC; Column: Chiralpak AD-H, 4.6100 mm, 3 micron; Mobile phase: 20% IPA/80% CO.sub.2; Flow conditions: 2 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm. Peak 1, RT=3.49 min, >99.5% ee; Peak 2, RT=4.43 min, >99.5% ee. Intermediate 182-2 product Peak #2 was collected and carried forward to produce example 182.

[0695] Procedure for example 182: Example 182 was prepared from 166-2, employing 182-2 (peak 2, isomer 2), according to the method described for example 108. A subsequent removal of the tert-butyl ester was accomplished as in the procedure to prepare example 168. Analytical data for example 182 (isomer 1): .sup.1H NMR (500 MHz, CDCl.sub.3) 10.14 (d, J=7.7 Hz, 1H), 8.72 (br d, J=9.1 Hz, 1H), 8.46 (d, J=2.5 Hz, 1H), 8.00 (dd, J=6.1, 2.8 Hz, 1H), 7.80-7.70 (m, 2H), 7.61 (s, 1H), 7.46-7.38 (m, 2H), 7.11-7.01 (m, 2H), 6.98 (d, J=8.8 Hz, 1H), 5.96 (d, J=9.1 Hz, 1H), 4.73-4.65 (m, 2H), 4.04 (s, 3H), 3.18 (br t, J=3.7 Hz, 1H), 3.03 (dd, J=10.6, 4.0 Hz, 1H), 2.69 (br t, J=3.7 Hz, 1H), 2.13 (s, 3H), 2.06-1.98 (m, 1H), 1.88-1.80 (m, 1H), 1.64-1.49 (m, 3H), 0.89-0.76 (m, 2H), 0.44-0.34 (m, 2H). LC-MS RT: 1.11 min; MS (ESI) m/z=712.2 (M+H)+; Method A.

Example 183

##STR00120## ##STR00121##

[0696] Intermediate 183-1: Intermediate 183-1 was prepared from VIII-3 according to the method described for intermediate 182-1 with the replacement of Ac.sub.2O with Boc.sub.2O. LC-MS RT=1.14 min; MS (ESI) m/z=406.0 (M+H).sup.+; Method A.

[0697] Intermediate 183-2: Intermediate 183-2 was prepared employing that same conditions that were used for intermediate 140-1, except at a temperature of 60 C. for 18 h. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.38 (d, J=1.9 Hz, 1H), 7.80 (dt, J=8.7, 2.0 Hz, 1H), 7.46 (dd, J=7.4, 2.5 Hz, 1H), 7.36 (dddd, J=8.8, 4.4, 2.2, 1.1 Hz, 1H), 7.19-7.13 (m, 2H), 5.67 (br d, J=5.2 Hz, 1H), 5.25 (br d, J=6.3 Hz, 1H), 4.16 (s, 3H), 1.46 (br s, 9H), 1.44 (s, 9H). Racemic 183-2 was separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Berger MG II; Column: Chiralpak ID, 21250 mm, 5 micron; Mobile phase: 20% MeOH/80% CO.sub.2; Flow conditions; 45 m/min, 120 Bar, 40 C.; Detector wavelength: 209 nm; Injection details: 49 injections in MeOH. Analytical chromatographic conditions: Instrument: Waters UPC2 analytical SFC; Column: Chiralpak IC, 4.6100 mm, 3 micron; Mobile phase: 25% MeOH/75% CO.sub.2; Flow conditions: 2 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm. Peak 1, RT=4.22 min, 95.7% ee; Peak 2, RT=5.11 min, >99% ee. Intermediate 183-2 product Peak #2 was collected and carried forward to produce intermediate 183-3.

[0698] Intermediate 183-3: Intermediate 183-3 was prepared from 183-2 according to the method described for example 108. A subsequent removal of the tert-butyl ester was accomplished as in the procedure to prepare example 120. LC-MS RT=0.99 min; MS (ESI) m/z=698.3 (M+H).sup.+; Method A.

[0699] Procedure for example 183: Example 183 was prepared from 183-3. A 2 dram vial was charged with 183-3, DIEA (0.06 mmol, 5 equiv.) and 4-chlorobenzoyl chloride (0.035 mmol, 3.0 equiv.). The solution was stirred at 23 C. for 30 min and subsequently quenched with MeOH. The reaction contents were concentrated under reduced pressure to provide crude product that was purified via preparative RP-HPLC to give example 183. Analytical data for example 183: .sup.1H NMR (500 MHz, CDCl.sub.3) 9.98 (br d, J=8.0 Hz, 1H), 8.77-8.68 (m, 1H), 8.49 (d. J=2.5 Hz, 1H), 7.96 (dd, J=6.3, 2.5 Hz, 1H), 7.91-7.84 (m, 2H), 7.77-7.71 (m, 1H), 7.69 (t, J=1.7 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.55 (ddd, J=8.3, 4.3, 2.2 Hz, 1H), 7.43-7.39 (m, 1H), 7.37-7.31 (m, 1H), 7.27-7.24 (m, 1H), 7.08 (dd, J=10.6, 8.7 Hz, 1H), 7.01-6.95 (m, 2H), 6.21 (d, J=8.5 Hz, 1H), 5.61 (q, J=7.4 Hz, 1H), 4.83-4.74 (m, 1H), 4.04 (s, 3H), 3.41 (br s, 1H), 3.14 (dd, J=10.5, 4.1 Hz, 1H), 2.88 (t, J=3.9 Hz, 1H), 2.30-2.22 (m, 1H), 2.01-1.95 (m, 1H), 1.73-1.62 (m, 2H). LC-MS RT: 1.21 min; MS (ESI) m/z=836.3 (M+H)+; Method A.

Example 192

##STR00122##

[0700] Procedure for example 192: Example 192 was prepared from example 120, employing BHFFT as the coupling reagent. To a 2 dram pressure rated vail charged with example 120 (0.043 mmol, 1.3 equiv.) was added BHFFT (0.049 mmol, 2.0 equiv.) followed by DCM (1 mL) and DIEA (0.15 mmol, 4.5 equiv.). The reaction mixture was stirred at 23 C. for 30 min, then heated to heated to 80 C. for 18 h. The reaction mixture was allowed to cooled to 23 C., the vial contents were dissolved in DMF (1.5 mL), and the residue purified by RP-HPLC. Analytical data for example 192: LC-MS RT: 2.41 min; MS (ESI) m/z=735.1 (M+H)+; Method C.

Example 199

##STR00123## ##STR00124##

[0701] Intermediate 199-1: Intermediate 199-1 was prepared employing that same conditions that were used for intermediate 140-1, except at a temperature of 65 C. for 18 h. .sup.1H NMR (500 MHz, CDCl.sub.3) 10.87 (s, 1H), 8.11-8.04 (m, 2H), 7.95 (ddd, J=8.5, 4.8, 2.3 Hz, 1H), 7.68 (dt, J=8.5, 1.9 Hz, 1H), 7.18 (dd, J=10.0, 8.7 Hz, 1H), 7.09 (d, J=8.5 Hz, 1H), 3.99 (s, 3H), 1.66-1.59 (m, 9H). LC-MS RT=1.20 min; MS (ESI) m/z=347.1 (M+H).sup.+

[0702] Intermediate 199-2: To a 1 dram vial charged with intermediate 199-1 was added potassium carbonate (53.5 mg, 0.39 mmol), DMF (0.4 mL), and 1-bromo-2-(2-methoxyethoxy)ethane (70.8 mg, 0.39 mmol). The reaction mixture was stirred at 23 C. for 18 h then heated to 40 C. for an additional 18 h. The reaction mixture was concentrated with a stream of nitrogen gas, the residue diluted with ethyl acetate and water and the resulting solution extracted with ethyl acetate (310 mL). The combined organic portions were dried over sodium sulfate, filtered and concentrated under reduced pressure to give 199-2 (80 mg, 0.18 mmol, 92% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.08 (dd, J=7.7, 2.2 Hz, 1H), 8.00 (dd, J=2.2, 1.1 Hz, 1H), 7.94 (ddd, J=8.5, 4.8, 2.3 Hz, 1H), 7.66 (dt, J=8.7, 2.0 Hz, 1H), 7.17 (dd, J=10.0, 8.7 Hz, 1H), 7.09 (d, J=8.8 Hz, 1H), 4.28 (t, J=5.1 Hz, 2H), 3.97-3.93 (m, 2H), 3.91 (s, 3H), 3.81-3.77 (m, 2H), 3.61-3.57 (m, 2H), 3.44-3.39 (m, 3H), 1.61 (s, 9H). LC-MS RT=1.11 min; MS (ESI) m/z=449.1 (M+H).sup.+; Method A.

[0703] Intermediate 199-3: Intermediate 199-3 was prepared by lithium hydroxide hydrolysis of intermediate 199-2 in a manner similar to intermediate 3-3. LC-MS RT=1.02 min; MS (ESI) m/z=348.1 (M+H).sup.+; Method A.

[0704] Procedure for example 199: Example 199 was prepared from 125-2, employing 199-3, according to the method described for example 108. A subsequent removal of the tert-butyl ester was accomplished as in the procedure to prepare example 120. Analytical data for example 199: LC-MS RT: 1.15 min; MS (ESI) m/z=765.2 (M+H)+; Method A.

Example 201

##STR00125## ##STR00126##

[0705] Intermediate 201-1: Intermediate 201-1 was prepared from 166-2, employing 120-6 according to the method described for example 108. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.40 (br d, J=8.0 Hz, 1H), 8.40 (d, J=1.1 Hz, 1H), 8.08 (dd, J=7.7, 2.2 Hz, 1H), 8.02-7.93 (m, 3H), 7.64 (dt, J=8.6, 1.9 Hz, 1H), 7.49 (dt, J=8.6, 3.5 Hz, 1H), 7.18 (dd, J=10.0, 8.7 Hz, 1H), 7.12-7.03 (m, 2H), 4.89-4.81 (m, 1H), 4.63 (d, J=9.4 Hz, 1H), 4.05 (s, 3H), 3.20 (t, J=3.9 Hz, 1H), 3.10 (dd, J=10.6, 3.2 Hz, 1H), 2.72 (t, J=3.9 Hz, 1H), 2.24-2.16 (m, 1H), 1.93-1.85 (m, 1H), 1.71-1.63 (m, 2H), 1.61 (s, 9H), 1.53-1.41 (m, 1H), 0.74 (dt, J=7.8, 3.7 Hz, 2H), 0.41-0.30 (m, 2H). LC-MS RT=1.30 min; MS (ESI) m/z=697.3 (M+H).sup.+; Method A.

[0706] Intermediate 201-2: To a 2 dram vial charged with intermediate 201-1 (88 mg, 0.126 mmol) was added DCM (1.25 mL) followed by Boc.sub.2O (0.51 mmol), DMAP (0.06 mmol), and DIEA (0.51 mmol). The solution was stirred at 23 C. for 18 h and then concentrated under reduced pressure. The resulting crude material was purified by normal phase silica gel chromatography to give intermediate 201-2 (94 mg, 0.12 mmol, 93% yield). LC-MS RT=1.34 min; MS (ESI) m/z=797.5 (M+H).sup.+; Method A.

[0707] Procedure for example 201: Example 201 was prepared from 201-2. To a 1 dram vial charged with 201-2 (0.013 mmol) was added DCM (0.3 mL) and cyclopentyl amine (0.125 mmol, 10 equiv.). The solution was stirred at 23 C. for 18 h and concentrated under reduced pressure to give the crude intermediate. A subsequent removal of the tert-butyl ester was accomplished as in the procedure to prepare example 120. Analytical data for example 201: .sup.1H NMR (500 MHz, DMSO-d6) 9.78 (br d, J=7.0 Hz, 1H), 7.85-7.75 (m, 3H), 7.74-7.67 (m, 1H), 7.48 (br d, J=8.5 Hz, 1H), 7.16 (br t, J=9.5 Hz, 1H), 7.05 (d, J=8.9 Hz, 1H), 4.36 (d, J=9.5 Hz, 1H), 4.04 (dt, J=10.0, 5.2 Hz, 1H), 3.81-3.73 (m, 4H), 2.83-2.76 (m, 1H), 2.66-2.60 (m, 1H), 1.69-1.45 (m, 4H), 1.40-1.29 (m, 2H), 1.28-1.16 (m, 3H), 1.15-1.01 (m, 4H), 0.53-0.39 (m, 2H), 0.06 (br d, J=3.1 Hz, 2H). LC-MS RT: 2.33 min; MS (ESI) m/z=547.4 (M+H)+; Method C.

Example 206

##STR00127## ##STR00128##

[0708] Intermediate 206-2: Into the reaction vessel was added 3-bromo-4-fluorobenzaldehyde (206-1, 235 mg, 1.15 mmol), DMF (3.5 mL), (trifluoromethyl)trimethylsilane (0.34 mL, 2.3 mmol), and K.sub.2CO.sub.3 (8.0 mg, 0,058 mmol). The reaction mixture was stirred at rt for 60 min and 2N HCl (3 mL) was added. After stirring at rt for an additional 1 h, the reaction mixture was diluted with EtOAc (15 mL), and the solution washed with sat NH.sub.4Cl. The aqueous phase was extracted with addition al EtOAc (10 mL2). The combined organic portions were dried over Na.sub.2SO.sub.4, filtered, concentrated, and purified by silica gel chromatography to produce 206-2 (205 mg, 0.751 mmol, 64.9% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) d 7.74 (dd, J=6.5, 2.1 Hz, 1H), 7.43 (ddd, J=8.4, 4.8, 2.2 Hz, 1H), 7.19 (t, J=8.4 Hz, 1H), 5.11-4.98 (m, 1H), 2.69 (d, J=4.4 Hz, 1H).

[0709] Intermediate 206-3: Into the reaction vessel containing 206-2 (100 mg, 0.366 mmol) was added 5-borono-2-methoxybenzoic acid (93 mg, 0.48 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (45 mg, 0.055 mmol), Na.sub.2CO.sub.3 (155 mg, 1.46 mmol), and H.sub.2O (1 mL). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 65 C. for 3 h. After allowing to cool to rt, the reaction mixture was quenched by the addition of 1N HCl, the solution extracted with EtOAc, dried over Na.sub.2SO.sub.4, filtered, concentrated and purification by HPLC to produce 206-3 (50.5 mg, 0.147 mmol, 40.1% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.39 (d, J=1.9 Hz, 1H), 7.83 (dt, J=8.7, 2.1 Hz, 1H), 7.59 (dd, J=7.3, 2.1 Hz, 1H), 7.53-7.45 (m, 1H), 7.23 (dd, J=10.2, 8.8 Hz, 1H), 7.18 (d, J=8.5 Hz, 1H), 5.11 (q, J=6.6 Hz, 1H), 4.17 (s, 3H).

[0710] Intermediate 206-4: Racemic 206-3 was separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: Berger MG II; Column: Kromasil 5-CelluCoat, 21250 mm, 5 micron; Mobile phase: 15% IPA-ACN (0.1% DEA)/85% CO.sub.2; Flow conditions; 45 mL/min, 120 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 0.4 mL of 15 mg/mL in ACN-IPA (1:1). Peak #2 was collected to afford intermediate 206-4. Analytical chromatographic conditions: Instrument: Aurora Infinity Analytical SFC; Column: Kromasil 5-CelluCoat, 4.6250 mm, 5 micron; Mobile phase: 20% IPA-ACN (0.1% DEA)/80% CO.sub.2; Flow conditions: 2 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm. Peak 1, RT=9.12 min, 99% ee; Peak 2, RT=10.19 min, 98% ee.

[0711] Example 245: Into the reaction vessel was added intermediate 166-2 (7.0 mg, 0.017 mmol), intermediate 206-4 (6.2 mg, 0.018 mmol), MeCN (1 mL), DIEA (9.1 l, 0.052 mmol), and HATU (7.2 mg, 0.019 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure, and subjected to prep-HPLC purification to produce example 245 (9.5 mg, 0.014 mmol, 78% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.57 (d, J=7.7 Hz, 1H), 8.33 (dd, J=2.2, 0.8 Hz, 1H), 8.05 (s, 1H), 7.99 (dd, J=6.3, 2.5 Hz, 1H), 7.66 (dt, J=8.7, 2.0 Hz, 1H), 7.57 (dd, J=7.3, 2.1 Hz, 1H), 7.56-7.52 (m, 1H), 7.45-7.40 (m, 1H), 7.17 (dd, J=10.2, 8.5 Hz, 1H), 7.11-7.04 (m, 2H), 5.11-5.04 (m, 1H), 4.77-4.70 (m, 1H), 4.57 (d, J=9.4 Hz, 1H), 4.06 (s, 3H), 3.42 (br s, 1H), 3.19 (t. J=4.1 Hz, 1H), 3.08 (ddd, J=10.7, 4.1, 1.2 Hz, 1H), 2.67 (t, J=4.0 Hz, 1H), 2.18-2.07 (m, 1H), 1.92-1.82 (m, 1H), 1.67-1.58 (m, 2H), 1.53-1.45 (m, 1H), 0.79-0.68 (m, 2H), 0.38-0.27 (m, 2H). LC-MS RT: 1.38 min; MS (ESI) m/z 695.3 (M+H).sup.+; Method A.

[0712] Example 246: Prepared from intermediate 166-2 and the enantiomer of 206-4 (peak 1 from chiral SFC purification) following the procedure for the synthesis of example 246. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.53 (d, J=7.7 Hz, 1H), 8.34 (dd, J=2.5, 0.8 Hz, 1H), 8.01 (s, 1H), 7.97 (dd, J=6.2, 2.6 Hz, 1H), 7.66 (dt, J=8.7, 2.0 Hz, 1H), 7.57-7.50 (m, 2H), 7.48-7.40 (m, 1H), 7.18 (dd, J=10.2, 8.5 Hz, 1H), 7.12-7.02 (m, 2H), 5.13-5.03 (m, 1H), 4.81-4.71 (m, 1H), 4.60 (d, J=9.6 Hz, 1H), 4.06 (s, 3H), 3.19 (t, J=3.7 Hz, 2H), 3.09 (ddd, J=10.8, 4.1, 1.1 Hz, 1H), 2.70 (t, J=4.0 Hz, 1H), 2.19-2.11 (m, 1H), 1.92-1.84 (m, 1H), 1.70-1.60 (m, 2H), 1.51-1.42 (m, 1H), 0.77-0.70 (m, 2H), 0.36-0.30 (m, 2H). LC-MS RT: 1.38 min; MS (ESI) m/z 695.3 (M+H).sup.+; Method A.

[0713] Example 206: Into the reaction vessel was added example 245 (6.0 mg, 8.6 mol), DCM (1 mL), pyridine (7.0 l, 0.086 mmol), 4-nitrophenyl carbonochloridate (8.7 mg, 0.043 mmol), and DMAP (1.0 mg, 8.6 mol). After stirring at rt for 2 h, bicyclo[1.1.1]pentan-1-amine (7.2 mg, 0.086 mmol) was added. The reaction mixture was stirred at rt for 1 h, concentrated under reduced pressure and subjected to prep-HPLC purification to produce 1-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)-2,2,2-trifluoroethyl bicyclo[1.1.1]pentan-1-ylcarbamate (example 206, 3.8 mg, 4.7 mol, 54% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.95 (br d, J=6.3 Hz, 1H), 8.55 (br s, 1H), 8.24 (br d, J=4.2 Hz, 1H), 8.13 (br s, 1H), 7.86-7.75 (m, 1H), 7.69 (br t, J=9.4 Hz, 2H), 7.58-7.38 (m, 3H), 7.33 (d, J=8.8 Hz, 1H), 6.43-6.30 (m, 1H), 4.69 (d, J=9.6 Hz, 1H), 4.51-4.41 (m, 1H), 4.06 (s, 3H), 3.16 (br dd, J=10.1, 3.8 Hz, 1H), 3.11 (br s, 1H), 2.72 (br s, 1H), 2.39-2.34 (m, 1H), 2.02-1.89 (m, 6H), 1.88-1.77 (m, 2H), 1.54-1.47 (m, 1H), 1.45-1.36 (m, 2H), 0.79-0.69 (m, 2H), 0.35 (br s, 2H). LC-MS RT: 1.27 min; MS (ESI) m/z 804.5 (M+H).sup.+; Method A.

Example 222

##STR00129##

[0714] Example 222: Into the reaction vessel was added example 246 (11 mg, 0.017 mmol), DCM (1 mL), pyridine (8.0 l, 0.099 mmol), and isocyanatobenzene (9.9 mg, 0.083 mmol). After stirring at rt for 12 h, the reaction mixture was concentrated and subjected to prep-HPLC purification to produce 1-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)ethyl phenylcarbamate (example 222, 11.8 mg, 0.0160 mmol, 94.0% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.52 (s, 1H), 9.92 (br d, J=7.3 Hz, 1H), 9.72 (br s, 1H), 8.22 (br d, J=4.9 Hz, 1H), 8.14 (s, 1H), 7.81-7.75 (m, 1H), 7.70 (br d, J=8.2 Hz, 1H), 7.54 (br d, J=6.7 Hz, 1H), 7.50-7.38 (m, 4H), 7.35-7.27 (m, 2H), 7.25 (br t, J=7.8 Hz, 2H), 6.96 (t, J=7.5 Hz, 1H), 5.89-5.80 (m, 1H), 4.69 (d, J=9.5 Hz, 1H), 4.49-4.41 (m, 1H), 4.05 (s, 3H), 3.16 (br dd, J=10.8, 3.5 Hz, 1H), 3.11 (br s, 1H), 2.72 (br s, 1H), 1.92-1.74 (m, 2H), 1.56 (br d, J=6.1 Hz, 3H), 1.53-1.47 (m, 1), 1.45-1.35 (m, 2H), 0.82-0.66 (m, 2H), 0.39-0.29 (m, 2H). LC-MS RT: 1.26 min; MS (ESI) m/z 760.5 (M+H).sup.+; Method A.

Example 230

##STR00130## ##STR00131##

[0715] Intermediate 230-1: Into the reaction vessel was added 206-1 (577 mg, 2.84 mmol), DMF (15 mL), (difluoromethyl)trimethylsilane (530 mg, 4.26 mmol), and CsF (216 mg, 1.42 mmol). After stirring at 50 C. for 12 h, the reaction mixture was diluted with EtOAc (15 mL), and the solution washed with sat NH.sub.4Cl. The aqueous phase was extracted with additional EtOAc (10 mL2). The combined organic portions were dried over Na.sub.2SO.sub.4, filtered, concentrated, and purified by silica gel chromatography to produce 1-(3-bromo-4-fluorophenyl)-2,2-difluoroethan-1-ol (230-1, 98 mg, 0.38 mmol, 13% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67 (dd, J=6.6, 2.1 Hz, 1H), 7.36 (ddd, J=8.4, 4.6, 2.1 Hz, 1H), 7.16 (t, J=8.4 Hz, 1H), 5.87-5.57 (m, 1H), 4.86-4.78 (m, 1H), 2.50 (br s, 1H).

[0716] Intermediate 230-2: Into the reaction vessel containing 230-1 (220 mg, 0.863 mmol) was added 5-borono-2-methoxybenzoic acid (220 mg, 1.12 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (106 mg, 0.129 mmol), Na.sub.2CO.sub.3 (366 mg, 3.45 mmol), and H.sub.2O (3.5 mL). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 65 C. for 3 h. After allowing to cool to rt, the reaction mixture was quenched by the addition of 1N HCl, the resulting solution extracted with EtOAc, dried over Na.sub.2SO.sub.4, filtered, concentrated and subjected to prep-HPLC purification to produce 5-(2,2-difluoro-1-hydroxyethyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxylic acid (230-2, 186 mg, 0.570 mmol, 66.1% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 8.37 (d, J=1.8 Hz, 1H), 7.82 (dt, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=7.4, 2.1 Hz, 1H), 7.45-7.39 (m, 1H), 7.24-7.14 (m, 2H), 6.01-5.59 (m, 1H), 4.89 (td, J=10.1, 4.7 Hz, 1H), 4.15 (s, 3H).

[0717] Intermediate 230-3: Racemic 230-2 was separated into individual enantiomers using chiral SFC. Preparative chromatographic conditions: Instrument: PIC Solution SFC Prep-200; Column: Chiralpak IC, 30250 mm, 5 micron; Mobile phase: 10% MeOH/90% CO.sub.2; Flow conditions; 85 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 10 L of 1 mg/mL in MeOH. Peak #2 was collected to afford intermediate 230-3. Analytical chromatographic conditions: Instrument: Aurora Infinity Analytical SFC; Column: Chiralpak ID, 4.6250 mm, 5 micron; Mobile phase: 10% MeOH/90% CO.sub.2; Flow conditions: 2 m/min, 150 Bar, 40 C.; Detector wavelength: 220 nm. Peak 1, RT=11.85 min, 96% ee; Peak 2, RT=13.65 min, >99.5% ee.

[0718] Intermediate 230-4: Into the reaction vessel was added intermediate 166-2 (20 mg, 0.054 mmol), intermediate 230-3 (18 mg, 0.057 mmol), MeCN (1 mL), DIEA (0.028 mL, 0.16 mmol), and HATU (23 mg, 0.060 mmol). The reaction mixture was stirred at rt for 12 h. concentrated under reduced pressure, and subjected to silica gel chromatography purification to produce (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(5-(2,2-difluoro-1-hydroxyethyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxamido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide (230-4, 25 mg, 0.037 mmol, 68% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 9.49 (br d, J=7.7 Hz, 1H), 8.40-8.33 (m, 1H), 8.01 (s, 1H), 7.98-7.91 (m, 1H), 7.66 (dt, J=8.7, 2.0 Hz, 1H), 7.57-7.48 (m, 2H), 7.38 (dq, J=6.4, 4.2 Hz, 1H), 7.18 (ddd, J=10.2, 8.6, 1.2 Hz, 1H), 7.11-7.01 (m, 2H), 6.03-5.59 (m, 1H), 4.91-4.83 (m, 1H), 4.81-4.73 (m, 1H), 4.61 (d, J=9.5 Hz, 1H), 4.06 (s, 3H), 3.19 (t, J=3.7 Hz, 1H), 3.09 (dd, J=10.8, 3.3 Hz, 1H), 2.82 (br d, J=12.5 Hz, 1H), 2.70 (t, J=3.9 Hz, 1H), 2.22-2.12 (m, 1H), 1.95-1.85 (m, 1H), 1.72-1.61 (m, 2H), 1.50-1.41 (m, 1H), 0.79-0.69 (m, 2H), 0.39-0.28 (m, 2H).

[0719] Example 230: Into the reaction vessel was added intermediate 230-4 (6.0 mg, 8.9 mol), DCM (1 mL), pyridine (7.2 l, 0.089 mmol), 4-nitrophenyl carbonochloridate (8.9 mg, 0.044 mmol), and DMAP (1.1 mg, 8.9 mol). After stirring at rt for 2 h, cyclobutanamine (6.3 mg, 0.089 mmol) was added. The reaction mixture was stirred at rt for 1 h, concentrated under reduced pressure and subjected to prep-HPLC purification to produce 1-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)-2,2-difluoroethyl cyclobutylcarbamate (example 230, 4.5 mg, 5.8 mol, 66% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.94 (br d, J=7.2 Hz, 1H), 8.19 (br d, J=5.1 Hz, 1H), 8.09 (s, 1H), 7.94 (br d, J=7.8 Hz, 1H), 7.80-7.71 (m, 1H), 7.68 (br d, J=8.8 Hz, 1H), 7.53 (br d, J=6.7 Hz, 1H), 7.48-7.39 (m, 2H), 7.38-7.27 (m, 2H), 6.49-6.13 (m, 1H), 5.93-5.81 (m, 1H), 4.67 (d, J=9.6 Hz, 1H), 4.48-4.38 (m, 1H), 4.03 (s, 3H), 3.94-3.85 (m, 1H), 3.19-3.11 (m, 1H), 3.08 (br s, 1H), 2.70 (br s, 1H), 2.15-2.01 (m, 2H), 1.92-1.73 (m, 4H), 1.58-1.45 (m, 3H), 1.43-1.35 (m, 2H), 0.77-0.66 (m, 2H), 0.37-0.28 (m, 2H). LC-MS RT: 1.22 min; MS (ESI) m/z 774.3 (M+H).sup.+; Method A.

Example 233

##STR00132##

[0720] Example 233: Into the reaction vessel was added 230-4 (6.0 mg, 8.9 mol), DCM (1 mL), pyridine (0.014 mL, 0.17 mmol), and isocyanatobenzene (5.3 mg, 0.044 mmol). After stirring at rt for 12 h, the mixture mixture was concentrated under reduced pressure and subjected to prep-HPLC purification to produce 1-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)-2,2-difluoroethyl phenylcarbamate (example 233, 4.9 mg, 5.9 mol, 67% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 10.07 (br s, 1H), 9.93 (br d, J=7.0 Hz, 1H), 8.17 (br d, J=4.6 Hz, 1H), 8.10 (s, 1H), 7.79-7.59 (m, 3H), 7.50 (br s, 1H), 7.47-7.34 (m, 4H), 7.34-7.24 (m, 3H), 7.01 (br t, J=7.2 Hz, 1H), 6.55-6.25 (m, 1H), 6.08-5.98 (m, 1H), 4.68 (d, J=9.5 Hz, 1H), 4.48-4.39 (m, 1H), 4.02 (s, 3H), 3.19-3.10 (m, 1H), 3.08 (br s, 1H), 2.72-2.67 (m, 1H), 1.87-1.72 (m, 2H), 1.53-1.45 (m, 1H), 1.44-1.34 (m, 2H), 0.77-0.65 (m, 2H), 0.37-0.26 (m, 2H). LC-MS RT: 1.23 min; MS (ESI) m/z 796.2 (M+H).sup.+; Method A.

Example 238

##STR00133## ##STR00134##

[0721] Intermediate 238-1: Into the reaction vessel was added 166-2 (75 mg, 0.19 mmol), 183-2 (92 mg, 0.20 mmol), MeCN (5 mL), DIEA (0.097 mL, 0.56 mmol), and HATU (77 mg, 0.200 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure, and the residue subjected to silica gel chromatography purification to produce tert-butyl 2-((tert-butoxycarbonyl)amino)-2-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)acetate (238-1, 147 mg, 0.178 mmol, 96.0% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 9.42 (br d, J=7.9 Hz, 1H), 8.41 (dd, J=2.2, 1.3 Hz, 1H), 8.09-8.04 (m, 1H), 8.06 (s, 1H), 8.00 (dd, J=6.3, 2.5 Hz, 1H), 7.67-7.61 (m, 1H), 7.55-7.48 (m, 1H), 7.44 (dd, J=7.3, 2.4 Hz, 1H), 7.36-7.31 (m, 1H), 7.20-7.04 (m, 3H), 5.66 (br d, J=6.6 Hz, 1H), 5.24 (br d, J=7.0 Hz, 1H), 4.92-4.82 (m, 1H), 4.65 (d, J=9.5 Hz, 1H), 4.07 (s, 3H), 3.22 (t, J=3.9 Hz, 1H), 3.13 (dd, J=10.5, 3.6 Hz, 1H), 2.74 (t, J=3.7 Hz, 1H), 2.27-2.16 (m, 1H), 1.95-1.86 (m, 1H), 1.74-1.66 (m, 2H), 1.46 (br s, 9H), 1.43 (s, 9H), 1.39-1.34 (m, 1H), 0.81-0.72 (m, 2H), 0.43-0.33 (m, 2H).

[0722] Intermediate 238-2: Into the reaction vessel was added 238-1 (147 mg, 0.178 mmol), DCM (10 mL), sodium bicarbonate (112 mg, 1.33 mmol) and zinc bromide (1200 mg, 5.34 mmol). After stirring at for 24 h, the reaction mixture was quenched by the addition of TN HCl and the solution extracted with EtOAc. The combined organic portion was dried over Na.sub.2SO.sub.4, filtered, concentrated, and subjected to prep-HPLC purification to produce 2-amino-2-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)acetic acid, TFA (238-2, 62 mg, 0.079 mmol, 44% yield). MS (ESI) m/z 670.4 (M+H).

[0723] Example 238: Into the reaction vessel was added 238-2 (9 mg, 0.01 mmol), MeCN (1 mL), pyridine (2.8 l, 0.034 mmol), and tetrahydro-2H-pyran-4-carbonyl chloride (1.7 mg, 0.012 mmol) were added. After stirring at rt for 30 min, the reaction mixture was quenched by the addition of MeOH, concentrated under reduced pressure, and the residue subjected to prep-HPLC purification to produce 2-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)-2-(tetrahydro-2H-pyran-4-carboxamido)acetic acid (example 238, 8.9 mg, 0.011 mmol, 99% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.89 (br d, J=7.7 Hz, 1H), 8.26 (d, J=2.2 Hz, 1H), 7.99 (dd, J=6.2, 2.3 Hz, 1H), 7.84 (s, 1H), 7.74-7.62 (m, 2H), 7.54 (dd, J=7.3, 2.3 Hz, 1H), 7.49-7.42 (m, 1H), 7.37-7.31 (m, 1H), 7.12-7.05 (m, 1H), 7.02-6.94 (m, 2H), 5.80 (d, J=8.0 Hz, 1H), 4.77-4.69 (m, 1H), 4.64 (d, J=9.4 Hz, 1H), 4.06 (s, 3H), 4.03-3.90 (m, 2H), 3.49-3.36 (m, 2H), 3.14-3.09 (m, 1H), 3.06 (dd, J=10.6, 4.0 Hz, 1H), 2.73-2.66 (m, 1H), 2.57-2.48 (m, 1H), 2.16-2.10 (m, 1H), 1.92-1.84 (m, 2H), 1.82-1.74 (m, 4H), 1.67-1.54 (m, 2H), 1.54-1.46 (m, 1H), 0.86-0.74 (m, 2H), 0.41-0.32 (m, 2H). LC-MS RT: 1.26 min; MS (ESI) m/z 782.5 (M+H).sup.+; Method A.

Example 249

##STR00135##

[0724] Intermediate 249-1: Into the reaction vessel was added tert-butyl 5-bromo-2-fluorobenzoate (120 mg, 0.436 mmol), morpholine (0.19 mL, 2.2 mmol), and toluene (2 mL). After stirring at 90 C. for 12 h, the reaction mixture was concentrated under reduced pressure and the residue subjected to silica gel chromatography purification to produce tert-butyl 5-bromo-2-morpholinobenzoate (249-1, 117 mg, 0.342 mmol, 78.0% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.69 (d, J=2.4 Hz, 1H), 7.49 (dd, J=8.7, 2.5 Hz, 1H), 6.91 (d, J=8.8 Hz, 1H), 3.89-3.85 (m, 4H), 3.07-3.03 (m, 4H), 1.62 (s, 9H).

[0725] Intermediate 249-2: Into the reaction vessel containing 249-1 (30 mg, 0.088 mmol) was added 5-borono-2-methoxybenzoic acid (25.8 mg, 0.131 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (14 mg, 0.018 mmol), and Na.sub.2CO.sub.3 (46 mg, 0.44 mmol). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 65 C. for 2 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure and the residue subjected to prep-HPLC purification to produce 3-(tert-butoxycarbonyl)-4-methoxy-4-morpholino-[1,1-biphenyl]-3-carboxylic acid (249-2, 40 mg, 0.097 mmol, 110% yield). MS (ESI) m/z 414.0 (M+H).

[0726] Example 251: Into the reaction vessel was added intermediate 166-2 (15 mg, 0.037 mmol), 249-2 (20 mg, 0.048 mmol), MeCN (1 mL), DIEA (0.02 mL, 0.1 mmol), and HATU (18 mg, 0.048 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure, and the residue subjected to silica gel chromatography purification to produce tert-butyl 3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxy-4-morpholino-[1,1-biphenyl]-3-carboxylate (example 251.12 mg, 0.016 mmol, 42% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.87 (br d, J=7.7 Hz, 1H), 8.31 (d, J=2.2 Hz, 1H), 8.22 (s, 1H), 8.04 (dd, J=6.3, 2.5 Hz, 1H), 7.94 (d, J=2.2 Hz, 1H), 7.76 (br dd, J=8.3, 1.9 Hz, 1H), 7.60 (dd, J=8.7, 2.3 Hz, 1H), 7.56 (dt, J=8.7, 3.4 Hz, 1H), 7.47 (br d, J=8.0 Hz, 1H), 7.11 (t, J=9.4 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 4.62 (d, J=9.6 Hz, 2H), 4.07 (s, 3H), 4.07-4.04 (m, 4H), 3.50-3.38 (m, 4H), 3.17 (t, J=3.9 Hz, 1H), 2.97 (dd, J=10.7, 3.9 Hz, 1H), 2.69 (t, J=3.9 Hz, 1H), 2.12-2.05 (m, 1H), 1.90-1.81 (m, 1H), 1.62 (s, 9H), 1.61-1.54 (m, 2H), 1.50-1.43 (m, 1H), 0.78-0.69 (m, 2H), 0.37-0.28 (m, 2H). LC-MS RT: 1.23 min; MS (ESI) m/z 764.3 (M+H).sup.+; Method A.

[0727] Example 249: Into the reaction vessel was added example 251 (12 mg, 0.016 mmol), CH.sub.2Cl.sub.2 (2 mL), sodium bicarbonate (13.2 mg, 0.157 mmol) and zinc bromide (142 mg, 0.628 mmol). After stirring at 35 C. for 3 h, the reaction mixture was quenched by the addition of IN HCl and the solution extracted with EtOAc. The combined organic portion was dried over Na.sub.2SO.sub.4, filtered, concentrated, and subjected to prep-HPLC purification to produce 3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxy-4-morpholino-[1,1-biphenyl]-3-carboxylic acid, TFA (example 249, 5.2 mg, 6.2 mol, 40% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.71 (br d, J=7.7 Hz, 1H), 8.53 (d, J=2.2 Hz, 1H), 8.41 (d, J=2.5 Hz, 1H), 7.96 (dd, J=6.1, 2.5 Hz, 1H), 7.91-7.84 (m, 2H), 7.76 (dd, J=8.7, 2.6 Hz, 1H), 7.59 (dt, J=8.7, 3.5 Hz, 1H), 7.54 (d, J=8.3 Hz, 1H), 7.13 (t, J=9.4 Hz, 1H), 7.09 (d, J=8.8 Hz, 1H), 4.83-4.74 (m, 1H), 4.67 (d, J=9.6 Hz, 1H), 4.09 (s, 3H), 4.02 (br s, 4H), 3.23 (br t, J=4.0 Hz, 1H), 3.17 (br s, 4H), 3.10 (br dd, J=10.9, 3.4 Hz, 1H), 2.74 (t, J=3.9 Hz, 1H), 2.22-2.15 (m, 1H), 1.93-1.86 (m, 1H), 1.73-1.59 (m, 2H), 1.55-1.47 (m, 1H), 0.80-0.73 (m, 2H), 0.39-0.34 (m, 2H). LC-MS RT: 1.15 min; MS (ESI) m/z 708.4 (M+H).sup.+; Method A.

Example 253

##STR00136## ##STR00137## ##STR00138##

[0728] Intermediate 253-1: Into the reaction vessel was added 1-(3-bromo-4-fluorophenyl)-2,2,2-trifluoroethan-1-ol (100 mg, 0.366 mmol), 4,4,4,4,5,5,5,5-octamethyl-2,2-bi(1,3,2-dioxaborolane) (126 mg, 0.494 mmol), and 1,4-dioxane (3 mL). PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (29.9 mg, 0.037 mmol) and potassium acetate (90 mg, 0.91 mmol) were subsequently added and the reaction mixture was degassed by bubbling N.sub.2 for 10 min. The reaction mixture was stirred at 65 C. for 5 h, allowed to cool to rt and the solution extracted with EtOAc. The combined organic portions were dried over Na.sub.2SO.sub.4, filtered and concentrated. The resulting material (253-1) was used for next step without further purification.

[0729] Intermediate 253-2: Into the reaction vessel was added methyl 5-bromo-2-hydroxybenzoate (200 mg, 0.866 mmol), 2-(2-bromoethoxy)tetrahydro-2H-pyran (217 mg, 1.039 mmol), acetone (3 mL), and K.sub.2CO.sub.3 (239 mg, 1.73 mmol). After stirring at 50 C. for 12 h, the reaction mixture was concentrated under reduced pressure and the residue subjected to silica gel chromatography purification to produce methyl 5-bromo-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)benzoate (253-2, 112 mg, 0.312 mmol, 36.0% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.90 (d, J=2.6 Hz, 1H), 7.55 (dd, J=8.9, 2.6 Hz, 1H), 6.94 (d, J=8.9 Hz, 1l), 4.76 (t, J=3.5 Hz, 1H), 4.30-4.16 (m, 2H), 4.08 (dt, J=11.5, 4.6 Hz, 1H), 3.94-3.84 (m, 5H), 3.59-3.52 (m, 1H), 1.88-1.79 (m, 1H), 1.79-1.71 (m, 1H), 1.67-1.60 (m, 2H), 1.58-1.50 (m, 2H).

[0730] Intermediate 253-3: Into the reaction vessel containing 253-2 (80 mg, 0.22 mmol) was added 253-1 (93 mg, 0.29 mmol) PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (27 mg, 0.033 mmol), Na.sub.2CO.sub.3 (94 mg, 0.89 mmol), and H.sub.2O (0.5 mL). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 65 C. for 3 h. After cooling to rt, the reaction mixture was quenched by the addition of water, and the solution extracted with EtOAc. The combined EtOAc portions were dried over Na.sub.2SO.sub.4, filtered, concentrated and subjected to silica gel chromatography purification to produce methyl 2-fluoro-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)-5-(2,2,2-trifluoro-1-hydroxyethyl)-[1,1-biphenyl]-3-carboxylate (253-3, 66 mg, 0.14 mmol, 62% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95 (dd, J=2.4, 1.0 Hz, 1H), 7.64 (dt, J=8.7, 1.8 Hz, 1H), 7.52 (dd, J=7.3, 2.1 Hz, 1H), 7.47-7.40 (m, 1H), 7.19 (dd, J=10.2, 8.5 Hz, 1H), 7.09 (d, J=8.7 Hz, 1H), 5.10-5.03 (m, 1H), 4.77 (t, J=3.5 Hz, 1H), 4.31-4.25 (m, 2H), 4.15-4.08 (m, 1H), 3.95-3.87 (m, 5H), 3.60-3.52 (m, 1H), 2.98 (br d, J=3.5 Hz, 1H), 1.89-1.81 (m, 1H), 1.79-1.71 (m, 1H), 1.67-1.61 (m, 2H), 1.59-1.51 (m, 2H).

[0731] Intermediate 253-4: 253-3 (66 mg, 0.14 mmol) was dissolved in THF (4 mL) and a solution of lithium hydroxide monohydrate (31.7 mg, 0.754 mmol) in water (2 mL) was added. The reaction mixture was stirred at rt for 12 h, diluted with EtOAc (10 mL), and quenched by the addition of 1.0 eq of 1N HCl. The organic phase was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to yield 2-fluoro-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)-5-(2,2,2-trifluoro-1-hydroxyethyl)-[1,1-biphenyl]-3-carboxylic acid (253-4, 64 mg, 0.14 mmol, 100% yield) which was used for next step without further purification.

[0732] Intermediate 253-5: Into the reaction vessel was added intermediate 166-2 (25 mg, 0.068 mmol), 253-4 (31 mg, 0.068 mmol), MeCN (1 mL), DIEA (0.036 mL, 0.20 mmol), and HATU (28.4 mg, 0.0750 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure and the residue subjected to prep-HPLC purification to produce (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)-5-(2,2,2-trifluoro-1-hydroxyethyl)-[1,1-biphenyl]-3-carboxamido)bicyclo[2.2.1]heptane-2-carboxamide (253-5, 39 mg, 0.049 mmol, 72% yield). MS (ESI) m/z 809.2 (M+H).

[0733] Example 253: Into the reaction vessel was added 253-5 (15 mg, 0.019 mmol), DCM (1 mL), pyridine (0.015 mL, 0.19 mmol), 4-nitrophenyl carbonochloridate (19 mg, 0.093 mmol), and DMAP (2.3 mg, 0.019 mmol). After stirring at rt for 2 h, cyclobutanamine (13.2 mg, 0.185 mmol) was added. The reaction mixture was stirred at rt for 1 h and concentrated under reduced pressure. The residue was subjected to prep-HPLC purification to produce the corresponding carbamate. This product was not stable due to the presence of TFA. Standing at rt for 12 h followed by concentration and prep-HPLC purification produced 1-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-(2-hydroxyethoxy)-[1,1-biphenyl]-3-yl)-2,2,2-trifluoroethyl cyclobutylcarbamate (example 253, 11.0 mg, 0.0130 mmol, 70.0% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.54 (br d, J=8.5 Hz, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.76-7.67 (m, 2H), 7.57-7.47 (m, 3H), 7.43-7.36 (m, 1H), 7.21-7.14 (m, 2H), 7.10 (br d, J=8.9 Hz, 1H), 6.11-6.05 (m, 1H), 5.32 (br d, J=8.2 Hz, 1H), 4.93-4.85 (m, 1H), 4.69 (d, J=9.6 Hz, 1H), 4.49-4.43 (m, 1H), 4.32-4.24 (m, 2H), 4.17-4.09 (m, 2H), 3.17 (t, J=4.1 Hz, 1H), 3.13 (dd, J=10.5, 3.8 Hz, 1H), 2.75 (t, J=4.0 Hz, 1H), 2.42-2.24 (m, 2H), 2.20-2.14 (m, 1H), 1.98-1.85 (m, 3H), 1.80-1.61 (m, 4H), 1.53-1.46 (m, 1H), 0.82-0.73 (m, 2H), 0.40-0.33 (m, 2H). LC-MS RT: 1.33 min; MS (ESI) m/z 822.1 (M+H).sup.+; Method A.

Example 256

##STR00139##

[0734] Intermediate 256-1: Into the reaction vessel was added 3-bromo-4-fluorobenzaldehyde (1670 mg, 8.25 mmol), 2-methylpropane-2-sulfinamide (500. mg, 4.13 mmol), DCM (2 mL), MgSO.sub.4 (2483 mg, 20.63 mmol), and PPTS (52 mg, 0.21 mmol). The reaction mixture was stirred at rt for 24 h, loaded to silica cartridge, and subjected to silica gel chromatograph purification to produce (E)-N-(3-bromo-4-fluorobenzylidene)-2-methylpropane-2-sulfinamide (256-1, 1220 mg, 3.98 mmol, 97% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.51 (s, 1H), 8.11 (dd, J=6.6, 2.2 Hz, 1H), 7.77 (ddd, J=8.5, 4.7, 1.9 Hz, 1H), 7.24 (t, J=8.4 Hz, 1H), 1.28 (s, 9H).

[0735] Intermediate 256-2: Into the reaction vessel was added 256-1 (200 mg, 0.653 mmol), DMF (3 mL), (trifluoromethyl)trimethylsilane (0.19 mL, 1.3 mmol), and K.sub.2CO.sub.3 (45 mg, 0.33 mmol). The reaction mixture was stirred at rt for 60 min and 2N HCl (15 mL) was added. After string at rt for 1 h, the reaction mixture was diluted with EtOAc (30 mL), and the organic portion washed with sat NH.sub.4Cl. The aqueous phase was extracted with addition al EtOAc (10 mL2). The combined organic portion was dried over Na.sub.2SO.sub.4, concentrated, filtered, and purified by silica gel chromatography to produce N-(1-(3-bromo-4-fluorophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide (256-2, 163 mg, 0.433 mmol, 66% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.65 (dd, J=6.3, 2.1 Hz, 1H), 7.42-7.37 (m, 1H), 7.18 (t, J=8.4 Hz, 1H), 4.81 (quin, J=7.1 Hz, 1H), 3.58 (br d, J=6.6 Hz, 1H), 1.27 (s, 9H).

[0736] Intermediate 256-3: Into the reaction vessel containing 256-2 (50. mg, 0.13 mmol) was added 5-borono-2-methoxybenzoic acid (31 mg, 0.16 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (16 mg, 0.020 mmol), Na.sub.2CO.sub.3 (56 mg, 0.53 mmol), and H.sub.2O (0.5 mL). The reaction mixture was degassed by bubbling N.sub.2 for 10 min, sealed, and stirred at 65 C. for 3 h. After cooling to rt, the reaction mixture was quenched by the addition of TN HCl, the solution extracted with EtOAc, the combined organic portions dried over Na.sub.2SO.sub.4, filtered, concentrated and subjected to prep-HPLC purification to produce 5-(1-((tert-butylsulfinyl)amino)-2,2,2-trifluoroethyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxylic acid (256-3, 47 mg, 0.10 mmol, 79% yield). MS (ESI) m/z 448.1 (M+H).

[0737] Example 256: Into the reaction vessel was added 166-2 (10 mg, 0.027 mmol), 256-3 (12 mg, 0.027 mmol), MeCN (1 mL), DIEA (0.014 mL, 0.081 mmol), and HATU (11 mg, 0.030 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure and the residue subjected to prep-HPLC purification to produce (1R,2S,3R,4R,Z)-3-(5-(1-((tert-butylsulfinyl)amino)-2,2,2-trifluoroethyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxamido)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide (example 256, 7.5 mg, 9.3 mol, 34% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.95 (br t, J=6.4 Hz, 1H), 8.27-8.19 (m, 1H), 8.16 (s, 1H), 7.87-7.74 (m, 2H), 7.70 (br d, J=8.8 Hz, 1H), 7.66-7.58 (m, 1H), 7.48 (br t, J=9.7 Hz, 1H), 7.40-7.29 (m, 2H), 6.51 (d, J=9.6 Hz, 1H), 5.39-5.27 (m, 1H), 4.68 (d, J=9.7 Hz, 1H), 4.51-4.41 (m, 1H), 4.05 (s, 3H), 3.19-3.14 (m, 1H), 3.11 (br s, 1H), 1.88-1.75 (m, 2H), 1.56-1.46 (m, 1H), 1.44-1.35 (m, 2H), 1.14 (s, 9H), 0.79-0.68 (m, 2H), 0.39-0.30 (m, 2H). LC-MS RT: 1.25 min; MS (ESI) m/z 798.1 (M+H).sup.+; Method A.

Example 258

##STR00140##

[0738] Intermediate 258-1: Into the reaction vessel was added intermediate 166-2 (15 mg, 0.041 mmol) and THF (1 mL). After cooling to 0 C., LiAlH.sub.4 (0.5 mL, 0.500 mmol) was added. After stirring at 0 C. for 5 min, the reaction mixture was allowed to warm to rt and stir at rt for 20 min. The reaction mixture was diluted with EtOAc. After washing the organic solution with sat NaHCO.sub.3, the organic phase was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide (1R,2R,3R,4R,Z)-7-(cyclopropylmethylene)-3-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)methyl)bicyclo[2.2.1]heptan-2-amine (258-1, 7.0 mg, 0.020 mmol, 49% yield). This material was used for next step without further purification. MS (ESI) m/z 355.3 (M+H).

[0739] Example 258: Into the reaction vessel was added 258-1 (7.0 mg, 0.020 mmol), 120-6 (6.5 mg, 0.019 mmol), MeCN (1 mL), DIEA (9.4 l, 0.054 mmol), and HATU (7.5 mg, 0.020 mmol). The reaction mixture was stirred at rt for 12 h, concentrated under reduced pressure and the residue subjected to silica gel chromatography purification to yield a residue that was treated with 2:1 DCM/TFA at rt for 30 min. The resulting solution was concentrated and the residue purified by HPLC to produce 3-(((1R,2R,3R,4R,Z)-7-(cyclopropylmethylene)-3-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)methyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxylic acid, example 258, 6.5 mg, 8.4 mol, 47% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.59 (br d, J=7.4 Hz, 1H), 8.41 (d, J=1.4 Hz, 1H), 8.23 (dd, J=7.6, 2.1 Hz, 1H), 8.09 (ddd, J=8.5, 4.6, 2.1 Hz, 1H), 7.71 (br d, J=8.8 Hz, 1H), 7.26-7.22 (m, 1H), 7.08-7.02 (m, 2H), 6.99-6.94 (m, 2H), 4.65 (d, J=9.6 Hz, 1H), 4.63-4.57 (m, 1H), 4.03 (s, 3H), 3.32 (dd, J=11.4, 2.9 Hz, 1H), 3.09 (t, J=4.1 Hz, 1H), 3.04-2.97 (m, 1H), 2.59-2.52 (m, 2H), 1.83-1.74 (m, 1H), 1.73-1.67 (m, 1H), 1.64-1.55 (m, 2H), 1.47-1.39 (m, 1H), 0.76-0.69 (m, 2H), 0.41-0.31 (m, 2H). LC-MS RT: 1.31 min; MS (ESI) m/z 683.5 (M+H).sup.+; Method A.

Example 259

##STR00141##

[0740] Intermediate 259-1: 259-1 was prepared from intermediate 166-2 and 140-2 following the procedure described for Example 168. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.58-9.15 (br. s, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.17-7.93 (m, 1H), 7.90 (dd, J=6.1, 2.5 Hz, 1H), 7.56 (dt, J=8.9, 3.4 Hz, 1H), 7.41 (dd, J=8.5, 2.5 Hz, 1H), 7.08 (t, J=9.4 Hz, 1H), 6.92 (br d, J=7.7 Hz, 1H), 6.16 (dt, J=4.0, 2.1 Hz, 1H), 4.87-4.79 (m, 1H), 4.63 (d, J=9.6 Hz, 1H), 4.32-4.18 (m, 2H), 3.99 (s, 3H), 3.55 (br s, 2H), 3.18 (t, J=3.7 Hz, 1H), 3.11-3.06 (m, 1H), 2.71 (t, J=3.7 Hz, 1H), 2.31 (br d, J=2.8 Hz, 2H), 2.23-2.12 (m, 1H), 1.91-1.80 (m, 1H), 1.71-1.61 (m, 2H), 1.50 (s, 9H), 1.49-1.42 (m, 1H), 0.77-0.70 (m, 2H), 0.40-0.30 (m, 2H).

[0741] Intermediate 259-2: Into the reaction vessel was added 259-1 (13 mg, 0.019 mmol), DCM (1.5 mL), DIEA (0.012 mL, 0.067 mmol) and zinc bromide (150 mg, 0.665 mmol). After stirring at for 12 h, the reaction mixture was quenched with the addition of sat NaHCO.sub.3 and the solution extracted with EtOAc. The combined organic portion was dried over Na.sub.2SO.sub.4 filtered and concentrated to generate (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(1,2,5,6-tetrahydropyridin-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide (259-2, 12 mg, 0.021 mmol, 110% yield). This intermediate was used for next step without further purification. MS (ESI) m/z 584.4 (M+H).

[0742] Example 259: Into the reaction vessel was added 259-2 (11 mg, 0.019 mmol), MeCN (1 mL), 2-bromoacetic acid (1.5 mg, 0.011 mmol), and DIEA (9.9 l, 0.057 mmol). The reaction mixture was stirred at rt for 1 h and concentrated under reduced pressure. Preparative HPLC of the resulting residue, followed by SFC purification produced 2-(5-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-3,6-dihydropyridin-1(2H)-yl)acetic acid example 259, 4.1 mg, 5.4 mol, 28% yield). .sup.1H NMR (500 MHz, CD.sub.3OD) 10.31 (br d. J=7.2 Hz, 1H), 10.12 (s, 1H), 8.15 (dd, J=6.2, 2.6 Hz, 1H), 8.05 (d, J=2.5 Hz, 1H), 7.78-7.68 (m, 1H), 7.59 (dd, J=8.8, 2.5 Hz, 1H), 7.28 (t, J=9.6 Hz, 1H), 7.23-7.17 (m, 1H), 6.38-6.32 (m, 1H), 4.74 (d, J=9.4 Hz, 1H), 4.60-4.52 (m, 1H), 4.25 (br s, 4H), 4.09 (s, 3H), 3.25-3.19 (m, 1H), 3.17-3.11 (m, 1H), 2.77-2.68 (m, 3H), 2.01-1.89 (m, 2H), 1.59-1.47 (m, 3H), 0.80-0.71 (m, 2H), 0.41-0.29 (m, 2H). LC-MS RT: 0.94 min; MS (ESI) m/z 642.3 (M+H).sup.+; Method A.

Example 265

##STR00142##

[0743] Intermediate 265-1: To a vial containing 260-2 (10 mg, 0.013 mmol) in THF (1.3 mL) was added LiOH (63 l, 0.063 mmol) as a 1M solution in water. The reaction mixture was stirred at room temperature for 18 h, then diluted with 1N HCl. The resulting mixture was extracted with EtOAc (35 mL). The combined organics were dried over Na.sub.2SO.sub.4 filtered and concentrated to afford (1R,2S,3R,4R,Z)-3-(5-(tert-butoxycarbonyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxamido)-7-(cyclopropylmethylene)bicyclo[2.2.1]heptane-2-carboxylic acid which was used without further purification, (7.0 mg, 0.013 mmol, 100% yield). .sup.1H-NMR (500 MHz, DMSO-d6) 10.05 (br s, 1H), 8.12 (s, 1H), 8.01-7.97 (m, 1H), 7.96-7.92 (m, 1H), 7.74 (d, J=8.9 Hz, 1H), 7.45 (t, J=9.5 Hz, 1H), 7.33 (d, J=8.9 Hz, 1H), 4.66 (d, J=9.5 Hz, 1H), 4.34-4.25 (m, 1H), 4.04 (s, 3H), 3.15-3.09 (m, 1H), 2.99 (dd, J=10.8, 3.8 Hz, 1H), 2.68-2.61 (m, 1H), 1.76-1.63 (m, 2H), 1.56 (s, 9H), 1.47 (dt, J=8.7, 4.2 Hz, 1H), 1.42 (s, 2H), 0.84-0.60 (m, 2H), 0.44-0.23 (m, 2H). LC-MS RT: 1.17 min; MS (ESI) m/z 536 (M+H).sup.+; Method D.

[0744] Example 265: Into the reaction vessel was added 265-1 (4.0 mg, 0.022 mmol), MeCN (1 mL), DIEA (10 l, 0.060 mmol), and HATU (6.8 mg, 0.018 mmol). The reaction mixture was stirred at room temperature for 12 h then concentrated under reduced pressure and the residue dissolved in 1:2 TFA/DCM and stirred for 30 min. The reaction mixture was concentrated under reduced pressure, dissolved in DMSO and purified by HPLC to afford 3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-methyl-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxylic acid (3.4 mg, 5.3 mol, 35% yield). .sup.1H-NMR (500 MHz, DMSO-d6) 10.41 (s, 1H), 9.98 (d, J=6.7 Hz, 1H), 8.21-8.09 (m, 2H), 8.05-7.99 (m, 1H), 7.99-7.90 (m, 1H), 7.77-7.70 (m, 1H), 7.64 (dd, J=7.8, 1.1 Hz, 1H), 7.45-7.36 (m, 2H), 7.33 (d, J=8.5 Hz, 1H), 4.69 (d, J=9.5 Hz, 1H), 4.55-4.36 (m, 1H), 4.06 (s, 3H), 3.19-3.13 (m, 1H), 3.13-3.08 (m, 1H), 2.78-2.66 (m, 1H), 2.37 (s, 3H), 1.90-1.84 (m, 1H), 1.83-1.76 (m, 1H), 1.55-1.47 (m, 1H), 1.47-1.37 (m, 2H), 0.84-0.60 (m, 2H), 0.42-0.23 (m, 2H). LC-MS RT: 2.21 min; MS (ESI) m/z 653 (M+H).sup.+; Method A.

Example 310

##STR00143##

Intermediate 310-1

[0745] A solution of 5-borono-2-methoxybenzoic acid (0.200 g, 1.02 mmol) in EtOAc (10 ml) was treated with pinacol (0.121 g, 1.02 mmol) and the resulting solution stirred at rt overnight. The reaction mixture was then concentrated and the resulting solid used without further manipulation as 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.284 g, 1.02 mmol, 100% yield). This solid was coupled to intermediate 170-2 according to the same procedure as Example 108 to furnish intermediate 310-1.

[0746] The reaction mixture of 310-1 (50 mg, 0.076 mmol), PdCl.sub.2(dppf) (5.6 mg, 7.6 mol), 3-bromopyridine (0.1 mL) and K.sub.3PO.sub.4 (48.5 mg, 0.229 mmol) was heated to 80 C. The reaction mixture was cooled to rt, and partitioned between water and EtOAc. The organic layer was concentrated and the residue purified by reverse phase HPLC to furnish (1R,2S,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(pyridin-3-yl)benzamido)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptane-2-carboxamide (11.4 mg, 0.019 mmol, 24% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.68 (s, 1H), 9.99 (br d, J=6.8 Hz, 1H), 8.85 (s, 1H), 8.55 (br d, J=3.4 Hz, 1H), 8.24 (br d, J=2.3 Hz, 2H), 8.07-8.00 (m, 1H), 7.90 (dd, J=8.6, 2.4 Hz, 1H), 7.83-7.73 (m, 1H), 7.56-7.45 (m, 2H), 7.34 (d, J=8.8 Hz, 1H), 6.05-5.92 (m, 1H), 4.60-4.51 (m, 1H), 4.06 (s, 3H), 3.47 (s, 1H), 3.00 (br s, 1H), 2.74 (s, 1H), 2.02-1.95 (m, 1H), 1.94-1.87 (m, 1H), 1.51 (br d, J=6.6 Hz, 2H). LC-MS RT 2.47 min; MS (ESI) m/z=608.3 (M+H)+; Method C.

[0747] Example 320 was prepared analogously to Example 253 via the following intermediates.

Example 320

##STR00144##

Intermediate 320-1

##STR00145##

[0748] To a solution of methyl 5-bromo-2-hydroxybenzoate (750 mg, 3.25 mmol) and 4-(2-bromoethyl)morpholine (756 mg, 3.90 mmol) in DMF (12 mL) was added K.sub.2CO.sub.3 (1346 mg, 9.74 mmol) heated at 70 C. for 4 h. The reaction mixture was diluted with EtOAc, and the solution washed with water and brine solution. The separated organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by silica column to furnish methyl 5-bromo-2-(2-morpholinoethoxy)benzoate (320-1, 0.800 g, 2.32 mmol, 71.6% yield). MS, m/z: 343.9 (M+2H).

Intermediate 320-2

##STR00146##

[0749] To a solution of 320-1 (300 mg, 0.872 mmol) and tert-butyl 4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (309 mg, 0.959 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was added tripotassium phosphate (555 mg, 2.61 mmol) and the resulting mixture purged with nitrogen for 5 min. PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (71 mg, 0.087 mmol) was added and the reaction mixture purged for 2 min with nitrogen then heated in a sealed tube at 85 C. for 16 h. The reaction mixture was filtered through celite. The filtrate was diluted with EtOAc and the organic phase washed with water and brine solutions. The organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography to furnish 3-(tert-butyl) 3-methyl 6-fluoro-4-(2-morpholinoethoxy)-[1,1-biphenyl]-3,3-dicarboxylate (320-2, 0.310 g, 0.675 mmol, 77% yield). MS, m/z: 460.2 (M+H).

Intermediate 320-3

##STR00147##

[0750] To a solution of 320-2 (100 mg, 0.218 mmol) in THF (2 mL) was added NaOH (0.87 mL, 2.2 mmol) solution and stirred at 50 C. for 30 min. THF was removed under vacuum, 1 ml of water was added and acidified with 1.5N HCl to pH 4. The aqueous layer was extracted with EtOAc (220 ml). The combined organic layers were washed with water and brine solution, dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 5-(tert-butoxycarbonyl)-2-fluoro-4-(2-morpholinoethoxy)-[1,1-biphenyl]-3-carboxylic acid (40 mg, 0.090 mmol, 41% yield). MS, m/z: 446.2 (M+H).

Intermediate 320-4

##STR00148##

[0751] To a solution of 320-3 (30 mg, 0.076 mmol) and 170-2 (334 mg, 0.0760 mmol) in DMF (2 mL) were added DIPEA (0.07 mL, 0.4 mmol) and HATU (57.6 mg, 0.151 mmol), stirred for at room temperature for 12 h. The reaction mixture was diluted EtOAc, washed with water and brine solution. The separated organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated. The residue product was purified by silica gel chromatography to furnish tert-butyl 6-fluoro-3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-(2-morpholinoethoxy)-[1,1-biphenyl]-3-carboxylate (320-4, 50 mg, 0.061 mmol, 80% yield). MS, m/z: 824.3 (M+H).

[0752] To a solution of 320-4 (50 mg, 0.061 mmol) in DCM (2 mL) was added TFA (0.094 mL, 1.2 mmol) at 0 C., stirred for 4 h at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was purified reverse phase HPLC to furnish 6-fluoro-3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-(2-morpholinoethoxy)-[1,1-biphenyl]-3-carboxylic acid (20 mg, 0.025 mmol, 42% yield) as a white solid. .sup.1H NMR (400 MHz, DMSO-d6) ppm 13.27-13.08 (m, 1H), 10.47-10.37 (m, 1H), 10.02-9.81 (m, 1H), 8.91-8.75 (m, 1H), 8.16-7.94 (m, 3H), 7.89-7.79 (m, 1H), 7.76-7.60 (m, 2H), 5.82-5.67 (m, 1H), 4.68-4.61 (m, 1H), 4.61-4.43 (m, 1H), 4.01-3.83 (m, 2H), 3.75-3.61 (m, 2H), 3.58-3.48 (m, 3H), 2.84-2.78 (m, 2H), 2.70-2.63 (m, 5H), 2.02-1.85 (m, 2H), 1.81-1.65 (m, 2H), 1.62-1.45 (m, 2H). MS, m/z: 768.2 (M+H).

Example 323

##STR00149##

[0753] Intermediate 323-1

##STR00150##

[0754] To 120-4 (0.05 g, 0.1 mmol) dissolved in MeOH (0.5 mL) and THF (0.5 mL) was added Hunig's Base (0.021 mL, 0.12 mmol), triphenylphosphine (0.8 mg, 3 mol), and bis(triphenylphosphine)palladium (II) chloride (2 mg, 3 mol). The vessel was pressurized with carbon monoxide at 60 psi and heated at 70 C. for 36 h. The reaction solution was concentrated under vacuum and purified via flash chromatography to furnish methyl (Z)-2-((1R,2S,3R,4R)-2-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptan-7-ylidene)acetate 323-1. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.49 (br d, J=6.9 Hz, 1H), 7.96 (s, 1H), 7.86-7.72 (m, 2H), 7.23 (t, J=9.4 Hz, 1H), 5.76 (s, 1H), 4.51 (dt, J=10.5, 5.3 Hz, 1H), 3.93 (t, J=4.1 Hz, 1H), 3.86-3.75 (m, 3H), 3.18-3.05 (m, 1H), 2.89 (t, J=4.0 Hz, 1H), 2.06-1.87 (m, 2H), 1.78-1.64 (m, 2H).

Intermediate 323-2

##STR00151##

[0755] To MeOH (0.8 mL) was added AcCl (0.080 mL, 1.1 mmol) and stirred for 5 minutes and 323-1 added (0.029 g, 0.060 mmol) and the reaction mixture was stirred 32 h. The reaction mixture was concentrated under vacuum to furnish methyl (Z)-2-((1R,2R,3S,4R)-2-amino-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-7-ylidene)acetate, hydrogen chloride salt (323-2, 0.025 g, 0.060 mmol, 100% yield) which was used without further purification. MS (ESI) m/z 387.0 (M+H).

Intermediate 323-3

##STR00152##

[0756] To 323-2 and 120-6 (0.025 g, 0.072 mmol) dissolved in MeCN (0.6 mL) was added DIEA (0.03 mL, 0.2 mmol) followed by HATU (0.034 g, 0.090 mmol). The reaction mixture was stirred 16 h, concentrated under vacuum and purified via flash chromatography to furnish tert-butyl 6-fluoro-3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2-methoxy-2-oxoethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxy-[1,1-biphenyl]-3-carboxylate (323-3, 0.028 g, 0.039 mmol, 65% yield). MS (ESI) m/z 715.3 (M+H).

Intermediate 323-4

##STR00153##

[0757] To 323-3 (0.028 g, 0.040 mmol) dissolved in THF (1 mL) was added water (0.5 mL) and lithium hydroxide monohydrate (2 mg, 0.05 mmol) and stirred 16 h. The reaction mixture was diluted with water, neutralized with 1M HCl, and extracted into EtOAc. The organic layer was separated and dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to furnish (Z)-2-((1R,2R,3S,4R)-2-(5-(tert-butoxycarbonyl)-2-fluoro-4-methoxy-[1,1-biphenyl]-3-carboxamido)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-7-ylidene)acetic acid (323-4, 0.025 g, 0.036 mmol, 90% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.43 (s, 1H), 8.30-8.18 (m, 1H), 8.16-8.06 (m, 1H), 8.02-7.94 (m, 1H), 7.71 (br d, J=8.5 Hz, 1H), 7.25-7.13 (m, 2H), 7.00 (br d, J=8.8 Hz, 1H), 5.82 (s, 1H), 4.85-4.65 (m, 1H), 4.29 (br s, 1H), 3.97 (s, 3H), 3.16-2.96 (m, 2H), 2.22-2.09 (m, 1H), 2.04-1.86 (m, 2H), 1.75-1.58 (m, 9H) MS (ESI) m/z 701.3 (M+H).

[0758] Example 323 was prepared from Intermediate 323-4 by first making the amide according to the procedure for Example 34 followed by removal of the t-butyl group according to the procedure for Example 120. .sup.1H NMR (500 MHz, DMSO-d6) 10.67 (s, 1H), 9.85 (br d, J=7.0 Hz, 1H), 8.24 (br d, J=4.3 Hz, 1H), 8.11 (br s, 1H), 8.01 (br d, J=7.0 Hz, 1H), 7.93 (br s, 1H), 7.80 (br d, J=8.2 Hz, 1H), 7.72 (br d, J=8.2 Hz, 1H), 7.48 (br t, J=9.5 Hz, 1H), 7.37 (br t, J=9.5 Hz, 1H), 7.31 (br d, J=8.9 Hz, 1H), 6.14 (s, 1H), 4.58-4.44 (m, 1H), 4.06 (s, 3H), 3.54 (br s, 1H), 3.05 (s, 3H), 2.99 (s, 1H), 2.88 (s, 4H), 2.03-1.95 (m, 1H), 1.90-1.73 (m, 1H), 1.45 (br s, 2H). LC-MS RT: 2.19 min; MS (ESI) m/z=627.14 (MH)+; Method C.

Example 325

##STR00154##

Intermediate 325-1

##STR00155##

[0759] To 120-4 (0.05 g, 0.1 mmol) slurried in triethylamine (0.2 mL) was added ethynyltrimethylsilane (0.02 ml, 0.1 mmol), bis(triphenylphosphine)palladium (II) chloride (3 mg, 5 mol), and copper(I) iodide (2 mg, 10 mol). The reaction mixture was heated at 90 C. for 16 h. The reaction mixture was partitioned between EtOAc and pH 7.4 buffer and extracted in to EtOAc. The organic layer was separated and dried over Na.sub.2SO.sub.4, decanted and concentrated under vacuum, and the residue purified via flash chromatography to furnish (1R,2S,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)-7-(3-(trimethylsilyl)prop-2-yn-1-ylidene)bicyclo[2.2.1]heptane-2-carboxamide (325-1, 40 mg, 0.077 mmol, 77% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 9.39 (br d, J=6.9 Hz, 1H), 7.78-7.67 (m, 2H), 7.33 (s, 1H), 7.26-7.18 (m, 1H), 5.45 (s, 1H), 4.60-4.41 (m, 1H), 3.32 (t, J=4.1 Hz, 1H), 3.05 (ddd, J=10.5, 4.4, 1.4 Hz, 1H), 2.81 (t, J=4.1 Hz, 1H), 1.98-1.90 (m, 1H), 1.90-1.81 (m, 1H), 1.76-1.59 (m, 2H), 0.31-0.17 (m, 9H). MS (ESI) m/z 521.0 (M+H).

Intermediate 325-2

##STR00156##

[0760] To 325-1 (40 mg, 0.077 mmol) dissolved in THF (0.8 mL) was added 1 M TBAF in THF (0.2 mL, 0.2 mmol) and the reaction was stirred 16 h. The reaction mixture was concentrated under reduced pressure and purified via flash chromatography to furnish (1R,2S,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-(prop-2-yn-1-ylidene)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide (325-2, 38 mg, 0.084 mmol, quantitative yield) MS (ESI) m/z 499.0 (M+H).

Intermediate 325-3

##STR00157##

[0761] To a solution of 325-2 (0.017 g, 0.038 mmol), (azidomethyl)trimethylsilane (0.011 mL, 0.076 mmol) dissolved in DMF (0.3 mL) and water (0.1 mL) was added copper (II) sulfate pentahydrate (7 mg, 0.03 mmol), and sodium ascorbate (8 mg, 0.04 mmol) and stirred for 3 h. The reaction mixture was partitioned between EtOAc and water, and the organic layer was washed 2 with EtOAc, dried over MgSO.sub.4, filtered and concentrated under vacuum to furnish (1R,2S,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)-7-((1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)methylene)bicyclo[2.2.1]heptane-2-carboxamide 325-3, which was used without further purification. MS (ESI) m/z 578.1 (M+H).

Intermediate 325-4

##STR00158##

[0762] To MeOH (0.5 ml) was added AcCl (0.050 ml, 0.70 mmol) and the reaction mixture stirred for 5 min. 325-3 (0.022 g, 0.038 mmol) was added and the reaction mixture was stirred at 40 C. for 48 h. The reaction mixture was concentrated under reduced pressure and residual solvent removed under high vacuum to generate (1R,2S,3R,4R,Z)-3-amino-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-((1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)methylene)bicyclo[2.2.1]heptane-2-carboxamide (325-4, 0.018 g, 0.038 mmol, 100% yield) which was used without further purification. MS (ESI) m/z 482.2 (M+H).

Intermediate 325-5

##STR00159##

[0763] Intermediate 325-5 was prepared from 325-4 and 120-6 according to the procedure for Example 108.

[0764] Example 325 was prepared from 325-5 according to the procedure for Example 120. .sup.1H NMR (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.85 (br d, J=7.0 Hz, 1H), 8.15 (br d, J=4.6 Hz, 1H), 8.05 (br s, 1H), 7.99-7.81 (m, 3H), 7.71 (br s, 1H), 7.65 (br d, J=8.2 Hz, 1H), 7.40 (br t, J=9.6 Hz, 1H), 7.33 (br t, J=9.6 Hz, 1H), 7.24 (br d, J=8.5 Hz, 1H), 6.18 (s, 1H), 4.44 (br s, 1H), 3.98 (s, 3H), 3.90 (s, 2H), 3.48 (br s, 1H), 3.27-3.09 (m, 1H), 2.83 (br s, 1H), 1.96-1.72 (m, 2H), 1.41 (br d, J=5.8 Hz, 2H), 0.00 (s, 9H). LC-MS RT: 2.54 min; MS (ESI) m/z=754.36 (MH)+; Method C.

Example 329

##STR00160##

Intermediate 329-1

##STR00161##

[0765] To a solution of methyl 5-iodo-2-methoxybenzoate (500 mg, 1.71 mmol) and piperidin-3-ylmethanol (394 mg, 3.42 mmol) in DMSO (10 mL) was added K.sub.2CO.sub.3 (710 mg, 5.14 mmol), CuI (98 mg, 0.51 mmol) and L-proline (59 mg, 0.51 mmol). The resulting solution was degassed with N.sub.2 for 10 min followed by heating at 90 C. for 12 h. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over Na.sub.2SO.sub.4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to furnish methyl 5-(3-(hydroxymethyl)piperidin-1-yl)-2-methoxybenzoate (329-1, 350 mg, 1.25 mmol, 73.2% yield). MS (ESI) m/z 280.2 (M+H).

Intermediate 329-2

##STR00162##

[0766] To a solution of 329-1 (350 mg, 1.253 mmol) in MeOH (5 mL), THF (5 mL) and water (3 mL) was added LiOH (150 mg, 6.26 mmol) and stirred at rt for 3 h. The reaction mass was concentrated under reduced pressure, the aqueous layer was acidified to pH 4-5 with HCl, and the resulting precipitate was filtered and dried to furnish 5-(3-(hydroxymethyl)piperidin-1-yl)-2-methoxybenzoic acid (300 mg, 1.13 mmol, 90% yield) as white solid. MS (ESI) m/z 266.2 (M+H).

[0767] Example 329 was prepared from Intermediates 166-2 and 329-2 according to the procedure for Example 108. The stereoisomers were separated by Prep HPLC column Chiralcel OD-H (2504.6) mm, 5u to furnish (1R,2R,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(3-(hydroxymethyl)piperidin-1-yl)-2-methoxybenzamido)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptane-2-carboxamide (2.1 mg, 3.231 mol, 3.51% yield) MS (ESI) m/z 644.2 (M+H). .sup.1H NMR (400 MHz, DMSO-d6) ppm 10.43 (s, 1H), 8.41 (d, J=6.5 Hz, 1H), 8.12 (dd, J=2.5, 6.5 Hz, 1H), 7.88-7.75 (m, 1H), 7.48 (t, J=9.8 Hz, 1H), 7.20 (d, J=2.5 Hz, 1H), 7.11-6.95 (m, 2H), 5.82-5.64 (m, 1H), 4.65-4.56 (m, 1H), 4.52 (t, J=5.3 Hz, 1H), 3.83 (s, 3H), 3.51 (br s, 1H), 3.44-3.41 (m, 1H), 3.25-3.20 (m, 2H), 2.78 (d, J=4.0 Hz, 1H), 2.58-2.55 (m, 3H), 2.32-2.27 (m, 1H), 1.92 (td, J=4.7, 12.2 Hz, 1H), 1.80-1.65 (m, 6H), 1.56 (br s, 2H), 1.09-0.94 (m, 1H).

Example 346

##STR00163##

Intermediate 346-1

##STR00164##

[0768] To a solution of 4-bromo-1H-pyrazole (2.00 g, 13.6 mmol) in THF (100 mL) at 78 C. was added dropwise n-butyllithium (25.5 mL, 40.8 mmol). After completion of addition, the reaction mixture was allowed to raise to room temperature and stirred at room temperature for 1.5 hours. The mixture was then cooled back to 78 C. and a solution of diethyl oxalate (2.8 mL, 20 mmol) in THF (2.5 mL) was added and allowed to stir for 20 minutes. The reaction mixture was quenched by the addition of saturated ammonium chloride and the solution extracted with ethyl acetate. The organic layers were combined, concentrated under reduced pressure and purified using silica gel chromatography to yield 346-1 (496 mg, 20.6%). MS (ESI) m/z: 168.9 (M+H).

Intermediate 346-2

##STR00165##

[0769] To a solution of 346-1 (150 mg, 0.892 mmol) in acetonitrile (5 mL) was added DMAP (10.90 mg, 0.089 mmol), Di-tert-butyl dicarbonate (0.249 mL, 1.07 mmol) followed by TEA (0.149 mL, 1.07 mmol). The reaction mixture was then stirred at room temperature for 18 h. The reaction mixture was then concentrated under reduced pressure and purified using silica gel chromatography to yield 346-2 (185 mg, 73.4%). MS (ESI) m/z: 269.1 (M+H).

Intermediate 346-3

##STR00166##

[0770] A solution of 346-2 (185 mg, 0.690 mmol), sodium acetate (62.2 mg, 0.759 mmol) and hydroxylamine hydrochloride (86 mg, 1.241 mmol) in ethanol (3 mL) was heated at reflux for 1 hour. The reaction mixture was then concentrated under vacuum and diluted with ethyl acetate. The organic layer was washed with 5% HCl solution to give 346-3 (190 mg, 88%) which was used without further purification. MS (ESI) m/z: 183.9 (M+H-Boc).

Intermediate 346-3

##STR00167##

[0771] To a degassed solution of 346-3 (190 mg, 0.671 mmol) in ethanol (5 mL) was added palladium on carbon (143 mg, 0.134 mmol) and degassed with nitrogen. The reaction mixture was stirred under a hydrogen balloon for 1.5 hours. The reaction mixture was filtered over a pad of celite to yield 346-4 (181 mg, 100%) MS (ESI) m/z: 270.1 (M+H).

Intermediate 346-5

##STR00168##

[0772] To a solution of 346-4 (181 mg, 0.672 mmol) and tetrahydro-2H-pyran-4-carboxylic acid (87 mg, 0.672 mmol) in anhydrous DMF (2 mL), was added DIEA (0.587 mL, 3.36 mmol) followed by BOP (327 mg, 0.739 mmol). The reaction mixture was stirred at room temperature for 1 hour and filtered. The residue was concentrated under reduced pressure and purified using silica gel chromatography to yield 346-5 (120 mg, 44.5%). MS (ESI) m/z: 382.3 (M+H).

Intermediate 346-6

##STR00169##

[0773] To a solution of 346-5 (120 mg, 0.315 mmol) in DCM (4 mL) was added TFA (1.5 mL, 19.47 mmol) and the reaction mixture stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to yield 346-6 (125 mg, 90%). MS (ESI) m/z: 282.2 (M+H).

Intermediate 346-7

##STR00170##

[0774] To a solution degassed under N.sub.2 of 5-borono-2-methoxybenzoic acid (87 mg, 0.444 mmol), 346-6 (125 mg, 0.444 mmol) and boric acid (82 mg, 1.3 mmol) was added copper (II) acetate (81 mg, 0.44 mmol) and the reaction mixture stirred at room temperature for 18 h. The reaction mixture was concentrated under reduced pressure and purified using silica gel chromatography. MS (ESI) m/z: 432.3 (M+H).

[0775] Example 346 was prepared in a similar way as Example 108 from 170-2 and 346-7. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.66 (s, 1H), 10.03 (d, J=6.7 Hz, 1H), 8.59-8.51 (m, 1H), 8.46 (br. s., 1H), 8.32 (br. s., 1H), 8.24 (d, J=4.6 Hz, 1H), 7.98-7.88 (m, 1H), 7.79 (br. s., 1H), 7.72 (s, 1H), 7.50 (t, J=9.8 Hz, 1H), 7.33 (d, J=8.8 Hz, 1H), 6.00-5.88 (m, 1H), 5.38 (d, J=6.4 Hz, 1H), 4.54 (br. s., 1H), 4.17-4.09 (m, 2H), 4.05 (s, 3H), 3.36-3.20 (m, 2H), 3.00 (br. s., 1H), 2.01-1.82 (m, 2H), 1.69-1.55 (m, 5H), 1.50 (d, J=6.1 Hz, 2H), 1.17 (t, J=7.0 Hz, 3H); LC-MS (M+H)=810.1; HPLC RT=2.44 min; Method B.

Example 348

##STR00171##

Intermediate 348-1

##STR00172##

[0776] A mixture of furan-2,5-dione (10 g, 102 mmol) and phenylmethanol (31.7 mL, 306 mmol) in toluene (50 mL) was heated to 80 C. for 24 hours. The reaction mixture was then concentrated under reduced pressure and purified using silica gel chromatography to yield 348-1 (15.5 g, 73%). MS (ESI) m/z: 206.9 (M+H).

Intermediate 348-2

##STR00173##

[0777] To a solution of 348-1 (3.6 g, 17 mmol) in MeCN (40 mL) and water (0.400 mL) was added ferrocenium hexafluorophosphate (11.6 g, 34.9 mmol) and stirred in open atmosphere for 18 hours. The reaction mixture was concentrated under reduced pressure and diluted with DCM. The reaction mixture was treated with 1N HCl (40 mL) for 30 minutes. The organic layer was then separated and the aqueous layer was washed with DCM and separated. The organic layers were combined and washed with brine. The organic layer was concentrated under reduced pressure and purified using silica gel chromatography to yield 348-2 (1.8 g, 35%). MS (ESI) m/z: 289.1 (M+H).

Intermediate 348-3

##STR00174##

[0778] Into a 3 necked round bottom flask was added 348-2 (1.99 g, 6.90 mmol) and toluene (45 mL) followed by TEA (2.1 mL, 15 mmol) and diphenylphosphoryl azide (1.26 mL, 5.87 mmol). The reaction mixture was stirred for 2.5 hours at room temperature. To this reaction mixture was added 2-(trimethylsilyl)ethan-1-ol (3.94 mL, 28.3 mmol) and the resulting reaction mixture was heated at 80 C. for 28 hours. The reaction mixture was allowed to cool to room temperature, concentrated under reduced pressure and purified using silica gel chromatography to yield 348-3 (1.52 g, 51.8%). MS (ESI) m/z: 403.9 (M+H).

Intermediate 348-4

##STR00175##

[0779] To a solution of 348-3 (1.52 g, 3.77 mmol) in THF (24 mL) and water (8.0 mL) was added LiOH (5.65 mL, 11.3 mmol) and the solution was stirred at room temperature for 1 hour. The reaction mixture was acidified and extracted with ethyl acetate. The organic layers were combined and concentrated under reduced pressure to yield 348-4 (1.1 g, 92%). MS (ESI) m/z: 313.9 (M+H).

Intermediate 348-5

##STR00176##

[0780] To a solution of 348-4 (680 mg, 2.17 mmol) in anhydrous DMF (12 mL) was added 4-fluoro-3-(trifluoromethyl)aniline (0.28 mL, 2.2 mmol), 1-hydroxybenzotriazole hydrate (515 mg, 3.36 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (624 mg, 3.25 mmol). The reaction mixture was stirred at rt for 18 h and concentrated under reduced pressure. The residue was purified using silica gel chromatography to yield 348-5 (260 mg, 25%). MS (ESI) m/z: 474.9 (M+H).

Intermediate 348-6

##STR00177##

[0781] To a flask, under N.sub.2 was added a solution of DMSO (4 mL) and pyridine sulfur trioxide (279 mg, 1.75 mmol) to a solution of 348-5 (260 mg, 0.548 mmol) and TEA (0.61 mL, 4.4 mmol) in DMSO (4 mL) at 0 C. The reaction mixture was stirred for 1 hour and diluted with EtOAc and the organic phase washed with brine. The organic layer was concentrated under reduced pressure and the residue purified using silica gel chromatography to yield 348-6 (280 mg, 100%). MS (ESI) m/z: 473.0 (M+H).

Intermediate 348-7

##STR00178##

[0782] To a round bottom flask was added (bromomethyl)triphenylphosphonium bromide (388 mg, 0.889 mmol) and THF (5.0 mL). The reaction mixture was cooled to 78 C. and followed by addition of 1M NaHMDS (0.89 mL, 0.89 mmol) solution in THF dropwise over 2 minutes while keeping the internal temperature below 70 C. The resulting bright yellow suspension was stirred at 78 C. for 1 hour. To this reaction mixture was added to a solution of 348-6 (280 mg, 0.593 mmol) in anhydrous THF (1.0 mL) that was previously treated with NaHMDS (1.12 mL, 1.12 mmol) over 2 minutes while keeping the internal temperature below 70 C. The resulting reaction mixture was stirred at 78 C. for 3 hours. The reaction mixture was then quenched with slow addition of water (6 mL) followed by ethyl acetate (6 mL). The resulting reaction mixture was stirred for 5 minutes and then diluted with EtOAc. The combined organic portion was washed with brine and purified using silica gel chromatography. The residue was subjected to chiral separation using Chiralcel OD-H, 21250 mm, 5 micron column with a mobile phase of 5% MeOH/CAN/95% CO.sub.2 at a flow rate of 45 mL/min and 150 Bar. The separation was carried out at 40 C. and measured at a wavelength of 240 nm. Chiral separation yielded four peaks with retention times of 9.29 mins (>99.9% ee), 11.16 mins (>99.9% ee), 13.98 mins (>99.9% ee) and 15.30 mins (>81.0% ee). The desired product was found at 11.16 mins and had an ee of >99.9%. (peak 2 from chiral SFC) which was confirmed by 2D NMR analysis to yield 348-7 (82 mg, 25.16%). MS (ESI) n/z: 473.1 (M+H).

Intermediate 348-8

##STR00179##

[0783] To a suspension of 348-7 (83 mg, 0.15 mmol) and CuI (43.2 mg, 0.227 mmol) in anhydrous DMF (1 mL) and HMPA (1.2 mL, 7.0 mmol) at 75 C. under N.sub.2 was added methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.048 mL, 0.38 mmol) in anhydrous DMF (0.5 mL) dropwise over a period of 10 min. The resulting suspension was stirred at 75 C. under nitrogen for 12 hours. The reaction mixture was allowed to cool to room temperature, quenched by the addition of NaHCO.sub.3 (20 mL) and the solution, extracted with EtOAc. The organic layer was concentrated and subjected to silica gel chromatography to provide 348-8 (52 mg, 61%). MS (ESI) m/z: 539.1 (M+H).

Intermediate 348-9

##STR00180##

[0784] To a solution of 348-8 (52 mg, 0.097 mmol) in 1,4-Dioxane (1.5 mL) was added DCM (1.6 mL) and TFA (0.4 mL). The reaction mixture was stirred at room temperature for 30 minutes and concentrated under reduced pressure to yield 348-9 which was used without further purification (49 mg, 95%). MS (ESI) m/z: 394.9 (M+H).

Intermediate 348-10

##STR00181##

[0785] 348-10 was prepared according to the procedure for Example 230. MS (ESI) m/z: 818.2 (M+H).

Example 348

##STR00182##

[0786] To a solution of 348-10 (35 mg, 0.043 mmol) in acetone (1 mL) was added N-methylmorpholine N-oxide (10 mg, 0.086 mmol) followed by OsO.sub.4 in t-butanol (0.054 mL, 4.2 mol). The reaction mixture was stirred at rt for 18 h. The reaction mixture was diluted with EtOAc and the solution washed with sodium thiosulfate. The organic layer was separated and concentrated under reduced pressure and the residue purified using preparative reverse phase HPLC to yield example Example 348 (14.6 mg, 38.0%). .sup.1H NMR (400 MHz, CD.sub.3OD) a 10.41 (s, 1H), 10.15 (d, J=7.3 Hz, 1), 8.27 (d, J=1.3 Hz, 1H), 8.19 (dd, J=6.3, 2.5 Hz, 1H), 7.84-7.72 (m, 2H), 7.69-7.61 (m, 1H), 7.56-7.48 (m, 1H), 7.38-7.24 (m, 3H), 6.18 (q, J=7.0 Hz, 1H), 5.94 (q, J=7.5 Hz, 1H), 4.70 (ddd, J=10.9, 7.1, 4.2 Hz, 1H), 4.55 (d, J=6.4 Hz, 1H), 4.45 (d, J=6.4 Hz, 1H), 4.13 (s, 3H), 4.12-3.99 (m, 1H), 3.42 (d, J=1.5 Hz, 1H), 3.38 (s, 1H), 2.90 (d, J=4.0 Hz, 1H), 2.39-2.19 (m, 2H), 2.09-1.90 (m, 2H), 1.78-1.63 (m, 2H); LC-MS (M+H)=852.1; HPLC RT=11.48 min; Method C.

[0787] A solution of 351-5 (120 mg, 0.176 mmol) and LiOH (21.05 mg, 0.879 mmol) in MeOH (2 mL), THF (2 mL) and water (1 mL) was stirred at ambient temperature for 12 h. The reaction mass was concentrated and acidified with 1.5N HCL. The reaction was extracted with DCM and the organic layer was concentrated. The residue was purified by preparative reverse phase HPLC to get 4-fluoro-3-(1R,2R,3R,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxy-[1,1-biphenyl]-3-carboxylic acid (11.5 mg, 0.016 mmol, 9% yield). .sup.1H NMR. MS (E.sup.) m/z: 669.2 (M+H).

Example 352

##STR00183##

Intermediate 352-1

##STR00184##

[0788] Intermediate 352-1 was prepared from 120-5 and 177-4 according to the methods described for Example 108. LC-MS (M+H)=767.1; HPLC RT=1.25 min; Method A.

[0789] A slurry of 352-1 (0.038 g, 0.050 mmol), Na.sub.2CO.sub.3 (5.30 mg, 0.0500 mmol), (4,4-di-t-butyl-2,2-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-.sub.N)phenyl-.sub.C]iridium(III) PF.sub.6 (0.515 mg, 0.500 mol), NiCl.sub.2-ethylene glycol dimethyl ether complex (0.549 mg, 2.50 mol), 4,4-di-t-butyl-2,2-bipyridine (0.551 mg, 2.50 mol), (TMS).sub.3SiH (0.03 mL) and 3-(bromomethyl)-1,1-difluorocyclobutane (0.019 g, 0.10 mmol) in DME was degassed with N.sub.2 and irradiated with blue LED for 96 hours. The reaction mixture was diluted with EtOAc, filtered through silica gel and concentrated under reduced pressure. The residue was dissolved in DCM (0.4 mL) was treated with TFA (0.08 mL). After 15 min, the solution was diluted with toluene and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC to furnish 2-(3-(((1R,2R,3S,4R,Z)-7-(2-(3,3-difluorocyclobutyl)ethylidene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-6-fluoro-4-methoxy-[1,1-biphenyl]-3-yl)-2-hydroxyacetic acid (2.6 mg, 3.2 mol, 6.5% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.56 (br s, 1H), 9.92 (br dd, J=15.4, 7.2 Hz, 1H), 8.18 (br t, J=4.9 Hz, 1H), 8.08 (br d, J=11.0 Hz, 1H), 7.81-7.61 (m, 2H), 7.52-7.35 (m, 3H), 7.32-7.13 (m, 2H), 5.26-5.13 (m, 1H), 4.92 (br d, J=1.8 Hz, 1H), 4.38 (br d, J=4.3 Hz, 1H), 4.02 (s, 1H), 3.89-3.71 (m, 3H), 3.19-3.09 (m, 1H), 2.88 (s, 1H), 2.72 (s, 2H), 2.64 (br s, 2H), 2.32-2.06 (m, 5H), 1.89-1.66 (m, 2H), 1.38 (br s, 2H). LC-MS (M+H)=734.24; HPLC RT=2.48 min; Method C.

Example 360

##STR00185##

[0790] A slurry of Example 292 (0.025 g, 0.041 mmol), Na.sub.2CO.sub.3 (4.35 mg, 0.0410 mmol), (4,4-di-t-butyl-2,2-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-.sub.N)phenyl-.sub.C]Ir(III) PF.sub.6 (0.423 mg, 0.410 mol), NiCl.sub.2 ethyleneglycol dimethylether complex (0.451 mg, 2.05 mol), 4,4-di-t-butyl-2,2-bipyridine (0.551 mg, 2.50 mol), (TMS).sub.3SiH (0.03 mL) and 3-bromotetrahydrofuran (0.012 g, 0.082 mmol) in DME (1.641 ml) was degassed, blanketed under N.sub.2 and irradiated with blue LED. After 96 h the reaction mixture was diluted with EtOAc, filtered through silica gel and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC to furnish (1R,2S,3R,4R,Z)N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(tetrahydrofuran-3-yl)benzamido)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptane-2-carboxamide (3.5 mg, 5.5 mol, 13% yield) as a mixture of diastereomers. .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.78 (br d, J=5.8 Hz, 1H), 8.14 (br d, J=4.6 Hz, 1H), 7.81-7.65 (m, 2H), 7.49-7.28 (m, 2H), 7.04 (br d, J=8.5 Hz, 1H), 5.84 (q, J=7.9 Hz, 1H), 4.43 (br s, 1H), 3.95-3.78 (m, 5H), 3.74-3.64 (m, 1H), 3.37-3.07 (m, 2H), 2.89 (br s, 1H), 2.81 (s, 1H), 2.71-2.62 (m, 1H), 2.24-2.11 (m, 1H), 1.99-1.87 (m, 1H), 1.83-1.71 (m, 2H), 1.50-1.26 (m, 2H). LC-MS (M+H)=601.16; HPLC RT=2.58 min; Method C.

Example 378

##STR00186##

[0791] Intermediate 378-1: Preparation of methyl (E)-5-((hydroxyimino)methyl)-2-methoxybenzoate. Commercially available methyl 5-formyl-2-methoxybenzoate (1.16 g, 5.97 mmol) was dissolved in DCM (5 mL), and to this solution was added hydroxylamine.Math.HCl (415 mg, 5.97 mmol) followed by TEA (1 mL) and the reaction mixture was stirred at r.t. for 18 h. Water (100 mL) was added and the solution extracted with EtOAc (225 mL), the combined organic portions dried (MgSO.sub.4), filtered and evaporated under reduced pressure to generate 378-1, 1.19 g, 95% yield. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.13 (s, 1H), 8.03 (d, J=2.4 Hz, 1H), 7.78-7.67 (m, 1H), 7.03 (d, J=8.8 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H). MS (ESI) m/z=210.1 (M+H).

[0792] Intermediate 378-2: Preparation of methyl 5-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-methoxybenzoate. Intermediate 378-1 (55 mg, 0.26 mmol) was dissolved in DMF (2 mL), and to this solution was added NCS (35 mg, 0.26 mmol) and the reaction mixture was stirred at rt for 4 h. Water was added and the solution extracted with EtOAc (225 mL), the combined organic portions were dried (MgSO.sub.4), filtered, concentrated under reduced pressure and the residue immediately re-dissolved in DCM (5 mL). Allyl alcohol (61 mg, 1.05 mmol) was added to the solution followed by TEA (0.5 mL) and the resulting reaction mixture stirred at rt for 18 h. Water was added (20 mL) and the solution extracted with EtOAc (220 mL), the combined organic portions dried (MgSO.sub.4), filtered and purified by normal phase chromatography eluting with hexanes/EtOAc to yield 378-2, 58 mg, 85% yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.05 (d, J=2.4 Hz, 1H), 7.89 (dd, J=8.8, 2.4 Hz, 1H), 7.05 (d, J=8.9 Hz, 1H), 4.90 (dddd, J=10.8, 7.7, 4.6, 3.2 Hz, 1H), 4.08-3.85 (ss, 6H), 3.81-3.68 (m, 1H), 3.46-3.36 (m, 1H), 1.89 (br t, J=6.2 Hz, 1H), 1.57 (s, 2H). MS (ESI) m/z=266.1 (M+H).

[0793] Intermediate 378-3: 378-2 (58 mg, 0.22 mmol) was dissolved in THF (2 mL) and to this was added LiOH (6.3 g, 0.26 mmol) followed by water (2 mL) and methanol (1 mL) and stirred at r.t. for 4 h. Quenched to pH 7 with dil HCl (1N) and the solution extracted with EtOAc (225 mL), the combined organic portions dried (MgSO.sub.4), filtered and evaporated to 378-3. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.28 (d, J=2.3 Hz, 1H), 8.14 (dd, J=8.8, 2.4 Hz, 1H), 7.28-7.14 (m, 1H), 4.92 (dddd, J=10.8, 7.7, 4.6, 3.1 Hz, 1H), 4.16 (s, 3H), 4.09-3.89 (m, 1H), 3.72 (dd, J=12.4, 4.6 Hz, 1H), 3.48-3.39 (m, 1H), 3.38-3.29 (m, 1H), 1.94-1.72 (m, 1H), 1.60 (br s, 1H). MS (ESI) m/z=252.3 (M+H).

[0794] Intermediate 378-4 and 378-5. 378-3 was subjected to chiral SFC separation according to the following preparative method: Instrument: Berger MG II, Column: Chiralpak IC, 21250 mm, 5 micron Mobile Phase: 20% Methanol/80% CO.sub.2 Flow Conditions: 2 mL/min, 150 Bar, 40 C. Detector Wavelength: 220 nm Injection Details: 0.7 mL of 35 mg/mL in MeOH to afford 378-4 (Peak 1, >99% de, Analytical RT=5.6 min) and 378-5 (Peak 2, 99% de, Analytical RT=6.6 min), Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC (CTR-L410-SFC3), Column: Chiralpak IC, 4.6100 mm, 3 micron, Mobile Phase: 20% Methanol/80% CO2 Flow Conditions: 2.0 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm Injection Details: 5 L of 1 mg/mL in MeOH

[0795] (1R,2S,3R,4R,Z)-7-(cyclobutylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide 378 (diasteromeric mixture) was prepared by the coupling of intermediate 378-3 (4.6 mg, 0.018 mmol) with the cyclobutyl norbornyl intermediate 369-1 (7 mg, 0.02 mmol), BOP reagent (8.1 mg, 0.018 mmol) and Hunig's base (0.05 ml) in DMF. Purification via reverse phase HPLC afforded 378 as a solid (5 mg, 44% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.89 (dd, J=7.1, 2.8 Hz, 1H), 8.26-8.17 (m, 2H), 7.84-7.73 (m, 2H), 7.48 (br t, J=9.7 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 5.37 (d, J=8.4 Hz, 1H), 4.78-4.65 (m, 1H), 4.35 (br s, 1H), 4.03 (s, 3H), 3.63 (br s, 1H), 3.22-3.05 (m, 3H), 2.96 (br s, 1H), 2.70 (br s, 1H), 2.23-2.06 (m, 3H), 1.91-1.70 (m, 7H), 1.43-1.22 (m, 2H). MS (ESI) m/z=616.1 (M+H). HPLC Purity: 100%; Retention Time: 2.54 min; Method C.

Example 379

##STR00187##

[0796] Example 379. (1R,2S,3R,4R,Z)-7-(cyclobutylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide (homochiral isomer-2) was prepared (49% yield) by the coupling method described for example 378 using the cyclobutyl norbornyl intermediate 369-1 and intermediate 378-5. .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.88 (br d, J=7.0 Hz, 1H), 8.22 (s, 1H), 8.23 (d, J=7.0 Hz, 1H), 7.79 (br d, J=8.2 Hz, 2H), 7.49 (br t, J=9.6 Hz, 1H), 7.27 (d, J=8.5 Hz, 1H), 5.38 (br d, J=8.5 Hz, 1H), 4.70 (br d, J=3.1 Hz, 2H), 4.36 (br s, 1H), 4.04 (s, 3H), 3.51 (br s, 1H), 3.37 (br s, 2H), 3.22-3.04 (m, 2H), 2.97 (br s, 1H), 2.71 (br s, 1H), 2.19 (br d, J=5.8 Hz, 1H), 2.14 (br s, 1H), 1.92-1.71 (m, 6H), 1.37 (br s, 2H). MS (ESI) m/z=616.1 (M+H). HPLC Purity: 100%; Retention Time: 2.54 min; Method C.

Example 384

##STR00188##

Intermediate 384-1 (Racemate) and 384-2 (Homochiral Peak-1) and 384-3 (Homochiral Peak-2)

##STR00189##

[0797] Intermediate 384-1: The intermediate 5-(5-(tert-butoxycarbonyl)-4,5-dihydroisoxazol-3-yl)-2-methoxybenzoic acid was prepared from the product from 378-1 vial hydrolysis of the ester and treatment with NCS in DMF as described for 378-2 to afford 5-(chloro(hydroxyimino)methyl)-2-methoxybenzoic acid which on treatment with excess t-butyl acrylate afforded the desired intermediate 5-(5-(tert-butoxycarbonyl)-4,5-dihydroisoxazol-3-yl)-2-methoxybenzoic acid (384-1) in 76% yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.25 (d, J=2.3 Hz, 1H), 8.19 (dd, J=8.8, 2.4 Hz, 1H), 7.16 (d, J=8.9 Hz, 1H), 5.10 (dd, J=9.9, 8.7 Hz, 1H), 4.16 (s, 3H), 3.67-3.60 (m, 2H), 1.74-1.51 (m, 9H). MS (ESI) m/z=322.1 (M+H).

[0798] Intermediate 384-2 and 384-3: The 384-1 chiral intermediates were separated by chiral SFC by the following preparative chromatographic methods: Instrument: Berger MG II, Column: Chiralpak IC, 21250 mm, 5 micron, Mobile Phase: 20% Methanol/80% CO.sub.2, Flow Conditions: 2 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm, Injection Details: 0.7 mL of 35 mg/mL in MeOH to afford 384-2 (Peak 1, >99% de, Analytical RT=7.93 min) and 384-3 (Peak 2, >99% de, Analytical RT=9.65 min). Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC (CTR-L410-SFC3), Column: Chiralpak IC, 4.6100 mm, 3 micron Mobile Phase: 20% Methanol/80% CO.sub.2, Flow Conditions: 2.0 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm, Injection Details: 5 L of 1 mg/mL in Methanol.

[0799] 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid (diasteromeric mixture) was prepared (7% yield) by the coupling method described for example 378 using the norbornyl intermediate 166-2 and intermediate 384-1. .sup.1H NMR (500 MHz, DMSO-d6) 10.56 (s, 1H), 9.92 (d, J=7.0 Hz, 1H), 8.32-8.20 (m, 2H), 7.87-7.75 (m, 2H), 7.49 (t, J=9.8 Hz, 1H), 7.34-7.22 (m, 1H), 5.15 (dd, J=11.6, 6.7 Hz, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.45 (br s, 1H), 4.05 (s, 3H), 3.74 (dd, J=17.1, 11.6 Hz, 1H), 3.23-3.13 (m, 2H), 3.11 (br s, 2H), 2.86-2.64 (m, 1H), 1.88-1.68 (m, 2H), 1.62-1.46 (m, 1H), 1.42 (br s, 2H), 0.88-0.68 (m, 2H), 0.36 (br s, 2H). MS (ESI) m/z=616.3 (M+H). HPLC Purity: 100%; Retention Time: 2.38 min. Method C.

Example 385

##STR00190##

[0800] 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid, homochiral isomer-1 was prepared by the coupling of intermediate 384-2 (13.9 mg, 0.04 mmol) with intermediate 166-2 (16 mg, 0.04 mmol) in the presence of BOP reagent (19 mg, 0.04 mmol) and Hunig's base (0.05 mL) in DMF. The reaction mixture was concentrated under reduced pressure and water added (25 mL) and the solution was extracted with EtOAc (225 mL), the combined organic portions dried (MgSO.sub.4), filtered and concentrated under reduced pressure. The residue was dissolved in DCM (1 ml) and to this was added TFA (0.2 mL) and stirred at rt for 15 min. The solution was concentrated under reduced pressure and redissolved with DMF (1 mL) and purified via reverse phase HPLC to afford 385, 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo [2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid (homochiral) as a solid (12 mg, 99% yield). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.62 (s, 1H), 9.92 (br d, J=7.0 Hz, 1H), 8.24 (br s, 2H), 7.88-7.76 (m, 2H), 7.49 (br t, J=9.5 Hz, 1H), 7.27 (d, J=8.9 Hz, 1H), 5.01-4.84 (m, 1H), 4.69 (d, J=9.5 Hz, 1H), 4.45 (br s, 1H), 4.05 (s, 3H), 3.67-3.43 (m, 1H), 3.18 (br d, J=7.3 Hz, 1H), 3.12 (br s, 1H), 2.73 (br s, 1H), 1.92 (s, 1H), 1.88-1.66 (m, 2H), 1.51 (br d, J=4.3 Hz, 1H), 1.42 (br s, 2H), 0.89-0.68 (m, 2H), 0.35 (br s, 2H). HPLC purity 100%. Analytical LC-MS: 2.33 min; (ESI) m/z=616.28 (M+H)+, Method C.

Example 390

##STR00191##

Intermediate 390-1

##STR00192##

[0801] Intermediate 390-1 was prepared in an identical fashion (71% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with tert-butyl but-3-ynoate. .sup.1H NMR (400 MHz, CDCl.sub.3) 10.40 (br s, 1H), 8.29-8.25 (m, 1H), 8.18 (dd, J=8.8, 2.4 Hz, 1H), 7.16 (d, J=8.8 Hz, 1H), 5.21-5.09 (m, 1H), 4.23-4.12 (m, 3H), 3.58 (dd, J=16.8, 10.5 Hz, 1H), 3.17 (dd, J=16.7, 7.5 Hz, 1H), 2.82 (dd, J=15.8, 5.9 Hz, 1H), 2.61 (dd, J=15.8, 7.5 Hz, 1H), 1.52-1.43 (m, 9H). MS (ESI) m/z=336.1 (M+H).

[0802] Intermediate 390-2 and 390-3: The chiral intermediates of 390-1 were separated by chiral SFC by the following preparative chromatographic methods: Instrument: PIC Solution SFC Prep-200, Column: Chiralpak IC, 30250 mm, 5 micron Mobile Phase: 15% MeOH/85% CO.sub.2 Flow Conditions: 85 mL/min, 150 Bar, 40 C. Detector Wavelength: 227 nm, Injection Details: 0.5 mL of 53 mg/mL in MeOH to obtain 390-2 (Peak 1, 100% de, Analytical RT=11.3 min) and 390-3 (Peak 2, 93.8% de, Analytical RT=12.6 min). Analytical Chromatographic Conditions: Instrument: Aurora Infinity SFC. Column: Chiralpak IC, 4.6250 mm, 3 micron, Mobile Phase: 20% MeOH/80% CO.sub.2, Flow Conditions: 2.0 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm, Injection Details: 5 L of 1 mg/mL in MeOH.

[0803] 2-(3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)acetic acid, homochiral isomer-2, 390 was prepared (47% yield) by the coupling method described for example 378 using the cyclopropyl norbornyl intermediate 166-2 and intermediate 390-3 followed by deprotection with TFA. .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.92 (br d, J=7.2 Hz, 1H), 8.26-8.19 (m, 2H), 7.84-7.77 (m, 2H), 7.49 (t, J=9.6 Hz, 1H), 7.28 (d, J=8.9 Hz, 1H), 5.04-4.90 (m, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.46 (br s, 1H), 4.05 (s, 3H), 3.22-3.09 (m, 2H), 2.73 (br s, 1H), 2.70-2.59 (m, 2H), 2.55 (s, 2H), 1.89-1.71 (m, 2H), 1.51 (br d, J=4.9 Hz, 1H), 1.42 (br s, 2H), 0.87-0.69 (m, 2H), 0.36 (br s, 2H). MS (ESI) m/z=630.3 (M+H). HPLC Purity: 100%; Retention Time: 2 min. Method B.

Example 397

##STR00193##

Intermediate 397-1

##STR00194##

[0804] Intermediate 397-1 was prepared in an identical fashion (81% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with tert-butyl 3,3-dimethyl-2-methylenebutanoate. .sup.1H NMR (500 MHz, CD.sub.3OD) 8.12 (d, J=2.3 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.22 (d, J=8.9 Hz, 1H), 4.06-3.88 (s, 3H), 3.62 (q, J=18.0 Hz, 2H), 1.61-1.39 (m, 9H). MS (ESI) m/z=378.3 (M+H).

[0805] 5-(tert-butyl)-3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid diasteromeric mixture, 397 was prepared (54% yield) by the coupling method described for example 378 using the trifluoromethyl norbornyl intermediate 170-2 and intermediate 397-1 followed by treatment with TFA. .sup.1H NMR (500 MHz, DMSO-d6) 10.74-10.63 (m, 1H), 9.98-9.88 (m, 1H), 8.21 (br d, J=5.2 Hz, 1H), 7.79 (br s, 1H), 7.50 (br t, J=9.2 Hz, 1H), 7.26 (br s, 1H), 7.08 (br s, 1H), 5.99-5.86 (m, 1H), 4.50 (br s, 1H), 4.03 (s, 3H), 3.51 (br s, 3H), 3.24 (br s, 1H), 2.99 (s, 1H), 2.11-1.90 (m, 1H), 1.86 (br s, 1H), 1.49 (br s, 1H), 0.99 (br s, 9H). MS (ESI) m/z=700.3 (M+H). HPLC Purity: 98.8%; Retention Time: 2.07 min. Method B.

Example 406

##STR00195##

Intermediate 406-1

##STR00196##

[0806] Intermediate 406-1 was prepared in an identical fashion (31% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with cyclopent-3-en-1-ol as mixture of diasteromers. .sup.1H NMR (600 MHz, CDCl.sub.3) 8.04 (d, J=2.3 Hz, 1H), 7.85 (dd, J=8.8, 2.3 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 5.30 (ddd, J=9.4, 6.2, 2.9 Hz, 1H), 4.50 (quin, J=5.9 Hz, 1H), 4.19 (td, J=9.3, 4.7 Hz, 1H), 3.92 (s, 3H), 2.33-2.27 (m, 1H), 2.18-2.06 (m, 3H). MS (ESI) m/z=292.0 (M+H).

[0807] Intermediate 406-2 through 406-5 (chiral). The chiral intermediates of 406-1 were separated by chiral SFC by the following preparative chromatographic methods: Instrument: Berger SFC (LVL-L4021 Lab) Column: IC 253 cm ID, 5 m, Temperature: 40 C, Flow rate: 85 mL/min, Mobile Phase: gradient 75/25 CO.sub.2/MeOH for 12 min then to 45% MeOH, Detector Wavelength: 235 nm, Injection Volume: 1000 L to afford chiral 406-2 Peak-1, >99% de, Analytical RT=8.80 min), chiral 406-3 (Peak-2, >95% de, Analytical RT=9.86 min), chiral 406-4 (Peak-3, >99% de, Analytical RT=13.53 min), chiral 406-5 (Peak-4, >99% de, Analytical RT=16.67 min). Analytical Chromatographic Conditions: Instrument: Agilent SFC (LVL-L4021 Lab), Column: IC 2504.6 mm ID, 5 m, Temperature: Ambient, Flow rate: 2.0 mL/min, Mobile Phase: gradient 75/25 CO.sub.2/MeOH 12 min then to 45% MeOH.

[0808] (1R,2S,3R,4R,Z)-7-(cyclobutylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-hydroxy-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide diasteromeric mixture, 406 was prepared (74% yield) by the coupling method described for example 378 using the cyclobutyl norbornyl intermediate 369-1 and intermediate 406-1. .sup.1H NMR (500 MHz, DMSO-d6) 10.56 (s, 1H), 9.89 (d, J=7.3 Hz, 1H), 8.21 (br s, 2H), 7.78 (br d, J=8.7 Hz, 2H), 7.48 (br t, J=9.6 Hz, 1H), 7.26 (br d, J=8.8 Hz, 1H), 5.37 (d, J=8.3 Hz, 1H), 5.10 (br t, J=7.2 Hz, 1H), 4.34 (br s, 1H), 4.15 (br s, 1H), 4.12-4.05 (m, 1H), 4.03 (s, 3H), 3.72-3.56 (m, 3H), 3.20-3.02 (m, 2H), 2.95 (br s, 1H), 2.70 (br s, 1H), 2.16 (br s, 1H), 2.13-2.01 (m, 2H), 1.92-1.70 (m, 6H), 1.36 (br s, 2H). MS (ESI) m/z=642.1 (M+H). HPLC Purity: 100%; Retention Time: 2.49 min. Method C.

Example 413

##STR00197##

Intermediate 413-1 (Diasteromeric Mixture)

##STR00198##

[0809] Intermediate 413-1 was prepared in an identical fashion (10% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with (1R,3S)-cyclopent-4-ene-1,3-diol as a mixture of diastereomers. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.09-7.91 (m, 1H), 7.30 (s, 1H), 7.11-7.01 (m, 1H), 5.46-5.21 (m, 1H), 4.45-4.23 (m, 1H), 4.04-3.88 (ss, 6H), 3.02-2.98 (m, 1H), 2.92 (d, J=0.7 Hz, 1H), 2.45-2.35 (m, 1H), 2.02 (s, 2H). MS (ESI) m/z=294.1 (M+H).

Intermediate 413-2 (Diasteromeric Mixture)

##STR00199##

[0810] 413-2 was obtained from intermediate 413-1 via a two step sequence by the protection with excess TBDMS triflate (2.64 g, 9.99 mmol) and 2,6-lutidine (1.61 g, 14.9 mmol) in DCM (5 mL) followed by the hydrolysis of the ester with LiOH in THF/MeOH/water (1:1:1, 5 mL). H NMR (500 MHz, CDCl.sub.3) 8.48-8.46 (m, 1H), 8.04-8.00 (m, 1H), 7.10-7.05 (m, 1H), 5.06-5.02 (m, 1H), 4.33-4.29 (m, 1H), 4.23-4.18 (s, 3H), 4.15-4.13 (m, 1H), 4.12-4.10 (m, 1H), 4.00-3.94 (m, 1H), 1.29-1.24 (m, 1H), 0.93 (ss, 18H), 0.12 (s, 3H), 0.12-0.03 (m, 3H), 0.03 (s, 1H), 0.02 (s, 3H), 0.05-0.06 (m, 3H). MS (ESI) m/z 522.5 (M+H).

[0811] (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(5-(4,6-dihydroxy-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzamido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide diasteromeric mixture, 413 was prepared (36% yield) by the coupling method described for example 378 using the cyclopropyl norbornyl intermediate 166-2 and intermediate 413-2 followed by deprotection with tetrabutylammonium fluoride (1M in THF, 1 mL). .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.90 (br d, J=7.3 Hz, 1H), 8.43-8.37 (m, 1H), 8.21 (br d, J=6.1 Hz, 1H), 7.89 (dd, J=8.7, 2.3 Hz, 1H), 7.83-7.66 (m, 1H), 7.48 (t, J=9.6 Hz, 1H), 7.29 (d, J=8.9 Hz, 1H), 4.96 (dd, J=10.2, 2.0 Hz, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.45 (br s, 1H), 4.05 (s, 3H), 3.54 (br s, 1H), 3.21-3.07 (m, 2H), 3.00 (s, 1H), 2.54 (s, 1H), 2.85-2.64 (m, 1H), 1.92-1.76 (m, 3H), 1.76-1.62 (m, 1H), 1.52 (br s, 1H), 1.42 (br s, 2H), 0.85-0.68 (m, 2H), 0.36 (br s, 2H). MS (ESI) m/z=644.4 (M+H). HPLC Purity: 100%; Retention Time: 2.36 min. Method C.

Example 414

##STR00200##

Intermediate 414-3 (Racemate) and Chiral 414-4 (Chiral Peak-1), Chiral 414-5 (Chiral Peak-2), Chiral 414-6 (Chiral Peak-3), Chiral 414-7 (Chiral Peak-4)

##STR00201##

[0812] Intermediate 414-1: Commercially available methyl 5-formyl-2-methoxybenzoate (948 mg, 4.88 mmol) was dissolved in EtOH (10 mL) and to this solution was added NMeNHOH.Math.HCl (408 mg, 4.88 mmol) followed by K.sub.2CO.sub.3 (675 mg, 4.88 mmol) and the reaction mixture was stirred at rt for 1 h. with water was added (100 mL) and the solution was extracted with EtOAc (225 mL), the combined organic portions dried (MgSO.sub.4) and evaporated under reduced pressure to a solid. The solid was transferred to a vial and toluene (7 mL) was added followed by methyl acrylate (3 mL) and the vial sealed. The reaction mixture was heated at 95 C. for 18 h. The cooled reaction mixture was concentrated under reduced pressure and the residue purified by silica gel chromatography. 414-3 was isolated as an oil (200 mg, 13%). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.96 (m, 1H), 7.88 (m, 1), 7.02 (d, J=8.8 Hz, 1H), 4.01-3.84 (mss, 8H), 3.79-3.71 (m, 3H), 3.17-3.01 (m, 3H), 2.92-2.67 (m, 1H), 2.07-1.81 (m, 2H). MS (ESI) m/z=310.0 (M+H).

[0813] Intermediate 414-2: The product 414-1 (49 mg, 0.158 mmol) was dissolved in methanol (5 mL) in a Parr flask and to this was added Pd/C 10% (20 mg) and hydrogenated at 60 psi for 5 h. The reaction mixture was filtered over a celite pad and evaporated under reduced pressure to afford methyl 5-(4-hydroxy-1-methyl-5-oxopyrrolidin-2-yl)-2-methoxybenzoate as an oil (35 mg, 79%). .sup.1H NMR (500 MHz, CD.sub.3OD) 7.71 (d, J=2.4 Hz, 1H), 7.50 (dd, J=8.7, 2.4 Hz, 1H), 7.18 (d, J=8.7 Hz, 1H), 4.51-4.42 (m, 1l), 4.38 (t, J=8.5 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 2.84 (ddd, J=13.1, 8.4, 6.9 Hz, 1H), 2.58 (s, 3H), 1.74 (dt, J=13.0, 8.5 Hz, 1H). MS (ESI) m/z=280.2 (M+H).

[0814] Intermediate 414-3: The product 414-2 (30 mg) was dissolved in MeOH (1 mL), and to this solution was added LiOH followed by water (1 mL) and stirred at rt for 5 h. dil. HCl was added and the resulting solution concentrated under reduced pressure to a gummy solid. Methanol was added and the reaction mixture filtered and concentrated under reduced pressure to to generate (20 mg, 71% yield) 414-3. MS m/z=266.08 (M+H).

[0815] Chiral Intermediate 414-(4-7): 414-3 was separated by SFC under the following preparative conditions: Instrument: Berger SFC (LVL-L4021 Lab), Column: IG 253 cm ID, 5 m, Temperature: 40 C, Flow rate: 85 mL/min, Mobile Phase: 82/18 CO.sub.2/MeOH-0.1% DEA, Detector Wavelength: 220 nm, Injection Volume: 1200 L to afford chiral 414-4 (Peak-1, >99% de, Analytical RT=15.56 min), chiral 414-5 (Peak-2 >95% de, Analytical RT=18.09 min), chiral 414-6 (Peak-3, >99% de, Analytical RT=26.38 min) and chiral 414-7 (Peak-4, >95% de, Analytical RT=29.29 min). Analytical Chromatographic Conditions: Instrument: Agilent SFC (LVL-L4021 Lab), Column: IG 2504.6 mm ID, 5 m, Temperature: Ambient, Flow rate: 2.0 mL/min, Mobile Phase: 80/20 CO.sub.2/MeOH-0.1% DEA

[0816] (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(4-hydroxy-1-methyl-5-oxopyrrolidin-2-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide homochiral isomer-1, 414 was prepared (48% yield) by the coupling method described for example 378 using the cyclopropyl norbornyl intermediate 166-2 and intermediate 414-4. .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.89 (d, J=7.3 Hz, 1H), 8.23 (dd, J=6.6, 2.3 Hz, 1H), 7.89 (d, J=2.1 Hz, 1H), 7.84-7.67 (m, 1H), 7.49 (t, J=9.2 Hz, 1H), 7.44 (d, J=8.3 Hz, 1H), 7.24 (d, J=8.5 Hz, 1H), 4.70 (d, J=9.8 Hz, 1H), 4.34 (m, 1H), 4.20 (br s, 1H), 4.02 (s, 3H), 3.16 (br dd, J=10.7, 4.0 Hz, 1H), 3.09 (br s, 1H), 2.80-2.63 (m, 2H), 2.50-2.39 (m, 2H), 1.94-1.74 (m, 2H), 1.65-1.45 (m, 1H), 1.45-1.24 (m, 2H), 0.88-0.67 (m, 2H), 0.36 (br s, 2H). MS (ESI) m/z=616.2 (M+H). HPLC Purity: 100%; Retention Time: 2.12 min. Method C.

Example 416

##STR00202##

Intermediate 416-1: (Racemate) and Chiral 416-2 (Chiral Peak-1), 416-3 (Chiral Peak-2)

##STR00203##

[0817] Intermediate 416-1 was prepared in an identical fashion (50% yield) described for intermediate 378-1. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.98 (d, J=2.3 Hz, 1H), 7.86 (dd. J=8.8, 2.4 Hz, 1H), 7.04 (d, J=8.7 Hz, 1H), 5.38 (dd, J=9.2, 3.9 Hz, 1H), 4.34-4.26 (m, 2H), 4.20-4.09 (m, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.83-3.76 (m, 1H), 2.92-2.70 (m, 1H). MS (ESI) m/z=278.3 (M+H).

[0818] 416-2 & 416-3: The following chiral intermediates were separated by chiral SFC by the following preparative chromatographic methods from racemate DP39-1: Instrument: Berger MG II Column: Chiralpak IA, 21250 mm, 5 micron, Mobile Phase: 20% MeOH/80% CO.sub.2, Flow Conditions: 45 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm to afford chiral 416-2 (Peak-1, >99% de, Analytical RT=3.80 min) and chiral 416-3 (Peak-2, >98% de, Analytical RT=7.43 min). Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC, Column: Chiralpak IA, 4.6100 mm, 3 micron, Mobile Phase: 20% MeOH/80% CO.sub.2, Flow Conditions: 2.0 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm, Injection Details: 5 L of 1 mg/mL in MeOH. (1R,2S,3R,4R,Z)-7-(cyclobutylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide homochiral isomer-2, 416 was prepared (62% yield) by the method described for example 378 using the cyclobutyl norbornyl intermediate 369-1 and intermediate 416-2. .sup.1H NMR (500 MHz, DMSO-d6) 10.56 (s, 1H), 9.93 (dd, J=10.8, 7.2 Hz, 1H), 8.25-8.20 (m, 2H), 7.84-7.76 (m, 2H), 7.48 (t, J=9.8 Hz, 1H), 7.28 (d, J=8.9 Hz, 1H), 5.35 (dd, J=9.0, 3.2 Hz, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.54-4.41 (m, 2H), 4.12-4.02 (m, 3H), 3.90 (br d, J=9.5 Hz, 1H), 3.84-3.73 (m, 1H), 3.50 (br s, 1H), 3.16 (br dd, J=10.8, 4.4 Hz, 1H), 3.11 (br s, 1H), 2.73 (br s, 1H), 2.56 (s, 4H), 1.91-1.71 (m, 2H), 1.50 (br s, 1H), 1.42 (br s, 2H), 0.87-0.68 (m, 2H), 0.35 (br s, 2H). MS (ESI) m/z=614.2 (M+H). HPLC Purity: 100%; Retention Time: 2.42 min. Method C.

Example 419

##STR00204##

Intermediate 419-5 (Chiral Peak-1) and 419-6 (Chiral Peak-2)

##STR00205##

[0819] Intermediate 419-1: To methyl 4-fluoro-5-formyl-2-methoxybenzoate (0.15 g, 0.68 mmol) (prepared as described in Chen, Xiao-Yang, Sorensen, Eric, J. JACS, 2018, 140, 2789-2792) and NH.sub.2OH HCl (48 mg, 0.68 mmol) in DCM (10 mL) was added DIEA (0.12 mL, 0.68 mmol). After 24 h, the reaction mixture was diluted with water and white solid (0.15 g, 96%), methyl (E)-4-fluoro-5-((hydroxyimino)methyl)-2-methoxybenzoate, was collected by filtration, dried and used as is. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.53-8.37 (m, 1H), 8.33-8.22 (m, 2H), 6.79-6.61 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H). MS (ESI) m/z 228.2 (M+H)..sup.+

[0820] Intermediate 419-2: To intermediate 419-1 (0.15 g, 0.66 mmol) and DMF (1 mL) was added NCS (88 mg, 0.66 mmol). After 24 h, the reaction mixture was partitioned with water (20 mL) and ethyl acetate (50 mL). The aqueous layer was extracted with ethyl acetate (220 mL). The combined organic layers were washed with brine (15 mL) and dried (Na.sub.2SO.sub.4), to afford a solid To the solid in DCM (3 mL), was added 2,5-dihydrofuran (0.46 g, 6.6 mmol) and TEA (0.1 mL, 0.66 mmol). After 24 h, the reaction mixture was quenched with water (20 mL) and extracted with DCM (330 mL). The combined organic layers were washed with brine (15 mL) and dried (MgSO.sub.4). The residue was purified via silica gel chromatography using hexanes/EtOAc as eluents to afford methyl 4-fluoro-2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzoate (0.13 g, 66%) as a tan solid. MS (ESI) m/z=296.2 (M+H)..sup.+

[0821] Chiral Intermediate 419-3 and 419-4: Intermediate 419-2 was separated on a Jasco SFC Prep with a Chiralpak IA, 21250 mm column eluted with 20% MeOH/80% CO.sub.2 at 45 mL/min, 150 Bar, 40 C., detector wavelength 267 nm to afford 419-3 (33 mg, 0.11 mmol, 17% yield) (Peak-1, 99% ee, Analytical RT=1.693 min.); .sup.1H NMR (400 MHz, CDCl.sub.3) 8.45 (d, J=8.8 Hz, 1H), 6.75 (d, J=13.2 Hz, 1H), 5.39 (dd, J=9.1, 3.9 Hz, 1H), 4.40 (dt, J=4.6, 2.3 Hz, 1H), 4.34 (d, J=10.8 Hz, 1H), 4.11 (br d, J=9.7 Hz, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.86 (dd, J=9.7, 6.8 Hz, 1H), 3.79 (dd, J=10.8, 4.0 Hz, 1H); 419-4 (32 mg, 0.11 mmol, 16% yield) (Peak-2, 99% ee, Analytical RT=5.463 min.); .sup.1H NMR (400 MHz, CDCl.sub.3) 8.45 (d, J=8.6 Hz, 1H), 6.75 (d, J=13.4 Hz, 1H), 5.39 (dd, J=9.5, 4.0 Hz, 1H), 4.46-4.38 (m, 1H), 4.34 (d, J=11.0 Hz, 1H), 4.16-4.09 (m, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.86 (dd, J=9.7, 6.8 Hz, 1H), 3.79 (dd, J=10.8, 4.0 Hz, 1H). Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC, Column: Chiralpak IC, 4.6100 mm, 3 micron, Mobile Phase: 20% Methanol/80% CO.sub.2 Flow Conditions: 2.0 mL/min, 150 Bar, 40 C., Detector Wavelength: 220 nm

[0822] Intermediate 419-5: To 419-3 (33 mg, 0.11 mmol) in THF (2 mL)/MeOH (0.1 mL), cooled to 0 C., was added a 2 M aqueous solution of LiOH (0.17 ml, 0.34 mmol). After stirring 18 h, the reaction was quenched with dil HCl (10 mL) and extracted with EtOAc (330 mL). The combined organic layers were washed with brine (15 mL), dried (MgSO.sub.4), filtered and concentrated to afford 419-5 (31 mg, 0.11 mmol, 99% yield) as a white solid. .sup.1H NMR (600 MHz, DMSO-d6) 12.90 (br s, 1H), 8.07 (d, J=8.7 Hz, 1H), 7.17 (d, J=13.8 Hz, 1H), 5.34 (dd, J=9.2, 3.7 Hz, 1H), 4.49-4.42 (m, 1H), 4.09 (d, J=10.7 Hz, 1H), 3.90 (br d, J=9.7 Hz, 1H), 3.88 (s, 3H), 3.73 (dd, J=9.5, 6.9 Hz, 1H), 3.64 (dd, J=10.8, 3.7 Hz, 1H). LCMS(ESI) m/z=282.2 (M+H)..sup.+

[0823] Intermediate 419-6: 419-6 (30 mg, 0.11 mmol, 96% yield) was prepared in a similar manner as 419-5 substituting 419-4 for 419-3. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.62 (d, J=8.6 Hz, 1H), 6.86 (d, J=12.5 Hz, 1H), 5.40 (dd, J=9.2, 4.0 Hz, 1H), 4.55-4.28 (m, 2H), 4.11 (s, 3H), 4.08 (s, 1H), 3.87 (dd, J=9.7, 6.8 Hz, 1H), 3.79 (dd, J=10.8, 4.0 Hz, 1H). LCMS(ESI) m/z=282.2 (M+H)..sup.+

[0824] Example 419. (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(4-fluoro-2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide, 419 was prepared (5.9 mg, 67% yield) in a similar manner as example 378, by using the cyclopropyl norbornyl intermediate 20-4 and intermediate 419-5. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.67-10.38 (m, 1H), 9.89 (br d, J=7.0 Hz, 1H), 8.33 (br d, J=8.9 Hz, 1H), 8.20 (br d, J=4.0 Hz, 1H), 7.85-7.71 (m, 1H), 7.48 (br t, J=9.8 Hz, 1H), 7.22 (br d, J=13.1 Hz, 1H), 5.35 (br dd, J=9.5, 3.4 Hz, 1H), 4.69 (br d, J=9.5 Hz, 1H), 4.52-4.36 (m, 2H), 4.10 (br d, J=10.7 Hz, 1H), 4.05 (s, 3H), 3.77-3.66 (m, 1H), 3.66-3.54 (m, 2H), 3.22-3.12 (m, 1H), 3.09 (br s, 1H), 2.72 (br s, 1H), 1.90-1.79 (m, 1H), 1.79-1.66 (m, 1H), 1.50 (br dd, J=8.5, 4.3 Hz, 1H), 1.45-1.32 (m, 2H), 0.87-0.61 (m, 2H), 0.35 (br d, J=2.7 Hz, 2H). HPLC purity 98%. Analytical LC-MS: 2.48 min; MS (ESI) m/z=631.9 (M+H)..sup.+ Method B.

Example 423

##STR00206##

Intermediate 423-1

##STR00207##

[0825] Intermediate 423-1 was prepared in an identical fashion described for intermediate 378-3 which in this case by substituting allyl alcohol with propargyl alcohol. .sup.1H NMR (500 MHz, CD.sub.3OD) 8.28 (d, J=2.3 Hz, 1H), 8.01 (dd, J=8.7, 2.3 Hz, 1H), 7.27 (d, J=8.7 Hz, 1H), 6.75 (s, 1H), 4.91-4.82 (m, 5H), 4.73 (s, 2H), 4.00-3.96 (m, 3H). MS (ESI) m/z=250.3 (M+H).

[0826] (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-(hydroxymethyl)isoxazol-3-yl)-2-methoxybenzamido)bicyclo [2.2.1]heptane-2-carboxamide, 423 was prepared (77% yield) by the coupling method described for example 378 using the norbornyl intermediate 20-4 and intermediate 423-1. .sup.1H NMR (500 MHz, DMSO-d6) 10.56 (s, 1H), 9.95 (br d, J=7.0 Hz, 1H), 8.40 (d, J=1.8 Hz, 1H), 8.19 (br d, J=4.3 Hz, 1H), 7.97 (dd, J=8.5, 2.1 Hz, 1H), 7.77 (br d, J=8.9 Hz, 1H), 7.46 (br t, J=9.8 Hz, 1H), 7.32 (d, J=8.5 Hz, 1H), 6.84 (s, 1H), 4.69 (d, J=9.8 Hz, 1H), 4.61 (d, J=5.8 Hz, 2H), 4.45 (br s, 1H), 4.05 (s, 3H), 3.21-3.06 (m, 2H), 2.72 (br s, 1H), 1.92-1.73 (m, 2H), 1.62-1.45 (m, 1H), 1.41 (br s, 2H), 0.84-0.67 (m, 2H), 0.35 (br d, J=4.3 Hz, 2H). MS (ESI) m/z=600.1 (M+H). HPLC Purity: 100%; Retention Time: 2.39 min; Method B.

Example 427

##STR00208##

[0827] Preparation of methyl 5-(5-fluoro-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoate (diastereomer mixture). To 406-1 ester (0.1 g, 0.3 mmol) in DCM (2 mL) was added DAST (0.05 mL, 0.412 mmol). After 24 h, the reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography to afford the corresponding fluoride (66 mg, 0.23 mmol, 66% yield) as a clear film. .sup.1H NMR (400 MHz, CDCl.sub.3) 8.06 (d, J=2.4 Hz, 1H), 7.88 (dd, J=8.7, 2.3 Hz, 1H), 7.06 (d, J=8.8 Hz, 1H), 5.53-5.38 (m, 1H), 4.25 (dd, J=9.5, 2.0 Hz, 1H), 4.01-3.97 (m, 4H), 3.94-3.92 (m, 3H), 2.76-2.47 (m, 2H), 2.33-2.12 (m, 1H), 2.10-1.90 (m, 1H). LCMS(ESI) m/z=294.2 (M+H)..sup.+

[0828] Intermediate 427-2: Preparation of 5-(5-fluoro-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoic acid. To intermediate 427-1 (14 mg, 0.048 mmol) in THF (1 mL) was added a 2M aqueous solution of LiOH (72 l, 0.14 mmol). After 24 h, dil HCl (10 mL) was added and the solution extracted with EtOAc (330 mL). The combined organic layers were washed with brine (15 mL), dried (MgSO.sub.4), filtered and concentrated under reduced pressure to afford 427-2 (13 mg, 0.047 mmol, 98% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 8.28 (d, J=2.2 Hz, 1H), 8.13 (dd, J=8.8, 2.4 Hz, 1H), 7.20-7.12 (m, 1H), 5.95-5.83 (m, 1H), 5.45 (ddd, J=10.0, 6.8, 4.7 Hz, 1H), 5.38-5.18 (m, 1H), 4.28 (td, J=9.4, 7.5 Hz, 1H), 4.16 (s, 3H), 2.75-2.55 (m, 2H), 2.32-2.17 (m, 1H), 2.06-1.92 (m, 1H). LCMS(ESI) m/z=280.2 (M+H)..sup.+

[0829] (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-fluoro-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide, diasteromeric mixture, 427 was prepared (5.7 mg, 9.1 mol, 67% yield) using the cyclopropyl norbornyl intermediate 20-4 in a similar manner as Example 378, by using the cyclopropyl norbornyl intermediate 20-4 and intermediate 427-2. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.69-10.39 (m, 1H), 9.92 (br t, J=7.0 Hz, 1H), 8.49-8.08 (m, 2H), 7.91-7.71 (m, 2H), 7.50 (br t, J=9.6 Hz, 1H), 7.29 (d, J=8.9 Hz, 1H), 5.45-5.26 (m, 1H), 4.71 (br d, J=9.2 Hz, 1H), 4.46 (br s, 1H), 4.39-4.30 (m, 1H), 4.06 (d, J=2.4 Hz, 3H), 3.41 (br s, 1H), 3.18 (br dd, J=10.8, 3.5 Hz, 1H), 3.12 (br s, 1H), 2.74 (br s, 1H), 2.51-2.35 (m, 2H), 2.17-2.06 (m, 1H), 2.06-2.00 (m, 1H), 1.92-1.84 (m, 1H), 1.80 (br d, J=11.3 Hz, 1H), 1.61-1.50 (m, 1H), 1.49-1.36 (m, 2H), 0.86-0.68 (m, 2H), 0.37 (br s, 2H). HPLC purity 100%. Analytical LC-MS: 2.65 min; MS (ESI) m/z=630.3 (M+H)..sup.+ Method B.

[0830] 428 was prepared (6.1 mg, 69% yield) in a similar manner as example 379, by using the cyclopropyl norbornyl intermediate 20-4 and intermediate 428-1. .sup.1H NMR. HPLC purity 100%. Analytical LC-MS: 2.84 min; MS (ESI) m/z=638.2 (M+H)..sup.+ Method B.

Example 429

##STR00209##

Intermediate 429-1: Preparation of methyl 5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoate

##STR00210##

[0831] Intermediate 429-1 was prepared in an identical fashion (75% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with cyclopent-3-en-1-ylmethanol.

Intermediate 429-2: Preparation of 5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoic acid

##STR00211##

[0832] Methyl 5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoate (58 mg, 0.22 mmol) was dissolved in THF (1 mL)/MeOH (1 mL) was treated with LiOH monohydrate (36 mg, 0.86 mmol) in H.sub.2O (1 mL) at rt. After 3 h, the reaction mixture was diluted with H.sub.2O (5 mL) and liberated of organics. The pH of the remaining aq. layer was adjusted to pH 7 with 1M HCl solution, extracted with EtOAc (225 mL), washed with brine, dried (Na.sub.2SO.sub.4), filtered, and evaporated to give intermediate 429-2 (62 mg, 74.2%). The carboxylic acid was carried forward to the next reaction without further purification. MS (ESI) m/z=292.3 (M+H).

[0833] Example 429 was prepared by the coupling of intermediate 429-2 (3.95 mg, 0.014 mmol) with intermediate 166-2 (5 mg, 0.014 mmol) dissolved in anhydrous DMF (2 mL) the presence of DIEA (0.012 mL, 0.068 mmol) and BOP (6.60 mg, 0.015 mmol). After 3 h, the reaction mixture was filtered and purified by reverse phase preparative HPLC to give desired product (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide, diasteromeric mixture, 429 (5.1 mg, 0.0079 mmol, 58% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.90 (br d, J=6.4 Hz, 1H), 8.23-8.17 (m, 2H), 7.81-7.74 (m, 2H), 7.46 (br t, J=9.8 Hz, 1H), 7.26 (d, J=8.9 Hz, 1H), 5.15-5.07 (m, 1H), 4.68 (br d, J=9.5 Hz, 1H), 4.42 (br s, 1H), 4.20-4.14 (m, 1H), 4.02 (s, 3H), 3.58-3.47 (m, 2H), 3.39-3.18 (m, 2H), 3.17-3.06 (m, 2H), 2.73-2.68 (m, 1H), 1.99-1.73 (m, 5H), 1.66-1.59 (m, 1H), 1.56-1.37 (m, 4H), 0.78-0.68 (m, 2H), 0.38-0.29 (m, 2H). HPLC purity: 99.2%. Analytical LC-MS: 2.53 min; MS (ESI) m/z=642.2 (M+H); Method B.

Example 430

##STR00212##

Intermediate 429-4 (Chiral Peak-1), 429-6 (Chiral Peak-2), 429-8 (Chiral Peak-3), and 429-10 (Chiral Peak-4)

##STR00213##

[0834] Individual chiral diastereomer ester intermediates 429-4A, 429-6A, 429-8A, and 429-10A were obtained by chiral SFC of diasteromeric mixture intermediate 429 (524.9 mg, 1.72 mmol). Chiral SFC Preparative chromatographic conditions: Instrument: Berger MG II (SFC); Column: Chiralpak AD-H, 21250 mm, 5 micron; Mobile phase: 15% MeOH/85% CO.sub.2; Flow conditions: 45 mL/min, 150 Bar, 40 C.; Detector wavelength: 210 nm; Injections details: 0.5 mL of 35 mg/mL in MeOH. Analytical chromatographic conditions: Instrument: Shimadzu Nexera SFC; Column: Chiralpak AD-H, 4.6100 mm, 3 micron; Mobile phase: 15% MeOH/85% CO.sub.2; Flow conditions: 2.0 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 5 L of 1 mg/mL in MeOH.

[0835] Intermediate 429-4A (Peak-1, >99% de, analytical RT=4.02 min) was obtained as a film (152.8 mg, 29.1%). .sup.1H NMR (600 MHz, CDCl.sub.3) 8.04 (d, J=2.3 Hz, 1H), 7.87 (dd, J=8.7, 2.3 Hz, 1H), 7.01 (d, J=8.8 Hz, 1H), 5.23 (dd, J=8.8, 5.1 Hz, 1H), 4.10 (t, J=8.7 Hz, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.72-3.66 (m, 1H), 3.61 (dt, J=10.5, 5.2 Hz, 1H), 2.30-2.16 (m, 2H), 2.05 (dd, J=13.0, 6.1 Hz, 1H), 1.76 (ddd, J=12.9, 11.5, 9.4 Hz, 1H), 1.68-1.62 (m, 1H), 1.39 (br t, J=4.8 Hz, 1H).

[0836] Intermediate 429-4 (104.4 mg, 78%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 429-4A. MS (ESI) m/z=292.3 (M+H).

[0837] Intermediate 429-6A (Peak-2, >99% de, analytical RT=4.56 min) was obtained as a film (33.2 mg, 6.3%). .sup.1H NMR (600 MHz, CDCl.sub.3) 8.05 (d, J=2.3 Hz, 1H), 7.87 (dd, J=8.8, 2.3 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 5.25 (ddd, J=10.1, 6.2, 4.2 Hz, 1H), 4.04-3.98 (m, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.63-3.57 (m, 1H), 3.56-3.50 (m, 1H), 2.38-2.26 (m, 3H), 1.92-1.85 (m, 1H), 1.73-1.66 (m, 1H), 1.51 (t, J=5.3 Hz, 1H).

[0838] Intermediate 429-6 (20.2 mg, 92%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 429-6a. MS (ESI) m/z=292.3 (M+H).

[0839] Intermediate 429-8A (Peak-3, >99% de, analytical RT=5.67 min) was obtained as a film (160.8 mg, 30.6%). .sup.1H NMR: (600 MHz, CDCl.sub.3) 8.05-8.03 (m, 1H), 7.86 (dd, J=8.7, 2.3 Hz, 1H), 7.01 (d, J=8.8 Hz, 1H), 5.23 (dd, J=8.7, 5.2 Hz, 1H), 4.10 (t, J=8.7 Hz, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.69 (br dd, J=10.6, 5.2 Hz, 1H), 3.63-3.58 (m, 1H), 2.28-2.17 (m, 2H), 2.05 (br dd, J=12.9, 6.2 Hz, 1H), 1.76 (ddd, J=13.0, 11.5, 9.4 Hz, 1H), 1.64-1.60 (m, 1H), 1.49 (br s, 1H).

[0840] Intermediate 429-8 (121 mg, 85%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 429-8a. MS (ESI) m % z=292.3 (M+H).

[0841] Intermediate 429-10A (Peak-4, >99% de, analytical RT=9.78 min) was obtained as a film (47.1 mg, 9.0%). .sup.1H NMR: (600 MHz, CDCl.sub.3) 8.04 (d, J=2.3 Hz, 1H), 7.87 (dd, J=8.7, 2.3 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 5.24 (ddd, J=10.1, 6.2, 4.2 Hz, 1H), 4.03-3.98 (m, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.63-3.57 (m, 1H), 3.56-3.49 (m, 1H), 2.38-2.25 (m, 3H), 1.91-1.85 (m, 1H), 1.72-1.66 (m, 1H), 1.55 (br s, 1H).

[0842] Intermediate 429-10 (18.2 mg, 51.6%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 429-10A. MS (ESI) m/z=292.3 (M+H).

[0843] Example 430 was prepared in a similar manner as example 429 with intermediate 429-4 (Peak-1 from SFC). (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide homochiral isomer-1 (10.5 mg, 0.016 mmol, 60.3% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.90 (br d, J=7.0 Hz, 1H), 8.23-8.18 (m, 2H), 7.81-7.75 (m, 2H), 7.47 (br t, J=9.5 Hz, 1H), 7.26 (d, J=8.5 Hz, 1H), 5.11 (br dd, J=8.2, 5.5 Hz, 1H), 4.68 (d, J=9.8 Hz, 1H), 4.46-4.39 (m, 1H), 4.22-4.13 (m, 1H), 4.03 (s, 3H), 3.49-3.28 (m, 1H), 3.19-3.05 (m, 2H), 2.73-2.68 (m, 1H), 1.98 (br dd, J=13.6, 5.0 Hz, 1H), 1.93-1.74 (m, 4H), 1.69-1.60 (m, 1H), 1.58-1.36 (m, 4H), 0.77-0.68 (m, 2H), 0.37-0.30 (m, 2H). HPLC purity: 100%. Analytical LC-MS: 2.3 min; MS (ESI) m/z=642.3 (M+H); Method B.

Example 434

##STR00214##

Intermediate 434-2 (Diastereomeric Mixture)

##STR00215##

Intermediate 434-1: Preparation of tert-butyl 3-(4-methoxy-3-(methoxycarbonyl)phenyl)-3a,4,6,6a-tetrahydro-5H-pyrrolo[3,4-d]isoxazole-5-carboxylate

##STR00216##

[0844] Intermediate 434-1 (499.5 mg, 46%) was prepared by the method described for intermediate 429-1 which in this case by substituting cyclopent-3-en-1-ylmethanol with tert-butyl 2,5-dihydro-TH-pyrrole-1-carboxylate. .sup.1H NMR: (400 MHz, CDCl.sub.3) 7.99 (d, J=2.4 Hz, 1H), 7.84 (dd, J=8.7, 2.3 Hz, 1H), 7.04 (d, J=8.8 Hz, 1H), 5.31 (ddd, J=9.2, 5.4, 1.2 Hz, 1H), 4.21 (br dd, J=12.4, 9.1 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.72-3.61 (m, 2H), 1.43 (s, 9H). MS (ESI) m/z=377.4 (M+H).

[0845] Intermediate 434-2: Preparation of 5-(5-(tert-butoxycarbonyl)-3a,5,6,6a-tetrahydro-4H-pyrrolo[3,4-d]isoxazol-3-yl)-2-methoxybenzoic acid. 434-2 (151.4 mg, 43.7% over three steps) was prepared by the method described for intermediate 429-2 replacing intermediate 429-1 with intermediate 434-1. MS (ESI) m/z=363.4 (M+H).

Intermediates 434-4 and 434-6 (Homochiral)

##STR00217##

[0846] Intermediates 434-3 and 434-4 were obtained by chiral SFC of diastereomeric mixture intermediate 434-2 (499 mg, 1.33 mmol). Chiral SFC Preparative chromatographic conditions: Instrument: Berger MG II (SFC); Column: Regis Whelk-01, 21250 mm, 5 micron; Mobile phase: 15% MeOH/85% CO.sub.2; Flow conditions: 45 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injections details: 1.0 mL of 31 mg/mL in MeOH-ACN. Analytical chromatographic conditions: Instrument: Shimadzu Nexera SFC; Column: Regis Whelk-01, 4.6100 mm, 3 micron; Mobile phase: 15% MeOH/85% CO.sub.2; Flow conditions: 2.0 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 5 L of 1 mg/mL in Acetonitrile.

[0847] Intermediate 434-3 (Peak-1, >99% de, analytical RT=4.02 min) was obtained as a white solid (95.9 mg, 19.2% yield). .sup.1H NMR: (600 MHz, CDCl.sub.3) 7.99 (d, J=2.3 Hz, 1H), 7.86-7.82 (m, 1H), 7.04 (br d, J=8.7 Hz, 1H), 5.31 (ddd, J=9.2, 5.4, 1.3 Hz, 1H), 4.24-4.18 (m, 1H), 4.01-3.93 (m, 4H), 3.91 (s, 3H), 3.83-3.76 (m, 1H), 3.71-3.67 (m, 1H), 3.63 (br s, 1H), 1.43 (br s, 9H).

[0848] Intermediate 434-4. Preparation of 5-(5-(tert-butoxycarbonyl)-3a,5,6,6a-tetrahydro-4H-pyrrolo[3,4-d]isoxazol-3-yl)-2-methoxybenzoic acid. Intermediate 434-4 (52 mg, 67.5% yield) was prepared in a similar manner as intermediate 434-2 with the hydrolysis of intermediate 434-3. MS (ESI) nm/z=363.1 (M+H).

[0849] Intermediate 434-5 (Peak-2, 99.6% de, analytical RT=4.56 min) was obtained as a white solid (96.7 mg, 19.4% yield). .sup.1H NMR (600 MHz, CDCl.sub.3) 7.98 (d, J=2.3 Hz, 1H), 7.83 (dd, J=8.8, 2.2 Hz, 1H), 7.03 (d, J=8.7 Hz, 1H), 5.32-5.28 (m, 1H), 4.21 (td, J=8.8, 4.0 Hz, 1H), 4.01-3.94 (m, 1H), 3.95 (s, 3H), 3.90 (s, 3H), 3.83-3.73 (m, 1H), 3.68 (dd, J=11.4, 8.9 Hz, 1H), 3.65-3.58 (m, 1H), 1.43 (s, 9H).

[0850] Intermediate 434-6. Preparation of 5-(5-(tert-butoxycarbonyl)-3a,5,6,6a-tetrahydro-4H-pyrrolo[3,4-d]isoxazol-3-yl)-2-methoxybenzoic acid. Intermediate 434-6 (48 mg, 62.3% yield) was prepared in a similar manner as intermediate 434-2 with the hydrolysis of intermediate 434-5. MS (ESI) m/z=363.1 (M+H).

[0851] Example 434 was prepared in a similar manner as example 429 replacing intermediate 429-2 with intermediate 434-2. tert-butyl 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl) carbamoyl) bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-3a,4,6,6a-tetrahydro-5H-pyrrolo[3,4-d]isoxazole-5-carboxylate diasteromeric mixture, 434 (7.1 mg, 0.0098 mmol, 72.3% yield, diastereomeric mixture). .sup.1H NMR (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.91 (br d, J=6.7 Hz, 1H), 8.21 (br s, 2H), 7.78 (br d, J=7.0 Hz, 2H), 7.47 (br t, J=9.5 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 5.25 (br dd, J=8.9, 4.9 Hz, 1H), 4.68 (br d, J=9.5 Hz, 1H), 4.46-4.39 (m, 2H), 4.04 (d, J=3.1 Hz, 3H), 3.80-3.69 (m, 1H), 3.15 (br dd, J=11.0, 3.7 Hz, 1H), 3.10 (br d, J=3.4 Hz, 1H), 2.73-2.68 (m, 1H), 1.90 (s, 1H), 1.85-1.74 (m, 2H), 1.55-1.15 (m, 14H), 0.79-0.67 (m, 2H), 0.40-0.24 (m, 2H). HPLC purity: 98.5%. Analytical LC-MS: 2.81 min; MS (ESI) m/z=713.2 (M+H); Method B.

Example 437

##STR00218##

[0852] Prepared by the coupling of intermediate 434-2 (9.84 mg, 0.027 mmol) with intermediate 166-2 (10 mg, 0.027 mmol) dissolved in anhydrous THF (2 mL) the presence of DIEA (0.024 mL, 0.136 mmol) and BOP (13.21 mg, 0.030 mmol). After 1 h, the reaction mixture was concentrated, dissolved in DCM (1 mL), and treated with 50% TFA/DCM (1 mL). After 1 h, the reaction mixture was concentrated under reduced pressure and purified by reverse phase preparative HPLC to give 437 (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(3a,5,6,6a-tetrahydro-4H-pyrrolo[3,4-d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide diastereomeric mixture, (10.3 mg, 0.0140 mmol, 51.5% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.58-10.55 (m, 1H), 9.94 (dd, J=18.8, 7.1 Hz, 1H), 8.25 (dd, J=10.2, 2.0 Hz, 1H), 8.22-8.17 (m, 1H), 7.83-7.78 (m, 1H), 7.78-7.74 (m, 1H), 7.46 (br t, J=9.5 Hz, 1H), 7.29 (d, J=8.7 Hz, 1H), 5.43 (dd, J=9.3, 4.6 Hz, 1H), 4.69-4.64 (m, 2H), 4.44-4.37 (m, 1H), 4.04 (d, J=1.7 Hz, 3H), 3.72-3.65 (m, 2H), 3.46-3.38 (m, 1H), 3.16-3.11 (m, 1H), 3.09-3.05 (m, 1H), 2.73-2.68 (m, 1H), 1.83-1.70 (m, 2H), 1.51-1.34 (m, 4H), 0.76-0.66 (m, 2H), 0.33 (br d, J=3.2 Hz, 2H). HPLC purity: 98.6%. Analytical LC-MS: 2.32 min; MS (ESI) m/z=613.2 (M+H); Method C.

Example 438

##STR00219##

[0853] Intermediate 434-2 (9.84 mg, 0.027 mmol) and cyclopropyl norbornyl intermediate 166-2 (10 mg, 0.027 mmol) were dissolved in anhydrous THF (2.0 mL), then DIEA (0.024 mL, 0.136 mmol) and BOP (13.21 mg, 0.030 mmol) were added. After 2 h, the reaction mixture was concentrated, the resulting residue was re-dissolved in DCM (0.25 mL), and treated with 50% TFA/DCM (0.25 mL). After 1 h, the reaction mixture was concentrated to dryness. The amine was dissolved in THF (2.0 mL) and treated with TEA (0.019 mL, 0.13 mmol) followed by methyl chloroformate (2.6 mg, 0.027 mmol) at 0 C. After stirring 2 h at rt, the reaction mixture was concentrated under reduced pressure and purified by preparative RP-HPLC to give methyl 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl) carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-3a,4,6,6a-tetrahydro-5H-pyrrolo[3,4-d]isoxazole-5-carboxylate (diastereomeric mixture), 438 (2.6 mg, 0.0036 mmol, 14.2% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.92 (br t, J=6.1 Hz, 1H), 8.18 (br s, 2H), 7.81-7.74 (m, 2H), 7.45 (br t, J=9.8 Hz, 1H), 7.29-7.26 (m, 1H), 5.28 (br dd, J=8.5, 4.9 Hz, 1H), 4.68 (br d, J=9.5 Hz, 1H), 4.48-4.38 (m, 2H), 4.03 (d, J=3.1 Hz, 2H), 3.81-3.74 (m, 1H), 3.64-3.48 (m, 4H), 3.17-3.06 (m, 2H), 2.73-2.66 (m, 1H), 1.84-1.72 (m, 2H), 1.52-1.33 (m, 4H), 0.77-0.67 (m, 2H), 0.33 (br d, J=3.4 Hz, 2H). HPLC purity: 99.1%. Analytical LC-MS: 2.48 min; MS (ESI) m/z=671.1 (M+H); Method B.

Example 439

##STR00220##

Intermediate 439-1: Preparation of methyl 2-methoxy-5-(3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzoate

##STR00221##

[0854] Intermediate 439-1 was prepared in an identical fashion (128 mg, 23% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with cyclopentene.

Intermediate 439-2: Preparation of 2-methoxy-5-(3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzoic acid

##STR00222##

[0855] Intermediate 439-2 (45.2 mg, 60.3%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 439-1. MS (ESI) m/z=262.2 (M+H).

[0856] Individual chiral diastereomer ester intermediates 439-4A (chiral peak-1) and 439-6A (chiral peak-2) were obtained by chiral SFC of diasteromeric mixture intermediate 439-1 (128 mg, 0.465 mmol). Chiral SFC Preparative chromatographic conditions: Instrument: Jasco SFC Prep; Column: Chiralpak OJ-H, 21250 mm, 5 micron; Mobile phase: 5% IPA/95% CO.sub.2; Flow conditions: 45 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injections details: 0.5 mL of 35 mg/mL in IPA-ACN. Analytical chromatographic conditions: Instrument: Shimadzu Nexera SFC; Column: Chiralpak OJ-H, 4.6100 mm, 3 micron; Mobile phase: 10% IPA/90% CO.sub.2; Flow conditions: 2.0 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 5 L of 1 mg/mL in MeOH.

[0857] Intermediate 439-4A (Peak-1, >99% de, analytical RT=2.84 min) was obtained as a film (48.8 mg, 38.1%). .sup.1H NMR: (400 MHz, chloroform-d) 8.06 (d, J=2.4 Hz, 1H), 7.86 (dd, J=8.8, 2.2 Hz, 1H), 7.01 (d, J=8.8 Hz, 1H), 5.21 (dd, J=8.8, 4.6 Hz, 1H), 4.03 (td, J=8.4, 3.0 Hz, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.21-2.14 (m, 1H), 1.94-1.85 (m, 2H), 1.83-1.72 (m, 2H), 1.60-1.47 (m, 1H).

[0858] Intermediate 439-4 (41.9 mg, 90%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 439-4A. MS (ESI) m/z=262.3 (M+H).

[0859] Intermediate 439-6A (Peak-2, >95% de. analytical RT=3.60 min) was obtained as a film (51.5 mg, 40.2%). .sup.1H NMR: (400 MHz, CDCl.sub.3) 8.06 (d, J=2.4 Hz, 1H), 7.86 (dd, J=8.8, 2.4 Hz, 1H), 7.01 (d, J=8.8 Hz, 1H), 5.21 (dd, J=8.8, 4.6 Hz, 1H), 4.07-4.00 (m, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.21-2.15 (m, 1H), 1.94-1.87 (m, 2H), 1.83-1.71 (m, 2H), 1.60-1.49 (m, 1H).

[0860] Intermediate 439-6 (45.3 mg, 93%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 439-6A. MS (ESI) m/z=262.3 (M+H).

[0861] Example 439 was prepared in a similar manner as example 429 replacing intermediate 429-2 with intermediate 439-2. (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide diastereomeric mixture, 439 (6.2 mg, 0.010 mmol, 74.2% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.57-10.50 (m, 1H), 9.93-9.85 (m, 1H), 8.23-8.17 (m, 2H), 7.80-7.73 (m, 2H), 7.49-7.44 (m, 1H), 7.28-7.24 (m, 1H), 5.16-5.09 (m, 1H), 4.71-4.66 (m, 1H), 4.46-4.37 (m, 1H), 4.18-4.12 (m, 1H), 4.05-3.99 (m, 3H), 3.17-3.06 (m, 2H), 2.73-2.67 (m, 1H), 1.99-1.90 (m, 1H), 1.86-1.63 (m, 6H), 1.52-1.26 (m, 4H), 0.78-0.68 (m, 2H), 0.39-0.29 (m, 2H). HPLC purity: 99.4%. Analytical LC-MS: 2.82 min; MS (ESI) m/z 612.2 (M+H); Method B.

[0862] Prepared in a similar manner as example 429 replacing intermediate 429-2 with intermediate 439-6 (Peak-2 from SFC).). (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide homochiral isomer-2, 441 (10.9 mg, 0.017 mmol, 63.1% yield). .sup.1H NMR. HPLC purity: 100%. Analytical LC-MS: 2.71 min; MS (ESI) m/z=612.3 (M+H); Method B.

Example 442

##STR00223##

Intermediate 442-1: Preparation of methyl 5-(5,5-dioxido-3a,4,6,6a-tetrahydrothieno[3,4-d]isoxazol-3-yl)-2-methoxybenzoate

##STR00224##

[0863] Intermediate 442-1 was prepared in an identical fashion (128 mg, 23% yield) described for intermediate 378-3 which in this case by substituting allyl alcohol with 2,5-dihydrothiophene 1,1-dioxide.

Intermediate 442-2: Preparation of 5-(5,5-dioxido-3a,4,6,6a-tetrahydrothieno[3,4-d]isoxazol-3-yl)-2-methoxybenzoic acid

##STR00225##

[0864] Intermediate 442-2 (59.0 mg, 39.6%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 442-1. MS (ESI) m/z=312.2 (M+H).

[0865] Individual chiral diastereomer ester intermediates 442-4A and 442-6A were obtained by chiral SFC of diasteromeric mixture intermediate 441-1 (600 mg, 1.84 mmol). Chiral SFC Preparative chromatographic conditions: Instrument: PIC Solution SFC Prep-200; Column: Chiralcel OD-H, 21250 mm, 5 micron; Mobile phase: 25% MeOH/75% CO.sub.2; Flow conditions: 45 mL/min, 150 Bar, 40 C.; Detector wavelength: 271 nm; Injections details: 1.0 mL of 50 mg/mL in MeOH:ACN. Analytical chromatographic conditions: Instrument: Shimadzu Nexera SFC; Column: Chiralcel OD-H, 4.6100 mm, 3 micron; Mobile phase: 15% MeOH/85% CO.sub.2; Flow conditions: 2.0 mL/min, 150 Bar, 40 C.; Detector wavelength: 220 nm; Injection details: 5 L of 1 mg/mL in MeOH.

[0866] Intermediate 442-4A (Peak-1, >99% de, analytical RT=3.74 min.) was obtained as a white solid (108.1 mg, 18%). .sup.1H NMR: (400 MHz, chloroform-d) 7.96 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.2 Hz, 1H), 7.07 (d, J=9.0 Hz, 1H), 5.43 (ddd, J=10.1, 7.2, 4.1 Hz, 1H), 4.52-4.44 (m, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.66-3.47 (m, 3H), 3.14 (dd, J=13.6, 8.1 Hz, 1H).

[0867] Intermediate 442-4 (82 mg, 79%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 442-4A. MS (ESI) m/z=312.3 (M+H).

[0868] Intermediate 442-6A (Peak-2, >99% de, analytical RT=5.44 min.) was obtained as a white solid (108.8 mg, 18%). .sup.1H NMR: (400 MHz, chloroform-d) 7.96 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.2 Hz, 1H), 7.06 (d, J=8.8 Hz, 1H), 5.42 (ddd, J=10.1, 7.2, 4.1 Hz, 1H), 4.52-4.44 (m, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.66-3.46 (m, 3H), 3.14 (dd, J=13.6, 8.4 Hz, 1H).

[0869] Intermediate 442-6 (89.6 mg, 87%) was prepared in a similar manner as intermediate 429-2 with the hydrolysis of intermediate 442-6A. MS (ESI) m/z=312.3 (M+H).

[0870] Example 442 was prepared in a similar manner as example 429 replacing intermediate 429-2 with intermediate 442-2. (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(5-(5,5-dioxido-3a,4,6,6a-tetrahydrothieno[3,4-d]isoxazol-3-yl)-2-methoxybenzamido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide diastereomeric mixture, 442 (4.8 mg, 0.0072 mmol, 53.0% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.91 (br t, J=8.4 Hz, 1H), 8.26-8.20 (m, 2H), 7.81-7.74 (m, 2H), 7.48 (br t, J=9.9 Hz, 1H), 7.28 (d, J=8.9 Hz, 1H), 5.43-5.38 (m, 1H), 4.78-4.72 (m, 1H), 4.69 (br d, J=9.8 Hz, 1H), 4.43 (br s, 1H), 4.05 (s, 3H), 3.65 (br dd, J=14.3, 6.7 Hz, 1H), 3.44-3.33 (m, 1H), 3.18-3.08 (m, 3H), 2.72 (br s, 1H), 1.85-1.74 (m, 2H), 1.52-1.46 (m, 1H), 1.45-1.34 (m, 2H), 0.79-0.68 (m, 2H), 0.34 (br s, 2H). HPLC purity: 99.2%. Analytical LC-MS: 2.33 min; MS (ESI) m/z 662.2 (M+H); Method B.

TABLE-US-00002 Lengthy table referenced here US20250221966A1-20250710-T00001 Please refer to the end of the specification for access instructions.

Example 447

##STR00226##

Intermediate 447-1

##STR00227##

[0871] To a solution of (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide (250 mg, 0.407 mmol, Example 417) in DCM (4.1 mL) was added Boc.sub.2O (0.38 mL, 1.6 mmol), Hunig's base (0.28 l, 1.6 mmol), and DMAP (25 mg, 0.20 mmol). The reaction mixture was stirred for 14 h, then concentrated in vacuo. The residue was purified via silica gel chromatography to furnish tert-butyl ((1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carbonyl)(4-fluoro-3-(trifluoromethyl)phenyl)carbamate (242 mg, 0.339 mmol, 83.0% yield). LC-MS RT: 1.20 min; MS (ESI) m/z 736 (M+Na).sup.+; Method E.

Intermediate 447-2

##STR00228##

[0872] To a solution of Intermediate 447-1 (533 mg, 0.747 mmol) in THF (14 mL) was added LiOH (TM aqueous) (3.7 mL, 3.7 mmol). After 3 hours, the reaction mixture was diluted with water and extracted twice with EtOAc. The organic layers were reextracted with 1M NaOH, then the aqueous layer was acidified to ca. pH 1 with 1M HCl. The precipitated solid was filtered off, then the filtrate was extracted twice with EtOAc. The organic fractions were combined with the solid and concentrated under reduced pressure to give (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-3-(2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxylic acid

[0873] Example 447-2 (294 mg, 0.650 mmol, 87.0% yield). LC-MS RT: 0.75 min; MS (ESI) m/z 453 (M+H).sup.+; Method E.

Intermediate 447-3

##STR00229##

[0874] In each of two 40 mL pressure vials, 1-(1-methylcyclopropyl)ethan-1-one (0.500 g, 5.09 mmol) was dissolved in THF (10 ml). To this solution was added titanium(IV) ethoxide (2.1 ml, 10 mmol) and (R)-2-methylpropane-2-sulfinamide (0.617 g, 5.09 mmol). The reaction mixture was heated to 65 C. for 14 h then allowed to cool to room temperature. A suspension of sodium borohydride (1.54 g, 40.8 mmol) in 7 mL THF was cooled to 50 C. The vials containing the reaction solutions were cooled to 50 C. The reaction solutions were transferred to the sodium borohydride solution. After two hours, the reaction mixture was quenched with MeOH. After gas evolution ceased, the reaction mixture was poured into brine with stirring. The suspension was filtered through celite, rinsing with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography to give Intermediate 447-3 (982 mg, 47%). .sup.1H NMR (400 MHz, CDCl.sub.3) 3.22 (br s, 1H), 2.61 (qd, J=6.5, 3.2 Hz, 1H), 1.26-1.21 (m, 12H), 1.01 (s, 3H), 0.54-0.46 (m, 1H), 0.42-0.32 (m, 3H).

Intermediate 447-4

##STR00230##

[0875] To a solution of Intermediate 447-3 (100 mg, 0.492 mmol) in methanol (0.49 mL) was added HCl (4M in dioxane) (0.12 mL, 0.49 mmol). After 2.75 hours, the reaction mixture was concentrated in vacuo. The residue was sonicated with Et.sub.2O and filtered. The solid was dried to give (R)-1-(1-methylcyclopropyl)ethan-1-amine, HCl (60 mg, 0.44 mmol, 90% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) 2.66-2.52 (m, 1H), 1.38-1.27 (m, 3H), 1.09 (s, 3H), 0.65-0.55 (m, 1H), 0.55-0.41 (m, 3H).

Example 447

[0876] To a solution of Intermediate 447-2 (20 mg, 0.044 mmol) in DMF (0.5 mL) was added Intermediate 447-4 (24 mg, 0.18 mmol), HATU (22 mg, 0.057 mmol) and Hunig's base (0.046 mL, 0.27 mmol). After 1.5 hours, the reaction mixture was quenched with MeOH. The residue was purified via preparative HPLC to furnish Example 447 (15.2 mg, 64.0%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.07 (br d, J=6.7 Hz, 1H), 8.15 (d, J=2.4 Hz, 1H), 7.92 (d, J=8.6 Hz, 1H), 7.78 (dd, J=8.6, 2.4 Hz, 1H), 7.23 (d, J=8.8 Hz, 1H), 5.34 (dd, J=9.4, 3.5 Hz, 1H), 4.63 (d, J=9.4 Hz, 1H), 4.54-4.47 (m, 1H), 4.31-4.23 (m, 1H), 4.09 (d, J=10.9 Hz, 1H), 4.00 (s, 3H), 3.90 (d, J=10.0 Hz, 1H), 3.77 (dd, J=9.3, 6.7 Hz, 1H), 3.65 (dd, J=10.7, 3.6 Hz, 1H), 3.50-3.42 (m, 1H), 3.07-3.02 (m, 1H), 2.94 (dd, J=11.0, 4.0 Hz, 1H), 1.91-1.81 (m, 1H), 1.78-1.68 (m, 1H), 1.52-1.43 (m, 1H), 1.40-1.30 (m, 2H), 1.05-0.99 (m, 3H), 0.99-0.94 (m, 3H), 0.77-0.66 (m, 2H), 0.58-0.47 (m, 1H), 0.36-0.27 (m, 2H), 0.17 (br t, J=6.6 Hz, 2H). LC-MS RT: 2.26 min; MS (ESI) m/z 534.3 (M+H).sup.+; Method B.

Example 448

##STR00231##

Intermediate 448-1

##STR00232##

[0877] Methyl (Z)-5-(chloro(hydroxyimino)methyl)-2-methoxybenzoate (200 mg, 0.821 mmol) and bicyclo[2.2.1]hepta-2,5-diene (756 mg, 8.21 mmol) were dissolved in DCM (5 mL). To the solution was added TEA (1 mL) and stirred at r.t. for 14 h. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (225 mL), which were then dried (MgSO.sub.4), filtered and concentrated to an oil in vacuo. The residue was purified via silica gel chromatography and eluted with hex/EtOAc. Fractions containing pure product were isolated and concentrated under reduced pressure to methyl 2-methoxy-5-(3a,4,7,7a-tetrahydro-4,7-methanobenzo[d]isoxazol-3-yl)benzoate 448-1 (240 mg, 98% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.09 (d, J=2.3 Hz, 1H), 7.88 (dd, J=8.9, 2.3 Hz, 1H), 7.02 (d, J=8.7 Hz, 1H), 6.36 (dd, J=5.7, 3.0 Hz, 1H), 6.10 (dd, J=5.8, 3.2 Hz, 1H), 4.97 (dt, J=8.2, 1.2 Hz, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.29-3.25 (m, 1H), 1.71 (d, J=9.5 Hz, 1H), 1.62 (dt, J=9.4, 1.5 Hz, 1H). LCMS m/z=300.2 (M+H).sup.+.

Preparation of Intermediates Homochiral Isomers 448-2 and 448-3

##STR00233##

[0878] Intermediate 448-1 (180 mg, 0.60 mmol) was stirred as a slurry in t-BuOH (3 mL), and to the solution was added N-methylmorpholine oxide (146 mg, 1.20 mmol) followed by OsO.sub.4 (380 mg, 0.060 mmol). The reaction turned black instantaneously and was stirred at r.t. for 14 h. The reaction mixture was quenched with sat. sodium sulfite solution (20 mL), stirred for 5 min and extracted with EtOAc (225 mL), dried (MgSO.sub.4), filtered and evaporated under reduced pressure to methyl 5-(5,6-dihydroxy-3a,4,5,6,7,7a-hexahydro-4,7-methanobenzo[d]isoxazol-3-yl)-2-methoxybenzoate as a foam (220 mg). The compound was separated into two homochiral isomers 448-2 and 448-3 via chiral SFC. Preparative Chromatographic Conditions: Instrument: Berger MG II (CTR-L409-PSFC1) Column: Chiralpak IF, 21250 mm, 5 micron Mobile Phase: 30% MeOH/70% CO.sub.2 Flow Conditions: 45 mL/min. 150 Bar, 40 C. Detector Wavelength: 220 nm. Injection Details: 1.0 mL of 200 mg/3 mL in MeOH-ACN. Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC (CTR-L410-SFC3) Column: Chiralpak IF, 4.6100 mm, 3 micron. Mobile Phase: 30% MeOH/70% CO.sub.2. Flow Conditions: 2.0 mL/min, 150 Bar, 40 C. Detector Wavelength: 220 nm. Injection Details: 5 L of 1 mg/mL in MeOH. Two homochiral isomers were isolated 448-2 Isomer-1 >99% ee, RT=2.89 min (84 mg, 49% yield) and 448-3 Isomer-2 >99% ee, RT=6.03 min (78 mg, 46% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.07-8.04 (m, 1H), 7.89-7.87 (m, 1H), 7.05-7.00 (m, 1H), 4.67-4.59 (m, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.91-3.83 (m, 1H), 3.52-3.41 (m, 1H), 2.64-2.58 (m, 1H), 2.52-2.49 (m, 1H), 1.89-1.82 (m, 1H), 1.50-1.44 (m, 1H). LCMS m/z=334.2 (M+H).sup.+.

Preparation of Intermediate 448-4

##STR00234##

[0879] Methyl 5-(5,6-dihydroxy-3a,4,5,6,7,7a-hexahydro-4,7-methanobenzo[d]isoxazol-3-yl)-2-methoxybenzoate 448-3 (>99% ee) was dissolved in methanol (3 mL) and to the solution was added LiOH (20 mg, 0.47 mmol) followed by the addition of water (2 mL). The reaction mixture was stirred at r.t. for 14 h, then quenched with water (25 mL). The organics were extracted with EtOAc (225 mL), dried (MgSO.sub.4) and evaporated in vacuo to yield 5-(5,6-dihydroxy-3a,4,5,6,7,7a-hexahydro-4,7-methanobenzo[d]isoxazol-3-yl)-2-methoxy benzoic acid 448-4 (63 mg, 84% yield). LCMS m/z=320.3 (M+H). .sup.1H NMR (500 MHz, CD.sub.3OD) 8.17-8.12 (m, 1H), 7.90 (dd, J=8.7, 2.3 Hz, 1H), 7.23 (d, J=8.9 Hz, 1H), 4.81-4.61 (m, 1H), 3.97 (s, 3H), 3.92 (m, 1H), 3.78-3.75 (m, 1H), 3.71-3.58 (m, 1H), 2.4 5 (s, 1H), 2.35 (s, 1H), 1.84 (br d, J=11.1 Hz, 1H), 1.36-1.15 (m, 1H).

[0880] Example 448. Intermediate 448-4 (17 mg, 0.050 mmol) was prepared using the general procedure described for example 378 to (1R,2S,3R,4R,Z)-3-amino-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl) phenyl) bicyclo[2.2.1]heptane-2-carboxamide intermediate 166-2 (15 mg, 0.050 mmol) with BOP (10 mg, 0.050 mmol) reagent, and Hunig's base (0.1 mL). Example 448 was isolated as a solid (18 mg, 58% yield) via HPLC purification. HPLC purity: 98.3%; RT=2.35 min, [method D]. LCMS m/z=670.3 (M+H).sup.+. .sup.1H NMR (500 MHz, CD.sub.3OD) 8.41-8.36 (m, 1H), 8.16 (dd, J=6.6, 2.4 Hz, 1H), 7.91 (dd, J=8.7, 2.4 Hz, 1H), 7.84-7.74 (m, 1H), 7.32-7.22 (m, 2H), 4.85-4.82 (m, 1H), 4.79-4.70 (m, 1H), 4.67-4.51 (m, 1H), 4.14 (s, 3H), 3.92 (br d, J=6.9 Hz, 1H), 3.76 (d, J=5.6 Hz, 1H), 3.65 (d, J=8.1 Hz, 1H), 3.56-3.42 (m, 1H), 3.31-3.22 (m, 2H), 3.21-3.06 (m, 2H), 2.73 (br d, J=4.3 Hz, 1H), 2.45 (s, 1H), 2.35 (s, 1H), 2.06-1.97 (m, 1H), 1.97-1.91 (m, 1H), 1.83 (br d, J=11.1 Hz, 1H), 1.62-1.48 (m, 2H), 1.38-1.21 (m, 1H), 0.77 (br d, J=4.4 Hz, 2H), 0.37 (br s, 2H).

Example 449

##STR00235##

Intermediate 449-1

##STR00236##

[0881] Methyl 5-bromo-2-methoxybenzoate (2.0 g, 8.2 mmol) and tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.65 g, 8.98 mmol) in dioxane (55 mL)/water (10 mL) was degassed 5 min, then PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2 adduct (0.666 g, 0.816 mmol) and K.sub.3PO.sub.4 (5.64 g, 24.5 mmol) were added and the reaction mixture again degassed for 5 min, then the slurry was stirred at 100 C. for 4 h in a sealed tube. The reaction mixture was diluted with EtOAc, the solid filtered, washed with excess EtOAc and the filtrate was collected and concentrated under reduced pressure. The residue was purified by silica gel chromatography to furnish tert-butyl 3-(4-methoxy-3-(methoxycarbonyl)phenyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.2 g, 6.60 mmol, 81% yield) compound as a light brown solid. MS (ES): m/z=234.2 [M+H-Boc].

Intermediate 449-2

##STR00237##

[0882] To a solution of 449-1 (2.2 g, 6.6 mmol) in MeOH (100 mL) was added PdC (1.756 g, 16.50 mmol) at rt, and the slurry was stirred under hydrogen atmosphere for 12 h. The reaction mixture was filtered through celite, the celite washed with excess methanol and THF, the filtrates were collected and concentrated under reduced pressure to yield tert-butyl 3-(4-methoxy-3-(methoxycarbonyl)phenyl) pyrrolidine-1-carboxylate (1.7 g, 5.1 mmol, 77% yield) as a light brown semisolid. MS (ES): m/z=353.2 [M+H.sub.2O].

Intermediate 449-3

##STR00238##

[0883] LiOH (1.43 g, 59.6 mmol) in water (5.0 mL) was added to a solution of 449-2 (2.0 g, 6.0 mmol) in methanol (10 mL), THF (10 mL), the resulting reaction mixture was stirred at rt for 5 h. The volatiles were evaporated and dried under high vacuum. The residue was diluted with ice water (10 mL), then acidified using 0.1M HCl. A solid formed and was filtered, washed with water and dried under vacuum to yield 5-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methoxybenzoic acid (1.5 g, 4.7 mmol, 78% yield) compound as a white solid. MS (ES): m/z=320.2 [MH].

Intermediate 449-4

##STR00239##

[0884] HATU (206 mg, 0.543 mmol) and TEA (0.38 mL, 2.7 mmol) were added to a solution of 449-2 (349 mg, 1.09 mmol) and 166-2 (200 mg, 0.543 mmol) in DMF (30 mL) at rt, the reaction mixture was stirred for 3 h. The volatiles were removed under reduced pressure and the residue was purified by silica gel chromatography to furnish tert-butyl 3-(3-(((1R,2R,3R,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl)phenyl) carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)pyrrolidine-1-carboxylate (190 mg) as an off white solid. The solid subjected to SFC purification: Column Name: Welk-01(R,R) (250*4.6) mm. 5, Co-Solvent: 20% Vial No: LA8 Co-Solvent Name: 0.2% of Ammonia in Methanol Injected Volume: 30 l FlowRate: 4 ml/min Outlet Pressure: 100 bar Temperature: 35 C., to separate the diastereomers.

[0885] After SFC purification, the fractions were collected, concentrated under reduced pressure and lyophilized to generate tert-butyl 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl) phenyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl) pyrrolidine-1-carboxylate.

[0886] Peak-1, 449-4, (55 mg, 0.082 mmol, 14% yield) Chiral SFC RT9.9 min, .sup.1H NMR (400 MHz, DMSO-d6) ppm 10.50 (s, 1H), 9.82 (d, J=7.0 Hz, 1H), 8.22 (dd, J=2.5, 6.0 Hz, 1H), 7.82 (d, J=2.5 Hz, 2H), 7.48 (t, J=10.0 Hz, 1H), 7.43 (dd, J=2.5, 8.5 Hz, 1H), 7.14 (d, J=8.5 Hz, 1H), 6.88 (s, 11H), 4.69 (d, J=10.0 Hz, 1H), 3.97 (s, 3H), 3.68 (dd, J=7.5, 10.0 Hz, 1H), 3.49-3.36 (m, 5H), 3.31-3.21 (m, 5H), 3.20-3.05 (m, 4H), 2.73-2.69 (m, 1H), 2.19 (s, 3H), 1.86 (br d, J=10.5 Hz, 3H), 1.46-1.33 (m, 20H), 0.74 (br t, J=8.3 Hz, 2H), 0.35 (br d, J=2.5 Hz, 2H); LCMS: RT=1.565 min, MS (ES): m/z=616.4 [M+H-tBu]method B; tert-butyl 3-(3-(((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-((4-fluoro-3-(trifluoromethyl) phenyl) carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl) pyrrolidine-1-carboxylate (55 mg, 0.082 mmol, 15% yield) as a white solid.

[0887] Peak-2, (60 mg, 0.089 mmol, 16% yield) Chiral SFC RT10.98 min, .sup.1H NMR (400 MHz, DMSO-d6) ppm 10.49 (s, 1H), 9.81 (d, J=7.0 Hz, 1H), 8.22 (dd, J=2.5, 6.5 Hz, 1H), 7.82 (d, J=2.5 Hz, 11H), 7.76 (br s, 1H), 7.48 (t, J=9.8 Hz, 1H), 7.42 (dd, J=2.5, 8.5 Hz, 1H), 7.13 (d, J=8.5 Hz, 1H), 4.68 (d, J=9.5 Hz, 1H), 4.44 (br s, 1H), 3.97 (s, 3H), 3.67 (dd, J=7.5, 10.0 Hz, 1H), 3.49-3.34 (m, 2H), 3.29-3.06 (m, 4H), 2.72-2.67 (m, 1H), 2.56-2.52 (m, 2H), 2.18 (s, 2H), 1.86 (br t, J=9.3 Hz, 2H), 1.76 (br s, 1H), 1.50 (br d, J=4.5 Hz, 1H), 1.45-1.33 (m, 17H), 0.74 (br t, J=9.0 Hz, 2H), 0.34 (br s, 2H); LCMS: RT=1.716 min, MS (ES): m/z=616.3 [M+H-tBu]method B.

Intermediate 449-5

##STR00240##

[0888] TFA (0.16 mL, 2.0 mmol) was added to a solution of 449-4 (55 mg, 0.082 mmol) in DCM (5.0 mL) at 0 C., then the reaction mixture was stirred at rt for 2 h. The volatiles were removed under reduced pressure and the residue dried under vacuum to yield (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(pyrrolidin-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide (35 mg) as a light brown semi solid which was taken to next step without further purification. MS (ES): m/z=572.2 [M+H].

Example 449

[0889] HATU (13 mg, 0.035 mmol), DIPEA (0.06, 0.04 mmol) were added to a 449-5 (20 mg, 0.035 mmol) and 2-hydroxy-2-methylpropanoic acid (3.6 mg, 0.035 mmol) in DMF (2.0 mL) at rt. The reaction mixture was stirred at for 15 h and purified by preparative reverse phase HPLC to furnish (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide (13 mg, 49%) as a white solid. .sup.1H NMR (400 MHz, DMSO-d6) ppm 10.48 (s, 1H), 9.83 (dd, J=3.3, 6.7 Hz, 1H), 8.25-8.17 (m, 1H), 7.85 (br s, 1H), 7.77 (td, J=3.6, 8.7 Hz, 1H), 7.48 (t, J=9.9 Hz, 1H), 7.43 (dd, J=2.2, 8.6 Hz, 1H), 7.14 (dd, J=1.8, 7.9 Hz, 1H), 5.19-5.12 (m, 1H), 4.68 (d, J=9.5 Hz, 1H), 4.48-4.40 (m, 1H), 4.27 (br d, J=0.7 Hz, 1H), 4.08 (q, J=5.5 Hz, 1H), 3.97 (s, 4H), 3.78-3.65 (m, 1H), 3.58-3.47 (m, 1H), 3.24-3.06 (m, 4H), 2.74-2.68 (m, 1H), 2.13 (br d, J=0.7 Hz, 1H), 1.93-1.72 (m, 3H), 1.53-1.36 (m, 3H), 1.32-1.26 (m, 7H), 0.80-0.65 (m, 2H), 0.35 (dd, J=1.8, 4.8 Hz, 2H). LCMS: RT=2.465 min, MS (ES): m/z=658.3 [M+H.sup.+]method B.

Example 452

##STR00241##

Intermediate 452-1

##STR00242##

[0890] 452-1 (0.13 g, 0.49 mmol, 49% yield) was prepared in a similar manner as example 416 substituting methyl 5-formyl-2-hydroxybenzoate for methyl 5-formyl-2-methoxybenzoate. .sup.1H NMR (400 MHz, CDCl.sub.3) 10.98 (s, 1H), 8.04 (d, J=2.2 Hz, 1H), 7.82 (dd, J=8.8, 2.2 Hz, 1H), 7.04 (d, J=8.8 Hz, 1H), 5.38 (dd, J=9.1, 3.9 Hz, 1H), 4.36-4.30 (m, 1H), 4.30-4.25 (m, 1H), 4.14 (dd, J=9.2, 1.3 Hz, 1H), 3.99 (s, 3H), 3.89 (dd, J=9.4, 6.7 Hz, 1H), 3.79 (dd, J=10.8, 3.7 Hz, 1H). LCMS(ESI) m/z: 264 (M+H)..sup.+

Intermediate 452-2

##STR00243##

[0891] To 452-1 (0.1 g, 0.4 mmol) in DMF (2 mL) was added 1-chloro-2-methoxyethane (72 mg, 0.80 mmol), K.sub.2CO.sub.3 (0.16 g, 1.1 mmol), KI (63 mg, 0.38 mmol) and the reaction mixture was heated at 60 C. for 24 h. The reaction mixture was partitioned with water (10 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (220 mL), the combined organic layers were washed with brine (15 mL) and dried (MgSO.sub.4), filtered and concentrated under reduced pressure. The residue was purified by normal phase silica gel chromatography to afford 452-2 (62 mg, 0.20 mmol, 51% yield) clear oil. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.99 (d, J=2.3 Hz, 1H), 7.87 (dd, J=8.8, 2.4 Hz, 1H), 7.07 (d, J=8.7 Hz, 1H), 5.39 (dd, J=9.2, 3.9 Hz, 1H), 4.37-4.32 (m, 1H), 4.32-4.28 (m, 1H), 4.28-4.24 (m, 2H), 4.16 (dd, J=9.4, 1.3 Hz, 1H), 3.93-3.92 (m, 3H), 3.91-3.87 (m, 1H), 3.84 (dd, J=5.3, 4.3 Hz, 2H), 3.80 (dd, J=10.8, 3.9 Hz, 1H), 3.50 (s, 3H). LCMS(ESI) m/z: 322 (M+H)..sup.+

Intermediate 452-3

##STR00244##

[0892] 452-3 (41 mg, 0.13 mmol, 72% yield) was prepared by hydrolysis of 452-2 as described in 378-3. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.23-8.07 (m, 2H), 7.20-7.07 (m, 1H), 5.42 (dd, J=9.2, 3.9 Hz, 1H), 5.32 (s, 1H), 4.46-4.39 (m, 2H), 4.36-4.30 (m, 2H), 4.14 (d, J=9.5 Hz, 1H), 3.93-3.88 (m, 1H), 3.85-3.82 (m, 2H), 3.78 (dd, J=10.9, 3.9 Hz, 1H), 3.49 (s, 3H).

[0893] Example 452. A mixture of isomers was prepared by BOP coupling as described in example 378 substituting cyclopropyl norbornyl intermediate 166-2 and intermediate 452-3 for intermediate 378-3 and the cyclobutyl norbornyl intermediate 369-1. The isomeric mixture was separated using chiral SFC chromatography. Preparative chromatographic conditions Instrument: Waters 100 Prep SFC Column: Chiral OD, 30250 mm, 5 micron, Mobile Phase: 25% MeOH/75% CO.sub.2 w/0.1% DEA, Flow Conditions: 100 m/min, Detector Wavelength: 220 nm; Analytical method: Instrument: Shimadzu Nexera SFC, Column Chiral OD, 4.6100 mm, 5 micron, Mobile Phase: 25% MeOH/75% CO.sub.2 w/0.1% DEA, Flow Conditions: 2 mL/min, Detector Wavelength: 220 nm, to afford chiral peak-1, example 452 (9.3 mg, 14 mol, 23% yield), RT=2.92 min., >95% de and peak-2 (9.3 mg, 14 mol, 23% yield), RT=3.6 min, >95% de. For example 452: .sup.1H NMR (500 MHz, DMSO-d6) 10.49 (s, 1H), 9.60 (br d, J=7.9 Hz, 1H), 8.37-8.10 (m, 2H), 7.86-7.68 (m, 2H), 7.47 (t, J=9.9 Hz, 1H), 7.32 (d, J=8.9 Hz, 1H), 5.35 (dd, J=9.2, 3.7 Hz, 1H), 4.71 (d, J=9.5 Hz, 1H), 4.61-4.47 (m, 2H), 4.43 (br d, J=4.0 Hz, 2H), 4.11 (d, J=10.7 Hz, 1H), 4.07-3.98 (m, 1H), 3.95-3.86 (m, 1H), 3.83-3.74 (m, 1H), 3.66 (dd, J=10.7, 3.4 Hz, 1H), 3.28 (s, 1H), 3.21-3.13 (m, 1H), 3.09-2.99 (m, 1H), 2.74 (br s, 1H), 2.52 (br s, 3H), 2.03-1.84 (m, 2H), 1.63-1.51 (m, 1H), 1.48-1.31 (m, 1H), 0.89-0.67 (m, 2H), 0.46-0.27 (m, 2H). LCMS(ESI) m/z: 658.15 (M+H)..sup.+ HPLC purity 100% with retention time 2.42 min. [method C]

Example 461

##STR00245##

Preparation of Diasteromeric Intermediate 461-1

##STR00246##

[0894] Diasteromeric intermediate 461-1 (200 mg, 80%) was prepared in a similar manner as described for example 378 by the cycloaddition of dimethyl cyclobut-1-ene-1,2-dicarboxylate with Methyl (Z)-5-(chloro(hydroxyimino)methyl)-2-methoxybenzoate. LCMS m/z=378.2 (M+H). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.12 (d, J=2.4 Hz, 1H), 7.75 (dd, J=8.9, 2.4 Hz, 1H), 7.00 (d, J=8.9 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.87 (s, 3H), 3.68 (s, 3H), 3.21-3.09 (m, 1H), 2.79-2.67 (m, 1H), 2.62-2.52 (m, 2H).

Preparation of Homochiral Intermediates 461-3 and 461-4

##STR00247##

[0895] Diasteromeric intermediate 461-1 (112 mg, 0.29 mmol) was dissolved in THF (10 mL) and to this was added DIBAH (1M, 2.08 mL, 2.08 mmol) solution. The reaction mixture was stirred at rt for 14 h and was subsequently quenched with dil HCl (5 mL) followed by extraction of the organic material with EtOAc (225 mL). The combined organic layers were dried (MgSO.sub.4), filtered and concentrated under reduced pressure to afford the diasteromers (4-(3-(hydroxymethyl)-4-methoxyphenyl)-2-oxa-3-azabicyclo[3.2.0]hept-3-ene-1,5-diyl)dimethanol 461-2 as an oil (100 mg, 100% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.49 (m, 2H), 6.92-6.86 (m, 1H), 4.73-4.60 (m, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 3.74-3.65 (m, 1H), 3.05-2.82 (m, 1H), 2.54-2.32 (m, 2H), 2.19-1.97 (m, 2H), 1.95-1.37 (m, 1H), 1.33-0.84 (m, 1H). LCMS m/z=294.2 (M+H).sup.+. Intermediate 461-2 was chirally separated via chiral SFC conditions to afford homochiral intermediates 461-3 (Peak-1) and 461-4 (Peak-2). Preparative Chromatographic Conditions: Instrument: Berger MG II Column: Chiralpak IC, 21250 mm, 5 micron Mobile Phase: 30% Methanol/70% CO.sub.2 Flow Conditions: 45 mL/min, 150 Bar, 40 C. Detector Wavelength: 220 nm Injection Details: 0.5 mL of 55 mg/mL in Methanol. Analytical Chromatographic Conditions: Instrument: Shimadzu Nexera SFC Column: Chiralpak IC, 4.6100 mm, 3 micron Mobile Phase: 30% Methanol/70% CO.sub.2 Flow Conditions: 2.0 mL/min, 150 Bar, 40 C. Detector Wavelength: 220 nm Injection Details: 5 L of 1 mg/mL in Methanol. Analytical data for 461-3 Homochiral Peak-1 (57 mg, 15% yield >99% ee, RT=2.98 min); .sup.1H NMR (500 MHz, CDCl.sub.3) 7.64 (s, 1H), 7.60 (d, J=8.4 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 4.69 (br s, 2H), 4.05 (m, 2H), 3.91 (s, 3H), 3.81 (br s, 1H), 3.50 (s, 1H), 3.33 (br s, 1H), 2.56 (br s, 1H), 2.50-2.39 (m, 2H), 2.20-1.99 (m, 2H), 1.70 (br s, 1). Analytical data for 461-4 Homochiral Peak-2 (60 mg 60% yield, >99% ee, RT=5.72 min). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.64 (s, 1H), 7.60 (d, J=8.4 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 4.69 (d, J=6.3 Hz, 2H), 4.08 (m, 2H), 3.91 (s, 3H), 3.84-3.76 (m, 1H), 3.50 (d, J=4.7 Hz, 2H), 3.33 (br s, 1H), 2.56 (br t, J=6.5 Hz, 1H), 2.50-2.39 (m, 2H), 2.20-1.99 (m, 2H), 1.70 (s, 1H).

Preparation of Homochiral Isomer-1 Intermediate 461-4

##STR00248##

[0896] Homochiral isomer-1 intermediate 461-2 (4-(3-(hydroxymethyl)-4-methoxyphenyl)-2-oxa-3-azabicyclo[3.2.0]hept-3-ene-1,5-diyl)dimethanol (57 mg, 0.19 mmol) was dissolved in dry DCM (10 mL) and to the solution was added activated MnO.sub.2 (847 mg, 9.72 mmol). The reaction mixture was stirred at rt for 14 h. The reaction mixture was filtered and concentrated to an oil in vacuo. The oil was re-dissolved in t-BuOH (5 mL) and to the solution was added NaClO.sub.2 (37 mg, 0.41 mmol) followed by an aq. solution of NaH.sub.2PO.sub.4 (5 mL) to pH 3 and 2-methylbutene (10 mmol) was added. The reaction mixture was stirred at rt for 6 h then quenched with water (100 mL) and extracted with EtOAc (225 mL). The combined organic portion was dried (MgSO.sub.4), filtered and evaporated in vacuo to yield isomer-1 intermediate 461-4 as an oil (50 mg, 55% yield). .sup.1H NMR (500 MHz, CD.sub.3OD) 8.15 (d, J=2.3 Hz, 1H), 7.88 (dd, J=8.8, 2.4 Hz, 1H), 7.17 (d, J=8.9 Hz, 1H), 4.79-4.58 (m, 4H), 3.97 (s, 3H), 3.95-3.88 (m, 2H), 3.51-3.34 (m, 2H), 2.63-1.96 (m, 2H). LCMS m/z=308.2 (M+H).sup.+.

[0897] Example 461. Homochiral isomer-1 intermediate 461-4 (4.3 mg, 0.02 mmol) was coupled to intermediate 166-2 (5.2 mg, 0.02 mmol) with BOP (6 mg, 0.02 mmol) reagent, and Hunig's base (0.1 mL) as described for example 378. Example 461 was isolated as a solid after purification by reverse phase HPLC (4.3 mg, 45% yield). HPLC purity: 100%; RT=2.43 min [method D]. LCMS m/z=658.33 (M+H).sup.m. .sup.1H NMR (500 MHz, DMSO-d6) 10.55 (s, 1H), 9.93 (br d, J=7.0 Hz, 1H), 8.30-8.21 (m, 2H), 7.85-7.75 (m, 2H), 7.50 (br t, J=9.8 Hz, 1H), 7.27 (br d, J=8.9 Hz, 1H), 5.38 (br t, J=5.3 Hz, 1H), 4.85-4.67 (m, 2H), 4.45 (br s, 1H), 4.06 (s, 3H), 3.92-3.78 (m, 3H), 3.71 (br dd, J=11.9, 7.0 Hz, 1H), 3.38 (br s, 1H), 3.17 (br d, J=7.3 Hz, 1H), 3.12 (br s, 1H), 2.74 (br s, 1H), 2.33-2.19 (m, 1H), 2.15 (br s, 3H), 2.09 (s, 1H), 1.93 (s, 1H), 1.89-1.68 (m, 2H), 1.52 (br d, J=8.5 Hz, 1H), 1.42 (br s, 2H), 0.87-0.67 (m, 2H), 0.36 (br s, 2H)

Example 467

##STR00249##

[0898] Compound 467 was prepared by reduction of 166-2 (6 mg, 0.02 mmol) with catalytic Pd/C (10%) followed by coupling of the resulting (1S,2S,3R,4R)-3-amino-7-butyl-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide with with 429-8 (4.72 mg, 0.0200 mmol) and BOP (7.16 g, 0.0200 mmol) and Hunig's base (0.1 mL) in DMF as described for Example 378. The residue was purified via HPLC purification to generate 467 as a solid (0.7 mg, 7% yield). HPLC purity: 100%; RT=2.72 min [method C]. LCMS m/z=645.94 (M+H)+. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.64 (s, 1H), 8.37 (br d, J=7.3 Hz, 1H), 8.13 (br d, J=4.0 Hz, 1H), 7.94 (d, J=2.4 Hz, 1H), 7.87 (br s, 1H), 7.77 (br d, J=8.9 Hz, 1H), 7.50 (br t, J=9.6 Hz, 1H), 7.25 (d, J=8.9 Hz, 1H), 5.23-5.05 (m, 1H), 4.84 (br s, 1H), 4.23 (br t, J=9.2 Hz, 1H), 3.93 (s, 3H), 3.35 (br s, 1H), 2.77-2.54 (m, 2H), 2.43-2.27 (m, 2H), 2.17-1.95 (m, 2H), 1.95-1.86 (m, 1H), 1.80 (br d, J=12.8 Hz, 1H), 1.74-1.63 (m, 3H), 1.58 (br d, J=8.2 Hz, 1H), 1.54-1.44 (m, 2H), 1.36 (br d, J=6.7 Hz, 2H), 1.30-1.13 (m, 4H), 0.94-0.72 (m, 3H)

Example 453

##STR00250##

Intermediate 453-1

##STR00251##

[0899] To a solution of (1R,2S,3R,4R,Z)-3-amino-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide IV-2a (33 mg, 0.090 mmol) in DCM (0.9 mL) was added Boc.sub.2O (0.10 mL, 0.45 mmol), Hunig's base (78 l, 0.45 mmol) and DMAP (5.5 mg, 0.045 mmol). The reaction mixture was stirred for 14 h, then concentrated under reduced pressure and purified via silica gel chromatography to furnish tert-butyl ((1R,2S,3R,4R,Z)-3-((tert-butoxycarbonyl)amino)-7-(cyclopropylmethylene)bicyclo[2.2.1]heptane-2-carbonyl)(4-fluoro-3-(trifluoromethyl)phenyl)carbamate Intermediate 453-1 (43 mg, 0.076 mmol, 84% yield) was obtained. LC-MS RT: 1.37 min; MS (ESI) m/z 591 (M+Na).sup.+; Method A.

Intermediate 453-2

##STR00252##

[0900] To a solution of tert-butyl ((1R,2S,3R,4R,Z)-3-((tert-butoxycarbonyl)amino)-7-(cyclopropylmethylene)bicyclo[2.2.1]heptane-2-carbonyl)(4-fluoro-3-(trifluoromethyl)phenyl)carbamate Intermediate 453-1 (43 mg, 0.076 mmol) was added 2,2-dimethylpropan-1-amine (26.4 mg, 0.302 mmol). The reaction mixture was stirred for two days, then concentrated in vacuo and purified via silica gel chromatography to give tert-butyl ((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-(neopentylcarbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamate Intermediate 453-2 (20 mg, 0.053 mmol, 70% yield). LC-MS RT: 1.19 min; MS (ESI) m/z 377 (M+H).sup.+; Method A.

Intermediate 453-3

##STR00253##

[0901] tert-butyl ((1R,2R,3S,4R,Z)-7-(cyclopropylmethylene)-3-(neopentylcarbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamate (20 mg, 0.053 mmol) 453-2 was dissolved in THF (0.4 mL). HCl (4M in dioxane) (0.13 mL, 0.53 mmol) was added. After 1 hour, an additional 0.3 mL 4M HCl in dioxane was added. After 2 hours, the reaction mixture was concentrated in vacuo, then azeotroped with DCM/hexanes to give (1R,2S,3R,4R,Z)-3-amino-7-(cyclopropylmethylene)-N-neopentylbicyclo[2.2.1]heptane-2-carboxamide, HCl Intermediate 453-3 (20 mg, 0.064 mmol, 120% yield). LC-MS RT: 0.80 min; MS (ESI) m/z 277 (M+H).sup.+; Method A.

[0902] Example 453: To a solution of 429-8 (7.87 mg, 0.0270 mmol) and Intermediate 453-3 (8.45 mg, 0.0270 mmol) in DMF (0.4 mL) was added BOP (13 mg, 0.030 mmol) and Hunig's base (0.024 mL, 0.14 mmol). After 4 hours, the reaction mixture was diluted with MeOH, filtered through a syringe filter, and purified via preparative reverse phase HPLC to give Example 453 (7.4, 49%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.96 (d, J=6.8 Hz, 1H), 8.16 (d, J=2.3 Hz, 1H), 7.96 (br t, J=6.2 Hz, 1H), 7.77 (dd, J=8.7, 2.3 Hz, 1H), 7.22 (d, J=8.7 Hz, 1H), 5.11 (dd, J=8.7, 5.2 Hz, 1H), 4.62 (d, J=9.5 Hz, 1H), 4.53-4.48 (m, 1H), 4.34-4.25 (m, 1H), 4.19 (br t, J=8.6 Hz, 1H), 3.99 (s, 3H), 3.06-2.97 (m, 3H), 2.79 (dd, J=13.0, 5.7 Hz, 1H), 2.02-1.40 (m, 10H), 1.39-1.25 (m, 2H), 0.81 (s, 9H), 0.74-0.64 (m, 2H), 0.36-0.25 (m, 2H). LC-MS RT: 2.23 min; MS (ESI) m/z 550.1 (M+H).sup.+; Method B.

Example 475

##STR00254##

[0903] Intermediate 475-1: Preparation of methyl 2-(dimethylamino)-5-formylbenzoate: To a solution of methyl 2-fluoro-5-methylbenzoate (3.00 g, 17.8 mmol) in CCl.sub.4 (100 mL) was added N-bromosuccinimide (6.99 g, 39.2 mmol) and benzoyl peroxide (0.475 g, 1.96 mmol). The reaction mixture was heated at reflux for 14 h. The reaction mixture was allowed to cool to room temperature and the succinimide was removed by filtration. The filtrate was concentrated under reduced pressure to give an yellow liquid that was added to dimethylamine (40% aqueous) (90 mL, 711 mmol) and the contents were slowly heated to 56 C. for 15 mins, and the heat was then removed. The dark orange solution was poured in to DCM (275 mL) and the layers were separated. The organic layer was concentrated and purified using silica gel chromatography to yield intermediate 465-1 (2.2 g, 56% yield). MS (ESI) m/z: 208.2 (M+H).

Intermediate 475-2: Preparation of methyl (E)-3-chloro-2-(dimethylamino)-5-(hydroxyimino)methyl) benzoate

[0904] To a solution of intermediate 475-1 (2200 mg, 10.62 mmol) in DCM (25 mL) was added TEA (1.48 mL, 10.6 mmol). To this solution was then added hydroxylamine hydrochloride (885 mg, 12.7 mmol) and the reaction mixture was stirred at rt overnight. The reaction mixture was then concentrated to a solid and dissolved in EtOAc and washed with water. The organic layer was then dried over MgSO.sub.4 and concentrated under vacuum to yield intermediate 475-2 (2.1 g, 73% yield). MS (ESI) m/z: 257.1 (M+H).

[0905] Intermediate 475-3: Preparation of methyl (Z)-3-chloro-5-(chloro(hydroxyimino)methyl)-2-(dimethylamino)benzoate: To intermediate 475-2 (770 mg, 3.00 mmol) in DMF (15 mL) was added N-chlorosuccinimide (441 mg, 3.30 mmol). After quenching the reaction mixture with water an off-white solid was collected by filtration which was dried in vacuo to afford intermediate 475-3 (480 mg, 52% yield). MS (ESI) m/z: 291.0 (M+H).

[0906] 475-4: Preparation of methyl 3-chloro-2-(dimethylamino)-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzoate: To intermediate 475-3 (1.13 g, 3.88 mmol) and 2,5-dihydrofuran (2.72 g, 38.8 mmol) in DCM (12 mL) was added TEA (1.62 mL, 11.6 mmol). The reaction mixture was stirred at rt for 14 h, concentrated under vacuum and the residue purified using silica gel chromatography to yield intermediate 475-4 (440 mg, 35% yield). MS (ESI) m/z: 325.2 (M+H).

475-5: Preparation of 3-chloro-2-(dimethylamino)-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzoic acid

[0907] To a solution of intermediate 475-4 (100 mg, 0.308 mmol) in THF (3 mL) and water (1.000 mL) was added LiOH (0.462 mL, 0.924 mmol) and the reaction mixture stirred at rt for 2 h. The reaction mixture was concentrated under vacuum and used without further manipulation in the next step. MS (ESI) m/z: 311.1 (M+H).

[0908] Example 475: (1R,2S,3R,4R,Z)-3-(3-chloro-2-(dimethylamino)-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzamido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-(2,2,2-trifluoroethylidene)bicyclo [2.2.1]heptane-2-carboxamide 475 was prepared using the general procedures described for 378 by using cyclopropyl norbornyl intermediate 166-2 (75 mg, 0.15 mmol) and intermediate 475-5 to yield Example 475 (first eluting stereoisomer via reverse phase HPLC, 55 mg, 17% yield). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.45 (br d, J=5.2 Hz, 1H), 9.88 (br d, J=7.3 Hz, 1H), 8.12 (br d, J=4.6 Hz, 1H), 7.87 (s, 1H), 7.85-7.80 (m, 1H), 7.77 (br d, J=4.3 Hz, 2H), 7.45 (br t, J=9.8 Hz, 1H), 5.42-5.29 (m, 1H), 4.67 (br d, J=9.5 Hz, 1H), 4.55-4.37 (m, 2H), 4.09 (br dd, J=10.8, 5.0 Hz, 1H), 3.91 (br d, J=9.8 Hz, 1H), 3.70-3.57 (m, 2H), 3.15 (br d, J=11.0 Hz, 1H), 3.07 (br s, 1H), 2.82 (s, 6H), 2.72 (br s, 1H), 1.92 (br d, J=7.3 Hz, 2H), 1.60-1.47 (m, 1H), 1.42 (br d, J=18.3 Hz, 2H), 0.82-0.65 (m, 2H), 0.34 (br s, 2H). MS (ESI) m/z=661.0 (M+H). HPLC Purity: 99%; Retention Time: 2.96 min; Method B.

Example 489 & 530

##STR00255##

Intermediate 489-1

##STR00256##

[0909] Dess-Martin periodinane (417 mg, 0.983 mmol) was added to a solution of methyl 5-(5-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoate 429-8 (2.75 grams, 9.01 mmol) in DCM (90 mL). After 3 h, the reaction solution was transferred to a separatory funnel and washed successively with NH.sub.4Cl solution and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give methyl 5-(5-formyl-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)-2-methoxybenzoate 489-1 (1.46 grams, 53%) as a white solid. LC-MS RT=0.97 min; (M+H)=304.1; Method A.

Intermediate 489-2

##STR00257##

[0910] To a solution of 489-1 (100 mg, 0.330 mmol) in THF (3.3 mL) was added trimethyl(trifluoromethyl)silane (188 mg, 1.32 mmol) under a nitrogen atmosphere. The solution was cooled to 0 C. and TBAF (0.40 mL, 0.40 mmol) was added. After 10 min, the reaction mixture was allowed to come to rt and stirred for 14 h. The reaction was quenched with MeOH, concentrated under reduced pressure onto Celite, and purified by silica gel chromatography to give methyl 2-methoxy-5-(5-(2,2,2-trifluoro-1-hydroxyethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzoate 489-2 (82.2 mg, 66.8%). .sup.1H NMR (500 MHz, CDCl.sub.3) 8.05-8.01 (m, 1H), 7.84 (ddd, J=8.8, 4.7, 2.3 Hz, 1H), 7.04-6.98 (m, 1H), 5.24-5.17 (m, 1H), 4.08 (t, J=8.8 Hz, 1H), 3.94 (d. J=2.4 Hz, 3H), 3.89 (d, J=1.8 Hz, 3H), 2.38-2.23 (m, 2H), 2.10-1.96 (m, 2H), 1.89-1.81 (m, 1H). LC-MS RT=0.834 min; (M+H)=374; Method C.

Intermediate 489-3

##STR00258##

[0911] A solution of LiOH monohydrate (27.0 mg, 0.643 mmol) in H.sub.2O (0.5 mL) was added to 489-2 (80 mg, 0.214 mmol) in THF (2.1 mL)/MeOH (2.1 mL). After 3 h, the reaction mixture was concentrated under reduced pressure. The residue was suspended in water, acidified with 1.0M HCl solution, extracted with EtOAc, the extract washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Intermediate 489-3 (71.7 mg, 93%) was carried forward to the next reaction without further manipulation. LC-MS RT=0.759 min; (M+H)=360.0; Method C.

[0912] Example 489 was prepared by the coupling intermediate 489-3 (3.95 mg, 0.014 mmol) with intermediate 166-2 (5 mg, 0.014 mmol) dissolved in anhydrous DMF (2 mL) with DIEA (0.012 mL, 0.068 mmol) and BOP (6.60 mg, 0.015 mmol). After 3 h, the reaction mixture was filtered and purified by reverse phase preparative HPLC to give (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2-methoxy-5-(5-(2,2,2-trifluoro-1-hydroxyethyl)-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazol-3-yl)benzamido)bicyclo[2.2.1]heptane-2-carboxamide

[0913] Example 489 (52 mg, 35%) as the first eluting peak (RT=10.87 min). .sup.1H NMR: (500 MHz, DMSO-d.sub.6) 10.53-10.49 (m, 1H), 9.93-9.89 (m, 1H), 8.25-8.20 (m, 2H), 7.83-7.76 (m, 2H), 7.48 (t, J=9.8 Hz, 1H), 7.27 (d, J=8.9 Hz, 1H), 5.16-5.09 (m, 1H), 4.69 (d, J=9.5 Hz, 1H), 4.47-4.40 (m, 1H), 4.28-4.21 (m, 1H), 4.04 (s, 3H), 3.99-3.92 (m, 1H), 3.15 (dd, J=10.7, 4.1 Hz, 1H), 3.10 (br s, 1H), 2.74-2.68 (m, 1H), 2.06-1.96 (m, 2H), 1.94-1.87 (m, 1H), 1.86-1.72 (m, 4H), 1.54-1.35 (m, 3H), 0.78-0.69 (m, 2H), 0.38-0.31 (m, 2H). LC-MS RT=2.379 min; (M+H)=710.4; Method C.

[0914] Example 530 (25 mg, 17%) was isolated as the second eluting peak (11.52 min) from reverse phase preparative HPLC of Example 489. .sup.1H NMR: (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.92 (d, J=7.0 Hz, 1H), 8.27-8.21 (m, 2H), 7.84-7.77 (m, 2H), 7.49 (t, J=9.8 Hz, 1H), 7.28 (d, J=8.9 Hz, 1H), 5.15 (dd, J=8.9, 5.0 Hz, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.45 (ddd, J=10.3, 6.4, 4.2 Hz, 1H), 4.25 (t, J=8.9 Hz, 1H), 4.05 (s, 3H), 3.99-3.92 (m, 1H), 3.17 (dd, J=10.8, 4.2 Hz, 1H), 3.11 (t, J=3.5 Hz, 1H), 2.73 (t, J=4.1 Hz, 1H), 2.04-1.89 (m, 3H), 1.86-1.76 (m, 4H), 1.54-1.47 (m, 1), 1.45-1.38 (m, 2H), 0.79-0.70 (m, 2H), 0.39-0.33 (m, 2H). LC-MS RT=2.382 min; (M+H)=710.4; Method C.

Example 511

##STR00259##

Intermediate 511-1

##STR00260##

[0915] 7-(4-methoxy-3-(methoxycarbonyl)phenyl)-5-oxa-6-azaspiro[3.4]oct-6-ene-2-carboxylic acid, 511-1 was prepared as described for intermediate 378-2 substituting 3-methylenecyclobutane-1-carboxylic acid for allyl alcohol to afford (1 g, 3 mmol, 200% yield) as a tan solid which was carried onto the next step without purification. LCMS(ESI) m/z: 320 (M+H)..sup.+

Intermediate 511-2

##STR00261##

[0916] To intermediate 511-1 (0.6 g, 2 mmol) in THF (15 mL) was added BH.sub.3.Math.Me.sub.2S (1.4 mL, 2.9 mmol). After 24 h, an additional equivalent of BH.sub.3.Math.Me.sub.2S was added and after a further 6 h, the reaction mixture was quenched with ice and 1N HCl (10 mL) and the aqueous solution extracted with ethyl acetate (330 mL). The combined organic layers were washed with brine (15 mL) and dried (MgSO.sub.4), filtered and concentrated under reduced pressure. The residue was purified by normal phase silica gel chromatography eluting with hexanes/EtOAc to afford intermediate 511-2 (170 mg, 0.56 mmol, 27% yield) as a white solid. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.05-7.93 (m, 1H), 7.90-7.82 (m, 1H), 7.06-6.97 (m, 1H), 3.97-3.93 (m, 3H), 3.90 (s, 3H), 3.70 (d, J=6.4 Hz, 2H), 2.73-2.65 (m, 2H), 2.62-2.54 (m, 1H), 2.52-2.44 (m, 1H), 2.40-2.31 (m, 1H), 2.22-2.14 (m, 2H), 1.87 (t, J=7.2 Hz, 1H). LCMS(ESI) m/z: 306.1 (M+H)..sup.+

Intermediate 511-3

##STR00262##

[0917] Preparation of 5-(2-(hydroxymethyl)-5-oxa-6-azaspiro[3.4]oct-6-en-7-yl)-2-methoxy benzoic acid. Intermediate 511-3 (135 mg, 0.460 mmol, 83.0% yield) was prepared by hydrolysis of 511-2 as described in 378-3. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.22 (dd, J=5.2, 2.3 Hz, 1H), 8.18-8.12 (m, 1H), 7.14 (dd, J=8.8, 3.6 Hz, 1H), 4.15 (d, J=1.8 Hz, 3H), 3.73 (d, J=6.3 Hz, 2H), 3.48 (s, 1H), 3.42 (s, 1H), 2.55-2.42 (m, 1H), 2.43-2.33 (m, 3H), 2.27-2.15 (m, 3H). LCMS(ESI) m/z: 291.2 (M+H)..sup.+

[0918] Example 511 (7.0 mg, 11 mol, 40% yield) was prepared by the procedure described for example 452, substituting intermediate 511-3 for intermediate 452-3. .sup.1H NMR (500 MHz, DMSO-d6) 10.54 (s, 1H), 9.91 (br d, J=7.0 Hz, 1H), 8.36-8.15 (m, 2H), 7.86-7.73 (m, 2H), 7.50 (t, J=9.8 Hz, 1H), 7.35-7.23 (m, 1H), 4.71 (d, J=9.5 Hz, 1H), 4.53-4.36 (m, 1H), 4.05 (s, 3H), 3.52 (s, 1H), 3.49-3.42 (m, 1H), 3.18 (br dd, J=10.7, 3.4 Hz, 1H), 3.12 (br s, 1H), 2.74 (br s, 1H), 2.49-2.40 (m, 1H), 2.38-2.31 (m, 1H), 2.30-2.21 (m, 1H), 2.15-2.09 (m, 2H), 2.08 (br s, 1H), 1.94-1.83 (m, 1H), 1.83-1.73 (m, 1H), 1.62-1.48 (m, 1H), 1.47-1.33 (m, 2H), 0.85-0.65 (m, 2H), 0.37 (br s, 2H). LCMS(ESI) m/z: 642.91 (M+H)..sup.+ HPLC purity 100% with retention time 2.42 min. [method B]

Example 536

##STR00263##

Intermediate 536-1

##STR00264##

[0919] To a solution of dianhydro-D-glucitol (3.0 g, 21 mmol) dissolved in DCM (80 mL) was added imidazole (2.8 g, 41 mmol) and cooled to 0 C. To this mixture was added TBSCl (3.9 g, 26 mmol) and the reaction mixture was allowed to warm to rt for 14 h. The reaction mixture was washed with water and the organic portion was concentrated under reduced pressure, then purified by silica gel chromatography utilizing in-line light scattering detection to afford Intermediate 536-1, Isolate 02, (3R,3aR,6S,6aS)-6-((tert-butyldimethylsilyl)oxy)hexahydrofuro[3,2-b]furan-3-ol (1.8 g, 7.0 mmol, 34% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.70-4.58 (m, 1H), 4.39-4.23 (m, 3H), 3.97-3.82 (m, 3H), 3.55 (dd, J=9.4, 6.1 Hz, 1H), 2.69 (d, J=7.7 Hz, 1H), 0.97-0.84 (m, 9H), 0.13 (d, J=2.0 Hz, 6H)

[0920] Peak 3, (3S,3aR,6R,6aS)-6-((tert-butyldimethylsilyl)oxy)hexahydrofuro[3,2-b]furan-3-ol (0.92 g, 3.5 mmol, 17% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.56 (t, J=4.7 Hz, 1H), 4.41 (d, J=4.4 Hz, 1H), 4.37-4.29 (m, 2H), 4.04-3.96 (m, 1H), 3.95-3.88 (m, 1H), 3.80 (dd, J=8.6, 5.9 Hz, 1H), 3.57 (dd, J=8.8, 6.8 Hz, 1H), 1.83 (d, J=5.3 Hz, 1H), 0.99-0.87 (m, 9H), 0.15 (d, J=5.7 Hz, 6H).

Intermediate 536-2

##STR00265##

[0921] To a solution of 536-1 (1.9 g, 7.1 mmol) dissolved in DCM (24 mL) was added Dess-Martin periodinane (6.1 g, 14 mmol) and the reaction mixture was stirred for 14 h. The reaction mixture was partitioned between DCM and pH 7.4 aqueous buffer, and extracted with DCM. The combined organic portions were concentrated under reduced pressure, then purified by silica gel chromatography utilizing in-line light scattering detection detection to afford (3aS,6S,6aS)-6-((tert-butyldimethylsilyl)oxy)tetrahydrofuro[3,2-b]furan-3(2H)-one (1.4 g, 5.4 mmol, 75% yield). .sup.1H NMR (500 MHz, CDCL.sub.3) 4.63 (d, J=4.0 Hz, 1H), 4.46 (d, J=3.2 Hz, 1H), 4.31 (d, J=4.0 Hz, 1H), 4.12 (d, J=17.4 Hz, 1H), 4.02 (dd, J=9.5, 3.4 Hz, 1H), 3.95-3.89 (m, 2H), 0.94-0.88 (m, 9H), 0.12 (d, J=4.4 Hz, 6H).

Intermediate 536-3

##STR00266##

[0922] A solution of 536-2 (1.4 g, 5.4 mmol) dissolved in THF (5.4 mL) was cooled to 0 C., (4-methoxyphenyl)magnesium bromide (11 mL, 5.4 mmol) was added and the reaction mixture was stirred for 48 h. The reaction mixture was partitioned with sat NH.sub.4Cl and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure, then purified via silica gel chromatography to afford (3R,3aS,6S,6aS)-6-((tert-butyldimethylsilyl)oxy)-3-(4-methoxyphenyl)hexahydrofuro[3,2-b]furan-3-ol (1.5 g, 4.1 mmol, 76% yield): .sup.1H NMR (500 MHz, CDCl.sub.3) 7.49 (d. J=8.9 Hz, 2H), 6.93 (d, J=8.9 Hz, 2H), 4.45-4.38 (m, 3H), 4.12 (d. J=9.3 Hz, 1H), 4.05-4.00 (m, 1H), 3.98-3.93 (m, 1H), 3.83 (s, 3H), 3.79 (d, J=9.3 Hz, 1H), 3.48 (s, 1H), 0.91-0.85 (m, 9H), 0.11 (d, J=3.1 Hz, 6H).

Intermediate 536-4

##STR00267##

[0923] To 536-3 (0.50 g, 1.4 mmol) was added TBAF 1M in THF (1.4 mL, 1.4 mmol) and the reaction mixture was stirred for 14 h. The reaction mixture was diluted with EtOAc, and washed successively with water, and brine. The organic portion was dried over Na.sub.2SO.sub.4 filtered and concentrated under reduced pressure, then purified by silica gel chromatography to afford (3R,3aS,6S,6aR)-3-(4-methoxyphenyl)hexahydrofuro[3,2-b]furan-3,6-diol (0.23 g, 0.92 mmol, 67% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.53-7.43 (m, 2H), 6.99-6.89 (m, 2H), 4.55 (d, J=4.1 Hz, 1H), 4.52-4.45 (m, 2H), 4.14-4.01 (m, 3H), 3.88-3.78 (m, 4H), 3.40 (s, 1H).

Intermediate 536-5

##STR00268##

[0924] To a solution of 536-4 (0.080 g, 0.32 mmol) dissolved in DCM (1 mL) was added triethylsilane (0.15 mL, 0.95 mmol) and TFA (1 mL), and the reaction mixture was stirred for 14 h. The reaction mixture was concentrated under reduced pressure, then purified by silica gel chromatography to afford (3S,3aR,6R,6aR)-6-(4-methoxyphenyl)hexahydrofuro[3,2-b]furan-3-ol (0.050 g, 0.21 mmol, 67% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.25 (d, J=8.4 Hz, 2H), 6.90 (d, J=8.7 Hz, 2H), 4.84 (t, J=3.8 Hz, 1H), 4.60 (d, J=3.7 Hz, 1H), 4.43-4.38 (m, 1H), 4.23 (t, J=8.1 Hz, 1H), 4.02 (dd, J=10.1, 3.8 Hz, 1H), 3.91-3.83 (m, 2H), 3.82 (s, 3H), 3.41 (ddd, J=11.6, 7.8, 4.0 Hz, 1H)

Intermediate 536-6

##STR00269##

[0925] To a solution of 536-5 (0.050 g, 0.21 mmol) dissolved in acetone (2.1 mL) was added NBS (0.040 g, 0.22 mmol) followed by 1 drop of TN HCl and stirred for 14 h. The reaction mixture was diluted with EtOAc and washed with 1M pH 7.4 phosphate buffer. The organic portion was concentrated under reduced pressure, then purified by silica gel chromatography to afford (3S,3aR,6R,6aR)-6-(3-bromo-4-methoxyphenyl)hexahydrofuro[3,2-b]furan-3-ol (quantitative) which was used in the next step without further manipulation.

[0926] To a slurry of (3S,3aR,6R,6aR)-6-(3-bromo-4-methoxyphenyl)hexahydrofuro[3,2-b]furan-3-ol (0.090 g, 0.21 mmol) dissolved in DMF (2.6 mL) was added Pd(OAc).sub.2 (0.019 g, 0.085 mmol), 1,3-bis(diphenylphosphino)propane (0.035 g, 0.085 mmol), TEA (0.12 mL, 0.85 mmol), and water (0.29 mL). The reaction mixture was blanketed under CO (100 psi) and heated to 100 C. for 14 h. The reaction mixture was diluted with EtOAc, partitioned with 1 N HCl, and extracted with EtOAc. The combined organic portions were concentrated under reduced pressure, then used without further manipulation in the next step as 5-((3R,3aR,6S,6aR)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yl)-2-methoxy benzoic acid (0.046 g, 0.16 mmol, 785 yield, two steps).

Example 536

[0927] To a solution of 166-2 (0.060 g, 0.16 mmol) dissolved in ACN (3.3 mL) was added 536-6 (0.046 g, 0.16 mmol), DIEA (0.085 mL, 0.49 mmol) and HATU (0.062 g, 0.16 mmol) and the reaction mixture stirred for 30 min. The reaction mixture was diluted with methanol and purified by preparative reverse phase HPLC to afford (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-((3R,3aR,6S,6aR)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yl)-2-methoxybenzamido)bicyclo[2.2.1]heptane-2-carboxamide (13 mg, 0.021 mmol, 13% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.53 (s, 1H), 9.84 (br d, J=7.0 Hz, 1H), 8.24 (br d, J=4.9 Hz, 1H), 7.88 (s, 1H), 7.83-7.71 (m, 1H), 7.50 (br t. J=9.5 Hz, 1H), 7.43 (br d, J=8.2 Hz, 1H), 7.12 (d, J=8.5 Hz, 1H), 5.26 (d, J=3.4 Hz, 1H), 4.76-4.61 (m, 2H), 4.52-4.39 (m, 2H), 4.17-4.06 (m, 2H), 3.99 (s, 3H), 3.81 (br dd, J=9.2, 3.1 Hz, 1H), 3.73-3.60 (m, 2H), 3.17 (br dd, J=10.8, 4.1 Hz, 1H), 3.10 (br s, 1H), 2.73 (br s, 1H), 1.91-1.84 (m, 1H), 1.83-1.71 (m, 1H), 1.51 (br dd, J=8.2, 4.6 Hz, 1H), 1.47-1.31 (m, 2H), 0.82-0.67 (m, 2H), 0.37 (br s, 2H). LC-MS RT: 2.34 min; MS (ESI) m/z 631.2 (M+H).sup.+; Method A.

Example 565

##STR00270##

[0928] To a solution of intermediate 447-1 (20 mg, 0.028 mmol) in DCM (0.5 mL) was added cyclopentanamine (24 mg, 0.28 mmol). The reaction mixture was stirred for 14 h, then concentrated under reduced pressure, dissolved in MeOH, and filtered through a syringe filter. The residue was purified via preparative reverse phase HPLC to furnish Example 565 (12.2 mg, 84%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.01 (d, J=6.8 Hz, 1H), 8.15 (d, J=2.4 Hz, 1H), 8.02 (d, J=7.6 Hz, 1H), 7.79 (dd, J=8.6, 2.4 Hz, 1H), 7.24 (d, J=8.7 Hz, 1H), 5.34 (dd, J=9.6, 3.2 Hz, 1H), 4.61 (d, J=9.7 Hz, 1H), 4.50 (dd, J=8.3, 6.6 Hz, 1H), 4.34-4.22 (m, 1H), 4.09 (d, J=10.8 Hz, 1H), 4.02 (s, 4H), 3.90 (d, J=9.3 Hz, 1H), 3.81-3.72 (m, 1H), 3.66 (dd, J=10.6, 3.9 Hz, 1H), 3.09-3.01 (m, 1H), 2.88 (dd, J=11.1, 4.4 Hz, 1H), 1.88-1.70 (m, 4H), 1.65-1.54 (m, 2H), 1.53-1.40 (m, 3H), 1.39-1.26 (m, 4H), 0.76-0.64 (m, 2H), 0.32 (br d, J=3.5 Hz, 2H). One proton is not visible in NMR, likely due to overlap with solvent peak. LC-MS RT: 2.14 min; MS (ESI) m/z 520.4 (M+H).sup.+; Method B.

Example 578

##STR00271##

Intermediates 578-1 and 578-2

##STR00272##

[0929] A solution of (S,E)-N-(cyclobutylmethylene)-2-methylpropane-2-sulfinamide (0.500 g, 2.67 mmol) was cooled in a dry ice/acetone bath. Ethylmagnesium bromide (3.6 M in 2Me-THF) (1.48 mL, 5.34 mmol) was added dropwise, and the reaction mixture was allowed to warm to rt for 14 h. The reaction mixture was quenched with sat. ammonium chloride solution and extracted twice with DCM. The organic layers were concentrated under reduced pressure. The residue was purified via silica gel chromatography to furnish 533 mg of a mixture of diastereomers. The diastereomers were separated via preparative SFC with the following conditions: Instrument: PIC Solution SFC Prep-200; Column: Chiralpak AD-H, 21250 mm, 5 micron; Mobile Phase 15% isopropanol-acetonitrile, 85% CO.sub.2; Flow Rate: 45 mL/min, 150 Bar; Column Temperature: 40 C.

[0930] (S)N((S)-1-cyclobutylpropyl)-2-methylpropane-2-sulfinamide Intermediate 578-1 Peak 1 RT: 6 min (70 mg, 0.32 mmol, 12% yield). Analytical SFC conditions: Instrument: Shimadzu Nexera SFC; Column: Chiralpak AD-H, 4.6100 mm, 3 micron; Mobile Phase 10% isopropanol-acetonitrile, 90% CO.sub.2; Flow Rate: 42 m/min, 150 Bar; Column Temperature: 40 C. RT: 2.09 min MS (ESI) m/z 218 (M+H)+

[0931] (S)N((R)-1-cyclobutylpropyl)-2-methylpropane-2-sulfinamide Intermediate 578-2 Peak 2 RT: 8.7 min. (350 mg, 1.61 mmol, 60.3% yield). Analytical SFC conditions: Instrument: Shimadzu Nexera SFC; Column: Chiralpak AD-H, 4.6100 mm, 3 micron; Mobile Phase 10% isopropanol-acetonitrile, 90% CO.sub.2; Flow Rate: 42 mL/min, 150 Bar; Column Temperature: 40 C. RT: 2.26 min MS (ESI) m/z 218 (M+H).sup.+.

Intermediate 578-3

##STR00273##

[0932] To a solution of 578-2 (350 mg, 1.61 mmol) in MeOH (0.8 mL) was added HCl (4M in dioxane) (0.81 mL, 3.2 mmol). After 45 minutes, the reaction mixture was concentrated in vacuo. Et.sub.2O was added, then the solid was filtered off and washed with Et.sub.2O/hexanes. The solid was collected and dried under vacuum to give (R)-1-cyclobutylpropan-1-amine 578-3 (175 mg, 1.55 mmol, 96% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) 3.06-2.97 (m, 1H), 2.55-2.41 (m, 1H), 2.17-2.04 (m, 2H), 2.03-1.80 (m, 4H), 1.73-1.59 (m, 1H), 1.55-1.42 (m, 1H), 0.99 (t, J=7.6 Hz, 3H).

Example 578

[0933] Example 578 (4.8 mg, 49%) was prepared from 578-3 following the procedure given for Example 378. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.04 (d, J=6.8 Hz, 1H), 8.15 (d, J=24 Hz, 1H), 7.78 (dd, J=8.6, 2.4 Hz, 1H), 7.70 (br d, J=9.1 Hz, 1H), 7.23 (d, J=8.8 Hz, 1H), 5.33 (dd, J=9.2, 3.5 Hz, 1H), 4.62 (d, J=9.6 Hz, 1H), 4.49 (br t, J=7.9 Hz, 1H), 4.33-4.24 (m, 1H), 4.09 (d, J=10.7 Hz, 1H), 4.00 (s, 3H), 3.92-3.87 (m, 1H), 3.77 (dd, J=9.2, 6.7 Hz, 1H), 3.71-3.59 (m, 2H), 3.09-3.01 (m, 1H), 2.98-2.88 (m, 1H), 2.33-2.19 (m, 1H), 1.95-1.60 (m, 8H), 1.51-1.41 (m, 1H), 1.40-1.25 (m, 3H), 1.19-1.03 (m, 1H), 0.82-0.62 (m, 5H), 0.31 (dd, J=4.5, 2.2 Hz, 2H). One proton is not visible in NMR, likely due to overlap with solvent peak. LC-MS RT: 2.58 min; MS (ESI) m/z 548.2 (M+H).sup.+; Method B.

Example 589 and 629

##STR00274##

Intermediate 589-1

##STR00275##

[0934] To a suspension of isobenzofuran-1,3-dione (372 mg, 2.51 mmol) and cyclopent-3-en-1-amine, HCl (300 mg, 2.51 mmol) in toluene (25 mL) was added Hunig's base (0.44 mL, 2.5 mmol). The reaction mixture was heated to 120 C. After ca. 5.5 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified via silica gel chromatography to furnish Intermediate 589-1 (369 mg, 69%). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.88-7.80 (m, 2H), 7.76-7.67 (m, 2H), 5.81 (s, 2H), 5.02 (tt, J=9.6, 7.4 Hz, 1H), 2.93-2.82 (m, 2H), 2.74-2.63 (m, 2H).

Intermediate 589-2 and 589-3

##STR00276##

[0935] In each of four pressure vials, sodium trifluoromethanesulfinate (234 mg, 1.50 mmol), 9-mesityl-10-methylacridin-10-ium, tetrafluoroborate salt (15 mg, 0.038 mmol), and rac-2-((1R,3R)-3-(trifluoromethyl)cyclopentyl)isoindoline-1,3-dione (273 mg, 0.964 mmol) were suspended in CHCl.sub.3 (3.4 mL) and trifluoroethanol (0.38 mL). Nitrogen was bubbled through the solution, then methyl 2-mercaptobenzoate (25 mg, 0.15 mmol) was added, and nitrogen was bubbled through the solution briefly. The vial was sealed and irradiated with a KSH 150B blue Kessil grow lamp, 34 W, 461 nm lambda max for 48 h. The reaction mixture was removed from the photoreactor and poured into saturated aq. NaHCO.sub.3. The reaction mixture was extracted three times with DCM. The organic layers were dried with sodium sulfate and concentrated in vacuo. The residue was purified via silica gel chromatography.

[0936] The first eluting peak was trans product rac-2-((1R,3R)-3-(trifluoromethyl)cyclopentyl)isoindoline-1,3-dione Intermediate 589-2 (273 mg, 0.964 mmol, 32.1% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.84 (dd, J=5.4, 3.1 Hz, 2H), 7.77-7.68 (m, 2H), 4.88-4.72 (m, 1H), 3.22-3.06 (m, 1H), 2.37 (ddd, J=14.0, 9.6, 6.9 Hz, 1H), 2.29-2.05 (m, 4H), 1.85-1.70 (m, 1H)

[0937] The second eluting peak was cis product Intermediate 589-3 rac-2-((1R,3S)-3-(trifluoromethyl)cyclopentyl)isoindoline-1,3-dione (38 mg, 0.134 mmol, 4.47% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.90-7.79 (m, 2H), 7.77-7.65 (m, 2H), 4.73-4.58 (m, 1H), 2.83-2.59 (m, 1H), 2.55-2.30 (m, 2H), 2.22-2.08 (m, 2H), 2.06-1.84 (m, 2H).

Intermediate 589-4

##STR00277##

[0938] To a suspension of Intermediate 589-2 in EtOH (1.8 mL) was added hydrazine hydrate (29 l, 0.39 mmol). The reaction mixture was heated to 75 C. After ca. 30 minutes, 1 mL EtOH was added. After 2.5 hours, the reaction mixture was allowed to cool, diluted with EtOH and filtered. 90 L 4M HCl in dioxane was added to the filtrate and the solution concentrated in vacuo. The residue obtained contained ca. 0.25 equiv of phthalazidinone. The residue was suspended in EtOH and filtered. The filtrate was concentrated under reduced pressure to give Intermediate 589-4 rac-(1R,3R)-3-(trifluoromethyl)cyclopentan-1-amine, HCl (83 mg, 0.44 mmol, 120% yield) which contained ca. 0.1 equivalent of phthalazadinone. .sup.1H NMR (400 MHz, CD.sub.3OD) 3.74-3.65 (m, 1H), 3.06-2.91 (m, 1H), 2.29-2.09 (m, 3H), 2.00-1.87 (m, 1H), 1.85-1.64 (m, 2H).

Example 629 and 589

[0939] The diastereomeric mixture of Example 629 and 589 was prepared according to the procedure given for Example 565. The diastereomers were separate via preparative SFC with the following conditions: Column: Chiral OD, 30250 mm, 5 micron; Mobile Phase 80% CO.sub.2/20% IPA w/0.1% DEA; Flow Rate: 100 mL/min, 120 Bar; Column Temperature: 40 C.

[0940] First eluting peak (RT=13.5 min) is Example 629 (0.8 mg, 3.7%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.95 (br d, J=7.0 Hz, 1H), 8.17 (br d, J=2.1 Hz, 2H), 7.79 (br d, J=8.2 Hz, 1H), 7.29-7.20 (m, 1H), 5.34 (br dd, J=9.2, 3.1 Hz, 1H), 4.62 (br d, J=9.5 Hz, 1H), 4.50 (br t, J=7.8 Hz, 1H), 4.35-4.25 (m, 1H), 4.18-4.07 (m, 2H), 4.02 (s, 3H), 3.94-3.86 (m, 1H), 3.82-3.72 (m, 1H), 3.69-3.61 (m, 1H), 3.05 (br s, 1H), 2.98-2.82 (m, 2H), 2.04-1.40 (m, 9H), 1.39-1.26 (m, 2H), 0.76-0.65 (m, 2H), 0.32 (br d, J=2.4 Hz, 2H). One proton is not visible in NMR, likely due to overlap with suppressed water peak. LC-MS RT: 2.30 min; MS (ESI) m/z 588.3 (M+H).sup.+; Method B.

[0941] Second eluting peak (RT=16.0 min) is Example 589 (0.7 mg, 3.4%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.95 (br d, J=7.3 Hz, 1H), 8.17 (br d, J=8.5 Hz, 2H), 7.79 (br d, J=8.5 Hz, 1H), 7.29-7.18 (m, 1H), 5.40-5.27 (m, 1H), 4.62 (br d, J=9.5 Hz, 1H), 4.54-4.45 (m, 1H), 4.35-4.25 (m, 1H), 4.16-4.06 (m, 2H), 4.02 (s, 3H), 3.90 (br d, J=5.8 Hz, 1H), 3.82-3.74 (m, 1H), 3.66 (br dd, J=7.0, 3.4 Hz, 1H), 3.08-3.02 (m, 1H), 2.98-2.83 (m, 2H), 2.02-1.41 (m, 9H), 1.40-1.26 (m, 2H), 0.76-0.66 (m, 2H), 0.32 (br d, J=3.7 Hz, 2H). LC-MS RT: 2.23 min; MS (ESI) m/z 588.5 (M+H).sup.+; Method B.

Example 591

##STR00278##

[0942] Preparation of intermediate 591-1. 5-(4-isopropyl-5,5-dimethyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-methoxybenzoic acid. LDA was generated by the addition of nBuLi (2.7M, 2.3 mL, 6.3 mmol) to a THF (15 mL) solution of disopropylamine (0.64 g, 6.33 mmol) cooled to 78 C. The reaction mixture was stirred cold for 0.5 h and methyl-3-cyclopentene carboxylate (0.4 g, 3.0 mmol) added followed by idodomethane (0.2 mL, 3.0 mmol). The reaction mixture was stirred cold for 4 h and gradually allowed to warm up to r.t. for 14 h. To the reaction mixture was then added methyl (E)-5-(chloro(hydroxyimino)methyl)-2-methoxybenzoate (1.05 g, 4.32 mmol) followed by the addition of TEA (1.4 mL, 9.1 mmol) and the resulting solution was stirred at r.t. for 14 h. The reaction was quenched by the addition of dil HCl (1N, 10 ml) and extracted with EtOAc (225 mL). The combined organic portion was dried (MgSO.sub.4), filtered and concentrated under reduced pressure to an oil. The oil was purified via silica gel chromatography using hexane/EtOAc as eluant to afford methyl 5-(4-isopropyl-5,5-dimethyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-methoxybenzoate intermediate by product (75 mg, 8% yield) as a solid. The solid was dissolved in MeOH (2 mL) and to the solution was added LiOH (10 mg, 0.24 mmol) and water (2 mL). The reaction mixture was stirred for 14 h at r.t. then concentrated under reduced pressure and quenched with dil HCl (1N, 5 mL). The solution was transferred to a separatory funnel and extracted the with EtOAc (225 mL), the organic portion dried (MgSO.sub.4), filtered and concentrated under reduced pressure to a solid 591-1 (60 mg, 85% yield) which was used without further manipulation. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.29-8.19 (m, 1H), 7.76 (dd, J=8.5, 2.3 Hz, 11H), 7.14 (d, J=8.3 Hz, 1), 4.12 (s, 3H), 3.61 (spt, J=7.0 Hz, 11H), 1.63 (s, 6H), 1.84-0.82 (d, 6H). LCMS m/z=293.3 (M+H).sup.+.

[0943] Example 591. Intermediate 591-1 (9 mg, 0.03 mmol) was coupled to 166-2 (11.34 mg, 0.03 mmol) with BOP (13.62 mg, 0.03 mmol) reagent, and Hunig's base (0.1 mL) as described for example 378 to afford example 591 as a solid (8.4 mg, 41% yield) after purification by preparative reverse phase HPLC. HPLC purity: 96.5%; RT=2.67 min [Method B]. LCMS m/z=643.18 (M+H).sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.54 (s, 1H), 9.96 (br d, J=6.7 Hz, 1H), 8.23 (br d, J=4.0 Hz, 1H), 8.03 (d, J=2.1 Hz, 1H), 7.79 (br d, J=8.9 Hz, 1H), 7.61 (dd, J=8.5, 2.1 Hz, 1H), 7.49 (br t, J=9.8 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 4.70 (d, J=9.5 Hz, 1H), 4.46 (br s, 1H), 4.07 (s, 3H), 3.68-3.48 (m, 1H), 3.41 (br s, 1H), 3.28-3.13 (m, 1H), 3.11 (br s, 1H), 2.73 (br s, 1H), 1.92-1.75 (m, 2H), 1.51 (s, 6H), 1.43 (br t, J=10.7 Hz, 2H), 1.06 (br d, J=6.7 Hz, 6H), 0.86-0.66 (m, 2H), 0.36 (br s, 2H)

Example 594

##STR00279##

Preparation of Intermediate 594-1

##STR00280##

[0944] Intermediate 594-1 (434 mg, 60.0% yield) was prepared in a similar manner as described for example 378 by the cycloaddition of methyl (Z)-5-(chloro(hydroxyimino)methyl)-2-methoxy benzoate (530 mg, 2.18 mol) with t-butylpropiolate (274 mg, 2.17 mmol) and TEA (2 mL) in DCM as previously described. LCMS m/z=334.3 (M+H).sup.+.

Preparation of Intermediate 594-2

##STR00281##

[0945] Intermediate 594-1 (100 mg, 0.30 mmol) was hydrolysed with LiOH (12 mg, 0.35 mmol) in methanol/water as previously described in Example 378 to afford 594-2 (75 mg) as a mixture of two products. LCMS m/z=278.2 (M+H) for the desired product. The other by product was the cleavage of the t-butyl ester to the acid product. The crude mixture was carried onto the next step without further manipulation

Preparation of Intermediate 594-3

##STR00282##

[0946] Intermediate 594-2 (60 mg, 0.22 mmol, part as a mixture) was dissolved in DMF (1 mL) and to this was added 4OH-piperidine (22 mg, 0.22 mmol) followed by BOP (6 mg, 0.22 mmol) reagent and Hunig's base (0.1 mL). The reaction mixture was stirred at rt for 14 h, quenched with water (25 mL) and extracted with EtOAc (225 mL). The combined organic portion was dried and concentrated in vacuo to an oil. LCMS m/z=361.2 (M+H). The oil obtained was dissolved in methanol (1 mL) and to this was added LiOH (10 mg, 0.2 mmol) followed by water (1 mL) and the reaction mixture stirred for 14 h. The reaction mixture was diluted with water (25 mL) and extracted with EtOAc (225 mL). The combined organic portion was dried (MgSO.sub.4) and concentrated in vacuo to yield 594-3 as an oil (LCMS m/z=347.3 (M+H) which was used without further purification in the next step.

[0947] Example 594. Intermediate 594-3 (8 mg, 0.02 mmol) was coupled to 166-2 (8.5 mg, 0.020 mmol) with BOP (10 mg, 0.02 mmol) reagent, and Hunig's base (0.1 mL) to afford Example 594 as a solid (3.6 mg, 22% yield) after purification by preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm19 mm, 5-m particles; Mobile Phase A: 5:95 acetonitrile: water with 0.05% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.05% trifluoroacetic acid. HPLC purity: 98.1%; RT=2.30 min [Method B]. LCMS m/z=697.01 (M+H).sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.55 (s, 1H), 9.94 (br d, J=6.4 Hz, 1H), 9.26-9.19 (m, 1H), 8.27 (d, J=2.3 Hz, 1H), 8.22 (br d, J=4.6 Hz, 1H), 7.80 (br dd, J=8.6, 2.1 Hz, 2H), 7.48 (br t, J=9.7 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.27-7.21 (bs, 1H), 7.17-7.13 (bs, 1H), 7.09 (bs, 1H) 4.69 (d, J=9.5 Hz, 1H), 4.44 (br s, 1H), 4.06 (s, 3H), 3.67 (br s, 1H), 3.51 (m, 2H), 3.34-3.13 (m, 1H), 3.10 (br s, 1H), 2.80-2.63 (m, 1H), 1.83 (br d, J=9.8 Hz, 1H), 1.77 (br s, 2H), 1.50 (br s, 1H), 1.45 (br s, 1H), 1.41 (br s, 2H), 1.16 (t, J=7.3 Hz, 1H), 1.10 (br s, 1H), 0.86-0.68 (m, 2H), 0.35 (br s, 2H)

Example 626

##STR00283##

Intermediate 626-1

##STR00284##

[0948] Preparation of 2-cyclopropyl-4-methoxybenzaldehyde. Intermediate 626-1 (0.30 g, 1.9 mmol, 84% yield) was prepared in the manner described for example 12 substituting 2-bromo-4-methoxybenzaldehyde and cyclopropylboronic acid for example 11 and furan-3-ylboronic acid and dioxane for THF. .sup.1H NMR (400 MHz, CDCl.sub.3) 10.46 (s, 1H), 7.83 (d, J=8.6 Hz, 1H), 6.84 (dd, J=8.7, 2.5 Hz, 1H), 6.62 (d, J=2.4 Hz, 1H), 3.89 (s, 3H), 2.70 (tt, J=8.5, 5.4 Hz, 1H), 1.15-1.07 (m, 2H), 0.86-0.76 (m, 2H). LCMS(ESI) m/z: 177.1 (M+H)..sup.+

Intermediate 626-2

##STR00285##

[0949] Preparation of 5-bromo-2-cyclopropyl-4-methoxybenzaldehyde. To 626-1 (0.30 g, 1.9 mmol) in MeOH (10 mL), cooled to 0 C., was added pyridine hydrobromide perbromide (0.60 g, 1.9 mmol). After 24 h, the solvent was removed in vacuo and the residue was purified by normal phase silica gel chromatography eluting with hexanes/EtOAc to afford intermediate 626-2 (0.31 g, 1.2 mmol, 65% yield) as a white solid. .sup.1H NMR (400 MHz, CDCl3) 10.45 (s, 1H), 8.04 (s, 1H), 6.63 (s, 1H), 3.98 (s, 3H), 2.68-2.55 (m, 1H), 1.20-1.11 (m, 2H), 0.88-0.78 (m, 2H).

Intermediate 626-3

##STR00286##

[0950] Preparation of methyl 4-cyclopropyl-5-formyl-2-methoxybenzoate. Intermediate 626-3 (0.16 g, 0.70 mmol, 58% yield) was prepared in a similar manner as intermediate 323-1 with the exception of using PdOAc.sub.2, dppf and DMSO/MeOH. .sup.1H NMR (400 MHz, CDCl.sub.3) 10.40 (s, 1H), 8.33 (s, 1H), 6.64 (s, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 2.96-2.71 (m, 1H), 1.25-1.13 (m, 2H), 0.87 (dd, J=5.3, 1.8 Hz, 2H). LCMS(ESI) m/z: 235.2 (M+H)..sup.+

Intermediate 626-4

##STR00287##

[0951] Preparation of 4-cyclopropyl-2-methoxy-5-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)benzoic acid. Following the general procedures for example 378 and example 416, but substituting 626-3 for methyl 5-formyl-2-methoxybenzoate afforded 626-4 (46 mg, 0.15 mmol, 91% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) 8.10 (s, 1H), 6.68 (s, 1H), 5.38 (dd, J=9.2, 3.7 Hz, 1H), 4.48 (t, J=7.5 Hz, 1H), 4.37 (d, J=10.6 Hz, 1H), 4.12 (s, 3H), 4.03 (d, J=9.5 Hz, 1H), 3.86-3.75 (m, 2H), 2.77-2.63 (m, 1H), 1.28-1.20 (m, 1H), 1.18-1.10 (m, 1H), 0.85-0.72 (m, 2H). LCMS(ESI) m/z: 304.3 (M+H)..sup.+

[0952] Example 626. A mixture of diastereomers was prepared by BOP coupling as described in example 378 substituting cyclopropyl norbornyl intermediate 166-2 and intermediate 626-4 for intermediate 378-3 and the cyclobutyl norbornyl intermediate 369-1. The mixture of diastereomers was separated into individual isomers using chiral SFC Instrument: Waters 100 Prep SFC Column: Chiral AD, 30250 mm, 5 micron, Mobile Phase: 25% MeOH/75% CO.sub.2 w/0.1% DEA, Flow Conditions: 100 mL/min, Detector Wavelength: 220 nm; Analytical method: Instrument: Shimadzu Nexera SFC, Column Chiral AD, 4.6100 mm, 5 micron, Mobile Phase: 25% MeOH/75% CO.sub.2 w/0.10% DEA, Flow Conditions: 2 m/min, Detector Wavelength: 220 nm, to afford chiral peak-1 (example 626) (8.2 mg, 12 mol, 16% yield), RT=2.6 min., >95% de and chiral peak-2 (8.1 mg, 12 mol, 16% yield), RT=3.3 min., >95% de. For example 626: .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.53 (s, 1H), 9.85 (br d, J=7.0 Hz, 1H), 8.31-8.18 (m, 1H), 7.90 (s, 1H), 7.82-7.74 (m, 1H), 7.48 (t, J=9.6 Hz, 1H), 6.68 (s, 1H), 5.32 (dd, J=9.0, 3.5 Hz, 1H), 4.69 (d, J=9.5 Hz, 1H), 4.56 (br t, J=7.6 Hz, 1H), 4.47-4.39 (m, 1H), 4.11 (br d, J=10.7 Hz, 1H), 4.04 (s, 3H), 3.76 (br d, J=8.9 Hz, 1H), 3.65 (br dd, J=10.5, 4.4 Hz, 1H), 3.48 (br s, 1H), 3.15 (br dd, J=10.8, 3.2 Hz, 1H), 3.09 (br s, 1H), 2.78-2.67 (m, 1H), 2.41-2.32 (m, 1H), 1.92-1.81 (m, 1H), 1.79-1.72 (m, 1H), 1.56-1.46 (m, 1H), 1.45-1.33 (m, 2H), 1.06 (br dd, J=8.7, 5.6 Hz, 1H), 1.02-0.94 (m, 1H), 0.93-0.87 (m, 1H), 0.87-0.81 (m, 1H), 0.79-0.67 (m, 2H), 0.35 (br s, 2H). LCMS(ESI) m/z: 653.93 (M+H)..sup.+ HPLC purity 95% with retention time 2.65 min. [method C].

Example 664 and Example 702

##STR00288##

Intermediate 664-1

##STR00289##

[0953] rac-tert-butyl ((1R,3S)-3-hydroxycyclopentyl)carbamate (260 mg, 1.29 mmol) was dissolved in in DCM (15 mL). Hunig's base (1.13 mL, 6.46 mmol) and MsCl (0.101 mL, 1.29 mmol) were added. After 2 hours, the reaction mixture was concentrated in vacuo. The residue was diluted with acetonitrile (20 mL), and tetrabutylammonium cyanide (347 mg, 1.29 mmol) was added. After 1 hour, the reaction mixture was concentrated in vacuo. The residue was purified via silica gel chromatography to furnish 664-1 (135 mg, 50%). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.48 (br d, J=4.3 Hz, 1H), 4.18-4.05 (m, 1H), 2.99-2.85 (m, 1H), 2.30-2.13 (m, 3H), 2.06-1.85 (m, 2H), 1.58-1.49 (m, 1H), 1.44 (s, 9H).

Intermediate 664-2

##STR00290##

[0954] rac-tert-butyl ((1R,3R)-3-cyanocyclopentyl)carbamate (65 mg, 0.31 mmol) was dissolved in DCM (1.9 mL). TFA (0.19 mL, 2.5 mmol) was added. After 3 hours, TFA (0.19 mL, 2.5 mmol) was added. After a further 1.5 hours, the reaction mixture was concentrated in vacuo, then azeotroped with DCM and hexanes. rac-(1R,3R)-3-aminocyclopentane-1-carbonitrile, TFA (131 mg, 0.584 mmol, 189% yield) was obtained and taken forward without further purification. .sup.1H NMR (400 MHz, CD.sub.3OD) 3.99-3.84 (m, 1H), 2.53-2.34 (m, 3H), 2.31-2.19 (m, 1H), 2.11-2.00 (m, 1H), 1.85 (dt, J=14.1, 7.0 Hz, 1H).

Example 642 and Example 702

[0955] A mixture of Example 642 and Example 702 was prepared from Intermediate 642-2 according to the procedure described for Example 447. The material obtained was purified via preparative reverse phase HPLC with the following conditions: Column: XBridge C18, 200 mm19 mm, 5-m particles; Mobile Phase A: 5:95 acetonitrile: water with ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with ammonium acetate; Gradient: a 0-minute hold at 25% B, 25-70% B over 30 minutes, then a 0-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation.

[0956] Peak 1 is Example 664 (6.3 mg, 41%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.95 (br d, J=7.0 Hz, 1H), 8.21-8.14 (m, 2H), 7.79 (dd, J=8.5, 2.1 Hz, 1H), 7.24 (d, J=8.5 Hz, 1H), 5.34 (dd, J=9.0, 3.2 Hz, 1H), 4.61 (br d, J=9.5 Hz, 1H), 4.50 (br t, J=7.3 Hz, 1H), 4.27 (br dd, J=6.3, 4.1 Hz, 1H), 4.22-4.15 (m, 1H), 4.09 (br d, J=10.7 Hz, 1H), 4.02 (s, 3H), 3.90 (br d, J=9.2 Hz, 1H), 3.77 (br dd, J=9.2, 7.0 Hz, 1H), 3.67-3.60 (m, 1H), 3.13-3.01 (m, 2H), 2.86 (br dd, J=11.0, 4.3 Hz, 1H), 2.16-2.01 (m, 2H), 2.00-1.92 (m, 1H), 1.87-1.78 (m, 2H), 1.78-1.66 (m, 2H), 1.50-1.40 (m, 2H), 1.39-1.24 (m, 2H), 0.77-0.64 (m, 2H), 0.31 (br d, J=2.4 Hz, 2H). One proton is not visible in NMR, likely due to overlap with solvent peak. LC-MS RT: 2.02 min; MS (ESI) m/z 545.2 (M+H).sup.+; Method B.

[0957] Peak 2 is Example 702 (5.1, 32%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 9.97 (d, J=6.8 Hz, 1H), 8.20-8.12 (m, 2H), 7.79 (dd, J=8.6, 2.3 Hz, 1H), 7.25 (d, J=8.8 Hz, 1H), 5.33 (dd, J=9.2, 3.5 Hz, 1H), 4.61 (d, J=9.6 Hz, 1H), 4.49 (br t, J=7.8 Hz, 1H), 4.32-4.24 (m, 1H), 4.23-4.14 (m, 1H), 4.13-4.06 (m, 1H), 4.03 (s, 3H), 3.90 (br d, J=8.9 Hz, 1H), 3.77 (dd, J=9.4, 7.0 Hz, 1H), 3.65 (dd, J=10.7, 3.5 Hz, 1H), 3.12-3.01 (m, 2H), 2.85 (dd, J=10.9, 4.2 Hz, 1H), 2.18-1.95 (m, 3H), 1.88-1.68 (m, 4H), 1.52-1.40 (m, 2H), 1.39-1.24 (m, 2H), 0.70 (quin, J=9.4 Hz, 2H), 0.40-0.21 (m, 2H). One proton is not visible in NMR, likely due to overlap with solvent peak. LC-MS RT: 1.86 min; MS (ESI) m/z 545.2 (M+H).sup.+; Method B.

Example 699

##STR00291##

Intermediate 699-1

##STR00292##

[0958] A solution of (R)-pyrrolidin-2-ylmethanamine, 2 HCl (70.2 mg, 0.406 mmol) in DCM (1.9 mL) was cooled in an ice bath. Hunig's base (0.14 mL, 0.81 mmol) and methyl 5-formyl-2-methoxybenzoate (75 mg, 0.39 mmol) were added. The reaction mixture was allowed to warm to rt. After 1 hour, NBS (72.2 mg, 0.406 mmol) was added and the reaction mixture was stirred for 14 h. The reaction mixture was concentrated under reduced pressure. The residue was purified via silica gel chromatograph to furnish Intermediate 699-1 (49 mg, 46%). .sup.1H NMR (400 MHz, CDCl.sub.3) 8.18 (d, J=2.0 Hz, 1H), 7.96 (dd, J=8.8, 2.0 Hz, 1H), 7.02 (d, J=8.7 Hz, 1H), 4.09-4.02 (m, 2H), 3.92 (s, 3H), 3.86 (s, 3H), 3.75 (q, J=9.4 Hz, 1H), 3.42-3.27 (m, 1H), 3.24-3.14 (m, 1H), 2.05-1.91 (m, 1H), 1.90-1.72 (m, 2H), 1.52-1.40 (m, 1H).

Intermediate 699-2

##STR00293##

[0959] To a solution of Intermediate 699-1 (49 mg, 0.18 mmol) in THF (1.9 mL) and MeOH (0.37 mL) was added LiOH (2M aqueous) (0.27 mL, 0.54 mmol). After 4 hours, the reaction mixture was acidified to pH 3 with 1M HCl and concentrated under reduced pressure to give methyl (R)-2-methoxy-5-(5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazol-3-yl)benzoate Intermediate 699-2 (49 mg, 0.18 mmol) which was used without further purification.

[0960] Example 699 was prepared from Intermediate 699-2 by the general procedure described for Example 378 (3.8 mg, 31%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) 10.61 (s, 1H), 9.98 (d, J=6.8 Hz, 1H), 8.38 (d, J=2.4 Hz, 1H), 8.21 (dd, J=6.3, 2.2 Hz, 1H), 7.98 (dd, J=8.8, 2.4 Hz, 1H), 7.83-7.73 (m, 1H), 7.52-7.43 (m, 2H), 4.69 (d, J=9.6 Hz, 1H), 4.55-4.39 (m, 2H), 4.13 (s, 3H), 4.08 (t, J=11.5 Hz, 1H), 3.81 (dd, J=11.9, 7.1 Hz, 1H), 3.74-3.64 (m, 1H), 3.17 (dd, J=10.2, 4.9 Hz, 1H), 3.10 (br s, 1H), 2.73 (br s, 1H), 2.17-2.08 (m, 1H), 2.07-1.96 (m, 2H), 1.88-1.72 (m, 2H), 1.72-1.60 (m, 1H), 1.52-1.35 (m, 3H), 0.79-0.66 (m, 2H), 0.39-0.27 (m, 2H). One proton is not visible in NMR, likely due to overlap with suppressed water peak. LC-MS RT: 2.20 min; MS (ESI) m/z 611.2 (M+H).sup.+; Method B.

Example 724

##STR00294##

[0961] Intermediate 724-1: Preparation of tert-butyl 5-bromo-2-methoxybenzoate: To a solution of 5-bromo-2-methoxybenzoic acid (3.67 g, 15.9 mmol) in THF (50 mL) was added Boc-anhydride (7.38 mL, 31.8 mmol) and DMAP (0.194 g, 1.59 mmol) To this mixture was then added t-BuOH (50 mL) and the reaction mixture was then heated for 14 h at 75 C. The reaction mixture was then concentrated under vacuum and the residue was subjected to silica gel chromatography to yield intermediate 724-1 (4.1 g, 81% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.81 (d, J=2.6 Hz, 1H), 7.52 (dd, J=8.9, 2.6 Hz, 1H), 6.85 (d, J=8.9 Hz, 1H), 3.88 (s, 3H), 1.61-1.57 (m, 9H)

[0962] Intermediate 724-2: Preparation of tert-butyl 5-(3-hydroxyprop-1-en-2-yl)-2-methoxybenzoate: To a solution of prop-2-en-1-ol (1.42 mL, 20.9 mmol) and intermediate 724-1 (1200 mg, 4.18 mmol) in DMSO (3 mL) was added TEA (1.05 mL, 7.52 mmol) and 1,3-bis(diphenylphosphino)propane (345 mg, 0.836 mmol) under argon. To the reaction mixture was added Pd(OAc).sub.2 (94 mg, 0.42 mmol) and the mixture was purged with argon for 10 mins. The reaction mixture was then sealed and stirred for 14 h at 60 C. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc and the organic portion washed with brine. The organic portion was dried over MgSO.sub.4, filtered and purified using silica gel chromatography to yield intermediate 724-2 (222 mg, 19.0% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.82 (d, J=2.4 Hz, 1H), 7.53 (dd, J=8.6, 2.5 Hz, 1H), 6.95 (d, J=8.7 Hz, 1H), 5.43 (d, J=0.8 Hz, 1H), 5.32 (q, J=1.2 Hz, 1H), 4.53 (d, J=5.3 Hz, 2H), 3.92-3.89 (s, 3H), 1.62-1.59 (m, 9H)

[0963] Intermediate 724-3: Preparation of dimethyl 2-((2-(3-(tert-butoxycarbonyl)-4-methoxyphenyl)allyl) oxy)malonate: To a solution of intermediate 724-2 (222 mg, 0.840 mmol) in toluene (5 mL) was added Rh.sub.2(OAc).sub.4 (19 mg, 0.042 mmol). The reaction mixture was then flushed with nitrogen before heating to reflux. To this refluxing solution was then added dimethyl 2-diazomalonate (133 mg, 0.840 mmol) in toluene (1 mL) over 5 minutes. After continued reflux for 30 minutes, the reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The residue was purified using silica gel chromatography to yield intermediate 724-3 (192 mg, 58.0% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.85 (d, J=2.4 Hz, 1H), 7.60 (dd, J=8.7, 2.4 Hz, 1H), 6.93 (d, J=8.7 Hz, 1H), 5.59-5.56 (m, 1H), 5.34 (d, J=0.9 Hz, 1H), 4.64 (s, 1H), 4.55 (d, J=0.8 Hz, 2H), 3.91 (s, 3H), 3.79 (s, 6H), 1.60 (s, 9H).

[0964] Intermediate 724-4: Preparation of dimethyl 2-((2-(3-(tert-butoxycarbonyl)-4-methoxyphenyl)allyl)oxy)-2-((dimethylamino)methyl)malonate: To a solution of intermediate 724-3 (192 mg, 0.487 mmol) in DCM (7 mL) was added Eschenmoser's salt (135 mg, 0.730 mmol) followed by TEA (0.10 mL, 0.73 mmol). The reaction mixture was stirred at rt for 14 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The residue was purified using silica gel chromatography to yield intermediate 724-4 (100 mg, 45% yield). MS (ESI) m/z=452.5 (M+H).

[0965] Intermediate 724-5: Preparation of 2-((2-(3-(tert-butoxycarbonyl)-4-methoxyphenyl)allyl)oxy)-3-methoxy-2-(methoxycarbonyl)-N,N,N-trimethyl-3-oxopropan-1-aminium: To a solution of intermediate 724-4 (100 mg, 0.221 mmol) in acetone (5 mL) was added methyl iodide (0.021 mL, 0.33 mmol) and the reaction mixture stirred at room temperature for 14 h. The reaction mixture was concentrated under vacuum to yield intermediate 724-5 which was used without further purification, (100 mg, 87% yield). MS (ESI) m/z=466.5 (M+H).

[0966] Intermediate 724-6: Preparation of tert-butyl 2-methoxy-5-(3-((3-methoxy-3-oxoprop-1-en-2-yl)oxy)prop-1-en-2-yl)benzoate: To a solution of intermediate 724-5 (100 mg, 0.214 mmol) in DMSO (4 mL) was added NaOH (2M, 0.13 mL, 0.26 mmol) and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under vacuum and purified using silica gel chromatography to yield intermediate 724-6 (50 mg, 64% yield). MS (ESI) m/z=349.0 (M+H).

[0967] Intermediate 724-7: Preparation of methyl 4-(3-(tert-butoxycarbonyl)-4-methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-1-carboxylate: To a solution of intermediate 724-6 (50 mg, 0.14 mmol) in DMSO (30 mL) was added (Ir[dF(CF.sub.3)ppy].sub.2(dtbpy))PF.sub.6 (1.6 mg, 1.4 mol) and the reaction mixture degassed three times under N.sub.2. The reaction mixture was stirred for 48 h in the presence of blue LED lights. The reaction mixture was diluted with EtOAc and the organic portion washed with brine. The organic portion was dried over MgSO.sub.4, filtered and purified using silica gel chromatography to yield intermediate 724-7 (13 mg, 23% yield). .sup.1H NMR (500 MHz, CDCl.sub.3) 7.75 (d, J=2.4 Hz, 1H), 7.45 (dd, J=8.6, 2.5 Hz, 1H), 6.93 (d, J=8.7 Hz, 1H), 5.28 (s, 1H), 5.07 (d, J=0.9 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.04-2.98 (m, 2H), 2.88-2.79 (m, 2H), 1.62-1.59 (m, 9H)

[0968] Intermediate 724-8: Preparation of 2-methoxy-5-(1-(methoxycarbonyl)-2-oxabicyclo[2.1.1]hexan-4-yl)benzoic acid, TFA: To a solution of intermediate 724-7 (13 mg, 0.037 mmol) in DCM (0.8 mL) was added TFA (0.20 mL, 2.6 mmol) and the reaction mixture stirred at rt for 30 mins. The reaction mixture was then concentrated under vacuum to yield intermediate 724-8 which was used without further purification, (11 mg, 95% yield). MS (ESI) m/z=293.2 (M+H).

[0969] Intermediate 724-9: Preparation of Methyl 4-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-1-carboxylate: Intermediate 724-9 was prepared by the general procedures described for 378 by using trifluoromethyl norbornyl intermediate 170-2 (25 mg, 0.049 mmol) and intermediate 724-8 to yield intermediate 724-9 (6 mg, 20% yield). MS (ESI) m/z=671.1 (M+H).

[0970] Example 724: 4-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)-4-methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-1-carboxylic acid 724 was prepared by dissolving intermediate 724-9 (6 mg, 9 mol) in THF (2 mL) and water (0.67 mL) and adding LiOH (2 M, 0.013 mL, 0.027 mmol). The reaction mixture was then stirred at rt for 2 h. The reaction mixture was concentrated under vacuum and purified using reverse phase preparative HPLC to yield 724 (4.8 mg, 75% yield). .sup.1H NMR (500 MHz, CD.sub.3OD) 10.26-10.17 (m, 1H), 8.14 (dd, J=6.3, 2.6 Hz, 1H), 8.00-7.92 (m, 1H), 7.80-7.72 (m, 1H), 7.50-7.42 (m, 1H), 7.29 (t, J=9.6 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 5.78-5.71 (m, 1H), 4.67-4.60 (m, 1H), 4.07 (s, 3H), 4.01-3.96 (m, 2H), 3.47-3.41 (m, 1H), 3.40-3.32 (m, 1H), 3.30-3.16 (m, 2H), 2.95-2.91 (m, 1), 2.76-2.70 (m, 1H), 2.44-2.35 (m, 2H), 2.21-2.13 (m, 3H), 1.63-1.54 (m, 2H). MS (ESI) m/z=657.4 (M+H). HPLC Purity: 92%; Retention Time: 1.35 min; Method A.

Examples 725-728

##STR00295##

Intermediate 725-1

##STR00296##

[0971] Methyl (E)-5-(3-hydroxyprop-1-en-1-yl)-2-methoxybenzoate (0.30 g, 1.3 mmol) in DMF (14 mL) was cooled to 0 C. and treated with NaH (60% in mineral oil) (0.059 g, 1.5 mmol). After 15 minutes, the reaction mixture was treated with allyl bromide (0.13 mL, 1.5 mmol) and the solution was allowed to warm to rt 14 h. The reaction mixture was diluted with saturated ammonium chloride solution and extracted with EtOAc (2). The organic portions were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to furnish methyl (E)-5-(3-(allyloxy)prop-1-en-1-yl)-2-methoxybenzoate (0.20 g, 0.76 mmol, 57% yield). MS (ESI) m/z 263.0 (M+H).sup.+.

Intermediates 725-2, 726-1 to 727-1, & 728-1

##STR00297##

[0972] To a solution of Intermediate 725-1 (0.20 g, 0.76 mmol) dissolved in acetonitrile (75 mL) was added (Ir[dF(CF.sub.3)ppy].sub.2(dtbpy))-PF.sub.6, (9 mg, 8 mol) and the solution irradiated with Blue LED for 60 h. The reaction mixture was concentrated under reduced pressure and the residue purified by SFC using two successive columns. First column: (A5-5 2504.6 mm ID, 5 m Temperature: Ambient, Flow rate: 2.0 mL/min, Mobile Phase: 85/15 CO.sub.2/MeOH) followed by (AD 2504.6 mm ID, 5 m, Temperature: Ambient, Flow rate: 2.0 m/min. Mobile Phase: 90/10 CO.sub.2/MeOH) to afford 726-2 (Peak 1: 33 mg, 0.13 mmol, 17% yield) MS (ESI) m/z 263.0 (M+H).sup.+, RT=7.2 min, AD 2504.6 mm ID, 5 m, Temperature: Ambient, Flow rate: 2.0 mL/min, Mobile Phase: 90/10 CO.sub.2/MeOH .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67 (d, J=2.3 Hz, 1H), 7.34 (dd, J=8.5, 2.4 Hz, 1H), 6.94 (d, J=8.5 Hz, 1H), 4.02-3.96 (m, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.65-3.60 (m, 1H), 3.53-3.50 (m, 1H), 3.23-3.17 (m, 1H), 3.01-2.93 (m, 2H), 2.31-2.22 (m, 1H), 2.21-2.13 (m, 1H).

[0973] 727-1 (Peak 2: 20 mg, 0.076 mmol, 10% yield) MS (ESI) m/z 263.0 (M+H).sup.+, RT=13.2 min, A5-5 2504.6 mm ID, 5 m Temperature: Ambient, Flow rate: 2.0 m/min, Mobile Phase: 85/15 CO.sub.2/MeOH: .sup.1H NMR (500 MHz, CDCl3) 7.70 (d, J=2.4 Hz, 1H), 7.36 (dd, J=8.5, 2.4 Hz, 1H), 6.96 (d, J=8.7 Hz, 1H), 4.00 (dd, J=9.2, 7.6 Hz, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.63 (dd, J=9.2, 5.4 Hz, 1H), 3.53 (dd, J=9.4, 4.0 Hz, 1H), 3.26-3.19 (m, 1H), 3.04-2.95 (m, 2H), 2.33-2.24 (m, 1H), 2.22-2.16 (m, 1H).

[0974] 728-1 (Peak 3: 5.3 mg, 0.020 mmol, 2.7% yield), MS (ESI) m/z 263.0 (M+H).sup.+, RT=6.11 min, AD 2504.6 mm ID, 5 m, Temperature: Ambient, Flow rate: 2.0 mL/min, Mobile Phase: 90/10 CO.sub.2/MeOH .sup.1H NMR (500 MHz, CDCl.sub.3) 7.58 (d, J=2.3 Hz, 1H), 7.40 (dd, J=8.5, 2.2 Hz, 1H), 6.97 (d, J=8.7 Hz, 1H), 3.91 (s, 3H), 3.91 (s, 3H), 3.86 (d, J=9.0 Hz, 1H), 3.73-3.64 (m, 2H), 3.44 (dd, J=9.0, 4.4 Hz, 1H), 3.37 (dd, J=10.0, 6.6 Hz, 1H), 3.20 (q, J=7.5 Hz, 1H), 3.08-2.99 (m, 1H), 2.46 (dddd, J=12.3, 10.3, 8.2, 2.3 Hz, 1H), 2.13 (ddd, J=12.1, 9.6, 6.6 Hz, 1H)

Intermediate 725-3

##STR00298##

[0975] Intermediate 725-3 was prepared from 725-2 by the general procedure used for Intermediate 4-2. LC-MS RT: 0.77 min; MS (ESI) m/z 249.0 (M+H).sup.+; Method A.

[0976] Example 725: Prepared from intermediate 725-3 and IV-2a according to the general procedure for Example 1 to afford (1R,2S,3R,4R,Z)-3-(5-(3-oxabicyclo[3.2.0]heptan-6-yl)-2-methoxybenzamido)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide (3.2 mg, 10% yield). .sup.1H NMR (500 MHz, DMSO-d6) 10.49 (s, 1H), 9.81 (d, J=7.2 Hz, 1H), 8.23 (dd, J=6.6, 2.6 Hz, 1H), 7.84 (d, J=2.4 Hz, 1H), 7.78 (dt, J=8.5, 3.8 Hz, 1H), 7.49 (t, J=9.8 Hz, 1H), 7.41 (dd, J=8.5, 2.4 Hz, 1H), 7.13 (d, J=8.7 Hz, 1H), 4.69 (d, J=9.6 Hz, 1H), 4.49-4.41 (m, 1H), 3.97 (s, 3H), 3.91-3.84 (m, 2H), 3.48 (dd, J=9.2, 5.8 Hz, 1H), 3.39 (dd, J=9.2, 4.7 Hz, 1H), 3.15 (dd, J=10.7, 4.3 Hz, 1H), 3.13-3.06 (m, 2H), 3.00-2.90 (m, 1H), 2.89-2.83 (m, 1H), 2.72 (t, J=3.7 Hz, 1H), 2.16 (dt, J=12.3, 8.1 Hz, 1H), 2.09-2.01 (m, 1H), 1.87 (br t, J=8.7 Hz, 1H), 1.81-1.74 (m, 1H), 1.55-1.47 (m, 1H), 1.46-1.34 (m, 2H), 0.82-0.70 (m, 2H), 0.36 (dd, J=4.5, 2.5 Hz, 2H). LC-MS RT: 2.7 min; MS (ESI) m/z 599.0 (M+H).sup.+; Method A.

TABLE-US-00003 Lengthy table referenced here US20250221966A1-20250710-T00002 Please refer to the end of the specification for access instructions.

TABLE-US-LTS-00001 LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).